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Resumen 
1. Introducción. Epigenética: relevancia biológica y oportunidades para 
el desarrollo de medicamentos basados en la modulación de dianas 
epigenéticas 
La información genética de un organismo es extremadamente heterogénea en lo que 
se refiere a la expresión de los genes sencillos, de tal forma que, mientras algunos genes se 
transcriben frecuentemente, otras áreas del genoma están silenciadas. La adaptación a los 
cambios ambientales y la especialización celular en organismos multicelulares requiere una 
organización compleja de la producción transcripcional del genoma, para lo cual las 
células han desarrollado formas de memoria molecular que les permiten recordar estímulos 
pasados y que se pueden transmitir a través de la división celular.1 Esta memoria celular no 
genética, que graba estímulos del desarrollo y ambientales o eventos internos sin que ello 
conlleve cambios irreversibles en la información genética, es la base de la epi-(sobre, por 
encima de, más allá)-genética. Los  mecanismos epigenéticos operan con anterioridad  a 
los procesos de transcripción y están codificados mediante diferentes patrones de 
metilación del DNA y también mediante modificaciones en las histonas.2 
Estos mecanismos no sólo son importantes para la diferenciación celular, sino que 
también son fundamentales para la regulación de muchos procesos celulares, tales como la 
expresión de genes y de micro RNAs, las interacciones DNA-proteína, la supresión de la 
movilidad de elementos transponibles, la embriogénesis, la inactivación del cromosoma X 
y la impronta genómica.  
La importancia de la epigenética en el mantenimiento de un desarrollo y una 
biologia normal se refleja en la observación de que muchas enfermedades se desarrollan 
cuando marcas epigenéticas erróneas se introducen en el momento o en el lugar 
equivocados.3 Por ejemplo, en la tumorogénesis, la inactivación epigenética de genes es 
una fuerza motora tan importante como la inactivación de genes por mutación 
(modificación del genotipo). Se ha demostrado que la represión transcripcional mediante 
mecanismos epigenéticos  tiene lugar en una gran variedad de tumores y  que ocurre a 
nivel de genes supresores de tumores, genes del ciclo celular, genes implicados en la  
reparación del DNA o genes que desencadenan la metástasis. La reexpresión de muchos de 
                                                 
1 Bonasio, R.; Tu, S.; Reinberg, D. Science 2010, 330, 612. 
2 Biel, M.; Wascholowski, V.; Giannis, A. Angew. Chem. Int. Ed. 2005, 44, 3186. 
3 Esteller, M. Oncogene 2002, 21, 5427. 
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estos genes puede conducir a la supresión del crecimiento de las células tumorales o a la 
alteración de la sensibilidad a terapias anticancerosas ya existentes.  
1.1 Modificaciones de las histonas 
En el núcleo de una célula, el genoma está condensado en una estructura de orden 
superior llamada cromatina, cuya unidad fundamental es el nucleosoma, que está formado 
por 145-147 pares de bases de DNA enrolladas de forma levógira describiendo 1.65 
vueltas en torno a un núcleo formado por un octámero de histonas (dos dímeros H2.A-
H2.B y un tetrámero H3-H4), y separado del siguiente nucleosoma por un fragmento de 
aproximadamente 50 pares de bases de DNA libre. Además, la histona H1 (histona 
conectora) se sitúa en el exterior uniéndose al DNA que separa dos complejos histonas y 
sellando el nucleosoma en el punto de entrada del DNA. De esta forma, se permite la 
condensación de esta unidad fundamental en estructuras de orden superior que son visibles 
como cromosomas durante la metafase del ciclo celular. 
La estructura de cada núcleo de histonas consiste esencialmente en un dominio 
globular en el que sólo los extremos N-terminal de las proteínas están presentes como 
cadenas flexibles  en la superficie del nucleosoma. Allí pueden sufrir varias modificaciones 
postraduccionales reversibles, llevadas a cabo por una serie de enzimas, que son, 
principalmente: 
¾ Histonas acetiltransferasas (HATs), responsables de la acetilación de  los residuos 
de lisina. 
¾ Histonas metiltransferasas (HMTs), capaces de transferir un metilo desde S-
AdoMet hasta los residuos de lisina y arginina. 
¾ Histona cinasas (HKs), que fosforilan determinados grupos serina. 
Otras modificaciones importantes de las histonas serían: 
¾ Unión de ubiquitina (Ub) o ubiquitinación 
¾ Unión de moléculas similares a la ubiquitina (SUMOs) o SUMOilación 
¾ Unión de unidades de poli-ADP-ribosa o ADP-ribosilación 
¾ Excisión de la histona H3 después del residuo Ala21, un nuevo tipo de 
modificación no covalente que corta 21 residuos y sus correspondientes 
modificaciones del extremo N-terminal.4  
                                                 
4 Santos-Rosa, H.; Kirmizis, A.; Nelson, C.; Bartke, T.; Saksouk, N.; Cote, J.; Kouzarides, T. Nat. Struct. 
Mol. Biol. 2009, 16, 17. 
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¾ Crotonilación de la lisina (KCr)5  
Todos estos moduladores epigenéticos actúan conjuntamente  con otras enzimas 
responsables de los procesos contrarios: 
¾ Histonas desacetilasas (HDACs) 
¾ Histonas desmetilasas (HDMs) 
¾ Histonas fosfatasas (PPs) 
¾ Histonas ubiquitin hidrolasas (Ubps) 
¾ Poli-ADP-ribosaglicohidrolasa (PARGs) 
Estas modificaciones en los extremos de la histona actúan de una forma 
combinada y secuencial para dar lugar a sucesos específicos “aguas arriba”,  constituyendo 
un verdadero vocabulario celular para la regulación de los procesos basados en la 
transcripción, que se conoce como el código de la histona. 
Las histonas pueden ser modificadas en diferentes sitios y con diferentes marcas 
de forma simultánea, lo que da lugar a interacciones mutuas. Esta comunicación puede 
ocurrir en el mismo sitio, en la misma cola de la histona o entre diferentes histonas. Por lo 
tanto, la combinación de todas estas marcas epigenéticas es quien determina el resultado 
final. El estado transcripcional se puede dividir, de forma muy general, en eucromatina que 
se transcribe activamente y heterocromatina, que es transcripcionalmente inactiva. 
Recientemente se ha descrito la existencia de 51 “estados de la cromatina” diferentes que 
se basan en el enriquecimiento de determinadas combinaciones de las modificaciones de 
las histonas, para cada uno de los cuales se proponen diferentes funciones biológicas.6 
El cambio del código epigenético a través del desarrollo de pequeñas moléculas 
que varíen las propiedades de los moduladores epigenéticos, podría llevar a la prevención 
de la transcripción de los oncogenes y a la activación de genes supresores de tumores, lo 
cual podría inducir la apoptosis de las células tumorales, forzarlas a la detención del ciclo 
de división celular o a su diferenciación. Estos efectos permiten el desarrollo de nuevas 
terapias para las enfermedades causadas por anormalidades de la red epigenética. 
                                                 
5 Tan, M.; Luo, H.; Lee, S.; Jin, F.; Yang, Jeong S.; Montellier, E.; Buchou, T.; Cheng, Z.; Rousseaux, S.; 
Rajagopal, N.; Lu, Z.; Ye, Z.; Zhu, Q.; Wysocka, J.; Ye, Y.; Khochbin, S.; Ren, B.; Zhao, Y. Cell 2011, 146, 
1016. 
6 a. Wang, Z.; Zang, C.; Rosenfeld, J. A.; Schones, D. E.; Barski, A.; Cuddapah, S.; Cui, K.; Roh, T-Y.; 
Peng, W.; Zhang, M. Q.; Zhao, K. Nat. Genet. 2008, 40, 897. b. Duan, Q.; Chen, H.; Costa, M.; Dai, W. J. 
Biol. Chem. 2008,  283, 33585. c. Nakanishi, S.; Lee, J. S.; Gardner, K. E.; Gardner, J. M.; Takahashi, Y.; 
Chandrasekharan, M. B.; Sun, Z.; Osley, M. A.; Strahl , B. D.; Jaspersen, S. L.; Shilatifard A. J. Cell Biol. 
2009, 186, 371. d. Ernst, J.; Kellis, M. Nat. Biotechnol. 2010, 28, 817. 
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1.2. Posicionamiento nucleosómico 
Los nucleosomas también pueden ser una barrera a la transcripción mediante el 
bloqueo del acceso de activantes y factores de transcripción a sus correspondientes sitios 
en el DNA.7 El empaquetamiento del DNA en los nucleosomas podría afectar a todas las 
etapas de la transcripción y, por lo tanto, a la regulación de la expresión génica. En 
particular, la posición concreta de los nucleosomas en torno a las posiciones de inicio de la 
transcripción (TSSs) tiene una influencia importante en la transcripción, de tal manera que, 
desplazamientos de tan solo 30 pares de bases en el TSS están implicados en cambios en la 
actividad de la RNApolimerasa II. Los extremos 5´y 3´ de los genes poseen regiones libres 
que son necesarias para el ensamblado y desensamblado de la maquinaria transcripcional. 
La pérdida de un nucleosoma directamente "aguas arriba" del TSS está relacionada con la 
activacion génica, mientras que la oclusion del TSS con un nucleosoma se asocia con la 
represión génica.  
También la incorporación de variantes de las histonas regula el posicionamiento de 
los nucleosomas y la expresión génica. Estas histonas, que se incorporan a la cromatina 
independientemente de la replicación del DNA, se distinguen del núcleo de histonas en sus 
colas, en sus dominios estructurales y en la identidad de unos cuantos aminoácidos.1 
1.3. Metilación del DNA  
La metilación del DNA es el mecanismo epigenético más ampliamente estudiado. 
Este tiene lugar mediante diferentes patrones de  metilación del DNA y se ejerce a través 
de la metilación específica  de algunas  bases del DNA. 
La metilación del DNA se produce en el genoma de diversos organismos, tanto 
procariotas como eucariotas. En procariotas, la metilación tiene lugar sobre la  citosina y la 
adenina, mientras que en eucariotas parece estar confinada a una parte de los residuos 
citosina (en humanos, el 3%) y está asociada a un estado reprimido de la cromatina y a la 
inhibición de la expresión génica.8 Este mecanismo también tiene un papel importante en 
la impronta genómica, en la que la hipermetilación en uno de los alelos parentales lleva a 
la expresión monoalélica, así como en la inactivación del cromosoma X que tiene lugar en 
las mujeres. 
                                                 
7 Vasudevan, D.; Chua, E. Y. D.; Davey, C. A. J. Mol. Biol. 2010, 403, 1. 
8 Klose, R. J.; Bird, A. P. Trends  Biochem.  Sci. 2006, 31, 89. 
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La metilación  del DNA de vertebrados ocurre principalmente en la posición 5 de 
las citosinas y, casi exclusivamente, sobre la secuencia dinucleotídica CG, que además es 
especialmente abundante en las regiones promotoras de los genes, dando lugar a los 
denominados islas o islotes CpG. Los dinucleótidos CpG son, normalmente, raros en los 
genomas de los mamíferos (~1%), pero aproximadamente el 60% de las regiones 
promotoras están asociados con islotes CpG que, en células normales, normalmente no 
están metilados, aunque alguno de ellos (6%) se metila durante el desarrollo temprano de 
forma específica para cada tejido o también en tejidos diferenciados. 
5
5-metildesoxicitidina
N
NH2
ON
OHO
H3C
OH  
La metilación del DNA no ocurre exclusivamente en los islotes CpG, sino también 
en las llamadas orillas de las islas CpG. Este término se ha acuñado recientemente para 
definir regiones de baja densidad de CpG que se encuentran próximas (~2 kb “aguas 
arriba”) a las islas CpG. La metilación de estas regiones está asociada a la represión 
transcripcional, particularmente en las regiones de metilación específica de cada tejido. 
De esta forma, los genes que se transcriben activamente poseen islotes CpG sin 
metilar (o islotes hipometilados), mientras que si están metilados el gen no se expresa. En 
el genoma se pueden encontrar diferentes patrones de metilación del DNA según las 
regiones en las que la metilación está localizada y según el efecto que producen. La 
alteración de estos patrones produce alteraciones celulares: 
(a) La hipermetilación de los islotes CpG en las regiones promotoras de los genes 
lleva a la inactivación de la transcripción.9 
(b) Este mismo patrón se observa en las llamadas orillas de las islas CpG.10   
(c) Aunque, normalmente, la metilación del DNA se asocia a la represión 
transcripcional, cuando ésta tiene lugar en el cuerpo del gen facilita la 
                                                 
9 Luque, J.; Herraez, A. Biología Molecular e Ingeniería Genética; Harcourt: Madrid, 2005. 
10 a. Doi, A.; Park, I.-H.; Wen, B.; Murakami, P.; Aryee, M. J.; Irizarry, R.; Herb, B.; Ladd-Acosta, C.; Rho, 
J.; Loewer, S.; Miller, J.; Schlaeger, T.; Daley, G. Q.; Feinberg, A. P. Nat. Genet. 2009, 41, 1350. b. Irizarry, 
R. A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montano, C.; Onyango, P.; Cui, H.; Gabo, K.; Rongione, M.; 
Webster, M.; Ji, H.; Potash, J. B.; Sabunciyan, S.; Feinberg, A. P. Nat. Genet. 2009, 41, 178. 
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transcripción. Se ha propuesto que esto podría estar relacionado con la 
eficiencia de la elongación y con la prevención de falsos inicios de la 
transcripción.11  
(d) Por último, la metilación también está asociada a secuencias repetitivas.12 
1.3.1 Patrón de metilación durante el desarrollo 
Como manifestación de la regulación mediante estos procesos de metilación, cada 
tejido presenta un patrón característico de metilación del DNA que constituye su 
componente epigenético. Éste se consigue y conserva durante el desarrollo embrionario, 
mediante tres procesos consecutivos de distribución de los grupos metilo que se detallan a 
continuación (Figura R1.1):9,11 
ADN con el patrón de metilación paterno
ADN hipometilado
Desmetilación global
Metilación de novo
ADN con el patrón de metilación embrionario
Metilación de 
Mantenimiento
 
Figura R1.1 Distribución de grupos metilo durante el desarrollo. 
1.3.2 DNA metiltransferasas 
Los procesos de metilación los realizan una familia de proteínas, las DNA 
metiltransferasas o metilasas (DNMTs), que emplean S-adenosilmetionina (S-AdoMet o 
SAM) como coenzima donador de grupos metilo (en este caso con especificidad por 
citidina adyacente a guanosina). 
                                                 
11 Jurkowska, R. Z.; Jurkowski, T. P.; Jeltsch, A. ChemBioChem 2011, 12, 206. 
12 Portela, A.; Esteller, M. Nat. Biotechnol. 2010, 28, 1057. 
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Se han podido aislar DNA metiltransferasas (DNMTs) de diversos organismos, 
incluido el hombre. Las de los mamíferos se clasifican en dos tipos generales,  según su 
preferencia por los distintos sustratos de DNA: 
o De novo metiltransferasas, responsables principalmente  de la metilación 
de la citosina en islotes CpG previamente desmetilados (familia de las 
DNMT3). 
o Metiltranferasas de mantenimiento, encargadas de copiar los modelos de 
metilación existentes en las nuevas hebras de DNA durante el proceso de 
replicación (DNMT1). 
 
Se han identificado  cinco miembros de la familia de las DNA metiltransferasas en 
células de mamíferos. La primera DNMT descrita, DNMT1, parecía funcionar como 
DNMT de mantenimiento debido a que exhibía mucha mayor actividad con DNA 
hemimetilado que con DNA desmetilado. A continuación, se identificaron dos enzimas 
más, DNMT3a y 3b  los cuales, a diferencia de DNMT1, no mostraban preferencia  por el 
DNA hemimetilado, por lo que se creyó que funcionaban principalmente como de novo 
metiltransferasas.13 Se observó una cuarta DNA metiltransferasa, DNMT2, que mostraba 
una débil actividad como DNMT in vitro, aunque la eliminación del correspondiente gen 
que la codificaba en sistemas celulares embriogénicos no causaba efectos detectables en la 
metilación global del DNA. Finalmente, DNMT3L es una proteína relacionada con las 
DNMTs que no contiene actividad intrínseca como DNA metiltransferasa, pero está 
físicamente asociada con DNMT3a y DNMT3b, modulando su actividad catalítica. 
La división de funciones entre metilación de mantenimiento y metilación de novo 
no es tan clara, ya que recientemente se ha propuesto que las DNMT3A/3B  también tienen 
un papel en la metilación de mantenimiento en las regiones heterocromáticas.14 De la 
misma manera, también se require la DNMT1 para la metilación de novo, ya que colabora 
con las DNMT3A y DNMT3B usando CpG hemimetilados generados por las enzimas 
DNMT3 como sustratos. 
 
                                                 
13 Brown, R.; Strathdee, G. Trends Mol. Med.  2002, 8, S43. 
14 Jones, P. A.; Liang, G. Nat. Rev. Genet. 2009, 10, 805. 
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La estructura de las DNMTs ha sido ampliamente estudiada,2,11,15 y se caracteriza 
por la presencia de un dominio catalítico en el extremo C-terminal altamente conservado, y 
un  dominio N-terminal que difiere de forma importante entre la DNMT1 y las enzimas 
DNMT3 y que no existen en el caso de la DNMT2.16 El dominio C-terminal es más 
pequeño que el N-terminal y está altamente conservado tanto en DNMTs de procariotas 
como de eucariotas. Este dominio constituye el sitio activo de la enzima y contiene diez 
aminoácidos característicos de todas las DNA metiltransferasas. El extremo N-terminal 
contiene varios motivos responsables de distintas funciones de regulación, como la 
localización nuclear o la interacción con otras proteínas.  
Los primeros datos disponibles de difracción de rayos X para las DNMTs 
corresponden a enzimas procariotas (M.HhaI and M.HhaIII),17 que tienen una estructura 
menos compleja que las DNMTs de mamíferos. Posteriormente, se obtuvieron estructuras 
cristalinas para la  DNMT2 humana,16 para el dominio PWWP de DNMT3B,18 un 
complejo entre  DNMT3L y H3K4 no metilada19 y un complejo entre los dominios C-
terminales de DNMT3A y DNMT3L.20 Finalmente, la contribución más reciente 
corresponde a Patel y colaboradores,21 que han resuelto las estructuras de DNMT1 de ratón 
y humano complejadas con S-adenosil-L-homocisteína (AdoHcy o SAH) y un dúplex de 
DNA formado por 19 pares de bases que contienen islotes CpG no metilados. Tajima y 
colaboradores también han resuelto la estructura cristalina de un fragmento más grande de 
la DNMT1 de ratón complejada con S-AdoMet y AdoHcy.22  
1.3.3 Metilación del DNA y cáncer 
La metilación del DNA es un proceso epigenético clave implicado en el control de 
la expression génica, la regulación de la impronta parental, la estabilización de la 
                                                 
15 a. Goll, M. G.; Kirpekar, F.; Maggert, K. A.; Yoder, J. A.; Hsieh, C.-L.; Zhang, X.; Golic, K. G.; Jacobsen, 
S. E.; Bestor, T. H. Science 2006, 311, 395. b. Hellebrekers, D. M. E. I.; Griffioen, A. W.; van Engeland, M. 
Biochim. Biophys. Acta -Rev. Cancer 2007, 1775, 76. c. Cheng, X.; Blumenthal, R. M. Structure 2008, 16, 
341. d. Sippl, W.; Jung, M. Epigenetic Targets in Drug Discovery; Wiley-VCH: Weinheim, 2009.  
16 Dong, A.; Yoder, J. A.; Zhang, X.; Zhou, L.; Bestor, T. H.; Cheng, X. Nucleic Acids Res. 2001, 29, 439. 
17 a. Klimasauskas, S.; Kumar, S.; Roberts, R. J.; Cheng, X. Cell 1994, 76, 357. b. Reinisch, K. M.; Chen, L.; 
Verdine, G. L.; Lipscomb, W. N. Cell 1995, 82, 143. 
18 Qiu, C.; Sawada, K.; Zhang, X.; Cheng, X. Nat. Struct. Mol. Biol. 2002, 9, 217. 
19 Ooi, S. K. T.; Qiu, C.; Bernstein, E.; Li, K.; Jia, D.; Yang, Z.; Erdjument-Bromage, H.; Tempst, P.; Lin, S.-
P.; Allis, C. D.; Cheng, X.; Bestor, T. H. Nature 2007, 448, 714. 
20 Jia, D.; Jurkowska, R. Z.; Zhang, X.; Jeltsch, A.; Cheng, X. Nature 2007, 449, 248. 
21 Song, J.; Rechkoblit, O.; Bestor, T. H.; Patel, D. J. Science 2011, 331, 1036. 
22 Takeshita, K.; Suetake, I.; Yamashita, E.; Suga, M.; Narita, H.; Nakagawa, A.; Tajima, S. Proc. Natl. 
Acad. Sci. U. S. A. 2011, 108, 9055. 
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inactivación del cromosoma X y el mantenimiento de la estabilidad cromosómica.11 
También está implicada en el desarrollo del sistema immune, en la reprogramación celular 
y en el funcionamiento y comportamiento del cerebro. Se han encontrado patrones de 
metilación aberrantes tanto en enfermedades psiquiátricas y del sistema inmune, como en 
el inicio y la evolución del cáncer.  
Las células cancerosas, comparadas con las normales, se caracterizan por una 
pérdida masiva global de la metilación del DNA, pero al mismo tiempo se observan 
patrones de metilación específicos en los islotes CpG de ciertos promotores de 
tumores.12,23  
La desmetilación global causa inestabilidad cromosómica, translocaciones, 
disrupciones de genes y reactivación de secuencias endoparasíticas. Por otra parte, la 
hipometilación de promotores específicos puede activar la expresión aberrante de 
oncogenes y la pérdida de patrones normales de impronta. Por el contrario, la 
hipermetilación se caracteriza por la metilación de novo de islotes CpG específicos. La 
inactivación transcripcional causada por esta hipermetilación afecta a genes implicados en 
los caminos celulares principales (apoptosis, reparación del DNA, control del ciclo celular, 
etc.).  
Estos patrones aberrantes de la metilación del DNA podrían estar causados por la 
desregulación de la expresión de las DNMTs, el reclutamiento aberrante de las enzimas o 
la expresión de mutantes truncados.15d  
1.3.4 Desmetilación del DNA 
La metilación del DNA es una de las modificaciones epigenéticas mejor 
caracterizadas. Sin embargo, las enzimas responsables del proceso contrario han sido 
difíciles de identificar. El patrón de metilación se genera mediante una combinación de 
reacciones de metilación y desmetilación catalizadas por DNA metiltransferasas y 
desmetilasas potenciales. Por lo tanto, la desmetilación también juega un papel importante 
en el desarrollo embrionario y en la tumorogénesis.  
La desmetilación pasiva tiene lugar cuando se suprime la actividad de las DNMTs y 
consiste en la pérdida del 50% de la metilación tras cada ronda de replicación. Por el 
contrario, la desmetilación activa ocurre independientemente de la replicación del DNA y 
require de la actividad catalítica, bien para eliminar directamente el grupo metilo de la base 
                                                 
23 Sebova, K.; Fridrichova, I. Anticancer Drugs 2010, 21, 565. 
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metilada, o bien para intercambiar completamente la base por una no metilada.11 Se han 
propuesto varios mecanimos de desmetilación activa en los que intervienen diferentes 
enzimas, tales como desaminasas (AID, APOBEC1), enzimas oxidasas de la familia TET, 
enzimas de reparación de error de emparejamiento T-G o glicosilasas (TDG, UGD, 
SMUG, etc.). Aunque el mecanismo principal de desmetilación no está claro, se propone 
que es la cooperación entre todos los posibles mecanismos lo que da lugar a la 
desmetilación del DNA.24 
 
Figura R1.2 Modelo integrado para la desmetilación de citosina. 
1.3.5 Inhibidores de DNMT  
Dado que las alteraciones epigenéticas constituyen importantes firmas moleculares 
del cáncer, las enzimas que modifican la cromatina, particularmente las DNA 
metiltransferasas y las histonas desacetilasas, representan dianas potenciales para el 
desarrollo de nuevos fármacos.25 Para el mantenimiento de ese “estado epimutado”, se 
                                                 
24 Nabel, C. S.; Manning, S. A.; Kohli, R. M. ACS Chem. Biol. 2012, 7, 20. 
25 Zheng, Y. G.; Wu, J.; Chen, Z.; Goodman, M. Med. Res. Rev. 2008, 28, 645. 
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require de la actividad continua de las DNMTs, que están normalmente sobreexpresadas en 
varios tumores. Este hecho justifica intervenciones terapéuticas para conseguir su 
reversibilidad mediante inhibidores específicos.26 En este sentido, se está explorando la 
combinación de diferentes epi-fármacos o la generación de compuestos moduladores de 
más de una enzima.27 La reexpresión de los genes epigenéticamente inactivados puede 
conducir a la supresión del crecimiento tumoral o a la alteración de la eficacia de las 
terapias anticancerosas ya existentes. 
Los inhibidores de DNMT se pueden dividir en dos grupos: inhibidores nucleósidos 
y no nucleósidos. Al primer grupo pertenecen los análogos de nucleósidos que se 
incorporan al DNA y actúan como inhibidores suicidas de DNMT mediante la formación 
de un aducto covalente (los también  llamados “inhibidores basados en el mecanismo”). El 
segundo grupo de compuestos actúa en la enzima libre de la misma manera que los 
“inhibidores enzimáticos clásicos”.15d  
1.3.5.1 Inhibidores covalentes de DNMT 
Este grupo está formado por análogos de nucleósidos que tienen un anillo de 
citosina modificado unido a una ribosa o a una desoxirribosa. Dos de estos compuestos han 
sido desarrollados clínicamente: 5-azacitidina y 5-aza-2’-desoxicitidina (decitabina). 5-
Azacitidina fue caracterizado por primera vez por Jones y colaboradores en la década de 
196028 y se identificó como un potente agente citotóxico de células cancerosas con 
capacidad de transformar células embrionarias de ratón en células musculares sin mutar el 
DNA. Otros compuestos que pertenecen a este grupo son 5-fluoro-2’-desoxicitidina 
(FCDR), zebularina y 5,6-dihidro-5-azacitidina (DHAC).  
Los inhibidores nucleósidos actúan como profármacos que no muestran actividad 
en los ensayos in vitro con DNMT,29 ya que sólo son capaces de bloquear las enzimas tras 
su incorporación al DNA. 
1.3.5.2 Inhibidores de DNMT no covalentes 
Este segundo grupo de inhibidores es más diverso, no son tan potentes como los 
inhibidores nucleósidos, pero son agentes complementarios efectivos para la terapia 
                                                 
26 Brueckner, B.; Lyko, F. Trends Pharmacol. Sci. 2004, 25, 551. 
27 Álvarez, R.; Gronemeyer, H.; Altucci, L.; de Lera, A. R. Curr. Top. Med. Chem. 2011, 11, 2749. 
28 Jones, P. A.; Taylor, S. M. Cell 1980, 20, 85. 
29 Stresemann, C.; Brueckner, B.; Musch, T.; Stopper, H.; Lyko, F. Cancer Res. 2006, 66, 2794. 
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epigenética anticancerosa. Como ya se ha mencionado, estos compuestos reducen la 
metilación del DNA sin incorporación a la molécula de DNA, lo cual debería disminuir la 
citotoxicidad y, por tanto, los efectos secundarios. Se pueden unir directamente al sitio 
catalítico de la enzima o a secuencias ricas en islotes CpG, dificultando la unión de las 
DNMTs a sus secuencias diana. Dentro de este grupo también se incluyen productos 
naturales o derivados que resultan de programas de optimización basados en la estructura 
de  productos naturales. Algunos ejemplos de este grupo serían la (-)-epi-galocatecina-3-
galato (EGCG), el principal compuesto polifenólico del té verde, la psammaplina A, 
inhibidor de DNMTs y de histonas desacetilasas que fue aislado de una esponja de la 
familia Psammaplysilla30 y los peyssoneninos A y B, aislados del alga Peyssonelia 
caulifera.31  
                                                 
30 a. Quiñoá, E.; Crews, P. Tetrahedron Lett. 1987, 28, 3229. b. Arabshahi, L.; Schimitz, F. J. J. Org. Chem. 
1987, 52, 3584. 
31 McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J. Nat. Prod. 2004, 67, 1010. 
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Figura R1.3 Inhibidores nucleósidos y no nucleósidos de DNMT. 
2. Síntesis total de las estructuras propuestas para los peyssoneninos, 
inhibidores de DNA metiltransferasas. Revisión estructural del 
peyssonenino B 
Se han sintetizado las estructuras propuestas para los peyssoneninos A y B, dos 
nuevos metabolitos con esqueleto de oxilipina aislados del alga roja Peyssonnelia 
caulifera.31 Estas estructuras, que biosintéticamente parecen derivar de un ácido graso ω3 
(derivados de monoacilglicerol), fueron descritas como isómeros geométricos del 
acetoxienodiino que es el grupo funcional principal de estos compuestos (Esquema R2.1). 
Para la formación del esqueleto básico de los peyssoneninos se ha utilizado como etapa 
clave una reacción de Cadiot-Chodkiewicz32 entre un yodoalquino y un alcohol 
propargílico (Esquema R2.1). La formación del enol acetato fue pospuesta a la penúltima 
etapa de la secuencia sintética.  
                                                 
32 a. Chodkiewicz, W. Ann. Chim. 1957, 2, 819. b. Chodkiewicz, W.; Cadiot, P. C. R. Hebd. Seances Acad. 
Sci. 1955, 241, 1055. 
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Esquema R2.1. Análisis retrosintético de los peyssoneninos. 
Es de destacar que la síntesis de la unidad penta-1,4-dieno presente en la cadena 
alquílica de los peyssoneninos se llevó a cabo mediante una acoplamiento, promovido por 
Cs2CO3 y en presencia de CuCl, de un alquino terminal y un bromuro propargílico,33  
seguido de la semihidrogenación de los alquinos.  
 
Esquema R2.2 Síntesis del fragmento que contiene el penta-1,4-dieno. 
Las geometrías E y Z de los acetoxienodiinos fueron corroboradas mediante la 
magnitud de las constantes de acoplamiento 3JH9-C7 medidas con la secuencia de 
espectroscopía bidimensional de RMN llamada EXSIDE, una variante de HSQC que 
permite calcular con bastante precisión las constantes de acoplamiento 1H-13C a larga 
distancia. Con este experimento se pudo comprobar que la constante de acoplamiento 
3JC7H9 es la más sensible a la configuración E/Z del doble enlace (con valores ≤ 5.24 Hz 
                                                 
33 Montel, F.; Beaudegnies, R.; Kessabi, J.; Martin, B.; Muller, E.; Wendeborn, S.; Jung, P. M. J. Org. Lett. 
2006, 8, 1905. 
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para geometrías Z y ≥10.49 Hz para E). Además, se observó que el desplazamiento 
químico de C en las proximidades del doble enlace también es sensible a su geometría, 
encontrando una diferencia de hasta 5 ppm en el C6 de ambos isómeros.34 La comparación 
de los datos espectroscópicos de los productos sintéticos y naturales reveló que sólo el 
isómero Z se correspondía con uno de los peyssoneninos, que resultó ser el peyssonenino 
A. Mediante un análisis de HPLC se comprobó que el peyssonenino B correspondía al 
regioisómero Z sn-2, isómero posicional del peyssonenino Z sn-1/3. Por lo tanto, se pudo 
concluir que los peyssoneninos A y B no son isómeros geométricos del enol acetato, sino 
dos regioisómeros del glicerol que se interconvierten en disolución (Esquema R2.3). 
 
Esquema R2.3. Interconversión dinámica de los regioisómeros del monoacilglicerol del peyssonenino A y 
estructura del peyssonenino B (original y corregida). 
Todos los compuestos sintetizados han sido ensayados biológicamente. Se ha 
encontrado que los cuatro diastereoisómeros sn-1/3 son inhibidores equipotentes de 
DNMT1 en un ensayo enzimático radiactivo de transferencia de C3H3 efectuado tras la 
inmunoprecipitación con el anticuerpo de DNMT1 de células humanas de leucemia K562. 
3. Determinación de la geometría de acetoxienodiinos y acetoxieninos 
mediante la medida de constantes de acoplamiento heteronucleares 13C- 
1H de RMN y desplazamientos de 13C-RMN. Asignación estructural de 
los productos naturales oxilipínicos peyssoneninos A y B 
                                                 
34 García, P.; Martín-Pastor, M.; de Lera, Á. R.; Álvarez, R. Mag. Res. Chem. 2010, 48, 543. 
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Se han utilizado métodos de RMN en disolución para la determinación estructural 
de la configuración E/Z del acetoxienodiino presente en los productos naturales marinos 
peyssoneninos A y B y sus análogos sintéticos derivados del ácido palmítico. La ausencia 
de protones en la proximidad de la funcionalidad acetoxienodiino de este tipo de 
compuestos impidió determinar la geometría del doble enlace mediante experimentos 
NOE, NOESY o ROESY.  Este problema se resolvió mediante la determinación de la 
magnitud de las constantes de acoplamiento heteronucleares 13C-1H a larga distancia, nJCH, 
medidas con experimentos 2D EXSIDE.35 2D EXSIDE es un experimento bidimensional 
1H-13C que permite calcular con bastante precisión las constantes 2JCH y 3JCH, que son 
relativamente pequeñas (2-15 Hz) comparadas con las 1JCH (las correlaciones 1H-13C a 
distancia de un enlace fueron eliminadas del espectro utilizando un módulo llamado 
TANGO36). El resultado del experimento EXSIDE permitió comprobar que la constante de 
acoplamiento 3JCH es la más sensible a la configuración E/Z del doble enlace.37 Los 
isómeros geométricos Z presentan valores de 3JCH considerablemente más pequeños (≤ 
5.24 Hz) que los correspondientes isómeros E (≥10.49 Hz). Además, se comprobó que el 
desplazamiento químico en la cercanía del doble enlace, es decir, de los carbonos Ca, Cb, 
Cc y Cd, también es sensible a su geometría, encontrándose diferencias de hasta 5 ppm 
entre los desplazamientos químicos del Cd de cada isómero. Esta diferencia también se 
puede usar de manera fiable como criterio para la asignación estructural. 
                                                 
35 Krishnamurthy, V. V. J. Magn. Reson. A 1996, 121, 33. 
36 Wimperis, S.; Freeman, R. J. Magn. Reson. A 1984, 58, 348. 
37 Contreras, R. H.; Peralta, J. E. Progr. Nucl. Magn. Reson. A 2000, 37, 321. 
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Figura R3.1 a) Estructura de las moléculas estudiadas, con la numeración IUPAC: peyssoneninos, 
palmiteninos y acetoxieninos derivados de los ácidos palmítico (3a), araquídico (3b), oleico (3c) y linoleico 
(3d). b) Los desplazamientos de 13C y las constantes de acoplamiento heteronucleares 1H-13C de los átomos 
marcados como a, b, c y d fueron la clave para asignar las configuraciones E y Z. 
Además, para ampliar el estudio a otros acetoxieninos y corroborar este criterio de 
asignación estructural de este tipo de compuestos, se sintetizaron una serie de análogos 
más simples derivados de cuatro ácidos grasos diferentes (Figura R3.1). La síntesis de 
estos compuestos se llevó a cabo mediante tres etapas que incluyen la formación de las 
amidas de Weinreb, la adición del anión de TIPS-acetileno generado in situ con n-BuLi a 
dichas amidas y la formación del enol acetato.38 Tras la separación por HPLC de los 
isómeros E/Z de todos los enol acetatos, se procesaron los espectros de los experimentos 
2D EXSIDE (Tabla R3.1). En todos los casos, se observó que la constante de acoplamiento 
3JCH es la más sensible a la configuración E/Z del doble enlace, mostrando valores que 
oscilan entre 2.6 y 5.2 Hz para el isómero Z y entre 10.5 y 12.7 Hz para el E. También se 
observó la correspondiente diferencia de 5 ppm entre los desplazamientos químicos de los 
Cd de los isómeros geométricos de cada molécula. 
                                                 
38 a. Compernolle, F.; Toppet, S.; Brossette, T.; Mao, H.; Koukni, M.; Kozlecki, T.; Medaer, B.; Guillaume, 
M.; Lang, Y.; Leurs, S.; Hoornaert, G. J. Eur. J. Org. Chem. 2006, 1586. b. Nahm, S.; Weinreb, S. M. 
Tetrahedron Lett. 1981, 22, 3815. c. Aoki, S.; Matsui, K.; Wei, H.; Murakami, N.; Kobayashi, M. 
Tetrahedron 2002, 58, 5417. 
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Esquema R3.1. Secuencia sintética para la obtención de los acetoxieninos derivados de los ácidos palmítico, 
araquídico, oleico y linoleico. 
Tabla R3.1 Constantes de acoplamiento  13C-1H  experimentales (Hz) y desplazamientos de 13C (ppm) para 
los átomos etiquetados como  a, b, c y d en las moléculas 1-3 (Figura 3.1). 
  Constantes de acoplamiento (Hz) (a)  Desplazamientos químicos de 
13C (ppm) (d)
Compuesto Geometría 1JHaCa 2JHaCb 3JHaCc Ca Cb Cc Cd
Z-1-2 Z 158.62 2.15 5.24 131.67 130.85 71.30 71.07(e) 75.37 
E-1-1 E 162.02 -2.50 12.68 131.94(b)    130.80(b) 68.89(b) 79.79(b)
Z-2-2 Z 156.70 3.06 4.37 132.55 130.62 71.06 75.27 
E-2-1 E 158.59 -3.06 12.24 133.06 131.08 69.31 80.00 
Z-3a Z 158.72 4.37 < 3 129.90 131.50 103.09 91.57 
E-3a E 160.05 -3.50 12.24 130.21 132.10 100.54 100.67(e) 97.28 
Z-3b Z 159.18 4.37 2.62 129.84 131.52 103.09 91.60 
E-3b E 159.62 -3.50 10.49 130.10 132.09 100.64 97.23 
Z-3c Z 158.30 4.37 < 3 129.83 131.50 103.08 91.50 
E-3c E 157.19 -3.94 10.49 130.13 132.11 100.67 97.22 
Z-3d Z 159.09 4.81 < 3 130.99 131.53 103.09 91.60 
E-3d E 157.06 -3.50 10.50 130.13 132.10 100.65 97.29 
(a) Con el método EXSIDE sólo se puede determinar la magnitud del acoplamiento escalar; el signo de este 
acoplamiento se escoge en función del signo predicho por los cálculos DFT. (b) Medido en el espectro 
HMBC; error de ±0.3 ppm en el desplazamiento químico. (c) La constante de acoplamiento no se pudo medir. 
(d) Medido en el espectro monodimensional de RMN de 13C; error de ±0.01 ppm en el desplazamiento 
químico. (e) Se encontraron inesperadas señales adicionales en el espectro de RMN de 13C de la muestra. 
Además de los anteriores resultados experimentales, también se llevaron a cabo 
estudios DFT para racionalizar las conclusiones de los experimentos de RMN.39 Utilizando 
                                                 
39 a. Gudat, D.; Niecke, E.; Ruban, A.; von der Gönna, V. Magn. Reson. Chem. 1996, 34, 799. b. Frisch, M. 
 
J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Jr., J. A. M.; Vreven, T.; 
Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; 
Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; 
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el modelo que se muestra en la figura R3.2 (el acetoxienodiino 7 para los peyssoneninos y 
palmiteninos y el acetoxienino 8 como modelo más simple) se calcularon los 
desplazamientos químicos y las constantes de acoplamiento 13C-1H y se compararon con 
los valores experimentales promedio calculados a partir de los experimentos 2D EXSIDE 
(Tabla R3.2). Aunque cuantitativamente los cálculos DFT no reproducen los resultados 
experimentales, cualitativamente se observa la misma tendencia, lo cual valida el uso tanto 
del valor de 3JHaCc como del desplazamiento químico de 13C-RMN del Cd para determinar 
de forma inequívoca la geometría del doble enlace.  
O
O
O
TIPS
Oa) b)
7 8
a b c
d a
b c
d
 
Figura R3.2. Enol acetatos 7 y 8 usados como sistema modelo para los cálculos DFT de parámetros de RMN 
de acetoxienodiinos (a) y de acetoxieninos (b). 
Table R3.2 Promedio del valor experimental de las constantes de acoplamiento  13C-1H (Hz) y 
desplazamientos de 13C (ppm) para los átomos etiquetados como a, b, c y d, y valores calculados por DFT de 
los mismos parámetros en las moléculas 1-3 y usando los sistemas modelo 7 y 8. 
 E-7 calc. 
PCM(a)      
E-7 calc. 
gas(b)
E-7 
exp.(c)
Z-7 calc, 
PCM(a)
Z-7 calc. 
gas(b)
Z-7 
exp.(c)
1JHa-Ca 168.96 165.80   160.30 149.53    162.61 157.66 
2JHa-Cb -0.95 -7.16      -2.78 13.52        4.44 2.60 
3JHa-Cc  9.14 9.77     12.46 3.62        5.25 4.80 
Ca  138.18 125.29    132.48 137.63   124.68 132.11 
Cb  134.00 122.37   130.85 133.43   121.54 130.73 
Cc  64.78 53.47     68.94 67.63     56.04 71.18 
Cd  84.13 71.03     79.93 79.17     66.56 75.32 
       
 E-8 calc. 
PCM(a)      
E-8 calc. 
gas (b)
E-8 
exp.(d)
Z-8 calc-
PCM(a)
Z-8 calc. 
gas(b)
Z-8 
exp. (d)
1JHa-Ca 169.91 164.01   158.48 162.49   161.5 158.82 
2JHa-Cb -1.33 -6.73      -3.61 13.14       4.85 4.48 
3JHa-Cc  8.76 8.33     10.93 3.81       4.69 ≤ 3 
Ca  136.16 141.18   130.14 135.60   140.84 130.14 
Cb  134.18 140.67   132.10 133.53   140.06 131.51 
                                                                                                                                                    
Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; 
Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, 
O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; 
Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; 
Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; 
Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; 
Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; 
Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, Revision D.02, Gaussian: 
Pittsburg, 2004. 
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Cc  99.04 102.82   100.62 102.11   106.01 103.08 
Cd  104.32 107.35     97.25 98.57   101.52 91.57 
(a) Cálc MPW1P  m  polariz CM ulos B3  fase gas. (c) 
Pr . s
Los monoacilgliceroles están presentes, en pequeñas proporciones, en aceites y 
grasas an
los isómeros de los monoacilgliceroles 
constituía un problem
                                                
ulos W91 con el odelo del continuo able (P ). (b) Cálc LYP en
omedio de los valores de los compuestos 1 y 2 estudiados en este trabajo (d) Promedio de los valores de lo  
compuestos 3a-d estudiados en este trabajo. 
4. Separación de regioisómeros y enantiómeros de monoacilgliceroles de 
ácidos grasos no derivatizados, saturados e insaturados, usando HPLC 
enantioselectivo 
imales junto con los diacilgliceroles y triacilgliceroles, que son los componentes 
mayoritarios.40 Estos compuestos están formados por tres isómeros, dos enantiómeros 
llamados sn-1/sn-3 y su regioisómero aquiral sn-2. Los MAGs puros son difíciles de 
sintetizar y de analizar cuantitativamente, debido a la facilidad con la que se produce la 
migración del grupo acilo, lo que tiene lugar bajo una gran variedad de condiciones (medio 
ácido, básico, moderadas temperaturas, etc.). Además, la naturaleza de la cadena del grupo 
acilo que migra también puede influir en la velocidad de isomerización. Esta migración del 
grupo acilo, desde la posición sn-1 a la sn-3 a través del regioisómero aquiral sn-2, tiene 
como consecuencia la pérdida de pureza enantiomérica de MAGs quirales no racémicos. 
Debido a esto, los MAGs, tanto los naturales como los sintéticos, presentan moderados o 
bajos excesos enantioméricos.41 
Hasta ahora, la separación directa de 
a importante sin resolver en cromatografía de glicerolípidos. Ésta se 
llevaba a cabo bien utilizando columnas de HPLC (quirales y no quirales) en tándem que 
daban lugar a prolongados tiempos de retención, bien derivatizando previamente los 
compuestos, lo cual implicaba laboriosas reacciones químicas con varias etapas, que 
podrían favorecer la migración del grupo acilo.40c,42 
 
40 a. Isai, S. V.; Usol'tsev, A. A.; Stiba, E. N. Chem. Nat. Prod. 2003, 39, 325. b. Andrews, P. C.; Fraser, B. 
H.; Junk, P. C.; Massi, M.; Perlmutter, P.; Thienthong, N.; Wijesundera, C. Tetrahedron 2008, 64, 9197. c. 
Oil Chem. Soc. 2007, 84, 
rui, H.; 
Holčapek, M.; Jandera, P.; Fischer, J.; Prokeš, B. J. Chromatogr. A 1999, 858, 13. 
41 a. Martin, J. B. J. Am. Chem. Soc. 1953, 75, 5483. b. Crossley, A.; Freeman, I. P.; Hudson, B. J. F.; Pierce, 
J. H. J. Chem. Soc. 1959, 760. c. Compton, D.; Vermillion, K.; Laszlo, J. J. Am. 
343. d. Laszlo, J. A.; Compton, D. L.; Vermillion, K. E. J. Am. Oil Chem. Soc. 2008, 85, 307. 
42 a. Thomas, A.; Scharoun, J.; Ralston, H. J. Am. Oil Chem. Soc. 1965, 42, 789. b. Itabashi, Y.; Takagi, T. 
Lipids 1986, 21, 413. c. Takagi, T.; Ando, Y. Lipids 1991, 26, 542. d. Kim, J.-H.; Nishida, Y.; Oh
Meguro, H. J. Chromatography A 1995, 709, 375. e. Deng, L.; Nakano, H.; Iwasaki, Y. J. Chromatography 
A 2007, 1165, 93. f. Deng, L.; Nakano, H.; Iwasaki, Y. J. Chromatography A 2008, 1198, 67.  
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En este trabajo, se ha llevado a cabo la complicada separación de regioisómeros y 
enantiómeros de monoacilgliceroles (MAGs) de distintos ácidos grasos utilizando una 
única columna quiral de HPLC (Chiralpak® IC o Chiralpak® IA) y mezclas n-hexano/2-
propanol como eluyente. Además, no se ha necesitado una derivatización previa de los 
compuestos, como ocurre con otros métodos descritos en la bibliografía.42 La eficacia del 
método desarrollado es independiente de la longitud y del grado de insaturación de la 
cadena alquílica de los MAGs.   
Para el desarrollo del método analítico se han sintetizado los MAGs derivados de 
los ácidos oleico, linoleico, palmitoleico, erúcico, palmítico y araquídico utilizando una 
sencilla secuencia sintética de dos etapas: una primera esterificación de cada uno de los 
ácidos con ambos enantiómeros del isopropilidenglicerol y una posterior desprotección del 
acetal utilizando cantidades catalíticas de CAN (nitrato cérico amónico) en una mezcla 
acetonitrilo/agua (1:1) a 70 ºC. 
Todos los MAGS sintetizados se pudieron resolver utilizando las mismas 
condiciones (Figura R4.1), y presentaron tiempos de retención más cortos que los 
previamente descritos en la bibliografía usando otras condiciones. También hay que 
destacar que el orden de elución de los picos de especies moleculares con la misma 
configuración sigue la regla del número equivalente de carbonos ECN (ver Tabla R4.1), es 
decir, a mayor valor de ECN, menor tiempo de retención.   
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Figura R4.1. Separación de los isómeros sintéticos sn-1/3 del palmitato del glicerol (Chiralpak® IC, 250x4.6 
mm, 90:10 n-hexano/iPrOH, 1.0 mL/min). El pico a 18.3 min corresponde al regioisómero sn-2. 
Tabla R4.1. Valores de tiempos de retención (ti), factores de separación (α) y factores de resolución (Rs) 
para los diferentes MAGs, identificados según su número equivalente de carbonos (ECN). 
MAGs ECNa 
Tiempo de retención (min) αb Rsb 
sn-1 sn-3 sn-2 sn-1 vs  sn-3 
sn-1 vs 
 sn-2 
sn-1 vs 
 sn-3 
sn-1 vs 
 sn-2 
ác. linoleico 14 14.8 16.7 19.5 1.17 1.21 1.27 1.62 
ác. palmitoleico 14 14.6 16.7 19.4 1.19 1.18 1.14 1.20 
ác. oleico 16 12.8 14.4 16.2 1.17 1.22 1.19 2.22 
ác. palmítico 16 13.6 15.5 18.1 1.18 1.20 1.48 1.90 
ác. erúcico 20 11.9 13.4 15.3 1.18 1.19 1.45 1.86 
ác. araquídico 20 12.0 13.5 15.6 1.18 1.22 1.31 1.82 
a ECN = CN - 2DB, donde CN es el número de átomos de carbono y DB es el número de dobles enlaces.  
b
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Por último, también se ha llevado a cabo una monitorización del curso temporal de 
pérdida de exceso enantiomérico del MAG derivado del ácido linoleico en hexano y en 
tiomérica 
mucho mayor en disolución (particularmente en disolventes polares hidroxílicos) que en 
estado sólido. 
ovedoso nhib  d A  
ura del p uct tura yss ino
 ha caract ado evo ulad igen  que stra dad  
inhibidor de DNMT1 y activante de DNMT3a. Este compuesto es un derivado de ácido 
to 
atural peyssonenino. Siguiendo la estrategia sintética anteriormente desarrollada para la 
síntesis de los peyssoneninos,43 se llevó a cabo la preparación de varios análogos que 
difieren en la naturaleza del grupo (alquilo, arilo o heteroarilo) unido a un acetoxienodiino 
o a un
disolventes polares hidroxílicos. Se ha observado una pérdida de pureza enan
5. Un n  i idor e DN metiltransferasas inspirado en la
estruct rod o na l pe onen  
Se eriz un nu  mod or ep ético  mue activi como
palmítico que incorpora el presunto grupo functional reactivo (una diinona) del produc
n
a enodiinona y también en el grupo carboxílico. Entre estos análogos destaca la 
                                                 
43 García-Domínguez, P.; Lepore, I.; Erb, C.; Gronemeyer, H.; Altucci, L.; Álvarez, R.; de Lera, A. R. Org. 
Biomol. Chem. 2011, 9, 6979. 
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diinona 8 derivada del ácido palmítico, que presenta una destacable actividad biológica 
(Figura 5.1) 
 
Figura R5.1 Análogos de los peyssoneninos. 
5.1 Actividad en DNMTs humanas 
Se estudió la capacidad de los acetoxienodiinos 17A y 17B, 18-20 y de las diinonas 
8, 21 y 22 para interferir con la actividad de la DNMT1 humana mediante 
inmunoprecipitación de células humanas de leucemia K562 tratadas con anticuerpos anti-
DNMT1, seguido por un ensayo radiactivo. A una concentración de 50 µM estos 
compuestos inhiben la actividad de DNMT1 al menos tan eficazmente como el conocido 
inhibidor RG108 4,44 pero con menor potencia que SGI-1027 (otro conocido inhibidor) a 
la misma concentración.45 Sorprendentemente, bajo las mismas condiciones, 17A y 17B, y 
las diinonas 8, 21 y 22 estimularon la actividad intrínseca como metiltransferasa de 
DNMT3A. Los análogos 18-20 resultaron ser considerablemente menos potentes en este 
ensayo. También se observó un efecto activante más moderado para 17A/B y las diinonas 
18, 21 y 22 en DNMT3b (Figura R5.2).   
                                                 
44 Brueckner, B.; Boy, R. G.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; Wiessler, 
M.; Lyko, F. Cancer Res. 2005, 65, 6305. 
. 
45 Datta, J.; Ghoshal, K.; Denny, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, 
S. T. Cancer Res. 2009, 69, 4277
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Figura R5.2. Ensayos radiactivos in vitro para evaluar el efecto de los compuestos en las enzimas DNMT1 
(A), DNMT3A (B) y DNMT3B (C). La actividad se expresa de forma relativa a los compuestos de referencia 
RG108 y SGI-1027.  
5 la diferenciación de las células U937  .2 Efectos en el ciclo celular y en 
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Se llevó a cabo un análisis del ciclo celular mediante FACS en células de leucemia 
humana U937. Tras 24 horas de tratamiento con los compuestos a 50 μM, la diinona 8 
produjo una apoptosis masiva, mientras que el resto de compuestos no tuvieron un efecto 
reseñable. Los mismos compuestos no produjeron efecto en la diferenciación celular 
medida mediante la expresión del antígeno de superficie CD11c. Sólo las diinonas 8 y 22 a 
50 μM mostraron un incremento de células positivas en CD11c con respecto al control y al 
compuesto de referencia. 
 
Figura R5.3 Análisis del ciclo celular mediante FACS después de la estimulación de células U937 con los 
compuestos durante 24 horas. 
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Figura R5.4.  Análisis de la diferenciación de las células U937, medida como expresión de CD11c, tratadas 
con los compuestos durante 24 horas. 
5.3 Efecto diferencial en la viabilidad de fibroblastos normales e inmortalizados 
La diinona 8 resultó tóxica para fibroblastos humanos normales (BJ) y para 
fibroblastos embrionarios de ratón (MEF), pero no para fibroblastos humanos 
azacitidina.  Por lo tanto, este compuesto interfiere de una manera muy específica con 
caminos de señalización que presentan actividad diferenciada en células normales e 
inmortalizadas. Esta toxicidad recuerda a los efectos de la ablación de Dnmt1 en 
fibroblastos de ratón. De hecho, algunos de los genes desregulados por la pérdida de 
Dnmt1 están igualmente desregulados por 8, pero no por el inhibidor de DNMT SGI-1027. 
                                                
inmortalizados (BJEL), un efecto único no observado con el inhibidor de DNMT 
46
 
46 Jackson-Grusby, L.; Beard, C.; Possemato, R.; Tudor, M.; Fambrough, D.; Csankovszki, G.; Dausman, J.; 
Lee, P.; Wilson, C.; Lander, E.; Jaenisch, R. Nat. Genet. 2001, 27, 31. 
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Figure R5.5 La diinona 8 mostró el mayor impacto en la viabilidad de fibroblastos normales humanos y de 
ratón.  
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5.4 Estudios mecanísticos para una mejor comprensión del posible mecanismo de 
inhibición de DNMT1 por los compuestos 17, 8, 21 y 22 
Como posible mecanismo de inhibición, se propone que los dos ésteres presentes en 
los peyssoneninos  o, por analogía, en los palmiteninos 17, se hidrolizan in vivo y, 
mediante una tautomería ceto-enólica, dan lugar a la diinona, una funcionalidad reactiva 
como  aceptor de Michael.47 Esa diinona (8 en el caso de los acetoxienodiinos 17, o 21 y 
22 en el caso de los peyssoneninos) es la especie activa que podría reaccionar con el 
residuo de cisteína conservado de la enzima DNMT para dar lugar a una unión covalente. 
Tras varios intentos fallidos de reacción de la diinona 23, análoga de 8, con el éster 
metílico de la N-Boc-L-cisteína, se hizo reaccionar otra diinona sintéticamente más 
accesible (24), con cisteína en presencia de Et3N. Esta reacción dio lugar a una mezcla de 
productos que, tras una separación mediante HPLC, fueron identificados como los aductos 
de Michael-1,4 y -1,6, lo cual constituye una prueba indirecta de la naturaleza reactiva de 
las 2,4-diinonas. 
 
Esquema R5.6  Reactividad de diinonas con el éster metílico de la N-Boc-L-cisteína. 
6. Valoración de las diferentes aproximaciones sintéticas a 
acetoxienodiinos naturales (peyssoneninos) y no naturales 
Se han desarrollado tres aproximaciones sintéticas estereoselectivas, convergentes y 
complementarias a los peyssoneninos, tras una optimización previa con un sistema modelo 
basado en derivados del ácido palmítico. Estas nuevas estrategias, basadas en la 
construcción estereoselectiva de los enol acetatos E y Z, se diferencian en la metodología 
                                                 
47 Kwan, J. C.; Luesch, H. Chem. Eur. J. 2010, 16, 13020. 
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usada para la formación del enlace Csp-Csp o Csp2-Csp de los peyssoneninos (Esquema 
R6.1). 
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Esquema R6.1. Análisis retrosintético, basado en las desconexiones clave, de los acetoxienodiinos a través 
de las rutas (A, B, C y D) estudiadas en el trabajo. 
6.1 Estrategias de formación de enlaces Csp-Csp 
La ruta A ha sido descrita en el apartado 2. En la ruta B, la preparación 
estereoselectiva de los enol acetatos se llevó a cabo mediante la utilización de diferentes 
amiduros de litio en condiciones cinéticas (-78 ºC).48 Tras la formación estereoselectiva y 
su posterior separación mediante HPLC, los enol acetatos E y Z se acoplaron con el 
correspondiente alquino terminal (R)-14, utilizando para ello una nueva metodología 
recientemente descrita por Lei y colaboradores.49 Se trata de un acoplamiento oxidativo 
co-catalizado por Ni y Cu que permite obtener 1,3-diinos no simétricos. En el caso de los 
peyssoneninos y palmiteninos esta metodología dio lugar a los compuestos deseados en 
rendimientos bajos, lo que haría necesario una optimización en sistemas funcionalizados. 
Los correspondientes alcoholes propargílicos (peyssoneninos y palmiteninos) que 
se utili ompuestos, 
también se emplearon como componentes de este acoplamiento catalizado por Ni/Cu, y 
           
zaron en la primera estrategia sintética desarrollada para este tipo de c
dieron lugar a los correspondientes diinoles en rendimientos similares a los anteriores. 
                                      
48 a. Bartlett, P. A. Tetrahedron 1980, 36, 2. b. Galiano-Roth, A. S.; Kim, Y. J.; Gilchrist, J. H.; Harrison, A. 
T.; Fuller, D. J.; Collum, D. B. J. Am. Chem. Soc. 1991, 113, 5053. c. Hall, P. L.; Gilchrist, J. H.; Collum, D. 
B. J. Am. Chem. Soc. 1991, 113, 9571. d. Juaristi, E.; Beck, A. K.; Hansen, J.; Matt, T.; Mukhopadhyay, T.; 
Simson, M.; Seebach, D. Synthesis 1993, 1993, 1271. e. Evans, D. A.; Dart, M. J.; Duffy, J. L.; Yang, M. G. 
J. Am. Chem. Soc. 1996, 118, 4322. f. Xie, L.; Isenberger, K. M.; Held, G.; Dahl, L. M. J. Org. Chem. 1997, 
62, 7516. g. Davis, F. A.; Yang, B. J. Am. Chem. Soc. 2005, 127, 8398. 
2009, 11, 709. 49 Yin, W.; He, C.; Chen, M.; Zhang, H.; Lei, A. Org. Lett. 
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Esquema R6.1.1 Etapa clave de la ruta B para la preparación de los palmiteninos y los peyssoneninos. 
6. 2 Estrategias de formación de enlaces Csp2-Csp  
Dentro de este grupo se han desarrollado dos estrategias diferentes. La ruta C está 
basada en un acoplamiento de Sonogashira entre un α-cloroenol acetato 7 y un diino 5 
(Esquema R6.2.1). La principal limitación de esta secuencia sintética es la exclusiva 
obtención de los cloroenol ésteres de geometría Z empleando la metodología conocida.50 
La síntesis de este tipo de sustratos requiere de dos o tres etapas que implican la formación 
                                                 
50 Bejot, R.; Tisserand, S.; Reddy, L. M.; Barma, D. K.; Baati, R.; Falck, J. R.; Mioskowski, C. Angew. 
Chem. Int. Ed. 2005, 44, 2008. 
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de un triclorometilcarbinol y un triclorometilcarbinol éster.51 El estudio se llevó a cabo 
utilizando como sistema modelo el Z-cloroenol acetato derivado del decanal. La reacción 
final de Sonogashira entre este compuesto y el TIPS-acetileno comercial permitió obtener 
el acetoxienino en un rendimiento del 28% empleando paladio tetrakis(trifenilfosfina) y 
CuI en una mezcla THF/Et3N (4:1), a temperatura ambiente. Debido a este resultado sería 
necesaria una optimización del método para acceder a estos compuestos.52 
Esquema R6.2.1 Secuencia sintética de la ruta C. 
Finalmente, la ruta D se centró en la condensación de la amida de Weinreb 6 con el 
anion diinilo derivado del compuesto 5. Tras varias reacciones en las que se usaron 
diferentes organolíticos, sólo se consiguió recuperar la amida de Weinreb de partida. 
 
Esquema R6.2.2 Etapa clave de la ruta D. 
                                                
Dado que el fracaso de estos experimentos podría ser debido a la acidez de los 
protones enolizables en posición α, se pensó en una ruta alternativa en la que el éster del 
diino sería sustituido por un silil éter, menos reactivo. En este caso, la reacción de 
condensación con la amida de Weinreb correspondiente a los peyssoneninos dio lugar al 
 
51 a. Aggarwal, V. K.; Mereu, A. J. Org. Chem. 2000, 65, 7211. b. Corey, E. J.; Link, J. O. J. Am. Chem. Soc. 
1992, 114, 1906. c. Russell, J.; Roques, N. Tetrahedron 1998, 54, 13771. 
 C. Org. Biomol. Chem. 2006, 4, 1213. 
52 a. Biagetti, M.; Bellina, F.; Carpita, A.; Rossi, R. Tetrahedron Lett. 2003, 44, 607. b. Fairlamb, I. J. S.; 
O'Brien, C. T.; Lin, Z.; Lam, K.
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compuesto deseado en un rendimiento excelente (Esquema R6.2.3). La desprotección del 
silil éter para dar lugar al alcohol, las oxidaciones secuenciales a los correspondientes 
aldehídos y ácidos carboxílicos, la esterificación con el isopropilidenglicerol y la 
desprotección final de éste, completan esta ruta sintética hacia los peyssoneninos. 
 
No. LiNR2 Z/E 
Rto (%) 
etapa b
Rto (%) 
etapa c 
Rto (%) 
etapa d + e 
1 (Me2PhSi)2NLi 67:33  50 59 74 
2 LHMDS 13:87  82 46 78 
Esquema R6.2.3 Síntesis de los peyssoneninos mediante la ruta D. 
7. Aproximaciones sintéticas a SGI-1027, un inhibidor de DNMT, y 
estudio de su efecto en la línea celular de leucemia U937 
 El SGI-1027 es un conocido inhibidor no nucleósido de DNMT1, 3A y 3B con una 
estruct
tumores (concretamente, tres en células humanas cancerosas). Además, es importante 
ura basada en el heterociclo de quinolina, que parece actuar como competidor de la 
S-adenosilmetionina en la reacción de metilación, probablemente por el acceso al sitio 
activo de la enzima.45 Este compuesto induce la degradación selectiva de DNMT1 en una 
amplia variedad de líneas celulares y reactiva la expresión de algunos genes supresores de 
destacar que no causa desmetilación global del genoma (en algunas líneas celulares de 
rata), por lo que el efecto citotóxico es mínimo.  
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Se ha llevado a cabo la síntesis del SGI-1027 mediante dos secuencias sintéticas 
(convergente y por etapas), que también han permitido aislar un derivado de mayor masa 
molecular de este compuesto. 
 
Esquema R7.1 Síntesis de primera generación de SGI-1027. 
En la primera ruta sintética se utilizó como etapa clave la re  
enlaces N-CAr catalizada por Pd(OA  XPh as co es por 
Buchw  en las l preca r con agua.53 Se adaptaron estas condiciones 
tanto a la primera como a la última etapa de la síntesis. Sorprendentemente, en la última 
etapa, el acoplamiento del compuesto 12 con 4-cloroquinolina dio lugar al producto de bis-
t-BuOH, hizo 
 
acción de formación de
c)2 y os con l ndicion mejoradas 
ald  que se activa e talizado
aminación de la 4-cloroquinolina en un 70% de rendimiento. Este resultado, que se debe 
probablemente a la escasa solubilidad de los compuestos de partida en 
necesario el desarrollo de una nueva estrategia sintética (Esquema R7.2)
 
                                                 
53 Fors, B. P.; Krattiger, P.; Strieter, E.; Buchwald, S. L. Org. Lett. 2008, 10, 3505. 
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Esquem
gments 9 y 17, que a su vez fueron obtenidos mediante las 
correspodientes reacciones de formación de enlaces N-CAr catalizadas por paladio. 
Los perfiles biológicos de SGI-1027 y su derivado 14 han sido estudiados en la 
línea celular de leukemia U937. Se ha demostrado que ambos compuestos a 50 µM 
reducen la actividad de DNMT1 in vitro y poseen una actividad inhibidora superior al 
conocido inhibidor RG108. 
a R7.2 Síntesis de segunda generación de SGI-1027. 
En esta nueva ruta, más convergente, se seleccionó como última etapa la formación 
del enlace amida entre los fra
 
Figura R7.3 Efecto de SGI-1027 en la actividad enzimática de DNMT1. 
Además, se ha estudiado el efecto de estos compuestos en la apoptosis y el ciclo 
celular. Se ha observado que estos dos compuestos incrementan la proporción de células en 
la fase pre-G1 tras 30 horas de tratamiento y que este incremento de la apoptosis depende 
de la dosis (Figura R7.4A). Sin embargo, no se observan alteraciones importantes en las 
fases del ciclo celular cuando se emplean los dos compuestos a 5 µM y 50 µM (Figura 
R7.4B). 
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Figura R7.4 Efectos del SGI-1027 en la apoptosis (A) y el ciclo celular de células de leucemia humana U937 
(B). 
 
  
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 

Introduction 
 
 
 
 
 
 
 
 
The genetic information of an organism is highly heterogeneous with regard to the
expression of single genes, so that some genes are continuously transcribed while other
areas of the genome are silenced.1 Adaptation to environmental changes and cel
specialization in multicellular organisms require a complex organization of the
transcriptional output of the genome. For this purpose, cells have evolved forms of
molecular memory that allow them to remember past stimuli which can be transmitted
through cell division.2 The maintenance of cell identity in multicellular organisms is an
example of such inheritable cellular memory since the zygotic genome gives rise to subsets
of differentiated cells with distinct programmes of gene expression to fulfill specific
functions during lifetime, even though the differentiation signal was experienced only once
during embryonic development. To achieve this, the 
gene expression to each progeny cell is require
multicellular organism have identical DNA sequences and therefore the same genetic 
instruction sets, however they maintain different terminal phenotypes. This nongenetic 
cellular memory, which accounts for developmental and environmental cues, is the basis of 
epi-(above and beyond)-genetics.3 For a mechanism or system to be considered epigenetic 
it must be heritable, self-perpetuating and reversible. 
Epigenetics is generally understood as the study of mechanisms that control gene 
expression in a potentially heritable way.4 The term “epigenetic landscape” was coined by 
Conrad Waddington in 1940s to define the molecular mechanisms that convert the genetic 
information into observable traits or phenotypes.5 Later, with the discovery of inheritable 
                                                
 
 
l 
 
 
 
 
 
 
 
transmission of a complex pattern of 
d upon division. Then, cells in a 
 
1 Biel, M.; Wascholowski, V.; Giannis, A. Angew. Chem. Int. Ed. 2005, 44, 3186. 
2 Bonasio, R.; Tu, S.; Reinberg, D. Science 2010, 330, 612. 
3 Riddihough, G.; Zahn, L. M. Science 2010, 330, 611. 
4 Portela, A.; Esteller, M. Nat. Biotech. 2010, 28, 1057. 
5 a. Waddington, C. H. An Introduction to Modern Genetics; The Macmillan Company: New York, 1939. b. 
Waddington, C. H. Endeavour 1942, 1, 18. 
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patterns of DNA methylation and the regulatory role of histone post-translational 
modifications, the definition of epigenetics became “a stably heritable phenotype resulting 
from changes in a chromosome without alterations in the DNA sequence”.6 As a looser 
definition epigenetics can be considered as “the inheritance of variation (-genetics) above 
and beyond (epi-) changes in the DNA sequence”. On a molecular level the driving 
epigenetic mechanisms are the DNA methylation, the covalent modifications of histones 
and the changes in the positioning of nucleosomes. It is important to highlight that the 
observed outcome is always the sum of their interactions. These mechanisms are not only 
important for cellular differentiation, but they are also fundamental to the regulation of 
many cellular processes such as gene and microRNA expression, DNA-protein 
interactions, suppression of transposable element mobility, embryogenesis, X-chromosome 
inactivation and genomic imprinting.  
Epigenetic mechanisms can be classified in two types depending on their way of 
acting: trans epigenetic signals or cis-acting molecular signatures physically associated 
with the DNA sequence they regulate.2 The trans-acting mechanism (figure 1.1A) is the 
system used for the cellular memory of prokaryotes and single-cell eukaryotes and it 
mainly consists of networks of transcription factors (TFs) which activate or repress their 
own transcription (meiotic epigenetics). They are transmitted by partitioning of the cytosol 
during cell division and maintained by feedback loops. On the other hand, cis signals 
(mitotic epigenetics) are physically associated and inherited along with the chromosome on 
which they act and constitute DNA methylation and changes in histones. Although it is 
difficult to distinguish experimentally between both kinds of epigenetics they influence 
each other to create the transcriptional landscape. 
 
                                                 
6 a. Riggs, A. D.; Martienssen, R. A.; Russo, V. E. A. In Epigenetic Mechanisms of Gene Regulation; Cold 
Spring Harbor Laboratory Press: New York, 1996; Vol. 32, p 1. b. Berger, S. L.; Kouzarides, T.; Shiekhattar, 
R.; Shilatifard, A. Genes Dev. 2009, 23, 781.  
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Figure 1.1 A. Trans-epigenetic signals: in this simple regulatory loop, after cell division the epigenetic signal 
induces it own division. B. Cis molecular signals are associated with DNA and inherited via chromosome 
segregation (adapted from reference 2). 
The importance of epigenetics in maintaining normal development and biology is 
reflected on the observation that many diseases develop when the wrong type of epigenetic 
marks are introduced at the wrong time and place. For example, in tumorogenesis, the 
epigenetic inactivation of genes is a driving force as important as gene inactivation by 
mutation (genotype modification). It has been demonstrated that transcriptional repression 
through epigenetic mechanisms occurs in a variety of tumours (tumour suppressor genes, 
cell-cycle genes, DNA repair genes and genes involved in invasion and metastasis). Re-
express
sed into structures of 
aging unit is the nucleosome, in which 145-
ion of many of these genes could lead to suppression of tumour cell growth or to 
the alteration of other anticancer therapies that already exist.   
1.1 Histone modifications and the histone code hypothesis 
In the nucleus of a cell, the eukaryotic genome is conden
higher order called chromatin.7 The basic pack
                                                 
7 Zheng, Y. G.; Wu, J.; Chen, Z.; Goodman, M. Med. Res. Rev. 2008, 28, 645. 
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147 DNA base pairs are wrapped left-handed in 1.65 turns  around a core octamer of 
histone proteins, which consists of two H2.A-H2.B dimers and a H3-H4 tetramer. 
Neighboring nucleosomes are separated by, on average, ~50 base pairs of free DNA (linker 
DNA).4 The histone H1 is called the linker histone. It does not form part of the nucleosome  
but binds to the linker DNA and  seals off the nucleosome at the location where DNA 
enters and leaves, allowing the condensation of this fundamental unit to structures of 
higher order, which are visible under the microscope as chromosomes during metaphase of 
the cell cycle.1 The structure of each core histone is essentially a globular domain except 
for their highly conserved N-terminal tails, which are unstructured flexible chains on the 
surface of the nucleosome, where they can undergo various post-translational 
modifications carried out by different enzymes, most importantly: 
 
¾ 
, a recently described new type of non-
covalent modification that cuts off the N-terminal 21 residues and associated post-
transcriptional modifications.8  
¾ Propionylation, butyrylation, formylation, citrullination and proline isomerization, 
recently reported as posttranslational marks.9 
                                                
Acetylation of specific lysine residues by histone acetyltransferases (HATs). 
¾ Methylation of specific lysine and arginine residues by histone methyltransferases 
(HMTs in general, HKMTs for lysine and PRMTs for arginine). 
¾ Phosphorylation of specific serine residues by histone kinases (HKs). 
¾ Ubiquitination: attachment of ubiquitin (Ub) to the ε-amino function of lysine 
residues by a succession of three enzymatic steps. 
¾ SUMOylation: attachment of SUMOs (small ubiquitin-like modifiers) to the ε-
amino function of lysine residues by a succession of three enzymatic steps. 
¾ ADP-ribosylation: successive attachment of anionic ADP-ribose monomers to 
generate poly(ADP-ribose) chains (PAR) by PAR polymerases (PARPs). 
¾ Clipping of the H3 after the Ala21 residue
 
8 Santos-Rosa, H.; Kirmizis, A.; Nelson, C.; Bartke, T.; Saksouk, N.; Cote, J.; Kouzarides, T. Nat. Struct. 
Mol. Biol. 2009, 16, 17. 
9 Tan, M.; Luo, H.; Lee, S.; Jin, F.; Yang, Jeong S.; Montellier, E.; Buchou, T.; Cheng, Z.; Rousseaux, S.; 
Rajagopal, N.; Lu, Z.; Ye, Z.; Zhu, Q.; Wysocka, J.; Ye, Y.; Khochbin, S.; Ren, B.; Zhao, Y. Cell 2011, 146, 
1016. 
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Very recently Tao and co-workers have identified 67 new histones marks both in 
the N-terminal tail and within globular domains. Among them, the most remarkable are 
tyrosine hydroxylation (Yoh) and lysine crotonylation (Kcr).9 
 
All these enzymes act together with enzymes responsible for the opposite 
processes, i.e., for removal of the mentioned modifications: 
 
¾ Histone deacetylases (HDACs) 
¾ Histone demethylases (HDMs) 
¾ Histone phosphatases (PPs) 
¾ Ubiquitin hydrolases (Ubps) 
¾ Poly(ADP-ribose)glycohydrolases (PARGs) 
 
Of all these enzymes methyltransferases, demethylases and kinases are the most 
specific to individual histone residues and subunits. Histone acetyltransferases (HATs), 
ously (within the same site, in the same histone tail or 
among
f active genes) and H3K79. 
On the other hand, heterochromatin contains low levels of acetylation and high levels of 
trated that actively 
transcribed genes are characterized by high levels of trimethylated H3K4, acetylated 
                                                
and deacetylases (HDACs) are not highly specific and modify more than one residue. 
These modifications mutually affect each other. The various modifications can 
occur at different sites simultane
 different histone tails) acting in a combinatorial and sequence-dependent manner to 
yield specific downstream events. This cross-talk among different marks gives rise to 
unique biological outcomes and represents a cellular vocabulary for the regulation of 
different transcription-based processes that is known as “the histone code”. Thus, a single 
mark does not determine an outcome alone, but the combination of all of them. It has been 
recently reported the existence of up to 51 distinct “chromatin states” based on the 
enrichment of specific combinations of histone modifications that would lead to distinct 
biological outcomes.10 The actively transcribed euchromatin is characterized by high levels 
of acetylated and trimethylated H3K4, H3K36 (in the bodies o
H3K9, H3K27 and H4K20 methylation.11 Recent studies have demons
 
10 Ernst, J.; Kellis, M. Nat. Biotech. 2010, 28, 817. 
11 Li, B.; Carey, M.; Workman, J. L. Cell 2007, 128, 707. 
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H3K27 and H2.BK5 and methylated H4K20 in the promoter and methylated H3K79 and 
H4K20 along the gene body.12  
 
Figure 1.2 General structure of a nucleosome (human H3T, nucleosome containing a testis-specific histone 
1.2 Nucleosome positioning 
Histones carry information in their primary sequence (histone variants), in the post-
translational modifications on their N- and C-terminal tails or in their position relative to 
variant, pdb 3AFA), and representation of histone tails with sites and types of epigenetic modifications.  
                                                 
12 Karlić, R.; Chung, H.-R.; Lasserre, J.; Vlahoviček, K.; Vingron, M. Proc. Natl. Acad. Sci. U. S. A. 2010, 
107, 2926. 
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the DN
anscription factors to their 
sites on DNA and inhibit the elongation of the transcripts by polymerases. Then, the 
packag
4 In particular, the position of 
nucleosomes around the transcription start sites (TSS) has an important influence on the 
ptionally active genes possess a nucleosome-free 
provide space for the assembly and disassembly of 
 the loss of a nucleosome directly upstream of the TSS 
clusion of the TSS by a nucleosome with gene 
ll known that the composition of the 
nucleosome core particle influences chromatin structure and nucleosome positioning.15 In 
this reg
tone 
variant
A sequence.23 Nucleosome positioning plays a key role in genomic regulation by 
defining a histone–DNA context that modulates access to specific sites.13 Nucleosomes are 
a barrier to transcription that block access of activators and tr
ing of DNA into nucleosomes influences the double-helix structure, what appears to 
affect all stages of transcription and thus, gene expression.
initiation of transcription. The transcri
region at the 5’ and 3’ ends needed to 
the transcriptional machinery. Thus,
is correlated with gene activation and the oc
repression (see Figure 1.3).14 In addition, it is we
ard, incorporation of different histone variants, which differ from core histones in 
their tails, their domain structure and in a few key amino acids can also regulate 
nucleosome positioning and gene expression, as for example occurs with the his
 H2A.Z, whose incorporation into chromatin may contribute to transcription 
activation by protecting genes against DNA methylation.16 Finally, DNA methylation and 
nucleosome positioning are also closely related to each other since methylated DNA seems 
to be associated with “closed” chromatin domains where no transcription exists, whereas 
unmethylated DNA is associated with “open” chromatin which allows transcription. 
 
                                                 
13 Vasudevan, D.; Chua, E. Y. D.; Davey, C. A. J. Mol. Biol. 2010, 403, 1. 
14 a. Schones, D. E.; Cui, K.; Cuddapah, S.; Roh, T.-Y.; Barski, A.; Wang, Z.; Wei, G.; Zhao, K. Cell 2008, 
132, 887. b. Cairns, B. R. Nature 2009, 461, 193.  
 2011, 2, 607. 
ff, S. Nature 2008, 456, 125. 
15 Jin, B.; Li, Y.; Robertson, K. D. Genes & Cancer
16 Zilberman, D.; Coleman-Derr, D.; Ballinger, T.; Heniko
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Figure 1.3 Nucleosome position patterns. The loss of a nucleosome upstream of the TSS is necessary for 
gene activation, whereas its occlusion leads to transcription repression (adapted from reference 4). 
1.3 DNA methylation 
DNA methylation is the most widely studied epigenetic modification in humans. It 
was first discovered in calf thymus DNA by Hotchkiss in 194817 and in mammals it occurs 
almost exclusively at the carbon-5 (C5) position of cytosines in the context of CpG 
dinucleotides and only occasionally at non-CpG sites. CpG dinucleotides tend to 
accummulate in regions called CpG islands (CGIs) that can be defined as regions of more 
than 200 bases with a G + C content of at least 50% and a ratio of observed to statistically 
expected CpG frequencies of at least 0.6.18 There are 56 million CpG sites in the human 
genome, about 60-80% of which are methylated, which corresponds to 4-6% of all 
cytosines.19 Approximately 60% of human gene promoters contain CpG islands, but they 
are usually unmethylated in normal cells. Some of them (~6%), however, become 
methylated in a tissue-specific manner during early development or in differentiated 
tissues.20 The mammalian CpG dinucleotides have become strongly underrepresented 
during evolution by a factor of 5-10 in relation to other dinucleotides (~1%).21 The reason 
of this can be found in the mutagenic property of 5-methylcytosine, since its spontaneous 
hydrolytic deamination (by DNA deaminases  from the Aid/Apobec family) gives rise to 
thymidine situated in a TG mismatch. Normally, the base pairing CG on the 
complementary DNA strand is not altered upon methylation and thus the genetic code is 
preserved. Long hypermethylated CpG stretches are frequently recognized by proteins with 
methyl-CpG-binding domains (MBDs). However, single 5-methylcytosines in DNA that 
are not complexed by these proteins are the ones prone to hydrolysis. The repair of TG 
22
the 
oxidation of the methyl group of 5-methylcytosine, has recently been discovered in the 
mismatch to TA leads to point mutations that can be pathogenic or beneficial.  In addition 
to 5-methylcytosines, 5-hydroxymetyl-2’-deoxycytidine (5hmC), which arises from 
                                                 
17 Hotchkiss, R. D. J. Biol. Chem. 1948, 175, 315.  
18 Takai, D.; Jones, P. A. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 3740. 
19 a. Lis
L.; Ye, Z.; Ngo  
Ong, C. T.; Low, H. M.; Kin Sung, K. W.; Rigoutsos, I.; Loring, J.; Wei, C.-L. Genome Res. 2010, 20, 320.  
20 Straussman, R.; Nejman, D.; Roberts, D.; Steinfeld, I.; Blum, B.; Benvenisty, N.; Simon, I.; Yakhini, Z.; 
Cedar, H. Nat. Struct. Mol. Biol. 2009, 16, 564. 
; Jung, M. Epigenetic Targets in Drug Discovery; Wiley-VCH: Weinheim, 2009. 
ter, R.; Pelizzola, M.; Dowen, R. H.; Hawkins, R. D.; Hon, G.; Tonti-Filippini, J.; Nery, J. R.; Lee, 
, Q.-M.; Edsall, L.; Antosiewicz-Bourget, J.; Stewart, R.; Ruotti, V.; Millar, A. H.; Thomson,
J. A.; Ren, B.; Ecker, J. R. Nature 2009, 462, 315. b. Laurent, L.; Wong, E.; Li, G.; Huynh, T.; Tsirigos, A.; 
21 Sebova, K.; Fridrichova, I. Anticancer Drugs 2010, 21, 565. 
22 Sippl, W.
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mammalian genome DNA, although this new modification needs to be further studied to 
determine its implication in normal and disease epigenetic regulation.23  
 
In general, CpG-island methylation is associated with gene silencing. For this 
reason it plays a key role in genomic imprinting, when hypermethylation of one of the 
parental alleles leads to monoallelic expression or similarly in the X-chromosome 
inactivation. 
DNA methylation can inhibit gene expression by various non-exclusive mechanisms: 
1.- Methylation of CpG islands at promoters leads to transcriptional inactivation either 
by directly avoiding the recruitment of the transcription factors to their target sites or by 
promoting the recruitment of methyl-CpG-binding domain (MBD) proteins (e.g., MeCP2), 
which in turn recruit histone-modifying and chromatin-remodeling complexes to 
methylated sites (Figure 1.4A).24  
2.- The same pattern is observed in the CpG island shores, which are regions of lower 
CpG density located in close proximity (~2 kilobases upstream) to the CpG islands (Figure 
1.4B). The methylation in the CpG island shores is associated with transcriptional 
inactivation and contains most of the tissue-specific DNA methylation.25 
3.- High levels of methylation in the gene body are correlated with active genes, since 
it is believed that block aberrant transcription initiation inside the gene and therefore help 
in avoiding the production of truncated mRNAs and proteins (Figure 1.4C).26  
4.- DNA hypermethylation can also be found in repetitive elements, which maintain 
chromosomal integrity by preventing the reactivation of endoparasitic sequences 
(transposons and endogenous retroviruses) that cause genome instability, translocations 
and gene disruption (Figure 1.4D).4 
                                                 
23 Tahiliani, M.; Koh, K. P.; Shen, Y.; Pastor, W. A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L. M.; 
Liu, D. R.; Aravind, L.; Rao, A. Science 2009, 324, 930. 
24 Luque, J.; Herraez, A. Biología Molecular e Ingeniería Genética; Harcourt: Madrid, 2005. 
; Herb, B.; Ladd-Acosta, C.; Rho, 
o, C.; Onyango, P.; Cui, H.; Gabo, K.; Rongione, M.; 
t. Genet. 2009, 41, 178.  
25 a. Doi, A.; Park, I.-H.; Wen, B.; Murakami, P.; Aryee, M. J.; Irizarry, R.
J.; Loewer, S.; Miller, J.; Schlaeger, T.; Daley, G. Q.; Feinberg, A. P. Nat. Genet. 2009, 41, 1350. b. Irizarry, 
R. A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montan
Webster, M.; Ji, H.; Potash, J. B.; Sabunciyan, S.; Feinberg, A. P. Na
26 Jurkowska, R. Z.; Jurkowski, T. P.; Jeltsch, A. ChemBioChem 2011, 12, 206. 
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Although in mammals DNA methylation occurs mainly in CpG dinucleotides, 
methylation in CHG and CHH sites (H = adenine, cytosine or thymine) has recently been 
reported. The mechanisms of these non-CpG methylation processes have not been 
em to be enriched in gene body and thus they contribute to 
transcr
The initial pattern of DNA methylation is generated during the early stages of 
n, when cells are not yet 
 dinucleotides are methylated except 
t chanisms not 
discovered yet, but they se
iptional activation.19a 
Figure 1.4 DNA methylation patterns (normal situation on the left and altered patterns on the right). 
A. Unmethylated CpG islands at promoters lead to active transcription whereas aberrant methylation leads to 
gene silencing. B. Unmethylated/methylated CpG island shores have the same effect than CpG islands. C. 
Methylation at gene bodies facilitates transcription whereas no methylation is associated with disease. D. 
Methylation of repetitive sequences prevents chromosomal instability. This pattern is also altered in disease 
(adapted from reference 4).  
1.3.1 DNA methylation pattern in mammalian development 
embryonic development (Figure 1.5). After fertilizatio
differentiated, the DNA methylation patterns inherited from the parental gametes are 
erased (global demethylation). At the time of implantation, when the different cell types 
are organized in different tissues, methylation patterns are newly established (de novo 
methylation) in a bimodal way: almost all the CpG
hose located in the CpG islands, which are protected from methylation by me
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completely elucidated. It has been suggested that the establishment of this de novo DNA 
methylation occurs through mediation of the histone modification H3K4.27 This pattern is 
perpetuated after each round of replication for the rest of the life of the animal, with only 
small tissue-specific changes (maintenance methylation). The methylation marks in the 
parental strand serves as pattern to re-methylate the daughter strand.24,26  
 
Figure 1.5 Methyl groups distribution during development (adapted from reference 24). 
hat catalyze 
the 
activity. 
1.3.2 DNA methyltransferases 
DNA methyltransferases (DNMTs or DNA MTases) are the enzymes t
transfer of the methyl group from the universal methyl donor S-adenosyl-L-methionine 
(S-AdoMet, SAM) to DNA. In mammals, five members of the DNMT family of enzymes 
have been reported: DNMT1, DNMT3A, DNMT3B, DNMT3L and DNMT2, but only the 
first three possess methyltransferase 
                                                 
27 Cedar, H.; Bergman, Y. Nat. Rev. Genet. 2009, 10, 295. 
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Figure 1.6 Methylation of cysteine residues use the methyl donor SAM as DNMT cofactor. 
The structure of DNMTs, which has been extensively reviewed,1,22,26,28 can be 
divided into a C-terminal catalytic domain and a N-terminal regulatory domain that  differs 
considerably between DNMT1 and 3 and is absent in DNMT2. The N-terminal part is a 
large multidomain with a variable size that guides the nuclear localization of the enzymes 
ixed seven-stranded β-sheet formed by six 
parallel β strand and a seventh strand in antiparallel orientation inserted into the sheet 
otifs are described by their 
functio
and mediates the interaction with other proteins. The C-terminal domain is smaller and is 
highly conserved in both procaryotic and eukaryotic DNMTs. It holds the active site of the 
enzyme and contains ten amino acids motifs characteristic of all DNA methyltransferases. 
The catalytic domain of all DNMTs share a common core structure called “AdoMet-
dependent MTase fold”, which consists of a m
between strands 5 and 6.28f The ten conserved sequence m
n:22,29 motifs I-III form the cofactor binding pocket, motif IV has a catalytic 
cysteine that forms the thiolate initiating the methyl group transfer, motifs VI, VIII and X 
                                                 
28 a. Dong, A.; Yoder, J. A.; Zhang, X.; Zhou, L.; Bestor, T. H.; Cheng, X. Nucleic Acids Res. 2001, 29, 439. 
b. Brown, R.; Strathdee, G. Trends Mol. Med. 2002, 8, S43. c. Brueckner, B.; Lyko, F. Trends Pharmacol. 
Sci. 2004, 25, 551. d. Goll, M. G.; Kirpekar, F.; Maggert, K. A.; Yoder, J. A.; Hsieh, C.-L.; Zhang, X.; Golic, 
K. G.; Jacobsen, S. E.; Bestor, T. H. Science 2006, 311, 395. e. Hellebrekers, D. M. E. I.; Griffioen, A. W.; 
van Engeland, M. Biochim. Biophys. Acta -Rev. Cancer 2007, 1775, 76. f. Cheng, X.; Blumenthal, R. M. 
Structure 2008, 16, 341.  
29 Medina-Franco, J. L.; Caulfield, T. Drug Discov. Today 2011, 16, 418. 
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comprise the substrate binding site and motifs V and VII form the target recognition 
domain.30 The non-conserved region between motifs VIII and IX, the so called target 
recognition domain (TRD) is involved in DNA recognition and specificity. 
 
Figure 1.7 Schematic representation of the mammalian DNMTs domains (adapted from reference 26). 
DNMT1 (DNA nucleotide methyltransferase 1) 
DNMT1 is the most abundant of the three DNA methyltransferases in the cell. It 
was the first mammalian DNA methyltransferase identified, cloned and biochemically 
characterized. This enzyme has a 30- to 40-fold preference for hemimethylated DNA over 
unmethylated DNA and is mostly localized at DNA replication foci during S phase of the 
MT1 is classified as maintenance methyltransferase, since 
it is responsible for the preservation of th
 lysine-glycine (KG) repeats. The N-terminal 
domain is composed of several functional domains:  
1) A charge-rich or DMAP1 (D
cell cycle. For these reasons DN
e methylation patterns during cell division by 
methylation of hemimethylated CpG dinucleotides produced by semi-conservative DNA 
replication. It also maintains the pattern during chromosome repair.31  
DNMT1 is a large enzyme made of 1616 amino acids in humans. The C-terminal 
and N-terminal parts are joined by a series of
NA methyltransferase associated protein 1) 
domain involved in the interaction of DNMT1 with Dmap1, a transcriptional 
                                                 
30 Lauster, R.; Trautner, T. A.; Noyer-Weidner, M. J. Mol. Biol. 1989, 206, 305. 
31 Mortusewicz, O.; Schermelleh, L.; Walter, J.; Cardoso, M. C.; Leonhardt, H. Proc. Natl. Acad. Sci. U. S. A. 
2005, 102, 8905. 
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repressor. This domain is also implicated in the stability of the enzyme and it 
was shown to bind DNA at CpG sites. 
2) A PBD region (PCNA binding domain) implicated in the binding to PCNA 
(proliferation cell nuclear antigen). The interaction of DNMT1 with PCNA 
ensures localization at the replication fork. 
3) At least three independent functional NLS (nuclear localization signal) 
sequences. 
4) A TS (targeting sequence) domain or replication foci-targeting domain (RFD) 
involved in the targeting of DNMT1 to centromeric chromatin and to 
replication foci. 
5) A CXXC or zinc domain that contains eight conserved cysteine residues 
clustered in two CXXCXXC repeats bound to two zinc ions. This domain is 
necessary for the catalytic activity of the enzyme. 
6) The BAH1 and BAH2 (Bromo-adjacent homology 1 and 2) domains that form 
the so-called PBHD domain (polybromo homology domain). It has been 
alized in gene 
terminal domain induces allosteric activation for the methylation of unmethylated 
s it is known that the phosphorylated Ser515 is involved in the 
interaction of the catalytic and regulatory domains necessary for the activity of the enzyme, 
proposed to act as protein-protein interaction module speci
silencing, but its function remains unknown. 
7)  The KG linker that might contribute to the targeting of DNMT1 to regions 
adjacent to the replication fork. 
The C-terminal domain holds the catalytic active center of the enzyme, although it 
is not active in its isolated form (target recognition domain TRD). It has been shown that 
its direct interaction with the N-regulatory domain is needed to activate the enzyme. In this 
regard, some studies have demonstrated that the binding of methylated DNA to the N-
substrates. On the contrary, an inhibitory effect of unmethylated substrates has been 
observed, suggesting that the binding of unmethylated DNA to the N-regulatory domain 
decreases the activity of DNMT1. This observation agrees with the fact that DNA 
methylation patterns in the human genome are bimodal: genomic regions tend to be highly 
methylated or completely unmethylated and this fact is provoked by allosteric binding of 
substrate DNA to a secondary site. 
The activity of DNMT1 can also be regulated by post-translational modifications 
such as phosphorylation (at Ser515, Ser717, Ser 958 and Ser1108), methylation and 
sumoylation. Wherea
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the function of the other marks needs to be elucidated. The monomethylation of lysine142 
promotes proteasomal degradation of the enzyme. 
DNMT2 
The DNMT2 protein can be found in mammalian cells. It is a relative small protein 
of 391 aminoacids that contains all the catalytic motifs of the other DNMT but lacks the N-
terminal regulatory domain. It has been reported that DNMT2 does not methylate DNA but 
instead methylates cytosine38 in the anticodon loop of aspartic acid transfer RNA 
(tRNAasp).32 Recent studies suggest that DNMT2 activity is not limited to tRNAasp and it 
represents a noncanonical enzyme of the DNMT family.  
DNMT3 
The mammalian DNMT3 family of methyltransferases includes DNMT3A, 
DNMT3B and DNMT3L. DNMT3A and DNMT3B are thought to be responsible for 
establishing the pattern of methylation during embryonic development (early mammalian 
lay any significant preference between 
hemimethylated and unmethylated DNA. DNM3L (DNMT3-like) has a high sequence 
similar
     
development and in germ cells), so they have been designated as de novo DNA 
methyltransferases because they do not disp
ity with DNMT3A, but lacks any catalytic activity due to the absence of conserved 
catalytic residues. However, DNMT3L acts as interacting partner of DNMT3A and 3B28f,33 
by enhancing their activity in the de novo methylation of retrotransposons (repeated 
sequences) in male germ cells and in the establishment of genomic maternal imprinting 
(genomic imprints in oocytes).34 This enzyme binds unmethylated H3K4 tails and induces 
de novo methylation by recruitment of DNMT3A2.35 Therefore, DNMT3L has a dual, 
gender-especific role because it is expressed during gametogenesis functioning as 
regulatory factor in both male and female germ cells.  
DNMT3A and 3B also possess a C-terminal catalytic region and a N-terminal 
regulatory region, but unlike the catalytic domains, the N-terminal regions of 
                                            
fe32 Schae
33 Jia, D.; Jurkowska, R. Z.; Zhang, X.; Jeltsch, A.; Cheng, X. Nature 2007, 449, 248. 
34 a. Bourc'his, D.; Xu, G.-L.; Lin, C.-S.; Bollman, B.; Bestor, T. H. Science 2001, 294, 2536. b. Bourc'his, 
eng, X.; Bestor, T. H. Nature 2007, 448, 714. 
r, M.; Lyko, F. Chromosoma 2010, 119, 35. 
D.; Bestor, T. H. Nature 2004, 431, 96. 
35 Ooi, S. K. T.; Qiu, C.; Bernstein, E.; Li, K.; Jia, D.; Yang, Z.; Erdjument-Bromage, H.; Tempst, P.; Lin, S.-
P.; Allis, C. D.; Ch
53 
Introduction 
DN
arrangem
MT3A/3B differ from those of DNMT1. DNMT3A and 3B have similar domain 
ents in this region: 
1) A cysteine-rich 3-Zn-binding domain called ADD (ATRX-DNMT3-
DNMT3L), also known as PHD (plant homeodomain). This domain 
comprises six CXXC motifs and it is involved in several protein-protein 
shown to be the part of the enzyme responsible for the interaction 
line(P
interactions (e.g. with HP1, SUV39H1, EZH2, etc.). In addition, it has been 
recently 
with unmethylated H3K4. 
2) A PWWP domain, which is a region of 100-150 aminoacids that contains 
conserved pro )-tryptophan(W) motifs. These domains belong to a 
sim
isol
en described (e.g., DNMT3A2, 
N-term ical properties and biological functions remain 
unknow
es containing methylated DNA,38 where they methylate 
           
Royal domain superfamily, members of which interact with various 
modifications of histone tails.36  
 
The catalytic domain of DNMT3A and 3B share approximately 85% sequence 
ilarity and, unlike the catalytic domain of DNMT1, they are enzymatically active in 
ated form. 
Some isoforms of DNMT3A and 3B have be
DNMT3B1, DNMT3B2, ΔDNMT3B, etc.), which differ either in the C-terminal or in the 
inal domain. Although their biochem
n, it is postulated that they might function as stimulators or inhibitors of de novo 
DNMTs.26  
Post-translational modifications of DNMT3 have not been deeply investigated yet. 
Only sumoylation of DNMT3A/3B in the N-terminal domains has been reported, but 
further studied are necessary to determine the influence of these modifications in the 
activity, stability and targeting of these enzymes. 
The division of labor between de novo and maintenance methylation is not so clear, 
since a revised model in which DNMT3A/3B also play a role in the maintenance of DNA 
methylation at heterochromatic regions has been recently proposed.37  So, despite the bulk 
of DNA methylation in dividing cells is maintained by DNMT1, DNMT3A and DNMT3B 
are anchored strongly to nucleosom
                                      
36 Taverna, S. D.; Li, H.; Ruthenburg, A. J.; Allis, C. D.; Patel, D. J. Nat. Struct. Mol. Biol. 2007, 14, 1025. 
37 Jones, P. A.; Liang, G. Nat. Rev. Genet. 2009, 10, 805. 
38 Jeong, S.; Liang, G.; Sharma, S.; Lin, J. C.; Choi, S. H.; Han, H.; Yoo, C. B.; Egger, G.; Yang, A. S.; 
Jones, P. A. Mol. Cell. Biol. 2009, 29, 5366. 
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the sites missed by DNMT1 at the replication fork. The reason of this might be found in 
the fact that these regions of repetitive elements are exceptionally CpG-rich, so the 
complete re-methylation might require the cooperation of both DNMT1 and DNMT3. In 
DNMT3A/3B can also methylate cytosine residues in a non-CpG context, 
particu
del of maintenance methylation
addition, 
larly in embryonic stem cells (ES), however the biological significance of this fact 
remains unknown. In the same way DNMT1 is also required for de novo methylation, since 
it might support DNMT3A and DNMT3B action by using hemimethylated CpG sites 
generated by DNMT3 enzymes as substrates, as it occurs in vitro. The preference of 
DNMT1 for hemimethylated over unmethylated CpG sites is not enough to copy the DNA 
methylation pattern of 56 millions CpG sites (classical mo ). 
models for DNA methylationFor this reason stochastic  have been developed. These new 
models supported by experimental studies led to the conclusion that biological function is 
attribut
 an
,40 for a complex between intact 
DNMT
The crystal structure of the DNMT3A-DNMT3L complex revealed that it is a linear 
heterotetramer formed by two DNMT3L units at the edges of the complex and two 
ut since DNMT3A 
ed to the average methylation state of a larger DNA region rather than to the 
methylation state of each individual CpG site. This modified view on DNA methylation 
patterns is consistent with the fact that DNA methylation patterns in the human genome is 
bimodal, with regions that are either highly methylated or unmethylated. The observed 
methylation patterns at specific sites are also in favour of mechanism in which both, site-
specific copying of methylation pattern by DNMT1 and region-specific targeting of 
DNMTs activity coexist. In conclusion, “maintenance DNA methylation” refers to the 
preservation of average levels of DNA methylation at certain regions, but not to  
accurate copying of site-especific DNA methylation patterns. 
 
The first X-ray diffraction data available for DNA methyltransferases were reported 
from prokaryotic enzymes (M.HhaI and M.HhaIII39
4
), which have a less complex structure 
than the mammalian DNMTs. Later, crystal structures were obtained for human 
DNMT2,28a  for the PWWP domain of DNMT3B
3L and unmethylated H3K435 and for a complex between the C-terminal domains 
of DNMT3A and DNMT3L.33 
DNMT3A units in the centre. It was crystallized without bound DNA, b
                                                 
39 a. Klimasauskas, S.; Kumar, S.; Roberts, R. J.; Cheng, X. Cell 1994, 76, 357. b. Reinisch, K. M.; Chen, L.; 
l. 2002, 9, 217. 
Verdine, G. L.; Lipscomb, W. N. Cell 1995, 82, 143.  
40 Qiu, C.; Sawada, K.; Zhang, X.; Cheng, X. Nat. Struct. Mol. Bio
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is similar to the bacterial M.HhaI, which was crystallized with DNA, the DNMT3A-
DNMT3L-DNA complex was modeled from the bacterial complex.33 Although DNMT3A 
ha
enzym
of the
for pro
. This interface is also present in DNMT3L and 
ediate the DNMT3A-DNMT3A contact to 
create the DNA binding site. 
esidues from these helices directly interact with the key catalytic or S-
AdoMe
g event. In addition, it has been recently reported that DNMT3A polymerizes 
on DN
s a relatively small DNA binding domain (~50 base pairs) compared to the bacterial 
e, in the heterotetramer two active sites come together which leads to the doubling 
 DNA binding surface. The DNMT3A C-terminal domain possesses two interfaces 
tein-protein interactions:  
- One hydrophobic FF interface characterized by the stacking interaction of 
two phenylalanine residues
creates the DNMT3A-DNMT3L contact. 
- One polar RD interface characterized by a network of hydrogen bonds 
between arginine and aspartate residues. This interface is not present in 
DNMT3L and its function is to m
The interaction of DNMT3A and DNMT3L through the FF interface presumably 
induces a conformational change of the DNMT3A active site by influencing the α helices 
C, D and E. R
t binding residues, which facilitates DNA and S-AdoMet binding and catalysis. In 
the crystal structure, the active sites of the two central DNMT3A units are separated by one 
DNA helical turn (~40 Å), which correspond to around 10 base pairs, suggesting that two 
CpG sites on opposite DNA strands separated by 10 bps could be methylated by DNMT3A 
in one bindin
A in vitro forming DNMT3A-DNA filaments,41 which positions adjacent 
methyltransferases that interacts with the same DNA strand at a distance of 8-10 bps, 
suggesting that these sites will become co-methylated by DNMT3A of different tetramers. 
 
                                                 
41 Jurkowska, R. Z.; Anspach, N.; Urbanke, C.; Jia, D.; Reinhardt, R.; Nellen, W.; Cheng, X.; Jeltsch, A. 
Nucleic Acids Res. 2008, 36, 6656. 
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Figure 1.8 Structure of the Dnmt3a/3L heterotetrameric complex. A. Crystal structure of the C-terminal 
domains of Dnmt3a/3L with the DNA molecule modelled from the crystal structure of DNA bound to the 
HhaI DNA methyltransferase. B. Model of polymerisation of the Dnmt3a/3L heterotetramer on DNA 
(adapted from reference 26). 
Since all known DNMTs use S-AdoMet as methyl donor the active site shows high 
structural similarity. For this reason the crystallographic data of bacterial 
methyltransferases M.HhaI and M.HhaIII and human DNMT2 was used to establish a 
homology model of the catalytic domain of DNMT1.42 This model demonstrated a 
significant conformational preservation of the catalytic site, but it also showed a number of 
unique structural features: i) His1459 of DNMT1 is substituted with alanine at the 
corresponding positions in the bacterial methyltransferases; ii) the side chains of Arg1310 
and Arg131 have different conformations compared to the corresponding side chains of 
M.HhaI y M.HaeIII, which influences the binding of the ribose ring of the cytosine ligand 
by crea
rivative of 5-azacytidine that showed efficient inhibition of 
DNA m
ting a tighter cavity; iii) differences were also found in the charged aminoacids that 
do not directly interact with the active site but are close to the active site and thus influence 
the binding of ligands. In addition, a 6 Å diameter sphere was defined around the cytosine 
in the DNMT1 catalytic site. The charge in this space was three-fold higher than in the 
bacterial enzymes and in human DNMT2. This homology model was used to design N4-
fluoroacetyl-5-azacytidine, a de
ethylation in human tumour cell lines. 
                                                 
42 Siedlecki, P.; Boy, R. G.; Comagic, S.; Schirrmacher, R.; Wiessler, M.; Zielenkiewicz, P.; Suhai, S.; Lyko, 
F. Biochem. Biophys. Res. Commun. 2003, 306, 558. 
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The most recent contribution to the crystallographic data of these enzymes was 
made by Patel and co-workers,43 since they solved the structures of  mouse (650-1602) and 
human (646-1600) DNMT1 in complex with S-adenosyl-L-homocysteine (AdoHcy) and a 
19-base pair duplex DNA-containing unmethylated CpG sites (the DNA sequence 
contained two unmethylated CpG dinucleotides separated by 8 bp). In the crystal structures 
of mouse and human DNMT1-DNA complexes, the CXXC and BAH1 domains are at 
op
(Figur
in the nker segment, which is disordered 
in the com
The m
additio
(TRD) NMT1, which exhibit 85% sequence identity, 
are ver
 
maintenance DNA methylation: unmethylated CpG sites are protected from de novo 
methylation through binding by the CXXC domain as they emerge from the replication 
complex. 
 
 
 
 
 
posite ends of the methyltransferase domain and are connected by a long linker segment 
e 1.9A). The BAH1 and BAH2 are separated by a α-helical linker and are positioned 
surface remote from the bound DNA. The (GK)n li
plex, connects BAH2 to the catalytic domain, which in turn contacts the DNA. 
olecule of AdoHcy is positioned in the active site of the catalytic domain. In 
n, four Zn2+ cations are present in the CXXC, BAH1 and target recognition domains 
. The structure of mouse and human D
y similar, which is suggestive of a common mechanism of action. The CXXC 
domain binds unmethylated CpG dinucleotides in a sequence-specific manner through 
base-specific and phosphodiester intermolecular interactions. This domain specifically 
binds unmethylated CpG sites since methylated cytosine would create severe steric 
interactions with residues of the protein. The methyltransferase domain comprises two 
subdomains: the target recognition domain (TRD) and the catalytic core. The CXXC-
BAH1 linker contains a highly acidic segment that is positioned directly between the DNA 
and the active site and this fact prevents the entrance of unmethylated DNA into the 
catalytic pocket. In addition, the TRD subdomain is held in a retracted position away from 
the DNA through interaction with a BAH2-TRD loop that also prevents the interaction of 
DNA with TRD (Figure 1.9B). All these findings reveal a mechanism of autoinhibition in
                                                 
43 Song, J.; Rechkoblit, O.; Bestor, T. H.; Patel, D. J. Science 2011, 331, 1036. 
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Figure 
ethylation activity. 
 of Patel and co-workers, suggest that 
multiple structural changes are needed for an accurate maintenance methylation. 
1.3.3 Biochemical mechanism of DNA methylation 
                                                
1.9 A. Domain architecture and numbering of mDNMT1 and hDNMT1 sequences. B. Structural 
overview of mDNMT1 (650-1602)-DNA 19-mer complex with bound AdoHcy. C. Electrostatic surface 
representation of mDNMT1 CXXC domain and the CXXC-BAH1 linker. In the autoinhibitory state, the 
CXXC domain and the autoinhibitory linker occlude the active site. In addition, the BAH2-TRD loop 
restrains the TRD in a retracted position that avoids interaction with CpG sites on the DNA (adapted from 
reference 43). 
Later, Tajima and co-workers reported the crystal structure of a large fragment 
(291-1620) of mouse DNMT1 and also its complexes with S-AdoMet and AdoHcy.44 This 
structure selectively methylated hemimethylated DNA in vitro. The structure of the free 
unbound DNMT1 showed, similarly to the structure published by Patel and co-workers, a 
multidomain formed by a replicacion foci domain (RFD), a zinc-finger-like motif (CXXC), 
two connected bromo-associated homology domains (BAH) and the catalytic domain. 
However, they found that the RFD was deeply inserted into the DNA-binding pocket 
(bound through several hydrogen bonds), thus precluding the binding of DNA. In addition, 
the linker between RTD and the CXXC motif was interacting with the PCQ loop of the 
catalytic center by hydrophobic interactions, what contributes to anchor RTD domain to 
the DNA-binding pocket by narrowing the entrance to the pocket. In their structure the 
CXXC motif was also positioned where the unmethylated DNA binds. According to these 
facts, the displacement of RTD from the catalytic centre and the movement of CXXC 
motif must be required for DNA methylation. In their study they also showed that the 
prebinding of S-AdoMet shifts the position of the side chain of the cysteine residue 1229 of 
the PCQ loop (C1229 is thought to form the covalent bond with the sixth carbon of the 
target cytosine base) towards the flipped-out cytosine. Then, after transferring of the 
methyl group AdoHcy is formed and the cysteine faces away. Finally, using a model based 
on the three-dimensional structure of the M.HhaI complex with DNA, they proved that 
residues tryptophan 1500 and 1502 were essential for the recognition of the 
hemimethylated DNA and thus, for the m
These results, together with the results
 
44 Takeshita, K.; Suetake, I.; Yamashita, E.; Suga, M.; Narita, H.; Nakagawa, A.; Tajima, S. Proc. Natl. 
Acad. Sci. U. S. A. 2011, 108, 9055. 
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The biochemical mechanism of cytosine methylation has been broadly studied.45 
After formation of the complex between DNMT and DNA, the cytosine that will be 
methylated flips out from the DNA base-pairing position.39a The thiol group of a cysteine 
residue located in a PCQ motif (motif IV of the active site)26 acts as a nucleophile that 
attacks the C6-position of the target cytosine (conjugate addition) to generate a covalent 
intermediate (a reactive enamine) between the enzyme and DNA (Figure 1.10). This 
reaction increases the negative charge at the C5 atom of the cytosine, which captures the 
methyl group of the cofactor S-AdoMet to form the 5-methyl covalent adduct and S-
nosyl-L-homocysteine (SAH). It has been postulated that the nucleophilic attack of the 
cysteine on the C6-position is assisted by a transient protonation of the cytosine ring at the 
endocyclic nitrogen atom (N3) by a conserved glutamic acid residue from the ENV motif 
(motif VI). This residue also contacts the exocyclic N4 amino group and stabilizes the 
flipped base. The carbanion formed might also be stabilized by resonance with the 
contiguous carbonyl group, where an arginine residue  from the RXR motif (motif VIII) 
might help the positioning of the glutamate and the flipped cytosine.29 Finally, the covalent 
complex between the methylated base and DNA is resolved with a retro-Michael-type 
elimination (β-elimination46) of the enzyme and the adjacent proton (C5) to generate the 
methylated cytosine and the free enzyme.22 Then, the 5-methylated cytosine flips back into 
its original position within the DNA double helix. Although the general base involved in 
the proton abstraction is not known the involvement of a water molecule or one of the
R arginine residues has been proposed for this purpose. In the absence of S-AdoMet a 
deamination to thymine has been proposed to occur from the first covalent intermediate 
between cytosine and DNMT with a subsequent base repair excision to cytosine. This can 
be formally considered as a demethylation reaction but not in a direct biochemical sense.47 
The two DNMT inhibitors approved for human use are based on this mechanism. 
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45 a. O'Gara, M.; Klimaŝauskas, S.; Roberts, R. J.; Cheng, X. J. Mol. Biol. 1996, 261, 634. b. Vilkaitis, G.; 
Merkiene˙, E.; Serva, S.; Weinhold, E.; Klimašauskas, S. J. Biol. Chem. 2001, 276, 20924. c. Schermelleh, 
L.; Spada, F.; Easwaran, H. P.; Zolghadr, K.; Margot, J. B.; Cardoso, M. C.; Leonhardt, H. Nat. Meth. 2005, 
2, 751. 
46 Bestor, T. H. Hum. Mol. Genet. 2000, 9, 2395. 
47 Metivier, R.; Gallais, R.; Tiffoche, C.; Le Peron, C.; Jurkowska, R. Z.; Carmouche, R. P.; Ibberson, D.; 
Barath, P.; Demay, F.; Reid, G.; Benes, V.; Jeltsch, A.; Gannon, F.; Salbert, G. Nature 2008, 452, 45. 
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Figure 1.10 Mechanism of DNA methylation. 
1.3.4 DNA methylation and cancer  
DNA methylation it is a key epigenetic process involved in the control of gene 
expression, regulation of parental imprinting, stabilization of X chromosome inactivation 
and in the maintenance of chromosomal integrity by preventing the reactivation of 
endogenous retroviruses and transposons.26 It is also implicated in the development of the 
immune system, in cellular reprogramming and in brain function and behavior. Aberrant 
DNA methylation patterns can be found in psychiatric and immune system diseases and in 
the onset and progression of cancer. 
Cancer cells, when compared with normal cells, are characterized by a massive 
global loss of DNA methylation (20-60% less overall 5-methylcytosine), but at the same 
time specific patterns of hypermethylation at the CpG islands of certain promoters are 
frequently observed (see Table 1.1).4,21 
Table 1.1 Epigenetic modifications in human diseases (adapted from reference 4). 
Aberrant epigenetic mark  Alteration Consequences Examples of genes affected and/or resulting disease 
Cancer 
DNA methylation  
hypermethylation  tumor types), p16
MLH1 (colon, endometrium, stomach), 
BRCA1 (breast, ovary), MGMT (several CpG island Transcription repression  
INK4a (colon) 
CpG island 
hypomethylation  Transcription activation  
MASPIN (pancreas), S100P (pancreas), 
SNCG (breast and ovary), MA
(melanomas) 
GE 
CpG island shore HOXA2 (colon),GATA2 (colon) hypermethylation  Transcription repression  
Repetitive sequences 
hypomethylation  recombination genomic instability 
L1, IAP, Sat2 
Transposition, 
Histone modification  
Loss of H3 and H4 
acetylation  Transcription repression  p21
WAF1 (also known as CDKN1A) 
Loss of H3K4me3  Transcription repression  HOX genes 
Loss of H4K20me3  Loss of heterochromatic structure  Sat2, D4Z4 
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Gain of H3K9me and 
H3K27me3  Transcription repression  CDKN2A, RASSF1 
Nucleosome positioning  
 
Silencing and/or 
mutation of remodeler 
subunits 
Diverse, leading to 
oncogenic transformation  BRG1, CHD5 
Aberrant recruitment 
of remodelers  Transcription repression  PLM-RARa recruits NuRD 
Histone variants 
replacement  
Diverse (promotion cell 
cycle/destabilization of 
chromosomal boundaries) 
H2A.Z overexpression/loss 
Neurological disorders 
DNA methylation  
CpG island 
hypermethylation  Transcription repression  Alzheimer’s disease (NEP) 
CpG island 
hypomethylation  Transcription activation  Multiple sclerosis (PADI2) 
Repetitive sequences 
aberrant methylation  
Transposition, 
recombination genomic 
instability 
ATRX syndrome (subtelomeric repeats) 
Histone modification  
Aberrant acetylation  Diverse  Parkinson’s and Huntington’s diseases 
Aberrant methylation  Diverse  Huntington’s disease and Friedreich’s ataxia 
Aberrant 
phosphorylation  Diverse  Alzheimer’s disease 
Nucleosome positioning  Misposition in trinucleotide repeats  
Creation of a ‘closed’ 
chromatin domain  Congenital myotonic dystrophy151 
Autoimmune diseases 
DNA methylation  
CpG island 
hypermethylation  Transcription repression  Rheumatoid arthritis (DR3) 
CpG island 
hypomethylation  Transcription activation  SLE (PRF1, CD70, CD154, AIM2) 
Repetitive sequences 
aberrant methylation  
Transposition, 
recombination genomic 
instability 
ICF (Sat2, Sat3), rheumatoid arthritis 
(L1) 
Histone modification  
Aberrant acetylation  Diverse  SLE (CD154, IL10, IFN-γ) 
Aberrant methylation  Diverse  Diabetes type 1 (CLTA4, IL6) 
Aberrant 
phosphorylation  Diverse  SLE (NF-κB targets) 
Nucleosome positioning  
SNPs in the 17q12-
q21 region  
Allele-specific differences 
in nucleosome distribution Diabetes type 1 (CLTA4, IL6) 
Histone variants 
replacement  
Interferes with proper 
remodeling  
Rheumatoid arthritis (histone variant 
macroH2A at NF-κB targets) 
 
Global hypomethylation was found mainly in the repetitive sequences (e.g., LINE, 
SINE, ALU, pericentromeric regions), intergenic regions and also in several oncogenes. 
This causes chromosomal instability, translocations, gene disruptions and reactivation of 
endoparasitic sequences. Hypomethylation at specific promoters can activate the aberrant 
expression of oncogenes and induce loss of normal imprinting patterns (e.g., 
hypomethylation of insulin-like growth factor 2, IGF2, which has been described in a wide 
range of tumours). DNA hypomethylation can occur in different stages of oncogenesis in a 
lation, hypermethylation is characterized by de 
hypermethylation of promoters affects genes involved in the main cellular pathways: DNA 
cancer type-specific manner and a correlation has been observed between the increasing 
DNA hypomethylation and aggressiveness level of cancer. 
In contrast to global hypomethy
novo methylation at specific CpG islands. The transcriptional inactivation caused by 
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repair, vitamin response, Ras signaling, cell cycle control, p53 network and apoptosis, 
among others. However, recent findings suggest that most aberrant DNA hypermethylation 
occurs in CpG shores and the majority of these changes (45-65%) seem to be associated 
with regions that become hypermethylated during normal tissue differentiation. 
Hypermethylation patterns are tumour-specific and it is not clear why some regions 
become hypermethylated and others remain unmethylated. 
These aberrant DNA  methylation patterns could be caused by dysregulation of 
DNMT expression, aberrant recruitment of the enzymes or expression of truncated 
mutants.22 DNMT1 and D  in many tumour types. 
ls (colorectal carcinoma cell line) led 
only to 20% of reduction of overall genomic methylation, probably due to compensation 
by oth
nzymes responsible of the opposite process has been 
elusive
s to return to a pluripotent state.  
consists of the loss of 50% methylation after each round of replication. On the contrary, 
epende  replic ymatic 
 either to remove the methyl group directly from the methylated base or to 
exchange the whole ba ethy
In plants activ ylation is carried out by 5 A 
such as D meter-like proteins,49 ass of enzymes has 
not been identified in In m
cytosine deaminases, t  to followed by T-G 
                                     
NMT3A/3B were found overexpressed
For example, knockout of DNMT1 in HCT116 cel
er DNMTs. However, genetic disruption of both DNMT1 and DNMT3B caused 
95% reduction of methylation content. This result demonstrates the cooperation of both 
enzymes and the relevance of targets for the development of anticancer drugs. 
1.3.5 DNA demethylation 
Although DNA methylation is one of the best-characterized epigenetic 
modifications, the identification of e
. The DNA methylation pattern is generated by a combination of methylation and 
demethylation reactions catalyzed by DNA methyltransferases and putative demethylases. 
Thus, DNA demethylation plays an important role in development and tumorigenesis  
since it is an essential process for cell
Passive demethylation takes place when the activity of DNMTs is suppressed and it 
active demethylation occurs ind ntly of DNA ation and requires enz
activity
se by an unm lated one.26,48  
e demeth
emeter and De
-methylcytosine (5mC) DN
but this clglycosylases 
 mammals. ammals, demethylation may be carried out by 
which conver 5-methylcytosine  thymine 
            
48 Ladwein, K. I.; Jung, M. t. Ed
49 Zhu, J.-K. Annu. Rev. Ge . 
Angew. Chem. In . 2011, 50, 12143. 
net. 2009, 43, 143
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mismatch repair that r  ou e base excision 
repair pathway). Two of e belong to this family of cytosine 
deaminases are AID (activation-induced inase) and APOBEC1 
Apolipoprotein B mR g Enzym  show 
strong 5mC deaminase activity  vitr (M g Domain 
DD45 (Growth Arrest and DNA-damage inducible 45) are involved 
cooperatively in demet NA.  w uitment of 
ethylatio to th A v  domain,15 
is also a G/T mismatc in yla er 
with AID form a deam se  vivo that ca he 
5, a pu o  demethylation in m ote 
demethylation by enhancing functional interactions e deaminase 
 (M 50 inc poss DNA 
y, DN ethylation in vivo may, in part, be mediated directly by this 
enzyme without the need of AID/APOBEC. Parathyroid hormone (PHT) represents 
ple of a induces demethylation of 5mC sites in the CYP27B1 
promoter of human 293  i th M 4. 
DNA demethylation is still poorl stood and con  a number 
echanis e been sug . Mamer and co-workers have proposed a 
DNA demethylation ased io ethylase 
 by a t hum fied f ased 
ideuteroformaldehyde from [Me-2H3]-5-methylcytosine in DNA. To detect the volatile 
dideute
 the 5-hydroxymethylcytosine, 
eplaces thymine with cytosine (thr gh BER or th
 examples nzymes that 
 cytosine deam
( NA Editin e, Catalytic polypeptide 1). Both of them
in o. AID, MBD4 ethyl-CpG Bindin
protein 4) and GA
hylation of D  MBD4, a protein hich assists the recr
the DNA dem n machinery e methylated DN ia its CpG-binding
h-specific thym e (DNA) glycos se of mammals that togeth
inase/glycosyla  pair in use DNA demethylation. T
role of GADD4 tative regulator f active ammals, is to prom
between th
(AID)/glycosylase BD4) pair.  S e MBD4 also esses 5-methylcytosine 
glycosylase activit A dem
another exam protein that 
F cells, but also n cooperation wi DB
y under troversial, although
of potencial m ms hav gested
mechanism b  on the observat n that a DNA dem
reaction catalyzed  recombinan an MBD2 puri rom SF9 insect cells rele
d
roformaldehyde by GC-MS (gas chromatography-mass spectrometry) it was 
reduced with sodium borodeuteride (NaB2H4) to CD3OH. Owing to the lack of structural 
information for MBD2, a computer model was generated for this protein using as template 
the available structure of MBD1. A close look at the model revealed that Tyr178 was 
perfectly positioned to participate in the demethylation process. Tyrosine side chains are 
known to form radicals and to be good nucleophiles. So, taking these findings into account 
the oxidative demethylation depicted in Figure 1.11 was proposed. In this mechanism a 
first single electron transfer, probably from a tyrosyl radical, and a second transfer by a 
hydroxyl radical or another radical species, would lead to
                                                 
50 Rai, K.; Huggins, I. J.; James, S. R.; Karpf, A. R.; Jones, D. A.; Cairns, B. R. Cell 2008, 135, 1201. 
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which in turn would undergo the addition of a nucleophile at C-6 to finally regenerate the 
double bond through elimination of formaldehyde and the nucleophile. 
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roposed mechanism for demethylation of 5mC in DNA. 
as found in bovine 
thymus
a two previously unknown cytosine 
derivat
                                                
Figure 1.11 P
Very recently it was demonstrated that the human TET1 (ten eleven translocation) 
hydroxylase protein, which belong to the Fe(II)/α-ketoglutarate-dependent oxygenase 
family of enzymes that includes histone demethylases, may also participate in active DNA 
demethylation through the oxidation of 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC), which has been found as minor base in DNA (~1%), as 
mentioned before.23,51 A glycosylase activity specific for 5hmC w
 extracts, which agrees with the fact that 5hmC is an intermediate in a pathway of 
active demethylation. In addition, conversion of 5mC to 5hmC may also facilitate passive 
DNA demethylation by excluding DNMT1, which recognizes 5hmC poorly.50  
Zhang and co-workers have shown that TET proteins  can also generate 5-
formylcytosine (5fC) and 5-carboxylcytosine (5c C), 
ives.52 Moreover, they proved that TET proteins can further oxidize 5hmC to 5fC 
and 5caC (TET 1, TET2 and, to a lesser extent, TET3) in vitro and that knockdown of 
TET1 reduced the genomic content of these three bases, indicating that this protein is at 
 
51 Ito, S.; D/'Alessio, A. C.; Taranova, O. V.; Hong, K.; Sowers, L. C.; Zhang, Y. Nature 2010, 466, 1129. 
He, C.; Zhang, Y. Science 2011, 333, 52 Ito, S.; Shen, L.; Dai, Q.; Wu, S. C.; Collins, L. B.; Swenberg, J. A.; 
1300. 
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least partially responsible for the generation of these cytosine derivatives. Furthermore, 
they proposed a mechanism in which TET proteins catalyze the oxidation to 5acC and 
then, a putative enzyme capable of decarboxylating 5acC-containing DNA completes the 
DNA demethylation process (Figure 1.12). Xu and co-workers also corroborated the 
existence of 5hmC and 5acC and their TET-mediated oxidation, however they suggested a 
more appealing model in which thymine-DNA glycosylase (TDG)-mediated base excision 
of 5acC to unmethylated cytosine is the last step of the active demethylation.53  
 
Figure 1.12 Proposed mechanism for oxidative demethylation initiated by TET proteins (alpha-ketoglutarate 
(α-KG)-dependent oxidation reaction). 
In addition to the role described above for TET proteins, it has also been 
demonstrated that TET1 binds mostly around the transcription start sites (TSSs) of high 
and intermediate density CpG promoters and within genes, and it is found together with the 
5hmC 
54
mark (this indicates that a significant part of 5mC is converted to 5hmC at the 
TSS).  TET1 target genes are involved in a variety of basic cellular processes as well as in 
development and differentiation; however there is not a clear correlation with 
transcriptional activation or repression. This enzyme can contribute to transcriptional 
repression by associating with the SIN3A co-repressor complex and histone deacetylases 
and to a minor extent to transcriptional activation by removing aberrant DNA methylation. 
This dual biological role of TET1 contributes to the regulation of the DNA methylation 
fidelity. 
To sum up, cytosine can be modified by methylation, deamination, oxidation or 
demethylation to generate a series of analogues that provide a new degree of diversity and 
complexity to the genome (Figure 1.13).55 It has several positions for modification, such as 
the C4 or C6 that are susceptible to nucleophilic attack, the C5 position that can be 
alkylated or oxygenated and the N-glycosidic bond that can be cleaved for base excision 
                                                 
53 He, Y.-F.; Li, B.-Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; Sun, Y.; Li, X.; 
Dai, Q.; Song, C.-X.; Zhang, K.; He, C.; Xu, G.-L. Science 2011, 333, 1303. 
54 Williams, K.; Christensen, J.; Pedersen, M. T.; Johansen, J. V.; Cloos, P. A. C.; Rappsilber, J.; Helin, K. 
Nature 2011, 473, 343. 
55 Nabel, C. S.; Manning, S. A.; Kohli, R. M. ACS Chem. Biol. 2012, 7, 20. 
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repair. The C4 position can also undergo deamination. In some cases, these modifications 
can lead to mutations, as mentioned above, but the DNA repair machinery has evolved to 
ensure integrity of DNA with BER (base excision repair) enzymes such as UDG (uracil 
DNA glycosylase) or SMUG (single-stranded monofunctional DNA glycosylase) and 
MMR (mismatch repair) enzymes such as TDG which targest T:G mispairs that arises 
from the deamination of 5mC. 
 
 
                                                
B
 
Figure 1.13 A. Cytosine analogues. Enzymatic modifications 
can generate 5-methylcytosine (5mC), 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), 5-
carboxylcytosine (5caC), 5-hydroxymethyluracil (5hmU), uracil 
(U), thymine (T). B. Modifying enzymes of cytosine includes 
deaminases of the AID/APOBEC family, DNA 
methyltransferases and TET family oxidases. 
 
5hmC is found throughout the genome at low frequency, but particularly it localizes 
upstream of the transcription start sites and in the gene bodies. Although some studies have 
shown that the levels of this mark in embryonic stem cells decrease during differentiation, 
its modulation in adult tissues remains poorly understood.56 Two epigenetic roles have 
been proposed for 5mC: 
 
, 
s, S.; Reik, W. Nature 2011, 473, 398. c. Ruzov, A.; Tsenkina, Y.; Serio, A.; Dudnakova, T.; 
 
56 a. Szwagierczak, A.; Bultmann, S.; Schmidt, C. S.; Spada, F.; Leonhardt, H. Nucleic Acids Res. 2010, 38
e181. b. Ficz, G.; Branco, M. R.; Seisenberger, S.; Santos, F.; Krueger, F.; Hore, T. A.; Marques, C. J.; 
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- As putative intermediate in the demethylation path, as mentioned above. 
- As a stable modification of cytosine that modulates the chromatin structure and, 
thus, the transcriptional activation or repression. The presence of this mark in the 
promoter region of a gene is associated with transcriptional repression and this 
hypothesis is supported by the observation that TET oxidases associate with the 
Sin3A repressor complex and with histone deacetylases. However, the role of this 
modification in intragenic regions is unclear (Figure 1.14). 
 
Figure 1.14 Cytosine methylation and hydroxymethylation regulate transcription. Methylation typically 
represses gene expression, but the role of hydroxymethylation needs to be explored (adapted from reference 
56). 
As conclusion there are currently two major models to explain the active 
demethylation in which AID/APOBEC deaminases, TET oxidases and DNA glycosylases 
are implied: a deamination-initiated pathway and several variants of an oxidation-initiated 
pathway (Figure 1.15).  
1. In the deamination-initiated pathway, 5mC is first deaminated by the 
AID/APOBEC family of enzymes to give thymine, that is subsequently recognize 
in a T:G mismatch and changed into an unmodified cytosine. Several factors 
suggest that this pathway cannot fully explain demethylation since deletion of AID 
is not embryonic lethal as it would be expected if this were the unique way of active 
demethylation.  
                                                                                                                                                    
Fletcher, J.; Bai, Y.; Chebotareva, T.; Pells, S.; Hannoun, Z.; Sullivan, G.; Chandran, S.; Hay, D. C.; Bradley, 
M.; Wilmut, I.; De Sousa, P. Cell Res. 2011, 21, 1332. 
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2. The oxidation-initiated mechanism starts with the oxidation of 5mC by TET 
proteins. After that, several potential pathways can be considered: direct-reversion, 
deamination-coupled or BER-coupled mechanisms. 
2.1. Direct-reversion mechanisms: although this is a possible mechanism, so far 
an enzyme for direct removal of the hydroxymethyl group 
(dehydroxymethylation) has not been discovered. 
2.2. Deamination-coupled mechanisms: 5hmC could be deaminated by 
AID/APOBEC enzymes to give 5hmU, which turn could be removed by 
TDG or SMUG enzymes (BER pathway). The presence of 5hmU has not 
been detected yet as an intermediate of demethylation
2.3. BER-coupled mechani
in 
. 
sms: repre re recent sents a mo appealing model that 
involves iterative oxidations with TET proteins coupled with BER pathway. 
5fC and 5caC result from e iterative oxida n by ETs. Zha g and co-
workers proposed an undiscovered decarboxylase to regenerate the cytosine 
from 5acC,52whereas He and colleagues suggest a more appealing m l in 
which TDG has DNA glycosylase activity against 5acC.53 This mechanism is 
consistent with the observation that TDG deficiency causes embryonic 
lethality and leads to perturbed methylation patterns in embryogenesis. 
According to these fact
mediated pathway, bu
weakened N-glycosidic 
 th tio  T n
ode
s, TDG does not necessarily implicate a deamination-
t it can directly excise cytosine analogues with 
bonds, as 5acC or 5fC.57  
                                                 
57 Maiti, A.; Drohat, A. C. J. Biol. Chem. 2011, 286, 35334. 
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Figure 1.15 Integrated model for cytosine demethylation (adapted from reference 56). 
r route to demethylation, but the deamination pathway could play an important 
accesso
inant event in cancer-related gene silencing as 
27 and H4K20 has been suggested as a prerequisite 
for subsequent DNA methylation, probably due to the physical association between the 
ethylation of H3K9) and EZH2 (which 
In summary, an iterative oxidation-initiated/BER-coupled mechanism could be the 
majo
ry role to accelerate demethylation in certain circumstances. 
1.3.6 DNA methylation and histone modifications 
DNA methylation is the dom
compared with histone modifications. However, both epigenetic modifications influence 
each other: histone methylation may direct DNA methylation patterns and DNA may serve 
as a template for the establishment of certain histone modifications after DNA 
methylation.50 Thus, for the reversion of the epigenetic state, the simultaneous inhibition of 
DNMTs and HDACs is being investigated. 
Trimethylation of H3K9, H3K
components of these histone methylation system and one or more DNMTs. The histone 
methyltransferases SUV39H1/2 (responsible for m
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methylates H3K27) interact directly with DNMT1, DNMT3A and DNMT3B and facilitate 
their binding to the target promoter of these enzymes, inducing CpG methylation. G9A (a 
methyl transferase acting on H3K9 and H3K27) also contributes to DNA methylation. 
silencing. T
targets DN cent CpG dinucleotides at 
methyltransf
SET
meth -specific demethylase 
and 
silen
repre
dom
repli
(prol
acts as a gu
mod ation pattern is ensured by 
DNMT1-PCNA and/or DNMT1-UHRF1 interactions. UHRF1 binds to hemimethylated 
DNA and also interacts with DNMT1 and with peptides that are methylated at H3K9, 
creating a feedback mechanism that involves the mutual reinforcement of histone and 
DNA methylation marks. 
The methyl-CpG-binding proteins (MBDs) also link DNA and the histone code. 
MBDs interact specifically with methylated DNA and form a complex with the histone 
lysine methyltransferase SETDB1, thus coupling both epigenetic modifications. For 
example, MeCP2 is a methyl-CpG-binding protein that binds the genome in a DNA-
methylation manner and associates with corepressor complexes containing HDACs. 
An inverse correlation exists between DNA methylation and H3K4 methylation, 
although the mechanism is not clear. DNMT3L specifically interacts with the extreme 
amino terminus of histone H3 and this interaction is inhibited by methylation at H3K4, but 
Histone arginine methylation has been also linked to DNA methylation and gene 
he symmetric dimethylation of H4R3 (H4R3me2s) catalyzed by PRMT5 
MT3A, which in turn induces methylation of adja
PRMT5 target genes. In addition to the direct recruitment of DNMTs, histone 
erases and demethylases may influence the stability of DNMTs. For example, 
7, a histone methyltransferase selective for H3K4, colocalizes with DNMT1 and 
ylates K142 to regulate its stability and degradation. The lysine
1 (LSD1) catalyzes the opposite modification. 
HP1 (heterochromatin protein 1) also provides a link between DNA methylation 
histone marks since it binds to methylated H3K9 and recruits DNMTs, mediating the 
cing of euchromatin genes. This protein also interacts with HDACs, transcriptional 
ssors and chromatin remodeling enzymes to further enhance or stabilize the repressive 
ains. 
Although DNA methylation patterns are faithfully reproduced after DNA 
cation, there is no template for nucleosome reassembly after replication. PCNA 
iferating cell nuclear antigen) plays a very important role in DNA synthesis and it also 
ide for other epigenetic modifications since it recruits a variety of epigenetic 
ulators, such as HDACs. The maintenance of the methyl
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not by modifications at other positions. DNMT3L recognizes unmethylated H3K4 and 
induces de novo methylation by recruitment of DNMT3A. 
As conclusion, it is possible that DNA methylation is a default state of the genome 
unless m lation of H3K4 or other histone marks maintain specific regions free of DNA 
methylation. 
1.3.7 DNMT inhibitors (DNMTis) 
As mentioned before, epigenetic alterations have been established in recent years as 
important molecular signatures of human cancer, and therefore chromatin modifying 
enzymes, particularly DNA methyltransferases and histone deacetylases, represent already 
validated cancer drug targets.7 All human cancer types appear to show a loss of the normal 
control of DNA methylation. Analysis of DNA methylation at a genome-wide level has 
demonstrated aberrant methylation of promoter regions of certain genes28b and an overall 
decrease of DNA methylation levels that promote chromosomal instability. To keep the 
genome in this “epimutated state” the continuous activity of DNMTs, which are found 
overexpressed in several tumours, is required, and this fact accounts for their reversibility 
using specific inhibitors.28c 
Re ssion of 
tumour growth or sensitization to other anti
acokinetics and 
pharmacodynamics of the combined substances have led to the search of alternatives, such 
 than a single enzyme.58  
In the case of histone deacetylases two inhibitors (SAHA, Vorinostat, Zolinza® and 
FK228, romidepsin, Istodax
this reason and given the importance of 
epigenetic therapies for fighting th
ethy
-expression of genes epigenetically inactivated can result in the suppre
cancer therapies. Simultaneous targeting of 
multiple epigenetic systems is currently sought. In this sense, combination of different epi-
drugs are being explored, however some problems regarding pharm
as the generation of compounds that can target more
®) have been approved for human use, and several other drugs 
are undergoing clinical trials and hundreds are in preclinical research phases. In the case of 
DNMTs inhibitors two compounds (5-azacytidine, azacitidine, AzaC, Vidaza® and 5-aza-
2’-deoxycytidine, decitabine, Dacogen®) have been approved for human used, but beyond 
those only a few unselective and not very potent inhibitors are known. This is an 
uncommon situation in drug discovery. For 
e onset and progression of diseases it is necessary to 
develop new epigenetic modulators for cancer and other therapies. 
                                                 
58 Álvarez, R.; Gronemeyer, H.; Altucci, L.; de Lera, A. R. Curr. Top. Med. Chem. 2011, 11, 2749. 
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DNMT inhibitors (DNMTis) can be divided into two groups, nucleoside and non-
nucleoside inhibitors. The first category includes nucleoside analogs that are incorporated 
into DNA and act as suicide inhibitors for DNMT via covalent adduct formation (for this 
reason they are also called “mechanism-based inhibitors”). Compounds of the second 
group act on the free enzyme in the same way as “classic” enzyme inhibitors do.22 
1.3.7.1 Covalent DNMT inhibitors 
This group is formed by nucleoside analogs that have a modified cytosine ring 
attached to either a ribose or deoxyribose moiety (see Figure 1.16). The two nucleosides 
that have been developed clinically (5-azacytidine and 5-aza-2’-deoxycytidine or 
decitabine) as well as 5-fluoro-2’-deoxycytidine (FCDR), zebularine and 5,6-dihydro-5-
azacyti
e and 5-aza-2’-deoxycytidine underwent early clinical testing for cancers in the 
1970s 
l]-5-azacytidine, also called NPEOC-5-aza-2'-deoxycitidine) 
has be
 by a 
           
dine (DHAC) belong to this group.  
The best studied DNMT inhibitor is 5-azacytidine, which was first characterized by 
Jones and co-workers in the 1970s,59 and identified as a potent anticancer agent and found 
also to be able to turn embryonic mouse cells into muscle without mutating DNA. Both 5-
azacytidin
and 1980s, but these trials were abandoned due to their toxicity.60 In the 1990s, 
research with these drugs was resumed, which led to their approval (Vidaza® in 2004 and 
Dacogen® in 2006) by the Food and Drug Administration (FDA) for the treatment of 
myelodysplastic syndrome (MDS), a preleukemia condition, where they demonstrate 
significant, although transient, improvement in patient survival.29 
Nucleoside inhibitors act as prodrugs that show no activity during in vitro DNMT 
assays.61 They are able to block DNMT only after incorporation into the DNA. In this 
regard an ester prodrug of prodrug decitabine (2’-deoxy-N4-[2-(4-
nitrophenyl)ethoxycarbony
en developed, and requires prior activation by a carboxyesterase to release 
decitabine.62 Deoxyribonucleosides such as decitabine or FCDR can be directly 
transformed into the triphosphates by deoxycytidine kinases, and then incorporated into 
DNA by DNA polymerases. Ribonucleosides need to be deoxygenated in the sugar moiety 
before their incorporation into DNA. This step is performed on the diphosphate
                                      
 P. A.; Taylor, S. M. Cell 1980, 20, 85. 59 Jones,
Lett. 2008, 266, 238. 
60 Kaiser, J. Science 2010, 330, 576. 
61 Stresemann, C.; Brueckner, B.; Musch, T.; Stopper, H.; Lyko, F. Cancer Res. 2006, 66, 2794. 
62 Byun, H.-M.; Choi, S. H.; Laird, P. W.; Trinh, B.; Siddiqui, M. A.; Marquez, V. E.; Yang, A. S. Cancer 
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ribonucleotide reductase, and after formation of the triphosphate, the false base is 
incorporated into DNA. Owing to this difference in the metabolism of both kinds of 
nucleo
into RNA, interfeering with protein synthesis and causing additional side-
effects (Figure 1.16B).63 These drugs, in addition to the mentioned limitation of metabolic 
nto DNA or RNA, face also problems of cytotoxicity, 
stabilit
ll lines with a combination of decitabine and zebularine 
resulte
                                                
sides, the rate of incorporation of azacitidine to DNA is much lower than that of 
decitabine or 5-fluoro-2’-deoxycytidine (FCDR). In addition, azacytidine as riboside is 
incorporated 
transformation to get incorporated i
y in aqueous solution (short half life-time) and poor bioavailability. In this sense, 
the related compound 5,6-dihydro-5-azacytidine (DHAC) has been found to possess better 
stability and lower toxicity and effectively reduces DNA methylation in different cancer 
models. Zebularine is a novel promising inhibitor because of its greater stability, lower 
toxicity and selectivity for tumour cells, although its potency is about 10-fold lower than 
that of the azacytosines. This compound also inhibits cytidine deaminase (CD), which is an 
enzyme that can deactivate cytidine analogs by catalyzing the irreversible hydrolytic 
deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively. Since 
this seems to be one of the mechanisms of resistance of these drugs, the treatment of 
murine and human leukemia ce
d in enhancement of the antileukemic activity of the former due to the inhibition of 
CD. Zebularine and the phosphoramidate of 5-aza-2’-deoxycytidine showed demethylation 
and reactivation of the silenced and hypermethylated p16 gen in bladder tumour cell 
lines.21 
 
63 Plagemann, P. G. W.; Behrens, M.; Abraham, D. Cancer Res. 1978, 38, 2458. 
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Figure 1.16 A. Nucleoside inhibitors. B. Metabolic activation of prodrug inhibitors. C. Mechanism of 
covalent DNMT inhibition. 
76 
Introduction 
Based on the structures of the different DNMT (human and bacterial DNA 
methyltransferases) known at the time and on the homology model established for 
DNMT1,42 several molecular modeling studies were performed that led to the proposal of 
different binding modes of DNMT inhibitors. In the case of nucleoside inhibitors, the 
docking-based binding modes were in agreement with the proposed mechanism for DNA 
methylation (Figure 1.16C). After incorporation into DNA, they undergo the nucleophilic 
attack of the DNMTs’ invariant active-site cysteine residue to form a covalent adduct. This 
adduct in most cases reacts with S-AdoMet to form a methylated adduct that is not able to 
release the enzyme due to the absence of an α-proton. The case of zebularine is somehow 
different since methylation is not required for inhibition. A stable intermediate is formed, 
even though elimination of the enzyme should be possible, too. 
There are some questions that remain unclear regarding the selectivity of some 
epigenetic drugs towards cancer cells and the exact mechanism of antitumor action. The 
covalent trapping of DNMTs leads to a depletion of these enzymes in the cell and 
subsequent DNA hypomethylation, which in turn results in activation of silenced genes. In 
addition, the covalent trapping of DNMT may inhibit RNA and DNA polymerases, which 
leads to an inhibition of protein synthesis and DNA strand breaks. This may induce 
apoptosis and hence toxicity. 
1.3.7.2 Non-covalent DNMT inhibitors 
The second, more diverse group of DNMT inhibitors has been developed as 
additional effective compounds for new epigenetic anticancer therapy. These compounds 
reduce DNA methylation without being incorporated into DNA molecule, and therefore 
this should shift the dual activity of reactivation of silenced genes and cytotoxicity towards 
the epigenetic effects, which may result in reduced side-effects. They can bind either 
directly to the catalytic site of the DNMT enzyme or to the CpG-rich sequences that 
prevent the binding between DNMTs and their target sequences (Figure 1.17). This group 
includes some compounds that are approved drugs for other indications like the 4-
aminobenzoic acid-derived compounds procaine, a local anesthetic, and procainamide, an 
antiarrhythmic drug, as well as hydralazine, an antihypertensive drug. Constrained analogs 
of procaine have also been reported. Using the homology model of DNMT1, docking and 
molecular dynamics of hydralazine showed a complex network of hydrogen bonds with 
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arginine and glutamic acid residues, which also play a major role in the methylation 
mechanism.64 In the same work, the putative binding modes of procaine and procainamide 
were explored leading to the conclusion that the carbonyl oxygen of both compounds 
occupy approximately the same position as that of the oxygen of the ribose ring of 2’-
deoxycytidine. This oxygen also plays a key role since it stabilizes the intermediate formed 
after the nucleophilic attack to S-AdoMet. However the DNA-demethylating action of 
procaine and procainamide is thought to be mediated by its binding to CpG-rich sequences 
that mask the DNMT target sequences.65 In a virtual screening of a compound collection 
with the homology-built DNMT1 model, the L-tryptophan derivative RG108 (NSC401055) 
was discovered.66 Compound NSC401077 was also identified as a DNMT1 inhibitor using 
the same protocol. In vivo and in vitro assays showed that RG108 selectively blocked the 
active domain of DNMT1 without covalent binding, with the carboxylate playing an 
important role in the interaction with the enzyme. In fact, the analog of RG108 without the 
carboxylic acid group was found to be inactive. Low micromolar concentrations of RG108 
induced significant demethylation of DNA without any detectable toxicity in HCT116 
cells. Synthetic analogs of RG-108 have recently been reported.67 Modeling suggests that 
the inhibitors binds deep in the active site, occupying the pocket of the native cytosine and 
close to the cysteine residue, but since the formation of the covalent adduct is unlikely 
these compounds are mechanism-independent inhibitors. In case of the maleimide analog 
of RG108 (Figure 1.17), which showed improved inhibitory activity relative to RG108, the 
binding mode in the catalytic site of bacterial M.HaI showed the carboxylate and carbonyl 
groups engaged in hydrogen bonding with arginine residues. In addition, being the 
maleimide moiety positioned close to the catalytic cysteine is suggestive of a putative 
conjugate addition of the thiol to the maleimide. More recently, a virtual screening of 
65,000 lead-like compounds from the NCI collection using the homology-built model for 
DNMT1 led to the identification of several novel scaffolds, the most potent and selective 
(DMNT1 vs DNMT3B) of which was the methylenedisalicylic acid NSC14778.68 A 
                                                 
64 Singh, N.; Dueñas-González, A.; Lyko, F.; Medina-Franco, J. L. ChemMedChem 2009, 4, 792. 
65 a. Piña, I. C.; Gautschi, J. T.; Wang, G.-Y.-S.; Sanders, M. L.; Schmitz, F. J.; France, D.; Cornell-Kennon, 
S.; Sambucetti, L. C.; Remiszewski, S. W.; Perez, L. B.; Bair, K. W.; Crews, P. J. Org. Chem. 2003, 68, 
3866. b. Villar-Garea, A.; Fraga, M. F.; Espada, J.; Esteller, M. Cancer Res. 2003, 63, 4984. 
66 a. Brueckner, B.; Boy, R. G.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; 
Wiessler, M.; Lyko, F. Cancer Res. 2005, 65, 6305. b. Siedlecki, P.; Boy, R. G.; Musch, T.; Brueckner, B.; 
Suhai, S.; Lyko, F.; Zielenkiewicz, P. J. Med. Chem. 2006, 49, 678. 
67 Suzuki, T.; Tanaka, R.; Hamada, S.; Nakagawa, H.; Miyata, N. Bioorg.  Med. Chem. Lett. 2010, 20, 1124. 
68 Kuck, D.; Singh, N.; Lyko, F.; Medina-Franco, J. L. Bioorg.  Med. Chem. Lett. 2010, 18, 822. 
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synthetic quinoline-based compound, SGI-1027, has been described as DNMT1, 
DNMT3A and DNMT3B inhibitor. This compound was found to reactivate tumor 
suppressor genes by blocking the enzymes and inducing their degradation. It functions as 
competitor of S-AdoMet but not of the substrate, for the active site.69  
S-adenosyl-L-homocysteine (AdoHcy) analogs have also been reported as selective 
DNMT1 inhibitors, presumably by binding in the cofactor binding pocket.70 In addition, 
the antisense oligodeoxynucleotide M98 was proposed as DNMT inhibitor since it 
prevents the translation of DNMT1 mRNA.71  
                                                 
69 Datta, J.; Ghoshal, K.; Denny, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, 
S. T. Cancer Res. 2009, 69, 4277. 
70 Isakovic, L.; Saavedra, O. M.; Llewellyn, D. B.; Claridge, S.; Zhan, L.; Bernstein, N.; Vaisburg, A.; 
Elowe, N.; Petschner, A. J.; Rahil, J.; Beaulieu, N.; Gauthier, F.; MacLeod, A. R.; Delorme, D.; Besterman, 
J. M.; Wahhab, A. Bioorg.  Med. Chem. Lett. 2009, 19, 2742. 
71 Amato, R. J. Clin. Genitourin. Cancer 2007, 5, 422. 
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Figure 1.17 Non-nucleoside inhibitors. 
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Natural products as DNMT inhibitors 
Natural products are attractive sources of DNMT inhibitors. Active compounds 
from natural sources can be drug themselves or can be the starting point for optimization 
programs. For example the main polyphenol compound from green tea, (-)-epi-
galloca
 the mechanism of 
methylation. Other polyphenols like catechin and epicatechin, and the bioflavonoids 
quercetin, fisetin, and myricetin are also implicated in DNA methylation inhibition. The 
catechol containing dietary epicatechin has been suggested to inhibit DNA methylation 
indirectly owing to the increased formation of AdoHcy, as a consequence of catechol-O-
methyltransferase(COMT)-mediated O-methylation of epicatechin. Other dietary catechols 
that might inhibit DNA methylation comprise the polyphenols from coffee (caffeic acid 
and chlorogenic acid) and apple. Genistein, the major isoflavone from soybean and two 
other isoflavones (biochanin A and daidzein) have also been reported to display 
demethylation activity.  
Other compounds with DNMT inhibitory activity have been isolated from marine 
sources: the pyridoacridine dercitin, the halogenated monoterpene halomon and other 
compound isolated from the red alga Portieria hornemannii, psammaplin A, bisaprasin and 
other disulfide bromotyrosine derivatives from Pseudoceratina purpurea (Verongida 
sponges) and the glycerol fatty acid peyssonenynes from the red alga Peyssonelia 
caulifera.72 Some of the psammaplins inhibit both DNMTs and HDACs. The mechanism 
of action of all these compounds on DNMT1 is not clear yet, but it might involve the 
binding to CpG-rich regions, thus perturbing the interactions between DNMT1 and the 
target sequences and/or the inactivation of the conserved cytosine residue of the catalytic 
site. 
Mitoxantrone (NovatroneTM),73 an antitumor antibiotic and inhibitor of 
topoisomerase II, and mithramycin A,74 a structurally complex anticancer antibiotic 
 
techin-3-gallate (EGCG), is a pleiotropic inhibitor with several inhibitory or 
stimulatory activities. The binding mode of EGCG in the homology model of DNMT1 
proposes hydrogen bonds of the gallate with glutamate and proline residues that also 
appear to stabilize the flipped cytosine through hydrogen bonding in
produced by the soil bacterium Streptomyces argillaceus, have been described to inhibit 
                                                
s 2007, 18, 1157. 
72 McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J. Nat. Prod. 2004, 67, 1010. 
73 Parker, B. S.; Cutts, S. M.; Nudelman, A.; Rephaeli, A.; Phillips, D. R.; Sukumar, S. Cancer Biology & 
Therapy 2003, 2, 257. 
74 Lin, R.-K.; Hsu, C.-H.; Wang, Y.-C. Anticancer Drug
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DNA methylation. Mithramycin A binds to GpC or CpG-rich sequences blocking the 
DNMT methylation activity. More recently, nanaomycin A, a quinone antibiotic isolated 
from a culture of Streptomyces, has been reported as the first non-SAH analog that inhibits 
DNMT3B selectively. The binding mode of nanaomycin A was proposed using docking 
with a homology model of the catalytic site of DNMT3B. In this model an extensive 
hydrogen-bond network of the carboxylic acid, the hydroxyl group and adjacent carbonyl 
oxygen is formed with the side chain of arginine. Interestingly these interactions were not 
found in the docking studies with DNMT1. Moreover, a nucleophilic Michael-type 
addition of the cysteine to the quinone is hypothesized with DNMT3B, but it is not 
plausible in the binding model with DNMT1. 
Other products with DNMT inhibitory activity includes: mahanine, a plant-derived 
carbazole alkaloid, parthenolide, the main sesquiterpene lactone of feverfew and curcumin, 
the major component of the Indian curry spice turmeric. For parthenolide and curcumin a 
similar mechanism of inhibition has been proposed using a homology model of the 
catalytic site of DNMT1, in which they inhibit the enzyme through alkylation of the 
cysteine. 
With some exceptions these non-nucleoside drugs are weaker than the nucleoside 
analogues and work better in some systems than others, but both type of inhibitors are 
effective modifiers of the cancer phenotype and thus promising cancer therapeutic agents. 
  
yssonenynes A and B isolated from Peyssonnelia 
an leukemia cells with anti-DNMT1 antibody. 
2. TOTAL SYNTHESIS OF THE PROPOSED 
STRUCTURES OF THE DNA METHYL 
TRANSFERASE INHIBITORS 
PEYSSONENYNES, AND STRUCTURAL 
REVISION OF PEYSSONENYNE B 
 
 
The purported structures of the pe
caulifera, and considered to be geometric isomers at the acetoxyenediyne moiety, have 
been synthesized. The E and Z geometries of the synthetic compounds were secured by the 
magnitude of the 3JH9-C7 values measured using the EXSIDE band-variant of the gradient 
HSQC pulse sequence and by the chemical shifts of C6. Comparison of the NMR data of 
the synthetic and natural products revealed that only those of the Z isomers matched, which 
correspond to peyssonenyne A. Using HPLC analysis it was found that peyssonenyne B 
must correspond to the sn-2 positional isomer of the Z sn-1/3 counterpart. The four 
synthetic sn-1/3 diastereomers are roughly equipotent as DNMT1 inhibitors when 
evaluated on a radioactive methyl transfer enzymatic assay after immunoprecipitation from 
K562 hum
 
 

Total Synthesis of the Peyssonenynes 
2.1 Introduction 
 
The oxylipin metabolites peyssonenynes A and B (1) were isolated in 2004 from 
the de 
oxylipins, which derive biogenetically from
occurre lity of 
the peyssonenynes is so far uni
 In vitro a d DNA methyl 
transferase 1 (DNMT1)  with IC50
membe
DNMT2 and DNMT3 (A, B and L). DNMT1 is responsible for maintenance of the DNA 
methylation e, whereas 
DNMT3A and DNMT3B are ethyltransferases that establish embryonic 
methylation patterns.  DNMT3L lacks intrinsic catalytic activity, but modulates the activity 
of DNMT3A and DNMT3B, to which it is physically associated. 
The transfer of a methyl group fro  S-adenosyl-L-methionine (SAM) to DNA 
cytosine C5 position within CpG dinucleotide-rich regions (CpG islands) is the best known 
Fijian red marine alga Peyssonnelia caulifera.1 These oxidized monoacylglyceri
 a ω3 polyunsaturated fatty acid, are a rare 
nce in red algae, and the 1,3-diyne2 conjugated to the enolacetate functiona
que to these natural products.3 
ssays showed that these peyssonenynes A and B inhibite
 values of 16 and 9 μM, respectively. DNMT1 is a 
r of the DNA methyl transferase protein family,4 which includes in mammals 
pattern during chromosome replication.5 DNMT2 has no defined rol
de novo m
m
of the covalent modifications of the epigenome. The patterns and extension of DNA 
methylation impacts on key biological activities, among them the control of gene 
expression, the regulation of parental imprinting, the stabilization of X-chromosome 
inactivation and the maintenance of genome integrity in eukaryotes. Aberrant patterns of 
DNA methylation are associated with several diseases, including the onset and progression 
of cancer. Cancer cells show global hypomethylation of CpG islands and site-specific 
hypermethylation of DNA promoter regions (in particular, of tumor suppressor genes) 
which are normally unmethylated.6  
                                                 
1 McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J. N
2
at. Prod. 2004, 67, 1010. 
 Diederich, F.; Stang, P. J.; Tykwinski, R. R. Acetylene Chemistry: Chemistry, Biology and Material 
cience; Wiley-VCH: Weinheim, 2005. 
3 Minto, R. E.; Blacklock, B. J. Prog. Lip. Res. 2008, 47, 233. 
4 (a) Hellebrekers, D. M. E. I.; Griffioen, A. W.; van Engeland, M. Biochim. Biophys. Acta - Rev. Cancer 
2007, 1775, 76. (b) Cheng, X.; Blumenthal, R. M. Structure 2008, 16, 341. (c) Jurkowska, R. Z.; Jurkowski, 
T. P.; Jeltsch, A. ChemBioChem 2011, 12, 206. 
5 (a) Biel, M.; Wascholowski, V.; Giannis, A. Angew. Chem. Int. Ed. 2005, 44, 3186. (b) Allis, C. D.; 
Jenuwein, T.; Reinberg, D.; Caparros, M.-L. Epigenetics; Cold Spring Harbor Laboratory Press: Cold Spring 
Harbor (NY), 2007. 
6 (a) Feinberg, A. P. Nature 2007, 447, 433. (b) Esteller, M. N. Engl. J. Med. 2008, 358, 1148. 
S
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Targeting enzymes that modify chromatin (the DNA and its associated histones) 
with epigenetic drugs is considered a novel and promising anticancer strategy.7 Selective 
DNMT inhibitors (DNMTis) might rapidly reactivate the expression of epigenetically-
silenced tumour suppressor genes, and this reactivation could lead to growth inhibition of 
tumour cells or alteration of their sensitivity to other anticancer therapies. Two DNMTis 
(5-aza-cytidine, Vidaza®, 5-aza-2’-deoxycytidine, Dacogen®) are already in the clinic for 
the treatment of myelodysplastic syndrome. However, these drugs are cytotoxic 
azanucleosides, and novel inhibitors with alternative mechanisms of action are actively 
sought.  
Our interest in the anticancer activities of natural product-based epigenetic 
modulators8 led us to address the total synthesis of the peyssonenynes, determine their 
DNMT inhibitory profile and validate these modulators in cell-based assays. Added to this 
aim was the need to authenticate the gross structure by unambiguous characterization of 
the enolacetate geometry and determination of the absolute configuration of the glycerol 
stereocenter. These issues have remained unsolved due to the instability of the 
peyssonenynes A and B and the minute amounts of these acetoxyenediyne oxylipins that 
were isolated from the natural source (1.3 and 0.4 mg, respectively, from 365 g of dry 
alga). 
2.2 Results and discussion 
In our retrosynthetic analysis the generation of the sensitive enolacetate of the 
peyssonenynes was postponed to a late stage of the sequence after construction of the 
diyne moiety9 by the Cadiot-Chodkiewicz coupling10 of a 1-iodoalkyne and a propargylic 
alcohol (Scheme 2.1). These fragments could be traced back to appropriate combinations 
of glycerol, two terminal alkynoic acids and a propargylic bromide. 
                                                 
7(a) Sippl, W.; Jung, M. Epigenetic Targets in Drug Discovery; Wiley-VCH: Weinheim, 2009. (b) 
Rodríguez-Paredes, M.; Esteller, M. Nat. Med. 2011, 17, 330. (c) Kelly, T. K.; De Carvalho, D. D.; Jones, P. 
A. Nat. Biotech. 2010, 28, 1069. (d) Szyf, M. Ann. Rev. Pharmacol. Toxicol. 2009, 49, 243. 
8 (a) Pérez-Balado, C.; Rodríguez-Graña, P.; Nebiosso, A.; Minichiello, A.; Miceli, M.; Altucci, L.; de Lera, 
A. R. J. Med. Chem. 2007, 50, 2497. (b) Souto, J. A.; Conte, M.; Alvarez, R.; Nebbioso, A.; Carafa, V.; 
Altucci, L.; de Lera, A. R. ChemMedChem 2008, 3, 1435. (c) Souto, J.; Benedetti, R.; Otto, K.; Miceli, M.; 
Álvarez, R.; Altucci, L.; de Lera, A. ChemMedChem 2010, 5, 1530. (d) Souto, J. A.; Vaz, E.; Lepore, I.; 
Pöppler, A.-C.; Franci, G.; Álvarez, R.; Altucci, L.; de Lera, Á. R. J. Med. Chem. 2010, 53, 4654. 
9 Negishi, E.-i.; Anastasia, L. Chem. Rev. 2003, 103, 1979. 
10 (a) Chodkiewicz, W.; Cadiot, P. C. R. Hebd. Seances Acad. Sci. 1955, 241, 1055. (b) Chodkiewicz, W. 
Ann. Chim. 1957, 2, 819. 
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Scheme 2.1. Retrosynthetic analysis of the peyssonenynes. 
Scheme 2 outlines the synthetic sequence that has been optimized for the 
preparation of the required building blocks. The chiral fragments of each
were derived from enantiopure glycerol isopropylidene ketal 3, 
 enantiomer of 1 
itself obtained from either 
D-mannitol or L-gulono-1,4-lactone (only the R series is shown in Scheme 2, which starts 
from (S)-3)  as described.11 DCC-induced coupling of (S)-3 with pent-4-ynoic acid 2 gave 
(R)-4 and iodination of the latter provided enantiopure ester (R)-5 in good yield. 
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Scheme 2.2 Reagents and reaction conditions: (a) DCC, DMAP, CH2Cl2, 25 ºC, 12h, 98%. (b) NIS, AgNO3, 
acetone, 12h, 25 ºC (69%). (c) EDC, DMAP, HN(OMe)Me . HCl, CH2Cl2, 25 ºC (100%). (d) Cs2CO3, NaI, 
                                                 
11 (a) Doyle, M. P.; Hu, W.; Phillips, I. M.; Moody, C. J.; Pepper, A. G.; Slawin, A. G. Z. Adv. Synth. Cat. 
2001, 343, 112. (b) Sugisaki, C. H.; Ruland, Y.; Baltas, M. Eur. J. Org. Chem.  2003, 672. (c) Johnson, M. 
81, 22, 303. R.; Rickborn, B. J. Org. Chem. 1970, 35, 1041. (d) Sum, F. W.; Weiler, L. Tetrahedron Lett. 19
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CuCl, D
 intermediates were difficult to handle because of their instability in solution, 
they w
ction of 11 using TBAF afforded propargylic alcohol 12 in good yield. 
The conditions reported by Alami and Ferri (CuI, piperidine)18 were selected for 
 given their experimental simplicity in comparison with 
the sta
MF, 25 ºC. (e) n-BuLi, THF, -40 to 25 ºC. (f) Ni(OAc)2 . 4H2O, NaBH4, ethylenediamine, EtOH, 1 
atm H2 (75% over the three steps). (g) TBAF, THF, 25 º C, 0.5 h (81%). 
Among the alternative routes to the skipped 1,4-diene unit of alkyne 12,12 we 
selected the Cs2CO3-promoted coupling between the terminal alkyne 7 and 1-bromopent-
2-yne 8 (Scheme 2)13 followed by semihydrogenation. Hex-5-ynoic acid 6 was converted 
into the Weinreb amide14 7 by treatment with N,O-dimethylhydroxylamine hydrochloride, 
EDC and DMAP.15 Upon Cu(I)-promoted condensation of alkyne 7 and propargylic 
bromide 8 in the presence of NaI and Cs2CO3, diyne 9 was obtained (Scheme 2.2). Since 
acetylenic
ere used in the next reactions without purification. Addition of the anion of TIPS-
acetylene to the Weinreb amide 9 afforded the propargylic ketone 10. Hydrogenation of 10 
in the presence of Lindlar catalyst failed to provide the desired product. We turned our 
attention to P2-Ni catalyst, which is generated in situ by reduction of nickel acetate with 
sodium borohydride in ethanol.16 Given the sensitivity of the reaction to the steric 
environment of the unsaturation, the hydrogenation was selective for the skipped diyne 
(the alkynylsilane remained unaffected) although the reagent also caused the reduction of 
the ketone to the corresponding alcohol and provided compound 11 (75%, 3 steps).17 
Deprote
the key cross-coupling reaction19
ndard Cadiot-Chodkiewicz protocol (CuCl, HONH2 . HCl, Et2NH, MeOH). 
Condensation of propargylic alcohol 12 and iodoalkyne (R)-5 provided diynol 13, which 
was oxidized to diynylketone 14 using the Swern conditions (Scheme 2.3). 
                                                 
12 Caruso, T.; Spinella, A. Tetrahedron 2003, 59, 7787. 
13 Montel, F.; Beaudegnies, R.; Kessabi, J.; Martin, B.; Muller, E.; Wendeborn, S.; Jung, P. M. J. Org. Lett. 
2006, 8, 1905. 
14 Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815. 
 skipped dienes, 
 Pfeffer, P. 
. Soc.  1977, 54, 380. 
.; Chao, L.; Zhang, H.; Wang, J.; Lei, A. J. Am. Chem. Soc. 2008, 130, 14713. 
15 Aoki, S.; Matsui, K.; Wei, H.; Murakami, N.; Kobayashi, M. Tetrahedron 2002, 58, 5417. 
16 (a) Brown, C. A.; Ahuja, V. K. J. Chem. Soc., Chem. Commun. 1973, 553. (b) Brown, C. A.; Ahuja, V. K. 
J. Org. Chem. 1973, 38, 2226. (c) For a recent application of P2-Ni to produce deuterated
see: Oger, C.; Bultel-Poncé, V.; Guy, A.; Balas, L.; Rossi, J.-C.; Durand, T.; Galano, J.-M. Chem. Eur. J. 
2010, 16, 13976.  
17 The cis,cis geometry and the 1,4-diene structure was inferred from the 3JH-H values of the vinyl protons in 
the 1H-NMR spectra and by the greater shielding of the allylic and bisallylic carbons in the 13C-NMR spectra 
(δ 20.5, 25.5 and 26.7 ppm, respectively, for C12, C9 and C6) relative to the triyne precursor. See
E.; Luddy, F. E.; Unruh, J.; Shoolery, J. N. J. Am. Oil Chem
18 Alami, M.; Ferri, F. Tetrahedron Lett. 1996, 37, 2763. 
19 Shi, W.; Luo, Y.; Luo, X
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A survey of methods for enol acetate formation starting from the unsaturated ketone 
14 revealed moderate E/Z stereoselectivities and low yields in most cases. However, the 
use of Et3N, DMAP and Ac2O20 provided a 1:2 mixture of enolacetate isomers 15 in 83% 
yield. Without separation the ketal protecting group of 15 was removed using catalytic 
quantities of cerium (IV) ammonium nitrate (CAN) at 70 ºC21 to afford acylglycerol 16 as 
a mixture of geometric isomers. These compounds were separated using RP-HPLC (Nova-
Pak-C18, 60 Å, 300 x 19 mm, 3:1 MeOH/H2O, 5 mL/min) to yield the desired (E,R)-16 
and (Z,R)-16 isomers in 35% and 16% yield, respectively. The same sequence (not shown) 
starting from (R)-3 afforded synthetic material matching (identical 1H- and 13C-NMR 
spectra) those described above, but with (S) configurations.22 
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Scheme 2.3. Reagents and reaction conditions: (a) CuCl, piperidine, 0 ºC, 6 h (71%). (b) i. DMSO, (COCl)2, 
CH2Cl2, - 60 ºC; ii. Addition of 13 at -60 ºC; iii. Et3N, -60 to 25 ºC (75%). (c) Et3N, DMAP, Ac2O, CH2Cl2, 
25 º C, 4 h (83%).  (d) CAN (3 mol%), CH3CN/H2O, 70 ºC (86%; (E,R)-16, 35%; (Z,R)-16, 16%, after RP-
HPLC separation) 
2.3 Separation and purification of the peyssonenynes 
                                                 
20 Compernolle, F.; Toppet, S.; Brossette, T.; Mao, H.; Koukni, M.; Kozlecki, T.; Medaer, B.; Guillaume, M.; 
Lang, Y.; Leurs, S.; Hoornaert, G. J. Eur. J. Org. Chem. 2006, 1586. 
21 Ates, A.; Gautier, A.; Leroy, B.; Plancher, J.-M.; Quesnel, Y.; Vanherck, J.-C.; Markó, I. E. Tetr hedron 
2003, 59, 8989. 
is called cryptochiral (Mislow, K.; Bickart, P. “An Epistemiological Note on Chirality” Isr. J. Chem. 
a
22 Inherent optical rotation magnitudes of (tri)glycerides, being very close to cero, are of little use: Eliel, E. 
L.; Wilen, S. H.; Mander, L. S. Stereochemistry of Organic Compounds; Wiley-Interscience: New York, 
1994; pp. 1074-1076; when an optical rotation of a substance is unobservable due to instrument limitations it 
1976/77, 15, 1); cryptochiral natural triglycerides with very low or zero optical activity may be characterized 
through the use of their piezoelectric properties. Alternatively, the enantiomeric excess determined by chiral 
HPLC was taken as an indirect measure of the optical purity of these glycerides. 
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The determination of the enantiomeric purity of the peyssonenynes (undisclosed in 
the original publication) was complicated by the known configurational instability of 
monoa
 geometric 
isomer
Attempts to determine the geometry of the enol acetate moiety using either analysis 
of 1H-NMR and 13C-NMR chemical shifts or NOE-difference experiments proved 
ty of the enolacetate functional group. 
cylglycerols.23 Monoacylglycerols consist of three isomers, two enantiomers termed 
sn-1/sn-3 and their achiral sn-2 regioisomer. It is known that rapid 1,2-acyl migrations 
from the sn-1 to the sn-3 position via the achiral sn-2 regioisomer cause significant erosion 
of their enantiomeric purity.24 RP-chiral HPLC25 (Chiralpak® IA, 250 x 10 mm, 100% 
MeOH, 1.5 mL/min) was very effective in the separation of the isomers of (E,R)-16 and 
(E,S)-16 and the enantiomer excess was determined as ee(R) = 72% and ee(S) = 69%. 
Although traces of acids and bases are reported to induce 1,2-acyl migration, the loss of 
configurational integrity of 16 is likely traced back to the thermal conditions (70 ºC) of the 
dioxolane deprotection step using CAN, a transformation that could not be induced at 
lower reaction temperatures. When the same conditions were applied to (Z,R)-16 and (Z,S)-
16, a baseline separation of sn-1/sn-3 enantiomers and sn-2 regioisomer could not be 
achieved using a variety of eluents in both normal or reverse phase modes (n-hexane/2-
propanol, n-hexane/2-propanol/CH2Cl2, n-hexane/AcOEt, n-hexane/AcOEt/CH2Cl2, n-
hexane/THF, THF/H2O) or other chiral columns recommended for the separation of 
monoacylglycerols of fatty acids like Chiracel OD-H or Chiralpak® IC.26 Despite this 
failure, it is reasonable to assume that the enantiomeric excess for both E and Z
s is the same since they underwent the same sequence of chemical transformations 
and purification steps.  
2.4 Structural assignment of the synthetic and natural peyssonenynes  
  
unsuccessful. Gerwick et al. could not complete the assignment of the peyssonenynes 
geometries due to the paucity of protons in the vicini
A  ca. 0.5 ppm 
                                                
lthough they noted that the geometric isomers showed a most significant
 
23 (a) Andrews, P. C.; Fraser, B. H.; Junk, P. C.; Massi, M.; Perlmutter, P.; Thienthong, N.; Wijesundera, C. 
(b) Deng, L.; Nakano, H.; 
Tetrahedron 2008, 64, 9197. (b) Laszlo, J. A.; Compton, D. L.; Vermillion, K. E. J. Am. Oil Chem. Soc. 
2008, 85, 307. 
24 Isai, S. V.; Usol'tsev, A. A.; Stiba, E. N. Chem. Nat. Prod. 2003, 39, 325. 
25 (a) Deng, L.; Nakano, H.; Iwasaki, Y. J. Chromatography A 2007, 1165, 93. 
Iwasaki, Y. J. Chromatography A 2008, 1198-1199, 67. 
26 García, P.; Franco, P.; Álvarez, R.; de Lera, Á. R. J. Sep. Sci. 2011, 34, 999. 
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chemic
xyenynes (3JH-C varies from 
2.6 to 5.2 Hz for Z, and from 10.5 to 12.7 Hz for E).28 We also showed that the values of 
the chemical shifts of the Csp-β carbons of the alkyne attached to the enolacetate are a 
more straightforward criteria for double bond configurational assignment in 
acetoxyenediynes (values for C-6 of δ 75.35 and δ 80.00 ppm for (Z,R)-16 and (E,R)-16, 
respectively, see Figure 2.2). 
al shift difference for the C6 and C8 atoms (C6: δ 74.1 ppm and 73.6 ppm; C8: δ 
129.5 ppm and 128.9 ppm, respectively), the low amounts of the natural specimens that 
remained left (80 μg) precluded the use of 2D-ROESY experiments for structural purposes. 
In our hands 2D-ROESY was also inconclusive despite having access to larger amounts of 
synthetic material. Our attention was then turned to a method for the determination of 
olefin geometry based on the magnitude of the long-range 1H-13C coupling constant (nJH-C) 
that uses a band-variant of the gradient HSQC pulse sequence termed EXSIDE (Excitation-
sculptured Indirect Detection Experiment).27 The 3JH-C values for the pair of double bond 
isomers (3JH-C = 5.24 Hz for Z; 3JH-C = 12.68 Hz for E; see Figure 2.1) fall within the range 
measured for isomers in series of acetoxyenediynes and aceto
 
                                                 
27 Krishnamurthy, V. V. J. Magn. Res. A 1996, 121, 33. 
28 García, P.; Martín-Pastor, M.; de Lera, Á. R.; Álvarez, R. Mag. Res. Chem. 2010, 48, 543. 
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Figure 2.1. (Left) 2D EXSIDE of compound (E,R)-16. (Right) The corresponding 1D vertical trace extracted 
from the 2D EXSIDE. The relevant signals for the extraction of the 1JH-C, 2JH-C and 3JH-C scalar coupling 
constants are indicated. 
These spectroscopic evidences allowed us to conclusively assign the enolacetate 
geometries of the (E,R)-16 and (Z,R)-16 isomers. Having secured the structure of the 
synthetic compounds, we proceeded to confirm the identity of the natural peyssonenynes A 
and B. However, some discrepancies between the NMR chemical shifts in CDCl3 and 
C6D6 of the natural and synthetic compounds were noted (see Tables 2.1 and 2.2). In the 
original publication it was shown that peyssonenynes A and B displayed nearly identical 
1H-NMR spectra in CDCl3 and some minor differences in the 13C-NMR chemical shifts of 
C-6 (A, δ 74.1 ppm; B, δ 73.6 ppm) and C-8 (A, δ 129.5 ppm; B, δ 128.9). Comparison of 
the data for the synthetic compounds (Z,R)-16 and (E,R)-16 revealed significant 
differences. In addition, we found that the diagnostic signal for C-6 at around δ  79.0 ppm 
of synthetic (E,R)-16 was absent in the data of the products isolated from Peyssonnelia 
caulifera. Puzzled by the inconsistencies, and reflecting on the stereochemical lability of 
monoacylglycerols, we entertained the possibility that the natural peyssonenyne B could be 
the sn-2 achiral isomer of peyssonenyne A, namely compound (Z)-17 (Figure 2.2).  
O
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OH
OH
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sn-1,3 glycerol isomer
peyssonenyne A
O
O
7
9
Z
1
6
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O
O
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3
O
O
JH9-C7 = +5.24 Hz
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O
O
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OHE
(E,R)-16
sn-1,3 glycerol isomer
original peyssonenyne B
C6 = 80.0 ppm (CDCl3)
3JH9-C7 = +12.68 Hz  
Figure 2.2. Dynamic interconversion of the monoacylglycerol positional isomers of peyssonenyne A, and 
structure of peyssonenyne B (original and corrected). 
x 4.6 mm, 3:1 MeOH/H2O, 
c x 10 mm, 45:45:10 n-
Using the conditions reported in the original publication for separation of 
peyssonenynes A and B by RP-HPLC (Sunfire-C18, 5 μm, 250 
0.7 mL/min), only two partially resolved peaks were obtained from (Z,S)-16. However, 
hanging to a chiral HPLC column (CHIRALPAK® IA, 250 
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hexane/EtOAc/CH2Cl2, 1.2 mL/min) we isolated the putative sn-2 regioisomer (Z)-17 
accompanying the however inseparable sn-1 and sn-3 enantiomers (an almost racemic 
sample kept at -78 ºC for two years was used). The 1H-NMR spectra of the minor 
component matched those published for peyssonenyne B (see Tables 2.1 and 2.2). 
Strikingly, however, the integration of the glycerol region of (Z)-17 did not reflect the 
number of magnetically equivalent protons expected for that fragment. Reinjection of the 
independent fractions obtained above confirmed the dynamic equilibrium between the 
glycerol isomers: the sn-2 isomer (Z)-17 rapidly afforded a mixture of sn-1,3/sn-2 (ca. 1:1 
ratio), whereas the sn-1,3 fraction showed a slower conversion to sn-2 (Z)-17, probably due 
to the greater stability of the chiral relative to the achiral positional isomer (Figure 2.3). 
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Figure 2.3 HPLC traces (CHIRALPAK® IA, 250 x 10 mm, 45:45:10 n-hexane/EtOAc/CH2Cl2, 1.2 mL/min) 
showing the interconversion of glycerol positional isomers in the peyssonenynes series. 
2.5 Biological characterization of the synthetic peyssonenynes 
Having prepared the enantioenriched and geometrically homogeneous Z and E 
isomers of the peyssonenynes, we proceeded to confirm their biological activities. The 
ability of the synthetic stereoisomers 16 to influence human DNMT1 activity was 
T1 antibody interrogated in K562 human cells by immunoprecipitation with anti-DNM
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followed by a radioactive methyl transfer assay (Figure 2.4). At 50 µM all diastereomers 
rather equaly inhibited DNMT1 activity at least as efficiently as the known DNMT1 
inhibitor RG10829 but less potently than the recently described specific inhibitor SGI-
102730 at the same concentration (Figure 2.4). 
Methylation-specific PCR (MSP) revealed a modest increase of unmethylated 
RARβ promoter (the RARβ2 is a tumor suppressor gene whose expression is silenced in 
cancer by methylation of CpG islands at promoters)31 upon treatment of the HCT116 cell 
line with the peyssonenynes at 10 µM relative to 5-azacytidine at 5 µM suggesting a 
possible methylation-inhibitory activity (Figure SI2.1). 
 
 
Figure 2.4. DNMT1 inhibition activities of synthetic stereoisomers 16 relative to control and to known 
DNMT1 inhibitors RG108 and SGI1027. 
2.6 Conclusion 
                                                 
29 Brueckner, B.; Boy, R. G.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; Wiessler, 
M.; Lyko
30 Datta,
, F. Cancer Res. 2005, 65, 6305. 
 J.; Ghoshal, K.; Denny, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, 
S. T. Cancer Res. 2009, 69, 4277. 
31 (a) Sirchia, S. M.; Ferguson, A. T.; Sironi, E.; Subramanyan, S.; Orlandi, R.; Sukumar, S.; Sacchi, N. 
Oncogene 2000, 19, 1556. (b) Widschwendter, M.; Berger, J.; Hermann, M.; Muller, H. M.; Amberger, A.; 
Zeschnigk, M.; Widschwendter, A.; Abendstein, B.; Zeimet, A. G.; Daxenbichler, G.; Marth, C. J. Natl. 
Cancer Inst. 2000, 92, 826. 
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The synthesis of both geometric isomers corresponding to the proposed structures 
of the peyssonenynes A and B has allowed to solve the identity puzzle of these natural 
products. We could confirm that the oxylipins isolated from Peyssonnelia caulifera are not 
geometric isomers of the acetoxyenediyne moiety. The geometry of the enolacetate is Z in 
both compounds, and instead they are, respectively, the sn-1,3 (= peyssonenyne A) and sn-
2 (= peyssonenyne B) positional isomers at the glycerol moiety. This stereochemical 
lability, due to reversible monoacylglycerol transacylations occurring in solution, makes 
highly unlikely the isolation of the enantiopure sn-1 (sn-3) from Nature. Progressive 
erosion of the enantiopurity is unavoidable, as we have proven with the synthesis of each 
antipode of the purported natural products. 
On DNMT1 inhibition assay the diastereomers are roughly equipotent. The enol 
acetate geometry and the configuration of the glycerol unit appear to play a minor role on 
their activity, the latter most likely due to the racemization through formation of the achiral 
sn-2 isomer in solution. Other functional assays are underway in our laboratories to 
epigenetically profile the peyssonenynes and structural analogues. 
2.7 Experimental Section 
General procedures. Solvents (acetone and EtOH) were dried according to published methods 
and distilled before use. THF, CH2Cl2, DMF and MeOH were dried using a PuresolvTM 
solvent purification system. Et3N and piperidine were dried by distillation with CaH2. All 
other reagents were commercial compounds of the highest purity available. All reactions were 
carried out under argon atmosphere, and those not involving aqueous reagents were carried out 
in oven-dried glassware. All solvents and anhydrous solutions were transferred through 
syringes and cannulae previously dried in the oven for at least 12 h and kept in a dessicator
with KOH. For reactions at low temperature, icewater or CO /acetone systems were used. 
lates with Merck 
Kieselgel 60F254 and visualised by UV irradiation (254 nm) or by staining with an ethanolic 
Flash column 
chromatography was carried out using Merck Kieselgel 60 (230-400 mesh) under pressure. 
UV/Vis
 
2
Analytical thin layer chromatography (TLC) was performed on aluminium p
solution of phosphomolibdic acid or an ethanolic solution of anisaldehyde. 
 spectra were recorded with a Cary 100 Bio spectrophotometer in MeOH. IR spectra were 
obtained on a JASCO IR 4200 spectrophotometer from a thin film deposited onto NaCl glass. 
Mass spectra were obtained on a Hewlett-Packard HP59970 instrument operating at 70 eV by 
electron ionization and APEX III FT-ICR MS (Bruker Daltonics, Billerica, MA), equipped 
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with a 7T actively shielded magnet. Ions were generated using an Apollo API electrospray 
ionization (ESI) source, with a voltage between 1800 and 2200 V (to optimize ionization 
efficiency) applied to the needle, and a counter voltage of 450 V applied to the capillary. 
Samples were prepared by adding a spray solution of 70:29.9:0.1 (v/v/v) CH3OH/water/formic 
acid to 
arts per million (ppm), and coupling 
constants (J) are given in Hertz (Hz). The proton spectra are reported as follows: δ 
(multiplicity, coupling constant J, number of protons, assignment). 13C NMR spectra were 
recorded in CDCl3 and C6D6 at ambient temperature on the same spectrometer at 100 MHz, 
with the central peak of CDCl3 (δC = 77.0 ppm) or C6D6 (δC = 128.0 ppm) as the internal 
reference. The DEPT135 pulse sequence was used to aid in the assignment of signals in the 13C 
NMR spectra. 
 
2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Pent-4-ynoate ((R)-4). General 
procedure for ester formation. To a stirred solution of 5-hexynoic acid 2 (0.37 g, 3.79 
mmol), DCC (0.783 g, 3.79 mmol) and DMAP (0.045 g, 0.379 mmol) in CH2Cl2 (7 mL) was 
added a solution of (S)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (S)-3 (0.5 g, 3.79 
mmol) in CH2Cl2 (5 mL). After stirring the mixture at room temperature overnight, the solvent 
was evaporated and the residue was purified by flash chromatograp tOAc) 
1
1 (dd, J = 11.5, 4.6 Hz, 1H, H1’), 4.2 – 4.1 (m, 2H, H1’ + 
H3’), 3.76 (dd, J = 8.4, 6.1 Hz, 1H, H3’), 2.61 (t, J = 7.5 Hz, 2H, 2H2), 2.6-2.5 (m, 2H, 2H3), 
H, H5), 1.44 (s, 3H), 1.38 (s, 3H) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ  171.3 (s, C1), 109.6 (s, C1’’), 82.1 (s, C4), 73.3 (d, C2’), 69.1 (d, C5), 66.1 (t), 64.7 (t), 33.0 
(t, C2), 26.5 (q), 25.2 (q), 14.1 (t, C3) ppm. HRMS (ESI+): Calcd for C11H17O4, 213.11237; 
-1
,3-dihydroxyprop-1-yl Pent-4-ynoate ((S)-4). Following the 
a solution of the sample at a v/v ratio of 1 to 5% to give the best signal-to-noise ratio. 
High resolution mass spectra were taken on a VG Autospec instrument. 1H NMR spectra were 
recorded in CDCl3 or C6D6 at ambient temperature on a Bruker AMX-400 spectrometer at 
400 MHz with residual protic solvent as the internal reference [CDCl3, δH = 7.26 ppm and 
C6D6, δH = 7.15 ppm]; chemical shifts (δ) are given in p
hy (80:20 hexane/E
to afford 0.79 g (98%) of the titled compound as a colourless oil. H-NMR (400.13 MHz, 
CDCl3): δ 4.4 – 4.3 (m, 1H, H2’), 4.2
1.99 (t, J = 2.3 Hz, 1
found 213.11214. IR (NaCl): ν  3286 (w, C≡C-H), 2987 (w, C-H), 2939 (w, C-H), 1741 (s, 
O), 1376 (m), 1252 (m), 1215 (m), 1C 165 (s), 1056 (m) cm . 
(2’S)-2,3-O-Isopropylidene-2
general procedure described above for ester formation, the reaction of 5-hexynoic acid 2 (0.32 
g, 3.22 mmol), DCC (0.67 g, 3.22 mmol), DMAP (0.04 g, 0.327 mmol) and (R)-2,3-O-
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isoprop
13 MHz, CDCl3): δ 4.3-4.5 (m, 1H, H2’), 4.0-4.2 
(m, 3H
H), 1739 (s, C=O), 1375 
(m), 1162 (s) cm-1. The enantiomeric excess was determined using chiral HPLC 
i-PrOH, 1.5 mL/min, tR= 28.1 min; >99% ee). 
ylidene-2,3-dihydroxy-1-propanol (R)-3 (0.043 g, 3.22 mmol) in CH2Cl2 (12 mL), 
afforded after purification by flash chromatography (80:20 hexane/EtOAc), 0.634 g (93%) of 
the titled compound as a colourless oil.  
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 5-Iodopent-4-ynoate ((R)-5). General 
procedure for the synthesis of iodo-alkynes. To a stirred solution of (2’R)-2,3-O-
isopropylidene-2,3-dihydroxyprop-1-yl pent-4-ynoate (R)-4 (0.59 g, 2.80 mmol) in acetone (4 
mL), NIS (0.756 g, 3.36 mmol) and AgNO3 (0.475 g, 2.80 mmol) were added and the reaction 
was stirred overnight at room temperature. The solvent was evaporated and the residue was 
purified by flash chromatography (80:20 hexane/EtOAc) to afford 0.652 g (69%) of the titled 
compound as a colourless oil. 1H-NMR (400.
, 2H1’ + H3’), 3.7-3.8 (m, 1H, H3’), 2.69 (t, J = 6.8 Hz, 2H, 2H2),  2.59 (t, J = 6.7 Hz, 
2H, 2H3), 1.44 (s, 3H, H1’’), 1.38 (s, 3H, H1’’) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 171.3 
(s, C1), 109.8 (s, C1’’), 92.1 (s, C4), 73.4 (d, C2’), 66.2 (t), 64.8 (t), 33.0 (t, C2), 26.6 (q), 25.3 
(q), 16.5 (t, C3), −5.0 (s, C5) ppm. HRMS (ESI+): Calcd for C11H15IO4Na, 360.9900; found, 
360.9907. IR (NaCl): ν 2985 (m, C-H), 2936 (m, C-H), 2888 (w, C-
(CHIRALPAK IA, 250 x 10 mm, 5% hexane/
(2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 5-Iodopent-4-ynoate ((S)-5). 
Following the general procedure described above for the synthesis of iodo-alkynylderivatives 
the reaction of (2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl pent-4-ynoate (S)-4 (0.576 
g, 2.72 mmol), NIS (0.733 g, 3.23 mmol) and AgNO3 (0.462 g, 2.72 mmol) in acetone (4 mL) 
afforded, after purification by flash chromatography (80:20 hexane/EtOAc), 0.766 g (84%) of 
the titled compound as a colourless oil. The enantiomeric excess was determined using chiral 
HPLC (CHIRALPAK® IA, 250 x 10 mm, 5% hexane/i-PrOH, 1.5 mL/min, tR= 26.4 min; 
>99% ee). 
N-Methoxy-N-methylhex-5-ynamide (7). To a solution of hex-5-ynoic acid 6 (3.0 g, 26.76  
mmol) in CH
R
2Cl2 (154 mL) was added N,O-dimethylhydroxylamine hydrochloride (3.91 g, 
40.14 mmol), EDCI (7.69 g, 40.14 mmol) and DMAP (4.90 g, 40.14 mmol) and the reaction 
was stirred overnight at room temperature. A saturated aqueous NaCl solution was added and 
the mixture was extracted with EtOAc (3x). The combined organic layers were washed with an 
aqueous HCl solution (5%) and brine, dried over Na2SO4 and the solvent was evaporated to 
afford 4.1 g (100%) of the titled compound as a colourless oil, which was used in the next step 
without further purification. H-NMR (400.13 MHz, CDCl1 3): δ  3.61 (s, 3H, OCH3), 3.08 (s, 
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3H, NCH3), 2.48 (t, J = 6.9 Hz, 2H, 2H2), 2.19 (dt, J = 6.8, 2.2 Hz, 2H, 2H4), 1.9-1.8 (m, 1H, 
H6), 1.8-1.7 (m, 2H, 2H3) ppm. C-NMR (100.62 MHz, CDCl13 3): δ  173.5 (s), 82.8 (s), 68.4 
(d), 60.2 (q), 31.1 (q), 29.4 (t), 22.3 (t), 17.0 (t) ppm. HRMS (ESI ): Calcd for C+ 8H14NO2, 
156.10152; found 156.10191. IR (NaCl): ν 3294 (m, C≡C-H), 2939 (m, C-H), 1662 (s, C=O), 
1420 (m), 1386 (m), 1179 (w), 995 (m) cm . 
 (7Z,10Z)-1-(Triisopropylsilyl)trideca-7,10-dien-1-yn-3-ol (11). To a stirred suspension of 
Cs
-1
2CO3 (0.19 g, 0.55 mmol), NaI (83 mg, 0.55 mmol) and CuCl (0.054 g, 0.55 mmol) in 
DMF (2 ml), N-methoxy-N-methylhex-5-ynamide 7 (0.10 g, 0.66 mmol) and propargylic 
bromide 8 (57 μL, 81 mg, 0.55 mmol) were added and the reaction was vigorously stirred at 25 
ºC for 3 h. After the addition of a saturated aqueous NH4Cl solution the mixture was extracted 
with EtOAc (3x). The combined organic layers were washed with water (4x), dried over 
Na2SO4 and the solvent was evaporated.  
To a stirred solution of triisopropylsilyl acetylene (0.20 g, 1.09 mmol, 0.24 mL) in THF (0.2 
mmol/mL) at -40 ºC, n-BuLi (0.53 mL, 1.57 M in THF, 0.82 mmol) was added dropwise and 
the solution was stirred for 1 h. Subsequently, a solution of the residue obtained above (0.12 g) 
1.0 (m, 21H, i-Pr3Si), 0.97 (t, J = 7.5 
in THF (0.84 mmol/mL) was added dropwise at -10 ºC and the reaction was further stirred for 
1 h at -10 ºC and for 1 h at room temperature. A saturated aqueous solution of NH4Cl was 
added and the mixture was extracted with Et2O (3x). The combined organic layers were 
washed with brine, dried over Na2SO4 and the solvent was evaporated. This reaction afforded 
0.2 g of a residue which was used in the next step without further purification.  
A solution of sodium borohydride (0.02 g, 0.05 mmol) in ethanol (2 mL) was added to a 
suspension of nickel acetate tetrahydrate (0.02 g, 0.09 mmol) in ethanol (3 mL) under a H2 
atmosphere and the reaction was vigorously stirred for 30 min. Then a solution of the residue 
obtained above (0.2 g) in ethanol (3 mL) was added and the mixture was stirred for 4 hours, 
filtered through a small pad of silica gel and the solvent was evaporated. The residue was 
purified by flash chromatography (silica gel, 95:5 hexane/EtOAc) to afford 0.14 g (75% over 
three steps) of 11 as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ  5.4-5.2 (m, 4H, H7 + 
H8 + H10 + H11), 4.4-4.3 (m, 1H, H3), 2.77 (t, J = 5.8 Hz, 2H, 2H9), 2.2-2.0 (m, 4H, 2H6 + 
2H12), 1.8-1.7 (m, 2H, 2H4), 1.6-1.5 (m, 2H, 2H5), 1.1-
Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ  131.9 (d), 129.4 (d), 128.6 (d), 127.2 
(d), 108.7 (s), 85.6 (s, C1), 62.9 (d), 37.5 (t), 26.7 (t), 25.5 (t), 25.1 (t), 20.5 (t), 18.6 (q, 6x, 
SiCH(CH3)2), 14.3 (q), 11.1 (d, 3x, SiCH(CH3)2) ppm. HRMS (ESI+): Calcd for C22H41OSi, 
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349.29269; found, 349.29312. IR (NaCl): ν 3600−3300 (br, ΟΗ), 2940 (s, C-H), 2866 (s, C-
H), 2168 (w, -C≡C-), 1463 (m), 1000 (m)  cm-1.  
d the solvent was removed under vacuum. The residue was purified by flash 
(7Z,10Z)-Trideca-7,10-dien-1-yn-3-ol (12). To a stirred solution of (7Z,10Z)-1-
(triisopropylsilyl)trideca-7,10-dien-1-yn-3-ol 11 (1.40 g, 4.01 mmol) in THF (15 mL) was 
added n-Bu4NF (4.41 mL, 1M in THF, 4.41 mmol) and the reaction was stirred for 30 minutes 
at 25 ºC. A saturated aqueous solution of NaHCO3 was added and the mixture was extracted 
with Et2O (3x). The combined organic layers were washed with brine, dried over Na2SO4 and 
the solvent was evaporated. The residue was purified by flash chromatography (silica gel, 
85:15 hexane/EtOAc) to afford 0.62 g (81%) of the titled compound as a colourless oil. 1H-
NMR (400.13 MHz, CDCl3): δ  5.4-5.2 (m, 4H, H7 + H8 + H10 + H11), 4.4-4.3 (m, 1H, H3), 
2.78 (t, J = 5.7 Hz, 2H, 2H9), 2.47 (d, J = 2.0 Hz, 1H, H1), 2.2-2.0 (m, 4H, 2H6 + 2H12), 1.8-
1.7 (m, 2H, 2H4), 1.6-1.5 (m, 2H, 2H5), 0.97 (t, J = 7.5 Hz, CH3) ppm. 13C-NMR (100.62 
MHz, CDCl3): δ 131.9 (d), 129.3 (d), 128.7 (d), 127.2 (d), 84.9 (s), 73.0 (d), 62.2 (d, C3), 37.2 
(t), 26.7 (t), 25.6 (t), 25.0 (t), 20.6 (t), 14.3 (q) ppm. HRMS (ESI+): Calcd for C13H21O, 
193.15815 ; found, 193.15869. IR (NaCl): ν 3600−3300 (br), 3303 (s, -C≡C-H), 3009 (m, C-
H), 2935 (s, C-H), 2868 (m, C-H), 2114 (w, -C≡C-) cm-1.  
(12Z,15Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-Hydroxyoctadeca-12,15-
dien-4,6-diynoate ((R)-13). General procedure for the Cadiot-Chodkiewicz cross-coupling 
reaction. To a stirred solution of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 5-
iodopent-4-ynoate (R)-5 (1.09 g, 3.24 mmol) and (7Z,10Z)-trideca-7,10-dien-1-yn-3-ol 12 
(0.62 g, 3.24  mmol) in degassed piperidine (2 mL), at 0 ºC, was added copper chloride (31 
mg,  0.32 mmol). After stirring for 2 hours, a saturated aqueous NH4Cl solution was added and 
the mixture was extracted with CH2Cl2 (3x). The combined organic layers were dried over 
Na2SO4 an
chromatography (silica gel, 80:20 hexane/EtOAc) to provide 0.92 g (71%) of a colourless oil 
that was identified as a 1:1 mixture of diastereomers. 1H-NMR (400.13 MHz, C6D6): δ  5.4-
5.2 (4H, 4H, H12 + H13 + H15 + H16), 4.19 (t, J = 6.4 Hz, 1H, H8), 4.0-3.8 (m, 3H, 2H1’ + H2’), 
3.7-3.6 (m, 1H, H3’), 3.45 (dd,  J = 8.3, 5.9 Hz, 1H, H3’), 2.74 (t, J = 6.1 Hz, 2H, 2H14), 2.22 (t, 
J = 7.0 Hz, 2H, 2H2 or 2H3), 2.10 (t, J = 7.0 Hz, 2H, 2H2 or 2H3), 2.0-1.9 (m, 4H, 2H11 + 
2H17), 1.7-1.5 (m, 2H, 2H9), 1.5-1.4 (m, 2H, 2H10), 1.35 (s, 3H, CH3), 1.25 (s, 3H, CH3), 0.90 
(t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ  170.9 (s), 131.9 (d), 129.7 
(d), 128.8 (d), 127.7 (d), 109.8 (s), 79.4 (s), 78.6 (s), 73.8 (d), 69.9 (s), 66.3 (t), 66.1 (s), 65.0 
(t), 62.5 (d), 37.4 (t), 32.7 (t), 27.0 (t), 26.9 (q), 25.9 (t), 25.6 (q), 25.4 (t), 20.9 (t), 15.3 (t), 14.5 
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(t)  ppm. HRMS (ESI+): Calcd for C24H34O5Na, 425.22978; found, 425.22985. IR (NaCl): 
ν 3600−3300 (br, OH), 2936 (m, C-H), 2870 (w, C-H), 2254 (w, -C≡C-), 1740 (s, CO), 1376 
(m), 1163 (s), 1053 (s) cm-1.  
(12Z,15Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-Hydroxyoctadeca-12,15-
lidene-2,3-dihydroxyprop-1-yl 8-Oxooctadeca-12,15-
 organic layers 
dien-4,6-diynoate ((S)-13). Following the general procedure described above for the Cadiot-
Chodkiewicz cross-coupling, the reaction of (7Z,10Z)-trideca-7,10-dien-1-yn-3-ol 5 (0.46 g, 
2.39 mmol), (2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 5-iodopent-4-ynoate (S)-5 
(0.77 g, 2.26 mmol) and copper chloride (23 mg,  0.239 mmol) in piperidine (4 mL) at 0 ºC 
afforded, after purification by flash chromatography (silica gel, 80:20 hexane/EtOAc), 0.70 g 
(73%) of the titled compound as a colourless oil.  
 (12Z,15Z)-(2’R)-2,3-O-Isopropy
dien-4,6-diynoate ((R)-14). General procedure for the Swern oxidation. To a stirred solution 
of oxalyl chloride (93 μL, 0.14 g, 1.07 mmol) in CH2Cl2 (7 mL) at – 60 ºC, DMSO (0.14 mL,  
0.14 g, 1.83 mmol) was added dropwise and the reaction was stirred for 5 min at this 
temperature. Then, a solution of (12Z,15Z)-(2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-
yl 8-hydroxyoctadeca-12,15-dien-4,6-diynoate (R)-13 (0.31 g, 0.76  mmol) in CH2Cl2 (7 mL) 
was added. After stirring for 30 min, Et3N (0.70 mL, 0.51 g, 5.04 mmol) was added and the 
reaction was stirred for 10 min at -60 ºC. The mixture was allowed to warm to room 
temperature, poured into water and extracted with CH2Cl2 (3x). The combined
were dried over Na2SO4 and the solvent was evaporated. The residue was purified by flash 
chromatography (silica gel, 75:25 hexane/EtOAc) to afford 0.23 g (75%) of the titled 
compound as a colourless oil. 1H-NMR (400.13 MHz, C6D6): δ  5.5-5.3 (m, 3H), 5.2-5.1 (m, 
1H), 4.0-3.8 (m, 3H, 2H1’ + H2’), 3.61 (dd, J = 8.3, 6.2 Hz, 1H, H3’), 3.37 (dd, J = 8.4, 5.8 Hz, 
1H, H3’), 2.72 (t, J = 6.8 Hz, 2H, 2H14), 2.2-2.1 (m, 2H, 2H2 or 2H3), 2.1-1.8 (m, 8H), 1.6-1.4 
(m, 2H, 2H10), 1.35 (s, 3H, CH3), 1.24 (s, 3H, CH3), 0.92 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-
NMR (100.62 MHz, C6D6): δ 185.7 (s), 170.3 (s), 132.1 (d), 129.5 (d), 128.9 (d), 127.5 (d), 
109.8 (s), 88.0 (s), 74.8 (s), 73.7 (d), 73.6 (s), 66.2 (t), 65.2 (t), 64.8 (s), 44.8 (t), 32.0 (t), 26.9 
(q), 26.4 (t), 25.8 (t), 25.5 (q), 23.8 (t), 20.9 (t), 15.3 (t), 14.5 (q) ppm. HMRS (ESI+): Calcd 
for C24H33O5, 401.23294; found, 401.23225. IR (NaCl): ν 2933 (m, C-H), 2235 (m, -C≡C-), 
2145 (w, -C≡C-), 1741 (s, CO), 1671 (s, CO), 1375 (m), 1251 (m), 1165 (s) cm-1. The 
enantiomeric excess was determined using chiral HPLC (CHIRALPAK® IA, 250 x 10 mm, 
5% hexane/i-PrOH, 1.5 mL/min, tR= 47.6 min; >99% ee). R
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(12Z,15Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-Oxooctadeca-12,15-dien-
4,6-diynoate ((S)-14). Following the general procedure described above for the Swern 
oxidation, the reaction of (12Z,15Z)-(2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 8-
hydroxyoctadeca-12,15-dien-4,6-diynoate (S)-13.  (0.24 g, 0.59 mmol), oxalyl chloride (72 μL, 
0.10 g, 0.82 mmol), DMSO (0.11 mL,  0.11 g, 1.41 mmol), Et3N (0.54 mL, 0.39 g, 3.87 
mmol) in CH2Cl2 (11 mL) afforded, after purification by flash chromatography (silica gel, 
75:25 hexane/EtOAc), 0.21 g (88%) of the titled compound as a colourless oil. The 
enantiomeric excess was determined using chiral HPLC (CHIRALPAK® IA, 250 x 10 mm, 
5% hexane/i-PrOH, 1.5 mL/min, tR= 46.1 min; >99% ee). 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-(2’R)-2,3-Dihydroxyprop-1-yl  8-Acetoxyoctadeca-
8,12,15-trien-4,6-diynoate ((R)-16). General procedure for the synthesis of enolacetates. To a 
stirred solution of (12Z,15Z)-(2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 8-
oxooctadeca-12,15-dien-4,6-diynoate (R)-14 (0.18 g, 0.45 mmol) in CH
R
mol), DMAP (0.03 g, 0.22 mmol) and acetic 
2Cl2 (11 mL) at 0 ºC 
were added Et3N (0.31 mL, 0.23 g, 2.23 m
anhydride (0.25 mL, 0.27 g, 2.68 mmol) and the reaction mixture was stirred for 2h at room 
temperature. A saturated NH4Cl aqueous solution was added and the mixture was extracted 
with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated. The residue was purified by flash chromatography (silica gel, 80:20 
hexane/EtOAc) to afford 0.16 g (83%) of the titled compound as a 2:1 mixture of E/Z isomers, 
which was used in the next step without further separation.  
General procedure for ketal deprotection. A stirred solution of the mixture of enolacetates 
(0.16 g, 0.37 mmol) in acetonitrile/water (2 mL, 1:1 v/v) was heated to 70 ºC and solid CAN (6 
mg, 0.01 mmol) was added. The resulting slightly yellow solution was stirred for 3 hours at 
this temperature. After cooling to room temperature, the reaction mixture was extracted with 
ether (3x). The combined organic layers were dried over Na2SO4 and the solvents were 
removed in vacuo. The residue was purified by flash chromatography (silica gel, 30:70 
hexane/EtOAc) to give 0.13 g (86%) of the titled compound as a 2:1 mixture of E/Z isomers, 
which were separated by RP-HPLC (Nova-Pak HR C18 6 μm, 19x300 mm, MeOH-H2O 3:1, 5 
mL/min) to yield 52 mg (35%) of the E isomer (tR= 37.4 min) and 23 mg (16%) of the Z 
isomer (t
R
RR
+ H13 + H15 + H16), 4.0-3.9 (m, 2H, 2H1’), 3.6-3.5 (m, 1H, H2’), 3.37 (dd, J = 11.0, 3.6 Hz, 1H, 
= 41.7 min) of (R)-16.  
(8E,12Z,15Z)-(2’R)-2,3-dihydroxyprop-1-yl 8-acetoxyoctadeca-8,12,15-trien-4,6-diynoate 
((E,R)-16). 1H-NMR (400.13 MHz, C6D6): δ 5.65 (t, J = 8.1 Hz, 1H, H9), 5.5-5.2 (m, 4H, H12 
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H3’), 3.29 (dd,  J = 11.3, 6.0 Hz, 1H, H3’), 2.72 (t, J = 6.5 Hz, 2H, 2H14), 2.3-2.2 (m, 2H, 2H3), 
2.10 (t, J = 7.0 Hz, 2H, 2H17), 2.0-1.9 (m, 6H, 2H2 + 2H10 + 2H11), 1.56 (s, 3H, OC(O)CH3), 
, 100% MeOH, 1.5 mL/min, tR= 13.1 min; 
0.91 (t, J = 7.4 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 171.1 (s), 168.2 (s), 
132.1 (d), 131.5 (d), 130.7 (s), 129.7 (d), 128.4 (d), 127.5 (d), 85.5 (s), 79.5 (s), 70.2 (d), 68.5 
(s), 65.9 (s), 65.7 (t), 63.4 (t), 32.4 (t), 28.2 (t), 26.7 (t), 25.9 (t), 20.9 (q), 20.0 (t), 15.5 (t), 14.5 
(q) ppm.  HRMS (ESI+): Calcd for C23H31O6, 403.20955; found. 403.21152. IR (NaCl): 
ν 3600−3300 (br, ΟΗ), 2921 (s, C-H), 2852 (m, C-H), 2361 (w, -  C≡C-), 2237 (w, -C≡C-), 
1736 (w, CO), 1462 (w), 1219 (w) cm-1. The enantiomeric excess was determined using RP-
chiral HPLC (CHIRALPAK® IA, 250 x 10 mm
72% ee). 
 (8Z,12Z,15Z)-(2’R)-2,3-Dihydroxyprop-1-yl 8-acetoxyoctadeca-8,12,15-trien-4,6-diynoate 
((Z,R)-16).1H-NMR (400.13 MHz, C6D6): δ  5.62 (t, J = 7.3 Hz, 1H, H9), 5.4-5.3 (m, 3H), 
5.3-5.2 (m, 1H), 4.0-3.9 (m, 2H, 2H1’), 3.6-3.5 (m, 1H, H2’), 3.37 (dd, J = 11.2, 3.9 Hz, 1H, 
H3’), 3.29 (dd, J = 11.2 and 6.0 Hz, 1H, H3’), 2.71 (t, J = 6.8 Hz, 2H, 2H14), 2.11 (t, J = 7.0 Hz, 
2H, 2H3), 2.0-1.9 (m, 8H, 2H2 + 2H10 + 2H11 + 2H17), 1.57 (s, 3H, OC(O)CH3), 0.91 (t, J = 
7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 171.7 (s), 168.0 (s), 132.6 (d), 
131.4 (d), 130.6 (s), 130.1 (d), 128.8 (d), 127.8 (d), 84.8 (s), 75.1 (s), 71.0 (s), 70.8 (d), 66.4 
(s), 66.1 (t), 64.0 (t), 33.0 (t), 27.1 (t), 26.7 (t), 26.2 (t), 21.3 (t), 20.2 (q), 15.9 (t), 14.8 (q) ppm. 
HRMS (ESI+): Calcd for C23H31O6, 403.21107; found, 403.21152. IR (NaCl): ν 
3600−3300 (br, ΟΗ), 2924 (s, C-H), 2854 (m, C-H), 2361 (w, -C≡C-), 2237 (w, -C≡C-), 1736 
(m, CO), 1458 (w), 1196 (m) cm-1. UV (MeOH): λmax 239, 252, 266, 281 nm. 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-(2’S)-2,3-Dihydroxyprop-1-yl  8-Acetoxyoctadeca-
8,12,15-trien-4,6-diynoate. (S)-16. Following the general procedure described above for the 
synthesis of enolacetates the reaction of (12Z,15Z)-(2’S)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl 8-oxooctadeca-12,15-dien-4,6-diynoate (S)-14.  (0.24 g, 0.61 mmol), Et3N 
(0.68 mL, 4.86 mmol), DMAP (0.037 g, 0.304 mmol) and acetic anhydride (0.34 mL, 3.64 
mmol) in CH2Cl2 (15 mL) afforded, after purification by flash chromatography (silica gel, 
80:20 hexane/EtOAc), 0.23 g (83%) of the title compound as a 2:1 mixture of E/Z isomers, 
which was used without further separation.  
Following the general procedure described above the reaction of the mixture of enolacetates 
(0.23 g, 0.5 mmol) and CAN (8 mg, 0.015 mmol) in acetonitrile-water (3 ml, 1:1 v/v) afforded, 
after purification by flash chromatography (silica gel, 30:70 hexane/EtOAc), 0.187 g (92%) of 
the title compound as a 2:1 mixture of E/Z isomers, which were separated by RPHPLC (Nova-
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Pak HR C18 6 μm, 19x300 mm, 3:1 MeOH/H2O, 5 mL/min) to yield 74 g (37%) of the E 
isomer (tR= 37.4 min) and 29 g (15%) of the Z isomer (tR RR= 41.7 min) of (S)-16. The 
enantiomeric excess of (E, S)-16 was determined using RP-chiral HPLC (CHIRALPAK® IA, 
250 x 10 mm, 100% MeOH, 1.5 mL/min, tR= 14.0 min; 69% ee). R
O
O
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Peyssonenynes A and B (1) 1'
 
Table 2.1. 13C- and 1H-NMR data for peyssonenyne A (CDCl3) and peyssonenyne B (CDCl3) at 600 MHz 
(natural source1), and for peyssonenyne E and Z at 400 MHz (synthetic compounds). 
 Natural source Synthetic compounds 
 Peyssonenyne A  Peyssonenyne B  Peyssonenyne E Peyssonenyne Z 
Atom 
no. δC δH (mult., J/Hz) δC
δH (mult., 
J/Hz) δC
δH (mult., 
J/Hz) δC
δH (mult., 
J/Hz) 
1 171.8 C  171.8 C  171.8 C  171. 8 C  
2 33.0 CH2 2.61 (ddd, 14.4, 2.0,1.0) 32.8 CH2 2.62 (m) 32.8 CH2 2.72 – 2.54 (m) 32.8 CH2 2.70 – 2.56 (m) 
  2.63 (ddd, 14.4, 9.1,1.4)    2.72 – 2.54 (m)  2.70 – 2.56 (m) 
3 15.8 CH2 2.65 (ddd, 14.4, 2.0,1.4) 15.6 CH2 2.66 (m) 15.8 CH2 2.72 – 2.54 (m) 15.7 CH2 2.70 – 2.56 (m) 
  2.66 (ddd, 14.4, 9.1,1.0)    2.72 – 2.54 (m)  2.70 – 2.56 (m) 
4 83.5 C  83.3 C  84.6 C  83.4 C  
5 65.81 C  65.7 C  65.6 C  65.6 C  
6 74.1 C  73.6 C  78.9 C  74.0 C  
7 69.8 C  70.0 C  67.5 C  70.0 C  
8 129.5 C  128.9 C  129.9 C  129.4 C  
9 131.1 CH 5.78 (t, 9.4) 131.1 H 5.78 ) 131.6 CH 5.81 (t, 7.9) 131.1 CH 5.78 (t, 7.4) C (m
10 26.2 CH2 2.13 (d, 10.5) 26.2 CH2 2.13 (m) 26.6 CH2 2.38 – 2.30 (m) 26.1 CH2 2.16 – 2.11 (m) 
11 26.6 CH2 2.13 (d, 10.5) 26.2 CH2 2.13 (m) 28.1 CH2 2.25 – 2.16 (m) 26.5 CH2 2.16 – 2.11 (m) 
12 129.9 CH 5.40 (m) 130.5 CH 5.40 (m) 129.7 CH 5.46 – 5.23 (m) 129.7 CH 5.45 – 5.23 (m) 
13 128.2 CH 5.31 (m) 128.0 CH 5.31 (m) 128.2 CH 5.46 – 5.23 (m) 128.1 CH 5.45 – 5.23 (m) 
14 25.8 CH2 2.75 (br t, 7.1) b 2.75 (t, 7.4) 25.7 CH2 2.77 (t, 6.6) 25.6 CH2 2.75 (t, 7.1) 
15 127.1 CH 5.29 (m) 127.2 CH 5.29 (m) 7.1 CH 5.46 – 5.23 (m) 127.0 CH 5.45 – 5.23 (m) 12  
16 132.3 CH 5.38 (m) 132.2 CH 5.38 (m) 132.2  CH 5.46 – 5.23 (m) 132.2 CH 5.45 – 5.23 (m) 
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17 20.8 CH2 2.06 (br p, 7.6) 20.5 CH2  2.06 (m) 20.7 CH2 2.12 – 2.01 (m) 20.7 CH2 2.10 – 2.00 (m) 
18 14.5 CH3 0.97 (t, 7.6) 14.1 CH3 0.97 (t, 7.4) 14.4 CH3 0.97 (t, 7.5) 14.4 CH3 0.97 (t, 7.5) 
1’ 65.83 CH
2
4.19 (dd, 14.4, 7.5) b 4.19 (m) 65.8 CH2
4.19 (dd, 11.6, 
6.0) 65.7 CH2
4.24 (dd, 11.6, 
4.8) 
  4.24 (dd, 14.4, 5.8)    4.25 (dd, 11.6, 4.7)  
4.18 (dd, 11.6, 
5.9) 
2’ 70.3 CH 3.96 (br s) b 3.96 (m) 70.2 CH 4.00 – 3.92 (m, 1H) 70.2 CH 3.99 – 3.91 (m) 
3’ 63.5 CH2 3.63 (dd, 14.1, 7.6) b 3.63 (m) 63.4 CH2 3.62 (dd, 11.3, 6.1) 63.4 CH2
3.61 (dd, 11.4, 
6.1) 
  3.72 (dd, 14.1, 4.5)  3.72 (m)  3.72 (dd, 11.3,  3.72 (dd, 10.6, 
1” 16
3.9) 3.0) 
8.4 C  168.1 C  169.1 C  168.4 C  
2” 20.8 CH3 2.17 (s) b 2.17 (s) 20.9 CH3 2.14 (s) 20.6 CH3 2.17 (s) 
Table 2.2 13C- and 1H-NMR data for peyssonenyne B (C6D6) at 600 MHz (natural source1), and for 
peyssonenyne E and Z (C6D6) at 400 MHz. 
 Natural source Synthetic 
 Peyssonenyne B (2) Peyssonenyne E Peyssonenyne Z 
Atom no. δC δH (mult., J/Hz) δC δH (mult., J/Hz) δC δH (mult., J/Hz) 
1 170.9 C  171.1 C  171.7  C  
2 32.4  CH2 1.90 (m) 32.4 CH2 2.0-1.9 (m, 6H, 2H2 + 2H10 + 2H11) 
33.0  CH2 2.0-1.9 (m, 8H, 2H2 + 
2H10 11 + 2H + 2H17) 
3 5.4  CH1 t, 2 2.07 (m) 15.5  CH2 2.3-2.2 (m, 2H, 2H3) 15.9  CH2 2.11 ( J = 7.0 Hz, 2H, 2H3) 
4 83.8  C  85.5  C  84.8  C  
5 65.7  C  65.9  C  66.4  C  
6 74.4  C  79.5  C  75.1  C  
7 70.5  C  68.5  C  71.0  C  
8 129.9 CH  130.7  C  130.6  C  
9 130.6  CH 5.62 (t, 6.9) 132.1  CH 5.65 (t, J = 8.1 Hz, 1H, H9) 132.6  CH 5.62 (t, J = 7.3 Hz, 1H, H9) 
10 26.2  CH2 1.99 (m) 26.7  CH2 2.0-1.9 (m, 6H, 2H2 + 2H10 + 2H11) 
26.7  CH2 2.0-1.9 (m, 8H, 2H2 + 
2H10 + 2H11 + 2H17) 
11 26.4  CH2 1.92 (m) 28.2  CH2 2.0-1.9 (m, 6H, 2H2 + 2H10 + 2H11) 
27.1  CH2 2.0-1.9 (m, 8H, 2H2 + 
2H10 + 2H11 + 2H17) 
12 128.1  CH 5.23 (m) 128.4  CH 5.5-5.2 (m, 4H, H12 + H13 + H15 + H16) 
131.4  CH 5.3-5.2 (m, 1H) 
13 129.9  CH 5.42 (m) 129.7  CH 5.H
5-5.2 (m, 4H, H12 + H13 + 
15 + H16) 
128.8  CH 5.4-5.3 (m, 3H) 
14 25.4  CH2 2.71 (t, 6.6) 25.9  CH2 2.72 (t, J = 6.5 Hz, 2H, 2H14) 26.2  CH2 2.71 (t, J = 6.8 Hz, 2H, 2H14) 
15 126.8  CH 5.37 (m) 127.5  CH 5.5-5.2 (m, 4H, H12 + H13 + H15 + H16) 
127.8  CH 5.4-5.3 (m, 3H) 
16 130.4  CH 5.42 (m) 131.5  CH 5.5-5.2 (m, 4H, H12 + H13 + H15 + H16) 
130.1  CH 5.4-5.3 (m, 3H) 
17 21.   CH3 2 2.02 (m) 20.0  CH2 2.10 (t, J = 7.0 Hz, 2H, 2H17) 21.3  CH2 2.0-1.9 (m, 8H, 2H2 + 2H10 + 2H11 + 2H17) 
18 
15.2  CH3 0.92 (t, 7.5) 14.5  CH3 0.91 (t, J = 7.4 Hz, 3H, CH3) 14.8 CH3 
 
0.91 (t, J = 7.5 Hz, 3H, 
CH3) 
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1’ 65.3  CH2 3.91 (d, 5.8) 65.7  CH3 4.0-3.9 (m, 2H, 2H1’) 
2’ 69.9  CH 3.52 (br s) 70.2  CH 3.6-3.5 (m, 1H, H
66.1  CH2 4.0-3.9 (m, 2H, 2H1’) 
2’ 70.8  CH 3.6-3.5 (m, 1H, H2’) ) 
3’ 63.2  CH2 3.29 (m) 63.4  CH2 3.37 (dd, J = 11.0, 3.6 Hz, 1H, H3’) 
64.0  CH2 3.37 (dd, J = 11.2, 3.9 Hz, 
1H, H3’) 
  3.23 (m)  3.29 (dd,  J = 11.3, 6.0 Hz, 1H, H3’) 
 3.29 (dd, J = 11.2 and 6.0 
Hz, 1H, H3’) 
1” 167.2  C  168.2  C  168.0  C  
2” 19.5  CH3 1.55 (s) 20.9  CH3 2.0-1.9 (m, 6H, 2H2 + 2H10 + 2H11) 
20.2  CH3 1.57 (s, 3H, OC(O)CH3) 
Biology 
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3. DETERMINATION OF THE GEOMETRY OF 
ACETOXYENEDIYNES AND ACETOXYENYNES 
BY NMR HETERONUCLEAR C- H SCALAR 
COUPLINGS AND C-NMR CHEMICAL 
SHIFTS. STRUCTURAL ASSIGNMENT OF THE 
OXYLIPIN NATURAL PRODUCTS 
PEYSSONENYNES A AND B 
13 1
13
 
 
Solution NMR methods were used for the structural characterization of the 
acetoxyenediyne E/Z configuration of the marine natural products peyssonenynes A and B 
and their synthetic analogues derived from palmitic acid. The scarcity of protons in the 
proximity of the olefin precluded the determination of the double-bond geometry using 1H 
NMR methods that rely on proton-proton scalar couplings or experiments such as NOESY 
or ROESY. Long range 13C-1H heteronuclear scalar couplings, nJCH, measured with the 2D 
EXSIDE experiment proved useful and highly reliable for the analysis of the enol acetate 
geometry. In addition, it was found that the chemical shift of some carbons atoms in the 
proximity of the olefin was also sensitive to the double bond configuration of these 
molecules providing an even simpler way to determine their geometry. This protocol 
showed its robustness by similar analysis of simpler silyl-protected acetoxyenynes derived 
from fatty acids. These NMR experimental results and stereochemical predictions were 
rationalized by DFT calculations. 

Structural Assignment of the Peyssonenynes 
3.1 Introduction 
 
The peyssonenynes A and B (1, Figure 3.1) are oxylipin metabolites recently 
isolated from the Fijian red marine alga Peyssonnelia caulifera by Gerwick and coworkers 
using a fractionation-guided isolation protocol.1  Worthy of note in their structure is the 
presence of the 1,3-diyne moiety2 conjugated to the enolether, which thus far has not been 
found in other natural products,3 and a fatty acid esterified with a glycerol unit as sn-1 
isomer. These monoacyl glyceride oxilipins are also a rare occurrence in red algae, and 
presumably derive biosynthetically from the oxidation of a ω3 polyunsaturated fatty acid. 
Interestingly, the peyssonenynes A and B were identified as micromolar inhibitors (16 and 
9 μM, respectively) of the enzyme DNA methyl transferase 1 (DNMT1). DNMT enzymes4 
are responsible for the de novo generation (DNMT3A and DNMT3B) and maintenance 
(DNMT1) of the DNA methylation pattern (affecting the cytosine C-5 position within CpG 
islands) during chromosome replication.5 Alteration of the methylation pattern (for 
example, by site-specific hypermethylation and global hypomethylation of tumour-
supressor genes) has been associated with cancer.6 The development of selective DNMT 
inhibitors (DNMTis)7 is an active area of research,8 since these drugs could offer novel 
therapies directed towards suppressing the growth of tumour cells or increasing their 
sensitivity to other anticancer agents. 
 
                                                 
1 McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J. Nat. Prod. 2004, 67, 1010. 
2 Haley, M. M. Pure Appl. Chem. 2008, 80, 519. 
3 a. Diederich, F.; Stang, P. J.; Tykwinski, R. R. Acetylene Chemistry: Chemistry, Biology and Material 
Science; Wiley-VCH: Weinheim, 2005. b. Haley, M. M.; Tykwinski, R. R. Carbon-Rich Compounds: From 
Molecules to Materials; Wiley-VCH: Weinheim, 2006. 
4 a. Hellebrekers, D. M. E. I.; Griffioen, A. W.; van Engeland, M. Biochim. Biophys. Acta - Rev. Cancer 
2007, 1775, 76. b. Cheng, X.; Blumenthal, R. M. Structure 2008, 16, 341. 
5 El-Osta, A. BioEssays 2003, 25, 1071. 
6 a. Das, P. M.; Singal, R. J. Clin. Oncol. 2004, 22, 4632. b. Klose, R. J.; Bird, A. P. Trends Biochem. Sci. 
2006, 31, 89. c. Feinberg, A. P. Nature 2007, 447, 433. 
7 Brueckner, B.; Lyko, F. Trends Pharm. Sci. 2004, 25, 551. 
8 Baylin, S. B. Nat. Clinical Pract. Oncol. 2005, 2, S4. 
101 
Structural Assignment of the Peyssonenynes 
Figure 3.1. Structures of the peyssonenynes A and B recently isolated from the Fijian red marine alga 
Peyssonnelia caulifera, showing the geometry assigned in this work. 
In this regard, the unprecedented chemotype exhibited by the peyssonenynes offers 
a novel scaffold for a program in drug design and development that uses the structure of a 
natural product as inspiration for epi-drug therapy.9 However, the minute amounts of these 
diyne enolacetate oxylipins isolated from the natural source (1.3 and 0.4 mg, respectively, 
from 365 g of dry alga) precluded getting further insights into their biological activities and 
hindered additional enzyme inhibition studies.1 In addition, the characterization of the enol 
acetate geometry and the determination of the absolute configuration of the glycerol 
stereocenter have remained unsolved due to the instability of the peyssonenynes A and B 
and the scarcity of diagnostic protons around the double bond.1 
Our efforts towards the synthesis of these natural products culminated in the 
preparation of the peyssonenynes 1 and the analogues derived from palmitic acid 2. In 
these molecules, there is only one proton in the double bond and therefore it is not possible 
to rely on proton-proton scalar couplings to assess the double bond configuration. Long 
range 1H-13C heteronuclear scalar couplings in principle are sensitive to the configuration 
of the double bond.10 However, the low sensitivity of 13C and the relative small values of 
these couplings compared to the linewidths have made the use of these couplings 
infrequent in the literature, although there are NMR experimental methods available to 
tackle the aforementioned difficulties.11 Another possibility to determine the configuration 
of the double bond are the 13C-NMR chemical shifts. It has been found that at least for 
certain types of compounds they can be sensitive to the Z or E configuration, an 
observation that can be further rationalized by DFT calculations.12  
In order to extend the study to acetoxyenynes and corroborate the methodology for 
structural determination of these compounds, we have also prepared a series of simpler 
analogues 3a-d derived from fatty acids (Figure 3.2a).  
                                                 
9 a. Mai, A.; Altucci, L. Int. J. Biochem. Cell Biol. 2009, 41, 199. b. Molinski, T. F.; Dalisay, D. S.; Lievens, 
S. L.; Saludes, J. P. Nat. Rev. Drug Disc. 2009, 8, 69. 
10 Contreras, R. H.; Peralta, J. E. Prog. Nucl. Magn. Reson. 2000, 37, 321. 
11 Marquez, B. L.; Gerwick, W. H.; Williamson, R. T. Magn. Reson. Chem. 2001, 39, 499. 
12 Gudat, D.; Niecke, E.; Ruban, A.; von der Gönna, V. Magn. Reson. Chem. 1996, 34, 799. 
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Figure 3.2. a) Structures of the molecules studied in the text, with their IUPAC numbering: peyssonenynes 
1, acetoxyenediynes derived from palmitic acid 2, and acetoxyenynes derived from palmitic acid 3a, 
araquidic acid 3b, oleic acid 3c, and linoleic acid 3d. b) 13C NMR chemical shifts and 13C-1H heteronuclear 
scalar couplings involving atoms marked as a, b, c, and d were relevant for the determination of the E and Z 
configurations. 
 
We describe herein the solution NMR methods that led to the structural 
characterization of the compounds depicted in Figure 3.1. We present the use of the long 
range 1H-13C heteronuclear scalar couplings, nJCH, measured with the 2D EXSIDE 
experiment13 to determine the double bond geometry in these molecules. In addition, we 
show that the chemical shift of some carbon atoms in the proximity of the double bond, 
carbons Ca, Cb, Cc, and Cd in Fig. 3.2, is also sensitive to the double bond configuration, 
thus providing simpler criteria for structural assignment. For instance, during the analysis 
of our NMR data, it was noted that for each pair of isomers the geometric isomers show a 
very significant ca. 5 ppm chemical shift difference for the Cd (Figure 3.2b) atom (for 
example, Cd: δ 75.37 ppm and 80.00 ppm for Z and E isomers of peyssonenyne 1, 
respectively). These observations were theoretically tested by DFT calculations, using the 
models shown in Figure 3.3. 
                                                 
13 Krishnamurthy, V. V. J. Magn. Res. A 1996, 121, 33. 
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Figure 3.3 Enol acetates 7 and 8 used as model systems for the DFT calculations of chemical shift and 13C-
1H coupling constants for acetoxyenediynes (a) and for acetoxyenynes (b). 
3.2 Experimental  
3.2.1 Synthesis 
The mixture of isomers at the enol acetate double bond of synthetic peyssonenynes 
1 and analogues 2 was separated by RP-HPLC (Nova-Pak-C18, 60 Å, 300 x 19 mm, 3:1 
MeOH/H2O, 5 mL/min). The individual isomers were named peyssonenynes A and B 
(likewise, A and B isomers derived from palmitic acid 2) in accordance with the original 
designation of these natural acetoxyenediynes.1 The series of acetoxyenynes 3a-d (Scheme 
3.1) used as model systems were derived from propargyl ketones 6a-d by enol acetate 
formation using acetic anhydride and triethylamine in CH2Cl2.14 In turn, ketones 6a-d 
were obtained from the addition of the anion of TIPS-acetylene (n-BuLi, THF, -78 ºC) to 
the Weinreb amides 5a-d15 derived from commercial fatty acids 4a-d using N,O-
dimethylhydroxylamine hydrochloride, EDC and DMAP.16  
 
                                                 
14 Compernolle, F.; Toppet, S.; Brossette, T.; Mao, H.; Koukni, M.; Kozlecki, T.; Medaer, B.; Guillaume, M.; 
Lang, Y.; Leurs, S.; Hoornaert, G. J. Eur. J. Org. Chem. 2006, 1586. 
15 Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815. 
16 Aoki, S.; Matsui, K.; Wei, H.; Murakami, N.; Kobayashi, M. Tetrahedron 2002, 58, 5417. 
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Scheme 3.1. Reagent and conditions: a. EDC, DMAP, HN(OMe)Me . HCl, CH2Cl2, 25 ºC (5a, 99%; 5b, 
76%; 5c, 99%; 5d 99%); b. TIPS-acetylene, n-BuLi, THF, -40 to 25 ºC (6a, 78%; 6b, 97%; 6c, 94%; 6d, 
94%); c. i. Et3N, DMAP, Ac2O, CH2Cl2, 25 ºC: ii. HPLC separation (Nova Pak® HR silica 60 Å, 300 x 19 
mm, 97:3 hexane/EtOAc, 3 mL/min) (Z-3a, 27%; E-3a, 30%; Z-3b, 36%; E-3b, 41%; Z-3c, 47%; E-3c, 44%; 
Z-3d, 39%; E-3d, 44%).  
3.2.2 NMR experiments 
NMR experiments were performed on a 17.6 T Varian INOVA NMR spectrometer 
operating at a 1H frequency of 750 MHz. The spectrometer was equipped with a gradient 
shielded 1H/13C/31P probe and the control software was VNMRJ 1.1d. The 13C resonances 
were referenced with respect to the signal of the C6D6 (99%) solvent used for the 
spectrometer lock. The residual C6H6 (1%) solvent was used for referencing the 1H 
signals. The spectra were processed and analyzed with MestRe-C® v3.9 software 
(Mestrelab Inc.). NMR samples of compounds 1, 2 and 3a-d shown on Figure 2 were 
prepared in 5 mm standard NMR tubes at a ~5 mM concentration in C6D6. For each 
compound the following NMR experiments were acquired: standard 1D 1H and 13C and 2D 
TOCSY; HMQC and HMBC experiments were used for the 1H and 13C signal assignment. 
                                                
A 2D EXSIDE experiment13 was acquired for the determination of 13C-1H scalar 
coupling constants, 1JCH, 2JCH and 3JCH. To eliminate any unwanted one-bond 13C-1H 
correlation in the spectrum a TANGO17 module was incorporated at the beginning13 whose 
delays were set according to a nominal value of 1JCH of 160 Hz. Two selective 180º proton 
pulses of 7.8 ms each were applied during the subsequent DPFGSE excitation sculpting 
module to select exclusively the signal of the Ha proton (~5.59 ppm) in the molecules 
studied in Fig. 1. Polarization transfer and refocusing delays were set according to a 
nominal value of the long range 13C-1H couplings of 8 Hz. A J-scaling factor of 20 was 
used. The 2D spectrum obtained was processed in the conventional way with linear 
prediction in F1 to generate a real spectrum of 2k x 4k data points in F1 and F2 
dimensions. The 1D 13C vertical trace was extracted and re-processed with forward linear 
prediction and zero-filling to 16k to achieve linewidths around 70 Hz with a nominal 
resolution of 2.2 Hz per point, which was useful for the accurate determination of the 13C-
1H splittings. 
3.2.3 NMR calculations 
 
17 Wimperis, S.; Freeman, R. J. Magn. Reson. 1984, 58, 348. 
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Calculations were performed with the Gaussian03 software.18 Simplified models of 
the molecules were built for the acetoxyenediynes 1 and 2 (7, Fig. 3.3) and for 3a-d (8, 
Fig. 3.3) using the ChemOffice suite of programs (CambridgeSoft).  
Calculation of NMR parameters was performed first in the gas phase using DFT at 
the B3LYP/6-311G(d,p) level of theory. To take solvent effects into account, the same 
NMR parameters were also calculated with the Polarizable Continuum Model (PCM) at the 
MPW1PW91/6-311G(d,p)  level of theory.19 
At each level of theory, 13C-NMR isotropic chemical shifts were calculated with the 
optimized geometries by the GIAO method, using the corresponding TMS shielding 
calculated at the same theoretical level as the reference.  
NMR heteronuclear 13C-1H scalar coupling constants were calculated with the 
optimized geometries at each theoretical level. Tight SCF convergence was employed. 
Electric field perturbation was applied to proton Ha in the model compounds of Figure 3.3 
with a value of  λ= 10-2 au or λ= 13-2 au for the calculations in the gas phase and PCM, 
respectively. The FC contribution was calculated by finite perturbation theory (FPT) (Eq. 
1): 
FCNMMN Ba
hJ λγγ
πβ
ππ
μ 11
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8
44 60
2
2
2
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=     Eq. 1 
where BFC is the Fermi-contact term in au, λ is the applied perturbation, γM and γN the 
magnetogyric ratios of the involved nuclei, and the other symbols have the usual 
meaning.20  
                                                 
18 Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Jr., J. A. M.; 
Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; 
Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, 
R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; 
Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, 
O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; 
Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; 
Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; 
Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; 
Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; 
Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, Revision D.02, Gaussian: 
Pittsburg, 2004. 
19 a. Perdew, J. P.; Chevary, J. A.; Vosko, S. H.; Jackson, K. A.; Pederson, M. R.; Singh, D. J.; Fiolhais, C. 
Phys. Rev. B 1992, 46, 6671. b. Perdew, J. P.; Chevary, J. A.; Vosko, S. H.; Jackson, K. A.; Pederson, M. R.; 
Singh, D. J.; Fiolhais, C. Phys. Rev. B 1993, 48, 4978. c. Adamo, C.; Barone, V. Chem. Phys. Lett. 1997, 
274, 242. 
20 Malkin, V. G.; Malkina, O. L.; Salahub, D. R. Chem. Phys. Lett. 1994, 221, 91. 
106 
Structural Assignment of the Peyssonenynes 
3.3 Results and discussion 
Acetoxyenediynes 1 and 2, and acetoxyenynes 3a-d displayed on Figure 3.2 were 
studied by solution NMR methods. The assignment of the 1H and 13C NMR signals of 
these compounds was accomplished by a combination of standard 1D and 2D solution 
NMR experiments. In this section we will focus only in the determination of the Z / E 
configuration of the double-bond employing solution NMR techniques.  
3.3.1 Determination of the double-bond configuration using 13C-1H scalar coupling 
constants 
Our initial efforts to determine the configuration of the double bond in the 
molecules of Fig. 3.1 by experiments relying in 13C-1H heteronuclear Overhauser Effect 
(HOE) involving nuclei at positions a, b, c and d were unsuccessful. The causes are likely 
related with the inherently poor sensitivity of the HOESY experiment together with the 
relatively low concentration of these samples (~5 mM). 
These difficulties were overcome by the measurement of 13C-1H long-range two 
and three bond scalar coupling constants, 2JCH and 3JCH, respectively. The 2D EXSIDE 
experiment13 was found to be an accurate and sensitive choice to determine these couplings 
in the samples studied herein. It establishes a two dimensional 1H / 13C correlation in which 
the couplings can be conveniently J-scaled up in the carbon dimension. It allows obtaining 
extra accuracy in the determination of the relatively small 13C-1H couplings (e.g., from 2 to 
15 Hz) as compared with the much larger linewidths that are achievable in the indirect 
carbon dimension. The sequence includes an initial step of excitation sculpting for the 
selection of the proton of interest and removal of undesired 13C-1H correlations mediated 
by other scalar couplings that may interfere with the results.  
Table 3.1 Experimental 13C-1H scalar couplings (Hz) and 13C chemical shifts (ppm) involving atoms labeled 
as a, b, c, and d in molecules 1-3. 
  Coupling constant (Hz) (a)  13C-NMR-Chemical Shifts (ppm) (b)
Compound Geometry 1JHaCa 2JHaCb 3JHaCc Ca Cb Cc Cd 
Z-1-2 Z 158.62 2.15 5.24 131.67 130.85 71.30  71.07(c) 75.37 
E-1-1 E 162.02 -2.50 12.68 131.94(d)    130.80(d) 68.89(d) 79.79(d)
Z-2-2 Z 156.70 3.06 4.37 132.55 130.62 71.06 75.27 
E-2-1 E 158.59 -3.06 12.24 133.06 131.08 69.31 80.00 
Z-3a Z 158.72 4.37 < 3 129.90 131.50 103.09 91.57 
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E-3a E 160.05 -3.50 12.24 130.21 132.10 100.54  100.67(c) 97.28 
Z-3b Z 159.18 4.37 2.62 129.84 131.52 103.09 91.60 
E-3b E 159.62 -3.50 10.49 130.10 132.09 100.64 97.23 
Z-3c Z 158.30 4.37 < 3 129.83 131.50 103.08 91.50 
E-3c E 157.19 -3.94 10.49 130.13 132.11 100.67 97.22 
Z-3d Z 159.09 4.81 < 3 130.99 131.53 103.09 91.60 
E-3d E 157.06 -3.50 10.50 130.13 132.10 100.65 97.29 
(a)Only the magnitude of the scalar coupling can be determined with the EXSIDE method; the sign of this 
coupling was chosen in accordance with the sign predicted by the DFT calculations. (b)Measured in the 1D-
13C NMR spectrum; error in chemical shift ±0.01 ppm. (c)The sample has unexpected extra signals in the 13C 
NMR spectrum. (d)Measured in the HMBC spectrum; error in chemical shift ±0.3 ppm. 
For each molecule of Figure 3.2, the 2D EXSIDE experiment provided three key 
13C-1H coupling constants, 1JHaCa, 2JHaCb, and 3JHaCc, that were important to asses the 
configuration of the double bond. These results are given in Table 3.1. As example, Fig. 
3.4 displays the 2D EXSIDE spectrum obtained for Z-1-2 upon selection of the Ha proton. 
Qualitatively, the experimental results of Table 1 show that 3JHaCc is the scalar coupling 
most sensitive to the configuration of the double bond in the compounds studied. Z 
configurations provided considerably smaller 3JHaCc values (≤ 5.24 Hz in our data) than the 
corresponding E isomers (≥10.49 Hz in our data). Values of  3JHaCc within similar ranges 
are typically found for Z and E isomers in other organic molecules.11 
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Figure 3.4 (left) 2D EXSIDE experiment of compound Z-1-2. The signal of Ha at δ 5.58 ppm was selected in 
the experiment. (right) The corresponding 1D vertical trace extracted from the 2D EXSIDE for Ha. The 
relevant signals for the extraction of the 1JHaCa, 2JHaCb and 3JHaCc scalar coupling constants are indicated. 
In order to test the reliability of the 13C-1H coupling constants for the determination 
of the Z/E configuration in the geometric isomers of Fig. 3.2, DFT calculations of the 
1JHaCa, 2JHaCb, and 3JHaCc scalar coupling constants were performed for each configuration 
using simplified models 7 and 8. In order to take into account potential solvent effects on 
the NMR parameters, these calculations were performed both in the gas phase and with the 
PCM solvent model.  
Table 3.2 Average experimental vs. DFT calculated values of  13C-1H scalar couplings (Hz) and 13C chemical 
shifts (ppm) involving atoms labeled as a, b, c, and d in molecules 1, 2, and 3a-d using model systems 7 or 8. 
 E-7 calc. 
PCM(a)      E-7 calc. gas
(b) E-7 exp.(c) Z-7 calc, PCM(a) Z-7 calc. gas
(b) Z-7 exp.(c)
1JHa-Ca 168.96 165.80 160.30 149.53 162.61 157.66 
2JHa-Cb -0.95 -7.16 -2.78 13.52 4.44 2.60 
3JHa-Cc  9.14 9.77 12.46 3.62 5.25 4.80 
Ca  138.18 125.29 132.48 137.63 124.68 132.11 
Cb  134.00 122.37 130.85 133.43 121.54 130.73 
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Cc  64.78 53.47 68.94 67.63 56.04 71.18 
Cd  84.13 71.03 79.93 79.17 66.56 75.32 
       
 E-8 calc. 
PCM(a) 
  
 
  E-8 calc. gas (b) E-8 exp.(d) Z-8 calc-PCM(a) Z-8 calc. gas
(b) Z-8 exp. (d)
1JHa-Ca 169.91 164.01 158.48 162.49 161.5 158.82 
2JHa-Cb -1.33 -6.73 -3.61 13.14 4.85 4.48 
3JHa-Cc  8.76 8.33 10.93 3.81 4.69 ≤ 3 
Ca  136.16 141.18 130.14 135.60 140.84 130.14 
Cb  134.18 140.67 132.10 133.53 140.06 131.51 
Cc  99.04 102.82 100.62 102.11 106.01 103.08 
Cd  104.32 107.35 97.25 98.57 101.52 91.57 
(a) MPW1PW91 calculations with the polarizable continuum model (PCM). (b) B3LYP calculations in the gas 
phase.  (c) Average of compounds 1 and 2 studied in this work. (d)Average of compounds 3a-d studied in this 
work.  
The results of the theoretical and the experimental average coupling constants (as 
calculated from Table 3.1) are given in Table 3.2. We considered the ability of each 
coupling constant to discriminate between Z and E configurations:  
1JHaCa: In Table 3.2 the experimental differences in 1JHaCa between the Z and E 
configuration are only  ∼0.2% for 8. Nevertheless, for these couplings the discrepancy 
between the DFT calculations and the correspondingly experimental value can be up to 7% 
and 3% for PCM and gas phase, respectively. These observations indicate that 1JHaCa is not 
reliable for the assignment of the double-bond geometry. 
2JHaCb: The DFT couplings obtained in gas phase and in solvent (PCM) of Table 
3.2 show a consistent difference in the sign of this coupling for the Z (positive sign) and E 
(negative sign) configurations. However, the EXSIDE experiment only allows the 
determination of the magnitude, but not the sign, of the 13C-1H scalar coupling. The 
experimental absolute value of 2JHaCb for the Z and E configurations is rather similar with 
differences of only 0.18 Hz. Therefore, unless the sign of the 2JHaCb is determined by using 
other type of NMR experiment, the magnitude of 2JHaCb is not a reliable parameter for the 
assignment of the configuration of the double bond in the molecules studied. The 
discrepancies of the DFT calculations were considerably large, in particular those 
couplings calculated for isomers Z with the PCM solvent model. 
3JHaCc: In Table 3.2 there is a consistent experimental difference of ∼7 Hz in the 
magnitude of this scalar coupling for the E relative to the Z isomer in the same type of 
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molecule. This trend is very well reproduced by the DFT calculations of Table 3.2, either 
in the gas phase or with the PCM solvent model. 
Overall, the results of Table 3.2 indicate that the use of 3JHaCc to determine the 
configuration of the double bond is the most reliable and sensitive coupling constant, while 
1JHaCa and 2JHaCb are more prone to cause errors.  
For the compounds studied herein the DFT calculations of coupling constants in the 
gas phase provided values that are in general similar or show a better qualitative agreement 
with the experimental results than those calculated with the PCM solvent model. 
3.3.2. Determination of the double-bond configuration using 13C chemical shifts 
During the NMR signal assignment of the molecules of Fig. 3.2, it was noticed 
some dependence of certain carbon chemical shifts with the Z/E configuration of the 
double bond isomers. Such observation was not completely unexpected since the 13C 
chemical shift is exquisitely sensitive to the shielding effect caused by the atoms in the 
proximity (within a few chemical bonds) of the target carbon. On the other hand the effects 
in the 13C chemical shift caused by the external conditions such as solvent, pH, temperature 
and sample concentration among others are usually relatively modest.  
Table 3.1 lists the experimental chemical shifts of Ca, Cb, Cc and Cd atoms of the 
molecules in Fig. 3.2, which are in the proximity of the double bond for the molecules 
studied herein. Clearly, the alkyne Cd and Cc atoms are the most sensitive to the 
configuration of the enolacetate double bond to which they are attached, with differences 
between the E and Z geometries of ca. +5 ppm and -2 ppm, respectively. Furthermore, in 
each group of compounds (1, 2 or 3) the chemical shift of Cd and Cc is relatively 
insensitive to the configuration, since the values spread out below ~0.3 ppm. The chemical 
shifts of Cd and Cc are relatively similar for isomers of 2 and 1 with the same 
configuration and are markedly different from the group of derivatives 3 since the latter 
incorporates a Si atom at the terminus of the triple bond. These observations indicate that 
the chemical shift of Cd and Cc can be used to assess the configuration of the double bond 
in these molecules. Such task can be accomplished by comparison with the reference 
average values of the chemical shifts of the Ca to Cd fragments reported on Table 3.2. 
Interestingly, the original data, acquired in CDCl3 revealed only minor chemical shift 
differences in the 13C-NMR spectra of the peyssonenynes A and B, most notably a ca. 0.5 
ppm for Cd (C6 chemical shifts of 74.1 for A and 73.6 for B).1 
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As a further test of the reliability of this method for the determination of the Z/E 
configuration based on carbon chemical shifts, theoretical DFT calculations of the 13C-
NMR chemical shifts were performed for each configuration using the simplified models 7 
and 8 shown in Fig. 3.3 corresponding to the structures of 1, 2 and independently of 3.  
The experimental and the DFT calculated chemical shift of carbons Ca to Cd in the 
gas phase and with the PCM solvent model are given in Table 3.2. As shown in this table, 
the chemical shifts of Cc and Cd are both experimentally and theoretically the most 
sensitive to the Z/E configuration of the double bond. The calculated chemical shifts of 
these carbons, either in gas phase or with PCM solvent, very satisfactorily reproduce the 
experimental differences between E and Z configurations. On the other hand, Ca and Cb 
were rather insensitive to the double bond configuration according to both the experimental 
and the theoretical calculations of Table 3.2. 
 For the compounds studied herein the DFT calculations of chemical shifts listed in 
Table 3.2 showed in general either similar or slightly better qualitative agreement with the 
experimental values using the PCM solvent model than in the gas phase. 
3.4 Conclusions 
Long range 3JHaCc scalar coupling and chemical shift of alkyne Cd and Cc nuclei 
are reliable parameters that can be used to asses the configuration of the double bond in 
enol acetates conjugated to an alkyne or a diyne. The geometry of the natural oxylipins 
peyssonenynes A and B has been unequivocally proven. It is expected that the method 
proposed will be of use for the determination of the configuration of geometric isomers of 
related compounds with scarce number of protons and relative similar substituents attached 
to the carbons in the double bond. 
3.5 Spectroscopic data 
General procedures for Weinreb amide formation, addition of TIPS-acetylene and enol acetate 
formation are described in chapter 2. 
N-methoxy-N-methylhexadecanamide (5a). M.p.: 63 ºC (hexane/ether). 1H-NMR (400.13 
MHz, CDCl3): δ 3.66 (s, 3H, OCH3), 3.16 (s, 3H, NCH3), 2.39 (t, J = 7.6 Hz, 2H, 2H2), 1.7-
1.6 (m, 2H, 2H3), 1.3-1.2 (m, 24 H, 12 x -CH2-), 0.86 (t, J = 6.8 Hz, 3H, CH3) pm. 13C-NMR 
(100.62 MHz, CDCl3): δ 174.2 (s, C1), 60.6 (q, OMe), 31.5 (t), 31.4 (t), 29.6 (t), 29.5 (t), 29.4 
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(t), 29.3 (t), 29.2 (t, 3x), 29.1 (t), 29.0 (t), 28.9 (t), 26.6 (q, NCH3), 24.2 (t), 22.2 (t), 13.6 (q, 
C16) ppm. MS (FAB+): m/z (%) 300 ([M+1]+, 100). HRMS (FAB+): Calcd for C18H38NO2 
([M+1]+, 300.2903; found, 300.2910. IR (NaCl): ν 2925 (s, C-H), 2855 (m, C-H), 1674 (m, 
C=O) cm-1.  
N-methoxy-N-methylicosanamide (5b). Elem. Anal. Calculated for: C22H45NO2: C, 
74.31%; H, 12.76%; N, 3.94% found: C, 74.38%; H, 12.84%; N, 3.78%. 1H-NMR (400 
MHz, CDCl3): δ 3.67 (s, 3H, OCH3), 3.17 (s, 3H, NCH3), 2.40 (t, J = 7.2 Hz, 2H, 2H2), 
1.7-1.6 (m, 2H, 2H3), 1.3-1.2 (m, 32H, 16 x CH2), 0.87 (t, J = 6.4 Hz, 3H, CH3) ppm. 13C-
NMR (100 MHz, CDCl3): δ 174.8 (s, C1), 61.2 (q, OCH3), 31.9 (t), 29.7 (t, 11x), 29.5 (t, 
2x), 29.4 (t), 29.3 (t), 24.7 (t), 22.7 (t), 14.1 (q, C20) ppm. MS (EI+): m/z (%) 355 (M+, 
0.03), 128 (11), 100 (12), 86 (89), 73 (100), 71 (15), 61 (21). HRMS (EI+): calculated 
355.3450 (C22H45NO2); found 355.3455. IR (NaCl): ν 2919 (s, C-H), 2851 (w, C-H), 
1673 (w, C=O) cm-1.  
: λmax 232 nm. 
(9Z)-N-methoxy-N-methyloctadec-9-enamide (5c).1H-NMR (400 MHz, CDCl3): δ 5.4-
5.3 (m, 2H, H9 + H10), 3.68 (s, 3H, OCH3), 3.18 (s, 3H, NCH3), 2.41 (t, J = 7.6 Hz, 2H, 
2H2), 2.1-2.0 (m, 4H, 2H8 + 2H11), 1.7-1.6 (m, 2H, 2H3), 1.3-1.2 (m, 20H, 2H4 +2H5 + 
2H6 + 2H7 + 2H12 + 2H13 + 2H14 + 2H15 + 2H16 + 2H17), 0.88 (t, J = 6.8 Hz, 3H, CH3) 
ppm. 13C-NMR (100 MHz, CDCl3): δ 174.5 (s, C1), 129.9 (d), 129.7 (d), 60.9 (q, OCH3), 
31.3 (t), 29.4 (t), 29.1 (t, 7x), 28.9 (t), 26.9 (t), 26.8 (q, NCH3), 25.4 (t), 24.4 (t), 22.3 (t), 
13.8 (q, C18) ppm. MS (FAB+): m/z (%) 326 (M+ + 1, 100), 325 (M+, 5), 324 (10). HRMS 
(FAB+): calculated 326.3059 (C20H40NO2); found 326.3058. IR (NaCl): ν 2926 (s, C-H), 
2856 (m, C-H), 1673 (m, C=O), 1461 (m), 1173 (m) cm-1. 
(9Z, 12Z)-N-methoxy-N-methyloctadeca-9, 12-dienamide (5d). 1H-NMR (400 MHz, 
CDCl3): δ 5.4-5.3 (m, 4H, H9 + H10 + H12 + H13), 3.68 (s, 3H, OCH3), 3.18 (s, 3H, 
NCH3), 2.77 (t, J = 7.3 Hz, 2H, 2H11), 2.41 (t, J = 7.4 Hz, 2H, 2H2), 2.1-2.0 (m, 4H, 2H8 + 
2H14), 1.7-1.6 (m, 2H, 2H3), 1.3-1.2 (m, 14H, 2H4 + 2H5 + 2H6 + 2H7  + 2H15 + 2H16 + 
2H17), 0.89 (t, J = 6.6 Hz, 3H, CH3) ppm. 13C-NMR (100 MHz, CDCl3): δ 174.7 (s, C1), 
130.0 (d), 129.9 (d), 127.9 (d), 127.8 (d), 61.0 (q, OCH3), 31.4 (t), 29.0 (t, 7x), 27.1 (t), 
26.9 (q, NCH3), 25.5 (t), 24.5 (t), 22.5 (t), 13.9 (q, C18) ppm. MS (EI+): m/z (%) 323 (M+, 
0.2), 95 (14), 86 (65), 81 (27), 79 (20), 73 (100), 67 (64). HRMS (EI+): calculated 
323.2824 (C20H37NO2); found 323.2833. IR (NaCl): ν 2927 (s, C-H), 2858 (m, C-H), 
1671 (s, C=O), 1461 (m) cm-1. UV (MeOH)
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1-(Triisopropylsilyl)-octadec-1-yn-3-one (6a). 1H-NMR (400 MHz, CDCl3): δ 2.54 (t, J 
= 7.4 Hz, 2H, 2H4), 1.7-1.6 (m, 2H, 2H5), 1.3-1.2 (m, 24H, 12 x CH2), 1.2-1.1 (m, 21H, 
iPr3Si), 0.88 (t, J = 6.8 Hz, 3H, CH3). 13C-NMR (100 MHz, CDCl3): δ 187.9 (s, C3), 
104.2 (s, C2), 95.2 (s, C1), 45.6 (t), 31.9 (t), 29.7 (t, 3x), 29.6 (t, 3x), 29.4 (t), 29.3 (t, 2x), 
29.0 (t), 24.3 (t), 22.7 (t), 18.4 (q, 6x, iPr3Si), 14.1 (q, C18), 11.0 (d, 3x, iPr3Si). MS (EI+): 
m/z (%) 421 (M+ + 1, 0.2), 420 (M+, 0.6), 378 (19), 377 (100), 167 (15). HRMS (EI+): 
calculated 420.3787 (C27H52OSi); found 420.3795. IR (NaCl): ν 2925 (s, C-H), 2855 (m), 
1681 (m, C=O), 1460 (m) cm-1. UV (MeOH): λmax 234 nm. 
.4494. 
1-(Triisopropylsilyl)-icos-1-yn-3-one (6b). 1H-NMR (400 MHz, CDCl3): δ 2.54 (t, J = 
7.4 Hz, 2H, 2H4), 1.69 (m, 2H, 2H5), 1.3-1.2 (m, 32H, 16 x CH2), 1.1-1.0 (m, 21H, 
iPr3Si), 0.87 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100 MHz, CDCl3): δ  188.1 (s, C3), 
104.2 (s, C2), 95.4 (s, C1), 45.7 (t), 31.9 (t), 29.7 (t, 10x), 29.6 (t), 29.4 (t), 29.3 (t), 29.0 
(t), 24.3 (t), 22.7 (t), 18.4 (q, 6x, iPr3Si), 14.1 (q, C22), 11.0 (d, 3x, iPr3Si) ppm. HRMS 
(ESI): calculated 477.4486 (C31H61OSi); found 477
(9Z)-1-(Triisopropylsilyl)-octadec-9-en-1-yn-3-one (6c).1H-NMR (400 MHz, CDCl3): 
δ 5.4-5.3 (m, 2H, H11 + H12), 2.54 (t, J = 7.4 Hz, 2H, 2H4), 2.1-2.0 (m, 4H, 2H10 + 2H13), 
1.68 (m, 2H, 2H5), 1.4-1.2 (m, 20H, 2H6 +2H7 + 2H8 + 2H9 + 2H14 + 2H15 + 2H16 + 2H17 
+ 2H18 + 2H19), 1.1-1.0 (m, 21H, iPr3Si), 0.87 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR 
(100 MHz, CDCl3): δ 188.1 (s, C3), 130.0 (d), 129.7 (d), 104.2 (s, C2), 95.4 (s, C1), 45.6 
(t, C4), 31.9 (t), 29.8 (t), 29.7 (t, 2x), 29.5 (t), 29.3 (t, 2x), 29.1 (t), 29.0 (t), 27.2 (t, 2x), 
24.3 (t), 22.7 (t), 18.5 (q, 6x, iPr3Si), 14.1 (q, C20), 11.0 (d, 3x, iPr3Si) ppm. HRMS (ESI): 
calculated 447.4017 (C29H55OSi); found 447.4017. 
(9Z, 12Z)--1-(Triisopropylsilyl)-octadec-9,12-dien-1-yn-3-one (6d). 1H-NMR (400 
MHz, CDCl3): δ 5.4-5.3 (m, 4H, H11 + H12 + H14 + H15), 2.76 (t, J = 6.2 Hz, 2H, 2H13), 
2.54 (t, J = 7.4 Hz, 2H, 2H4), 2.1-2.0 (m, 4H, 2H10 + 2H16), 1.7-1.6 (m, 2H, 2H5), 0.88 (t, 
J = 6.7 Hz, 3H, CH3), 1.3-1.2 (m, 14H, 2H6 + 2H7 + 2H8 + 2H9  + 2H17 + 2H18 + 2H19), 
1.2-1.0 (m, 21H, iPr3Si), 0.88 (t, J = 6.7 Hz, 3H, CH3) ppm. 13C-NMR (100 MHz, 
CDCl3): δ 188.0 (s, C3), 130.2 (d), 130.0 (d), 128.1 (d), 127.9 (d), 104.2 (s, C2), 95.4 (s, 
C1), 45.6 (t), 31.5 (t), 29.6 (t), 29.3 (t), 29.2 (t), 29.1 (t), 28.9 (t), 27.2 (t, 2x), 25.6 (t), 24.3 
(t), 22.6 (t, C19), 18.4 (q, 6x, iPr3Si), 14.1 (q, C20), 11.0 (d, 3x, iPr3Si) ppm. HRMS (ESI): 
calculated 445.3860 (C29H53OSi); found 445.3853. 
(E)-1-Triisopropylsilyloctadec-3-en-1-yn-3-yl Acetate ((E)-3a). 1H-NMR (500 MHz, 
C6D6): δ 5.65 (t, J = 8.0 Hz, 1H, H4), 2.4-2.3 (m, 2H, 2H5), 1.66 (s, 3H, CH3CO), 1.4-1.3 (m, 
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24H, 12 x CH2), 1.2-1.1 (m, 18H, iPr3Si), 1.1-1.0 (m, 3H, iPr3Si), 0.92 (t, J = 6.9 Hz, 3H, 
CH3) ppm. 13C-NMR (126 MHz, C6D6): δ 168.1 (s, CO), 131.8 (s, C3), 129.9 (d, C4), 100.4 
(s, C2), 97.0 (s, C1), 32.7 (t), 30.5 (t, 5x), 30.4 (t), 30.2 (t, 2x), 30.0 (t), 29.7 (t), 29.0 (t), 23.5 
(t), 20.6 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.7 (q, C18), 11.9 (d, 3x, iPr3Si) ppm. MS (FAB+): 
m/z (%) 463 ([M + 1]+, 24), 462 ([M]+, 6), 461 ([M - 1]+, 8), 421 (12), 419 (22), 377 (12), 174 
(14), 173 (100). HRMS (FAB+): Calcd for C29H55O2Si ([M + 1]+), 463.3971; found 
23), 377 
2x), 30.0 (t), 11.9 
2x), 29.9 (t), 29.2 
463.3963.  
(Z)-1-Triisopropylsilyloctadec-3-en-1-yn-3-yl Acetate ((Z)-3a). 1H-NMR (500 MHz, 
C6D6): δ 5.70 (t, J = 7.6 Hz, 1H, H4), 2.0-1.9 (m, 2H, 2H5), 1.69 (s, 3H, CH3CO), 1.4-1.2 (m, 
24H, 12 x CH2), 1.2-1.1 (m, 18H, iPr3Si), 1.1-1.0 (m, 3H, iPr3Si), 0.92 (t, J = 6.9 Hz, 3H, 
CH3) ppm. 13C-NMR (126 MHz, C6D6): δ 167.4 (s, CO), 131.2 (s, C3), 129.6 (d, C4), 102.8 
(s, C2), 91.3 (s, C1), 32.7 (t), 30.5 (t, 5x), 30.3 (t), 30.2 (t), 30.1 (t), 29.9 (t), 29.2 (t), 26.8 (t), 
23.5 (t), 20.4 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.7 (q, C18), 12.0 (d, 3x, iPr3Si) ppm. MS 
(FAB+): m/z (%) 463 ([M + 1]+, 27), 462 (M+, 7), 461 ([M - 1]+, 10), 421 (14), 419 (
(12), 174 (16), 173 (100). HRMS (FAB+): Calcd for C29H55O2Si ([M + 1]+), 463.3971; found 
463.3971.  
 (E)-1-Triisopropylsilylicosa-3-en-1-yn-3-yl Acetate ((E)-3b). 1H-NMR (500 MHz, 
C6D6): δ 5.62 (t, J = 8.0 Hz, 1H, H4), 2.4-2.3 (m, 2H, 2H5), 1.66 (s, 3H, CH3CO), 1.4-1.2 
(m, 32H, 16 x CH2), 1.2-1.1 (m, 18H, iPr3Si), 1.1-1.0 (m, 3H, iPr3Si), 0.91 (t, J = 6.5 Hz, 
3H, CH3) ppm. 13C-NMR (126 MHz, C6D6): δ 168.1 (s, CO), 131.8 (s, C3), 129.8 (d, C4), 
100.4 (s, C2), 96.9 (s, C1), 32.7 (t), 30.6 (t, 8x), 30.5 (t), 30.4 (t), 30.2 (t, 
(d, 3x, iPr3Si), 29.7 (t), 28.9 (t), 23.5 (t), 20.6 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.7 (q, 
C22) ppm. HRMS (ESI): calculated 519.4592 (C33H63O2Si); found 519.4590. 
(Z)-1-Triisopropylsilylicosa-3-en-1-yn-3-yl Acetate ((Z)-3b). 1H-NMR (500 MHz, 
C6D6): δ 5.67 (t, J = 7.6 Hz, 1H, H4), 2.0-1.9 (m, 2H, 2H5), 1.69 (s, 3H, CH3CO), 1.4-1.2 
(m, 32H, 16 x CH2), 1.2-1.1 (m, 18H, iPr3Si), 1.1-1.0 (m, 3H, iPr3Si), 0.91 (t, J = 6.9 Hz, 
3H, CH3) ppm. 13C-NMR (126 MHz, C6D6): δ 167.4 (s, CO), 131.2 (s, C3), 129.5 (d, C4), 
102.8 (s, C2), 91.2 (s, C1), 32.7 (t), 30.6 (t, 9x), 30.5 (t), 30.3 (t), 30.2 (t, 
(t), 26.8 (t), 23.5 (t), 20.4 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.7 (q, C22), 12.0 (d, 3x, 
iPr3Si) ppm. HRMS (ESI): calculated 519.4592 (C33H63O2Si); found 519.4593. 
(3E, 9Z)-1-Triisopropylsilyloctadeca-3,9-dien-1-yn-3-yl Acetate ((E)-3c).1H-NMR (500 
MHz, C6D6): δ 5.61 (t, J = 8.0 Hz, 1H, H4), 5.5-5.4 (m, 2H, H11 + H12), 2.4-2.3 (m, 2H, 
2H5), 2.1-2.0 (m, 4H, 2H10 + 2H13), 1.66 (s, 3H, CH3CO), 1.4-1.2 (m, 20H, 2H6 +2H7 + 
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2H8 + 2H9 + 2H14 + 2H15 + 2H16 + 2H17 + 2H18 + 2H19), 1.2-1.1 (m, 18H, iPr3Si), 1.1-1.0 
(m, 3H, iPr3Si), 0.90 (t, J = 6.9 Hz, 3H, CH3) ppm. 13C-NMR (126 MHz, C6D6): δ 168.1 
(s, CO), 131.8 (s, C3), 130.6 (d), 130.5 (d), 129.8 (d, C4), 100.3 (s, C2), 96.9 (s, C1), 32.7 
(t), 30.6 (t), 30.5 (t), 30.4 (t), 30.1 (t, 2x), 29.8 (t, 2x), 29.6 (t), 28.9 (t), 28.1 (t), 28.0 (t), 
3
 (t), 28.0 (t), 26.8 (t), 23.5 (t), 20.4 (q, CH3CO), 
x), 
(d), 102.8 (s, C2), 91.3 (s, C1), 32.2 (t), 30.2 (t), 30.1 (t), 29.8 (t), 29.7 (t), 29.1 (t), 28.0 (t, 
23.5 (t), 20.6 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.7 (q, C20), 11.9 (d, 3x, iPr Si) ppm. 
HRMS (ESI): calculated 489.4122 (C31H57O2Si); found 489.4132. 
(3Z, 9Z)-1-Triisopropylsilyloctadeca-3,9-dien-1-yn-3-yl Acetate ((Z)-3c). 1H-NMR 
(500 MHz, C6D6): δ 5.69 (t, J = 7.6 Hz, 1H, H4), 5.5-5.4 (m, 2H, H11 + H12), 2.1-2.0 (m, 
4H, 2H10 + 2H13), 2.0-1.9 (m, 2H, 2H5), 1.70 (s, 3H, CH3CO), 1.4-1.2 (m, 20H, 2H6 +2H7 
+ 2H8 + 2H9 + 2H14 + 2H15 + 2H16 + 2H17 + 2H18 + 2H19), 1.2-1.0 (m, 21H, iPr3Si), 0.91 
(t, J = 6.9 Hz, 3H, CH3) ppm. 13C-NMR (126 MHz, C6D6): δ 167.4 (s, CO), 131.2 (s, C3), 
130.6 (d), 130.5 (d), 129.5 (d, C4), 102.8 (s, C1), 91.3 (s, C2), 32.7 (t), 30.6 (t), 30.4 (t, 2x), 
30.1 (t, 2x), 29.8 (t), 29.7 (t), 29.1 (t), 28.1
19.2 (q, 6x, iPr3Si), 14.7 (q, C20), 12.0 (d, 3x, iPr3Si) ppm. HRMS (ESI): calculated 
489.4122 (C31H57O2Si); found 489.4105. 
(3E, 9Z, 12Z)-1-Triisopropylsilyloctadeca-3,9,12-trien-1-yn-3-yl Acetate ((E)-3d). 1H-
NMR (750 MHz, C6D6): δ 5.62 (t, J = 8.0 Hz, 1H, H4), 5.5-5.4 (m, 4H, H11 + H12 + H14 + 
H15), 2.89 (t, J = 7.0 Hz, 2H, H13), 2.4-2.3 (m, 2H, 2H5), 2.1-2.0 (m, 4H, 2H10 + 2H16), 
1.65 (s, 3H, CH3CO), 1.4-1.2 (m, 14H, 2H6 +2H7 + 2H8 + 2H9 + 2H17 + 2H18 + 2H19), 
1.2-1.1 (m, 18H, iPr3Si), 1.1-1.0 (m, 3H, iPr3Si), 0.89 (t, J = 6.9 Hz, 3H, CH3) ppm. 13C-
NMR (126 MHz, C6D6): δ 168.1 (s, CO), 131.8 (s, C3), 130.8 (d), 130.7 (d), 129.8 (d, C4), 
128.8 (d), 128.7 (d), 100.3 (s, C2), 97.0 (s, C1), 32.2 (t), 30.4 (t), 30.1 (t, 2x), 29.8 (t, 2
29.6 (t), 28.9 (t), 28.0 (t), 26.5 (t), 23.3 (t), 20.6 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.7 (q, 
C20), 11.9 (d, 3x, iPr3Si) ppm. HRMS (ESI): calculated 487.3966 (C31H55O2Si); found 
487.3955. 
(3Z, 9Z, 12Z)-1-Triisopropylsilyloctadeca-3,9,12-trien-1-yn-3-yl Acetate ((Z)-3d). 1H-
NMR (500 MHz, C6D6): δ 5.68 (t, J = 8.0 Hz, 1H, H4), 5.5-5.4 (m, 4H, H11 + H12 + H14 + 
H15), 2.87 (t, J = 6.5 Hz, 2H, H13), 2.1-2.0 (m, 4H, 2H10 + 2H16), 1.95 (q, J = 7.2 Hz, 2H, 
H5), 1.70 (s, 3H, CH3CO), 1.4-1.2 (m, 14H, 2H6 +2H7 + 2H8 + 2H9 + 2H17 + 2H18 + 
2H19), 1.2-1.0 (m, 21H, iPr3Si), 0.88 (t, J = 7.0 Hz, 3H, CH3) ppm. 13C-NMR (126 MHz, 
C6D6): δ 167.4 (s, CO), 131.2 (s, C3), 130.8 (d), 130.7 (d), 129.5 (d, C4), 128.8 (d), 128.7 
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2x), 26.8 (t), 26.5 (t), 23.3 (t), 20.4 (q, CH3CO), 19.2 (q, 6x, iPr3Si), 14.6 (q, C20), 12.0 (d, 
3x, iPr3Si) ppm. HRMS (ESI): calculated 487.3966 (C31H55O2Si); found 487.3978. 
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Theoretical calculations. SCF energies and cartesian coordinates of the species 
t. 
YP-GAS PHASE 
described in the tex
B3L
8E 8Z 
SCF Energy: -870.096950982  
C        -3.50 .4119 8704 C 87 81 78 0272    -1 50    -1.11  3.667 2 1.4748 -0.5124
Si       -2.84 .0630 1394 Si 90 599 11 7816    -0 25     0.02 3.097 5 -0.257  -0.0412
C        -3.20 .4852 2536 C 72 234 17 7768    -0 33     1.82 3.674 8 -1.516  -1.3189
C        -3.59 6102 5425 C 060 555 38 0149     1. 59 -0.42  1.25 2 -0.268  -0.0057
C        -1.01 0449 2120 C 527 315 33 5584     0. 52 -0.20  0.03 6 -0.299  -0.0091
C         0.185 180 9165 C 793 4376 40 087     0.1 43 -0.37  -1.38 9 -0.31  -0.0267
C          1.59 631 92983 O 533 785 91 1485     0.1 95 -0.5  -2.00 6 0.745 -0.7012
C          2.33 753 7970 C 031 580 96 8560     1.2 96 -0.61  -2.06 0 2.024 -0.1769
C         1.846 737 05531 C 381 059 29 843     2.6 81 -0.4  -1.53 4 2.219 1.2246
C          2.54 713 4301 C 045 0711 94 3237     3.3 80 0.77 -2.13 8 -1.32  0.4576
O          2.19 0613 11780 C 421 9787 76 5208    -1. 07 -0.9  -3.62 5 -1.41  0.4097
C         2.438 0306 2475 O 524 046 18 452    -2. 04 0.04 -2.53 7 2.886 -0.8556
O          2.87 .0819 5582 C 94 260 3 1906    -3 61 -0.32  3.726 1 -0.723  1.67354
C          2.16 .6678 2065 H 831 065 87 0194    -1 50 1.48 -1.58 5 -2.155  0.8947
H          3.39 1423 24350 H 716 66 2 8417     1. 89 -0.8  -1.98 0 1.5126 1.92335
H          2.03 2521 19671 H 432 51 6 4574     3. 60 -1.3  -0.45 1 2.0566 1.25705
H          0.76 6732 6012 H 552 70 16 4426     2. 41 -0.25  -1.75 3 3.2380 1.5336
H         2.696 .7614 2131 H 69 286 86 059    -0 44 1.77 4.767 6 -1.545  -1.3747
H          1.09 4777 7603 H 986 4470 02 6027    -1. 18 1.63 3.32 2 -2.52  -1.0735
H          2.47 4982 9637 H 884 4231 89 5685    -2. 13 2.10 3.29 1 -1.27  -2.3166
H        -4.67 978 2744 H 030 033 00 8977     1.5 59 -0.31  4.76 7 1.527 -0.5593
H        -3.20 068 5714 H 132 743 20 2322     2.4 10 0.21 3.28 3 1.770 -1.4915
H         -3.36 8831 60892 H 382 94 11 9060     1. 59 -1.4  3.33 6 2.2221 0.2126
H        -4.58 .5128 4219 H 130 6153 4 6263    -1 95 -1.02  4.82 1 -0.73  1.69902
H        -3.27 1930 66546 H 808 853 16 7929    -1. 78 -2.1  3.38 1 -0.013  2.4336
H         -3.05 3838 85627 H 914 212 71 6837    -2. 46 -0.8  3.37 2 -1.716  1.9717
H        -4.28 .5504 0175 C 0076 421 12 6023    -0 83 2.00 -4.1 6 -2.667  -0.3531
H          -2.770125    -1.446657 2.105525 H -4.009338 -1.465884 1.437303 
H          -2.807684     0.272425 2.502060 H -4.045011 -0.522073 -0.046350 
H          2.194982     4.402488 0.875658 H -5.191730 -2.733006 -0.342602 
H           2.338732     2.853914 1.715204 H -3.774646 -2.637288 -1.395359 
H            3.628319     3.400179 0.638851 H -3.707862 -3.585260 0.094013 
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B3LYP-GAS PHASE 
7E 7Z 
SCF Energy: -616.022794043 SCF Energy: -616.023000707 
C 2.408 .34 0.92 C -3 -2 -0415 3 0620 4846 .856797 .855491 .353669 
C 1.872 .65 -0.3 C -3 -1 0.016 2 6430 45916 .437669 .591542 420659 
C 2.370 .25 -0.4 C -1 -1 0.221 1 0213 95609 .950126 .400758 431706 
C 1.602 .14 -0.5 C -1 -0 -0354 0 7544 75019 .282794 .337499 .057023 
C 0.182 .12 -0.5 C 0 -0 -0361 0 8946 47068 .133362 .228373 .069452 
C -1.03 .04 -0.5 C 1 -0 -05866 0 7343 23086 .346577 .093829 .093751 
O 2.225 1.0 -0.8 O -1 0 -0998 - 86395 14070 .986981 .690996 .697455 
C 2.317 2.0 0.15 C -2 1 -0921 - 60339 9467 .108999 .951913 .146297 
O 2.808 3.1 -0.1 C -1 2 1.120 - 15531 46302 .539671 .164647 238383 
C 1.812 1.7 1.54 H -0 2 1.333 - 13960 2540 .448769 .073032 222984 
H 2.042 2.5 2.20 H -1 3 1.743 - 46852 7308 .817743 .165226 570539 
H 2.279 0.7 1.91 H -1 1 1.984 - 97152 5593 .919674 .417043 942052 
H 0.730 1.5 1.52 O -2 2 -0575 - 45456 6208 .672556 .794406 .793900 
H 3.446 .09 -0.5 H -3 -0 -0795 1 7748 52986 .924052 .711684 .010053 
H 3.504 .35 0.93 H -3 -1 1.642 3 2360 8166 .791817 .680816 458895 
H 2.067 .81 1.82 H -4 -2 -0224 2 9168 5903 .942975 .990768 .309169 
H 2.061 .37 0.98 H -3 -2 -1021 4 8083 0236 .564535 .782945 .406417 
H 2.192 .23 -1.2 H -3 -3 0.657 3 8368 22808 .387813 .753606 065415 
H 0.776 .66 -0.3 H -1 -2 0.836 2 6522 45112 .344607 .206459 841831 
C -2.39 0.0 -0.4 C 2 0 -06147 - 23199 97492 .702751 .036696 .116155 
C -3.61 0.0 -0.4 C 3 0 -01893 - 88761 79016 .914112 .157924 .137759 
C -5.06 0.1 -0.4 C 5 0 -09260 - 63866 31399 .369620 .272995 .160291 
H -5.39 1.1 -0.8 H 5 1 0.0987 - 34733 33222 .684596 .027249 574442 
C -5.64 .02 0.98 C 6 -1 0.1350 0 4939 8246 .084852 .062127 129683 
H -5.49 .59 -1.1 H 5 0 -10736 0 6610 03574 .685068 .655019 .141233 
H -6.73 0.0 0.96 H 7 -0 0.4232 - 40171 3589 .170259 .919780 100591 
H -5.26 0.7 1.66 H 5 -1 1.3994 - 46524 6389 .812262 .443703 118411 
H 
 
 
 
 
 
-5.36 .00 1.39 H 5 -1 -02097 1 1980 4328 .814796 .818353 .613661 
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B3LYP-PCM 
8E 8Z 
SCF Energy: -870.096876334 SCF Energy: -870.097413909 
C -3.541949 624 842 C   -1.288 -1.234 3.658978 1.477939 -0.512298
Si -2.856058 420 2 Si  3  -0.067 0.02317 3.104230 -0.258442 -0.03916
C -3.192453 838 1 C  3  -0.660 1.77940 3.697181 -1.515800 -1.31004
C -3.577930 81 99 C    1.6512 -0.2468 1.254363 -0.283265 -0.014221
C -1.023255 63 82 C     0.0385 -0.2156 0.038765 -0.314229 -0.018238
C 0.177797 71 24 C 0   0.1140 -0.3902 -1.38388 -0.321820 -0.037413
C 1.583781 10 65 O    0.1641 -0.5988 -1.988813 0.750479 -0.714596
C 2.334779 61 059 C    1.2730 -0.621 -2.053839 2.016116 -0.173964
C 1.844681 95 06 C    2.6715 -0.4074 -1.551694 2.196840 1.236531
C 2.542201 20 95 C  6  3.3658 0.7738 -2.139728 -1.31786 0.445753
O 2.189890 60 252 C  6  -1.0663 -0.915 -3.634343 -1.40009 0.401003
C 2.452822 88 30 O   5 -2.0173 0.0441 -2.519335 2.887562 -0.85265
O 2.901938 77 787 C 6  -3.0674 -0.320 3.725001 -0.71349 1.680828
C 2.175891 141 0 H    -1.652 1.48128 -1.607709 -2.157835 0.887410
H 3.396630 24 064 H   1.1392 -0.823 -2.025308 1.490091 1.921319
H 2.036226 78 010 H   3.2497 -1.321 -0.474701 2.022487 1.287205
H 0.762071 64 075 H   2.6736 -0.259 -1.768085 3.215609 1.550341
H 2.710183 152 5 H  8 -0.743 1.76593 4.790874 -1.536688 -1.35579
H 1.111485 269 1 H  6 -1.463 1.63671 3.357231 -2.525926 -1.06487
H 2.494041 18 7 H  2  -2.4782 2.11334 3.328290 -1.27706 -2.311387
H -4.664955 97 62 H     1.6400 -0.1174 4.751318 1.538336 -0.552826
H -3.169033 89 4 H     2.3761 0.46271 3.275354 1.766837 -1.494750
H -3.369226 95 30 H     2.0203 -1.2548 3.314231 2.223679 0.209551
H -4.626385 548 155 H     -1.391 -1.125 4.819398 -0.715998 1.711142
H -3.341859 808 31 H  5   -0.962 -2.2593 3.375546 -0.00408 2.436274
H -3.101431 80 553 H     -2.2819 -1.112 3.384737 -1.709054 1.979529
H -4.268994 62 02 C 0  0  -0.7301 1.9665 -4.12572 -2.652471 -0.34463
H -2.763437 871 09 H 9    -1.650 1.9586 -4.01543 -1.430904 1.430644
H -2.771882 0.022377 2.522616 H -4.049216 -0.503515 -0.063414 
H 2.195948 4.397646 0.874560 H -5.217298 -2.705529 -0.329469 
H 2.335276 2.848702 1.714568 H -3.802885 -2.639761 -1.388484 
H 3.627331 3.391449 0.638443 C -3.740861 -3.567936 0.114032 
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B3LYP-PCM 
7E 7Z 
SCF E 6.182212613 ergy: -616.182695672 nergy: -61 SCF En
C 2.405048 3.350056 0.903833 C -3.815266 -2.890894 -0.330841 
C 1.842127 2.655476 -0.347002 C -3.411735 -1.600914 0.403442 
C 2.34028 3 2 1.252075 -0.497879 C -1.928739 -1.395907 0.41414
C 1.580406 0.149428 -0.573393 C -1.269789 -0.330406 -0.067804 
C 0.164585 0.112450 -0.538717 C 0.142209 -0.207489 -0.079909 
C -1.048316 0.039108 -0.514771 C 1.351160 -0.087656 -0.103386 
O 2.212682 -1.084607 -0.819389 O -1.979648 0.699369 -0.708017 
C 2.346985 -2.045290 0.157939 C -2.135268 1.946367 -0.140983 
O 2.841625 -3.091320 -0.155651 C -1.593749 1.251434 2.151177 
C 1.878568 - 1.249097 1.697547 1.548995 H -0.502114 2.107415 
H 2.127989 -2.523658 2.211076 H -1.911681 1.602660 3.130379 
H 2.350784 -0.781007 1.908551 H -1.946946 1.378104 1.936932 
H 0.798716 -1.533900 1.565731 O -2.701488 2.782587 -0.786149 
H 3.417318 1.106392 -0.566137 H -3.909929 -0.742147 -0.050384 
H 3.498682 3.366470 0.893785 H -3.764824 -1.661372 1.441946 
H 2.086658 2.840028 1.816778 H -4.898061 -3.033547 -0.289600 
H 2.057984 4.384943 0.958860 H -3.519621 -2.853078 -1.382105 
H 2.144283 3.226829 -1.234805 H -3.345380 -3.770715 0.118203 
H 0.749507 2.670111 -0.326045 H -1.317781 -2.195877 0.827015 
C -2.405253 -0.035667 -0.486365 C 2.704379 0.043410 -0.123795 
C -3.615564 -0.105706 -0.466068 C 3.910919 0.161335 -0.143609 
C -5.069089 -0.188449 -0.424186 C 5.362493 0.282324 -0.164770 
H -5.377685 -1.166316 -0.813293 H 5.666472 1.053913 0.553032 
C -5.652349 0.021162 0.985438 C 6.085708 -1.039528 0.152893 
H -5.486284 0.555311 -1.113899 H 5.673077 0.648170 -1.150936 
H -6.742057 -0.051020 0.955002 H 7.167726 -0.891347 0.123365 
H -5.279054 -0.734023 1.680053 H 5.817701 -1.404040 1.146648 
H -5.385875 1.004683 1.377719 H 5.826515 -1.812418 -0.573447 
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4. SEPARATION OF REGIOISOMERS AND 
ENANTIOMERS OF UNDERIVATIZED 
ATURATED AND UNSATURATED FATTY 
ACID MONOACYLGLYCEROLS USING 
ENANTIOSELECTIVE HPLC 
 
 
 
The challenging separation of regioisomers and enantiomers of MAGs of fatty acids has 
been achieved using a single chiral HPLC column (Chiralpak® IC or Chiralpak® IA) and n-
hexane/2-propanol eluent mixtures, without previous derivatization of the samples. The 
efficacy of the method is independent of the chain length and the degree of unsaturation of 
the fatty acids of the MAG. In addition, the separation method allows monitoring the time 
course for the loss of enantiomeric purity of the fatty acid-derived MAGs in polar 
hydroxylic solvents. 
 

Separation of Regioisomers and Enantiomers of MAGs 
4.1. Introduction 
Monoacylglycerols (MAGs) are present in low amounts in natural oils and fats 
together with the major components diacylglycerols and triacylglycerols and they have 
found application as emulsifying agents in the food, pharmaceutical and cosmetic sectors.1 
Although rare as secondary metabolites a small group of MAGs and DAGs have been 
isolated from the red algae L 2 3
4
iagora farinosa,  Peyssonnelia caulifera  and Gracilariopsis 
lemaneiformis . 
MAGs consist of three isomers, two enantiomers termed sn-1/sn-3 and their achiral 
sn-2 regioisomer. Pure isomers of MAGs are difficult to synthesize and to analyze 
quantitatively owing to the easy acyl migration promoted by a variety of conditions such as 
the presence of catalytic amounts of acids s, or moderate temperatures, both in 
solution and in the solid state. In add natur  mig l cha only 
its length, but also the degree of unsaturation and branching of the acyl group) can also 
influence th merization.5 The migration of the acyl group from the sn-1 to the 
sn-3 position via the achiral sn-2 regioisomer results in the loss of enantiomeric purity of 
chiral non-racemic MAGs. Due to this fact MAGs exhibit moderate or low enantiomer 
excesses either as natural or as synthetic compounds. 
To complicate matters, the direct sep ration of monoacylglycerol isomers rem ins a 
major un  in glycerolipid chromatography. The separation of the sn-2 
regioisomer from the sn-1/sn-3 enanti as fi omplished using TLC on boric 
acid-impregnated silica gel.6 Subsequently, the com separation of the three MAGs 
isomers with different acyl chains could only be achieved by HPLC after their 
derivatization as bis-3,5-d itropheny es us ipax 00 or hiral 
OA-4100 as chiral columns. However, the recovery of the original monoacylglycerols was 
hampered by the higher st bility of th anes to the 7 Meguro and co-
                                                
or base
ition, the e of the rating acy in (not 
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solved problem
omers w rstly acc
plete 
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a e ureth relative  esters.
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workers8 carried out the separation of MAGs modified with a fluorescent chiral group, and 
the separation of the resulting diastereom
derivatization.  Many of the methods mentioned above involve laborious multi-step 
tty acids having different 
r derivatization, using a single HPLC chiral 
amounts of cerium (IV) ammonium 
                                                
ers could be performed with a normal phase 
achiral column (Develosil 60-3). More recently, Iwasaki and coworkers9 developed a 
method for the direct separation of MAGs based on the use of a conventional silica gel 
column and a chiral column (Chiralcel OD) in tandem, but the enantiomers could not be 
baseline-separated. The same group achieved the separation of regioisomers and 
enantiomers of MAGs using a single chiral column (Chiralcel OF), without prior 
10
chemical reactions and tedious separation protocols that could induce the spontaneous acyl 
migration. Moreover, most of the methods have been developed for the separation of 
MAGs derived from saturated fatty acids.1b Therefore a more direct method for the 
separation and enantiomeric resolution of both saturated and unsaturated fatty-acid 
containing MAGs is lacking. Herein, we report an improved method for baseline 
separation of regioisomer and enantiomers of MAGs-derived fa
saturated and unsaturated chains without prio
column.  
4.2. Experimental 
4.2.1. Preparation of MAGs 
Oleic acid, linoleic acid, palmitoleic acid, erucic acid, palmitic acid and arachidic 
acid were selected for analytical method development. The series of MAGs were 
synthesized following the novel reaction sequence summarized in Figure 4.1. Namely, a 
DCC-induced esterification of the fatty acids with enantiopure (R)- and (S)-glycerol 
isopropylidene acetals to afford the corresponding protected MAGs in good yields, 
followed by their deprotection to provide the required MAGs. Since the general method for 
deprotection of ketals and acetals is acid-mediated, this procedure is often incompatible 
with the presence of other sensitive functional groups in the substrate and causes parcial 
racemization of the generated diol. We turned our attention to the recently reported method 
for deprotection of ketals and acetals using catalytic 
 
8 Kim, J.-H.; Nishida, Y.; Ohrui, H.; Meguro, H. J. Chromatogr. A 1995, 709, 375. 
hromatogr. A 2008, 1198, 67. 
9 Deng, L.; Nakano, H.; Iwasaki, Y. J. Chromatogr. A 2007, 1165, 93. 
10 Deng, L.; Nakano, H.; Iwasaki, Y. J. C
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nitrate 
t 70-80 ºC using an acetonitrile-water mixture (1:1, v/v) as 
solvent and the MAGs-derived fatty acids were obtained in moderate to good yields. The 
purity present in the starting (R)- and (S)-glycerol isopropylidene acetals was determined 
by HPLC as detailed
(CAN),11 since the mild conditions tolerate a wide range of acid-labile 
functionalities and thus is appropriate to obtain MAGs with high enantiomeric excesses. 
The reactions were carried out a
enantiomeric excesses of these compounds, and thus the preservation of the enantiomeric 
 below. 
CA
CH3CN/H
70 ºC
R
N
2O (1:1) O
O
OH
OH
R
OH
O
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O
MA
CH , 25 º
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2Cl2 C
O
OH
R
O
O
O
a.
b.
O
1a-6a 1b
tty a
 a  b 
-6b  
Fa cid 
Step Step
Yield (% ee (%) Yield (% ee (%)  ) ) 
 
Oleic acid, 1 
(S)-1a-83 (S)-1a >99 (S)-1b >99 (S)-1b-94
(R)-1a-83 (R)-1a >99 (R)-1b >99 (R)-1b-80 
 
Linoleic acid, 2 
)-2a-84 
(S)-2a-81 
(R)-2a >99 
(S)-2a >99 
(R)-2b-91 
(S)-2b-71 
(R)-2b  
(S)-2b-98 
(R -92
 
Palmitoleic acid, 3 
(R)-3a-65 
(S)-3a-73 
(R)-3a >99 
(S)-3a >99 
(R)-3b-90 
(S)-3b-92 
(R)-3b-90 
(S)-3b-92 
 
Erucic acid, 4 
(R)-4a-82 
(S)-4a-85 
(R)-4a >99 
(S)-4a >99 
(R)-4b-90 
(S)-4b-99 
(R)-4b-96 
(S)-4b-96 
 
Palmitic acid, 5 
(R)-5a-86 
(S)-5a-81 
(R)-5a >99 
(S)-5a >99 
(R)-5b-96 
(S)-5b-82 
(R)-5b-96 
(S)-5b-72 
 
Arachidic acid, 6 
(R)-6a-86 
(S)-6a-81 
(R)-6a >99 
(S)-6a >99 
(R)-6b-96 
(S)-6b-82 
(R)-6b-82 
(S)-6b-86 
Figure 4.1. Synthesis of enantioenriched MAGs of saturated and unsaturated fatty acids (the absolute 
configuration is not indicated). Reagents and conditions: (a) DCC (dicyclohexylcarbodiimide), DMAP [4-
(N,N-dimethylamino)pyridine], CH2Cl2, 25 ºC. (b) C N (cerium ammonium nitrate), 1:1 acetonitrile/H2O, 
70 ºC. 
4.2.2. Chiral HPLC Separation  
                                                
A
 
, 8989. 
11 Ates, A.; Gautier, A.; Leroy, B.; Plancher, J.-M.; Quesnel, Y.; Vanherck, J.-C.; Markó, I. E. Tetrahedron 
2003, 59
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Chiralpak® IA [(amylose tris(3,5-dimethylphenylcarbamate)] immobilized on 5μm 
silica-gel, 250x10 mm, Chiral Technologies Europe) and Chiralpak® IC [(cellulose 
tris(3,5-dichlorophenylcarbamate)] immobilized on 5μm silica-gel, 250x4.6 mm, Chiral 
Technologies Europe) columns were selected for screening of mobile phases. These two 
columns are compatible with a large variety of solvents, either in normal or in reverse 
phase modes.12 For these samples we first optimized the flow rates from 1.0 to 1.5 mL/min 
at ambient temperature by injecting using a 100 μL loop a 15-40 μL aliquot of a 1:1 
mixture of both enantiomers of MAG fatty acids dissolved in the corresponding solvent. 
The peaks were detected using a WatersTM 996 Photodiode Array Detector (λ = 210 nm) 
and a Waters 410 Differential Refractometer. For the determination of the time course of 
racemization, all chromatographic runs were performed the number of times required to 
get 50% enantiomeric excesses of the MAG-derived fatty acids. 
4.3. Results and discussion 
The MAG derived from linoleic acid was selected as model substrate to evaluate 
eve the 
separation of the three isomers, given its tolerance to a broad polarity composition of 
solvent
p tively.  
                                                
the effect of mobile phase composition. Chiralpak® IA was firstly used to achi
s and versatility in the range of substrates. Different solvent mixtures were 
screening (n-hexane/2-propanol, n-hexane/EtOAc, n-hexane/THF), but none of them 
allowed baseline separation of the peaks (a single peak or partially resolved peaks were 
observed instead in all cases). Choosing reverse phase conditions with THF/H2O and 
MeOH/H2O mixtures did not solve the problem either. We next turned our attention to 
Chiralpak® IC. Although generally considered as complementary to IA and IB, IC is 
composed of a unique new chiral stationary phase with the potential to achieve separations 
not available with other chiral columns. A mixture of n-hexane/2-propanol (90:10) at a 
flow rate of 1 mL/min allowed the separation of sn-1, sn-3 and sn-2 isomers of linoleic 
MAGs with resolution factors (Rs) of 1.27 (sn-1 vs. sn-3) and 1.62 (sn-3 vs. sn-2) and 
separation factors (α) of 1.17 and 1.21, res ec
 
7, 1048. 
12 a. Zhang, T.; Nguyen, D.; Franco, P. J. Chromatogr. A 2008, 1191, 214. b. Zhang, T.; Nguyen, D.; Franco, 
P. J. Chromatogr. A 2010, 121
128 
Separation of Regioisomers and Enantiomers of MAGs 
After optimizing the separation of linoleic MAGs isomers, the method was 
extended to MAGs derived from the remaining fatty acids depicted on Figure 4.1. The 
results are shown in Table 4.1. 
re 4.1, identified according to their equivalent carbon number (ECN). 
Table 4.1 Values of retention times (ti), separation factors (α) and resolution factors (Rs) for the MAGs 
shown on Figu
MA  
Retention time (min) 
 
Rsb 
Gs ECNa
αb
sn-1 sn-2 sn-1 v sn-1 vs sn-2 -1 vs sn-3  vs sn-2 sn-3 s sn-3 sn sn-1
2b 14   14.8 16.7 19.5 1.17 1.21 1.27 1.62
3b 14 14.6 16.7 19.4 1.19 1.18 1.14 1.20 
1b 16 12.8 14.4 16.2 1.17 1.22 1.19 2.22 
5b 16 13.6 15.5 18.1 1.18 1.20 1.48 1.90 
4b 20 11.9 13.4 15.3 1.18 1.19 1.45 1.86 
6b 20 12.0 13.5 15.6 1.18 1.22 1.31 1.82 
a ECN = CN - 2DB, where CN is the number of carbon atoms and DB is the number of double bonds. 
b timevoidttimesretentiontt
tt
tt
==
−
−
= 012
01
02 ,;α   ( ) widthpeakwwtimesretentiontt
ww
ttRs ==+
−
= 2112
21
21 ,,;
2  
All MAGs were successfully resolved using the same conditions (see Figure 4.2). 
In all cases retention times are shorter than those previously reported1b,6,7,8,9,10 using other 
methods. The peak elution order of molecular species with the same configuration follows 
the equivalent carbon number rule,13 as shown in Table 4.1, i.e., the larger the ECN value 
the shorter the retention time. The pair of MAGs derived from linoleic acid/palmitoleic 
acid, oleic acid/palmitic acid and erucic acid/arachidic acid are eluted at almost the same 
retention time consistent with their equivalent carbon number (ECN). Peaks have 
resolution factors of 1.17 or higher and separation factors of 1.14 or higher. Moreover, the 
 for the separation of MAGs with saturated and unsaturated alkyl 
chains 
method can be used
of different length.  
 
 
                                                 
13 Christie, W. W. In High-Performance Liquid Chromatography and Lipids; Pergamon Press: Tokyo, 1987; 
p. 169. 
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Figure 4.2. Separation of the synthetic sn-1 glycerol palmitate enantiomers (Chiralpak® IC, 250x4.6 mm, 
90:10 n-hexane/iPrOH, 1.0 mL/min). The peak at tR =18.3 min corresponds to the sn-2 regioisomer. 
The migration of the acyl moieties in mono- and diacylglycerols has been reported 
to take place under several conditions.5 The progressive loss of enantiomeric purity in 
these compounds associated to acyl migration could become a major complication for 
biological studies if only one of the enantiomers shows activity. Thus, it would be of major 
importance to show the time course of the loss of enantiomeric purity of MAGs in solution. 
The data obtained by chiral HPLC would also be of interest to determine whether the 
migration of the acyl group in solution is an avoidable side reaction that occurs only under 
certain circumstances, and to show whether MAGs present always low enantiomeric 
excesses owing to spontaneous migration. The alternative method of specific optical 
rotation determination is of little use in this field, since the specific optical rotation of 
glycerides is inherently low in magnitude.   
In order to estimate the time course of racemization, the MAG derived from 
linoleic acid was selected as model substrate to follow the evolution of the enantiomeric 
excess with time. Between 1 and 3 mg of the compound was dissolved in n-hexane/2-
                                                
R
14
 
 Eliel, E. L.; Wilen, S. H.; Mander, L. S. In Stereochemistry of Organic Compounds; Wiley-Interscience: 
New York, 1994; p. 1074. 
14
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propanol (90:10) and the samples were kept in solution at ambient temperature. The ee was 
measured periodically by chiral HPLC on Chiralpak® IC and the results are listed in Table 
4.2. 
Table 4.2. Time course for the enantiomeric composition of linoleic MAGs in solution as determined by 
chiral HPLC. 
Time in solution 
(days) 
Linoleic Acid (ee) 
sn-1 
(n-hexane/2-propanol) 
sn-3 
(n-hexane/2-propanol) 
sn-3 
(n-hexane) 
sn-3 
(2-propanol) 
0 98% 91% 91% 91% 
5 77% 88% 91% - 
10 63% 82% 85% - 
26 36% 66% 79% - 
 
As both enantiomers should exhibit the same ee and the same rate of conversion, 
the differences observed between them could be attributed to small variations on the 
experimental method used for the deprotection with CAN or alternatively to the use of 
different concentration of the samples. If a new sample was prepared with the compounds 
kept as solids at -30 ºC, the enantiomer excesses sn-1 and 
sn-3, respectively. These results show that the enantiomeric purity decreases in solution 
much rapidly than in solid state, for which the loss of ee was not noticed after short time 
periods. The solvent also plays a fundamental role in the process, since similar experiments 
in 2-propanol (100%) and 
 were again of 98% and 91% for 
n-hexane (100%) showed a slightly slower racemization in the 
ifferent chain lengths and various degrees of unsaturation have been separated using 
latter relative to the n-hexane/2-propanol mixture, but extensive degradation with no well 
defined peaks in the chromatogram in solutions of the former. 
4.4. Conclusions 
In the present work a new method for the separation of regioisomers and 
enantiomers of MAG-derived fatty acids has been developed. With a single chiral column 
(Chiralpak® IC or Chiralpak® IA) and without prior derivatization, MAGs of fatty acids 
with d
n-hexane/2-propanol mixtures. In addition, retention times are shorter than those of other 
methods previously described. The influence of the solvent in the loss of enantiomeric 
excess of the enantioenriched compounds has been demonstrated by monitoring the 
131 
Separation of Regioisomers and Enantiomers of MAGs 
process with the separation protocol developed, and found to be much faster in polar 
hydroxylic solvents. 
4.5. Experimental 
General procedures. CH2Cl2 and AcN were dried using a PuresolvTM solvent purification 
system. HPLC grade solvents were used for HPLC purification. All other reagents were 
commercial compounds of the highest purity available. All reactions were carried out under 
argon atmosphere, and those not involving aqueous reagents were carried out in oven-dried 
glassware. All solvents and anhydrous solutions were transferred through syringes and 
cannulae previously dried in the oven for at least 12 h and kept in a dessicator with KOH. 
Analytical thin layer chromatography (TLC) was performed on aluminium plates with Merck 
Kieselgel 60F254 and visualised by UV irradiation (254 nm) or by staining with an ethanolic 
solution of phosphomolibdic acid or an ethanolic solution of anisaldehyde. Flash column 
chromatography was carried out using Merck Kieselgel 60 (230-400 mesh) under pressure. IR 
 the sample at a v/v ratio of 1 to 5% to give the best 
3 6 6
6
constant J, number of protons, assignment). C NMR spectra were recorded in CDCl  and 
CDCl3 (δC = 77.0 ppm) or C6D6 (δC = 128.0 ppm) as the internal reference. The DEPT135 
spectra were obtained on a JASCO IR 4200 spectrophotometer from a thin film deposited onto 
NaCl glass. Mass spectra were obtained on a Hewlett-Packard HP59970 instrument operating 
at 70 eV by electron ionisation and APEX III FT-ICR MS (Bruker Daltonics, Billerica, MA), 
equipped with a 7T actively shielded magnet. Ions were generated using an Apollo API 
electrospray ionization (ESI) source, with a voltage between 1800 and 2200 V (to optimize 
ionisation efficiency) applied to the needle, and a counter voltage of 450 V applied to the 
capillary. Samples were prepared by adding a spray solution of 70:29.9:0.1 (v/v/v) 
CH3OH/water/formic acid to a solution of
signal-to-noise ratio. High-resolution mass spectra were taken on a VG Autospec instrument. 
HPLC was performed using Waters 1525 Binary and Waters 515 Pumps, Waters 717plus 
Autosampler injector, Waters 2487 Dual λ Absorbance Detector, WatersTM 996 Photodiode 
Array Detector and Waters 410 Differential Refractometer. 1H NMR spectra were recorded in 
CDCl  and C D  at ambient temperature on a Bruker AMX-400 spectrometer at 400 MHz 
with residual protic solvent as the internal reference [CDCl3, δH = 7.26 ppm and C D6, δH = 
7.15 ppm]; chemical shifts (δ) are given in parts per million (ppm), and coupling constants (J) 
are given in Hertz (Hz). The proton spectra are reported as follows: δ (multiplicity, coupling 
13
3
C6D6 at ambient temperature on the same spectrometer at 100 MHz, with the central peak of 
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pulse sequence was used to aid in the assignment of signals in the 13C NMR spectra. Melting 
points were measured in a Stuart Scientific apparatus. 
Synthesis of fatty acid-derived MAGs and HPLC purification 
(9Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Octadeca-9-enoate (R)-2a. 
), 3.69 (dd, J = 8.1, 6.5 Hz, 1H, H3’), 2.29 (t, J = 7.5 
General procedure for ester formation. To a stirred solution of oleic acid (0.30 g, 1.06 
mmol, 0.34 mL), DCC (0.22 g, 1.06 mmol) and DMAP (0.13 g, 1.06 mmol) in CH2Cl2 (2 mL) 
was added a solution of (S)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (0.14 g, 1.06 
mmol, 0.13 mL) in CH2Cl2 (1.5 mL). After stirring the mixture at room temperature overnight, 
the solvent was evaporated and the residue was purified by flash chromatography (85:15 
hexane/EtOAc) to afford 0.35 g (83%) of the titled compound as a colourless oil. 1H-NMR 
(400.13 MHz, CDCl3): δ 5.3-5.2 (m, 2H, H9 + H10), 4.3-4.2 (m, 1H, H2’), 4.11 (dd, J = 11.3, 
4.5 Hz, 1H, H1’), 4.1-4.0 (m, 2H, H1’ + H3’
Hz, 2H, 2H2), 2.0-1.9 (m, 4H, 2H8 + 2H11), 1.6-1.5 (m, 2H, 2H3), 1.38 (s, 3H), 1.32 (s, 3H), 
1.3-1.2 (m, 20H), 0.83 (t, J = 6.7 Hz, 3H, 3H18) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ  173.4 (s, C1), 129.8 (d), 129.6 (d), 109.6 (s, C1’’), 73.5 (d, C2’), 66.2 (t), 64.4 (t), 33.9 (t), 
31.8 (t), 29.6 (t, 2x), 29.4 (t), 29.2 (t), 29.1 (t), 28.9 (t, 3x), 27.1 (t), 27.0 (t), 26.5 (q), 25.2 (q), 
24.7 (t), 22.6 (t), 14.0 (q, C18) ppm. HRMS (ESI+): Calcd for C24H44O4Na, 419.31318; found, 
419.31228. IR (NaCl): ν 2926 (s, C-H), 2856 (m, C-H), 1743 (m, C=O), 1459 (w), 1375 (w), 
1216 (w), 1164 (w), 1086 (w),  1060 (w) cm-1. The enantiomeric excess (>99% ee) was 
determined using Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, 
tR= 7.4 min). 
(9Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Octadeca-9-enoate (S)-2a. 
Following the general procedure described above for ester formation, the reaction of oleic acid 
(0.3 g, 1.06 mmol, 0.34 mL), DCC (0.22 g, 1.0 mmol), DMAP (0.13 g, 1.06 mmol) and (R)-
2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (0.14 g, 1.06 mmol, 0.13 mL) in CH
R
mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 6.6 
2Cl2 (3.5 
mL), afforded after purification by flash chromatography (85:15 hexane/EtOAc), 0.35 g (83%) 
of the titled compound as a colourless oil. The enantiomeric excess (>99% ee) was determined 
using Chiral HPLC (Chiralpak  IC, 250x4.6 ®
min). 
(9Z,12Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Octadeca-9,12-dienoate (R)-
1a. Following the general procedure described above for ester formation, the reaction of 
linoleic acid (0.3 g, 1.07 mmol, 0.33 mL), DCC (0.22 g, 1.07 mmol), DMAP (0.13 g, 1.07 
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mmol) and (S)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (0.14 g, 1.07 mmol, 0.13 mL) 
in CH2Cl2 (3.5 mL), afforded after purification by flash chromatography (85:15 
hexane/EtOAc), 0.36 g (84%) of the titled compound as a colourless oil. 1H-NMR (400.13 
MHz, CDCl3): δ  5.4-5.2 (m, 4H, H9 + H10 + H12 + H13), 4.3-4.2 (m, 1H, H2’), 4.13 (dd, J = 
11.5, 4.7 Hz, 1H, H1’), 4.1-4.0 (m, 2H, H1’ + H3’), 3.75-3.65 (m, 1H, 1H, H3’), 2.73 (t, J = 6.2 
Hz, 2H, 2H11), 2.31 (t, J = 7.5 Hz, 2H, 2H2), 2.1-2.0 (m, 4H, 2H8 + 1H14), 1.6-1.5 (m, 2H, 
2H3), 1.40 (s, 3H), 1.33 (s, 3H), 1.3-1.2 (m, 14H), 0.85 (t, J = 6.7 Hz, 3H, 3H18) ppm. 13C-
NMR (100.62 MHz, CDCl3): δ 173.4 (s, C1), 130.0 (d), 129.9 (d), 127.9 (d), 127.8 (d), 109.7 
(s, C1’’), 73.6 (d, C2’), 66.2 (t), 64.4 (t), 34.0 (t), 31.4 (t), 29.5 (t), 29.2 (t), 29.0 (t), 28.9 (t, 2x), 
27.1 (t, 2x), 26.6 (q), 25.5 (t), 25.3 (q), 24.8 (t), 22.5 (t), 14.0 (q, C18) ppm. HRMS (ESI+): 
Calcd for C24H42O4Na, 417.29753; found, 417.29668. IR (NaCl): ν 2928 (s, C-H), 2858 (m, 
C-H), 1742 (s, C=O), 1458 (w), 1375 (w), 1216 (w), 1164 (w), 1087 (w),  1059 (w) cm-1. The 
enantiomeric excess (>99% ee) was determined using Chiral HPLC (Chiralpak® IC, 250x4.6 
mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 8.1 min). 
 (9Z,12Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Octadeca-9,12-dienoate (S)-
1a. Following the general procedure described above for ester formation, the reaction of 
linoleic acid (0.3 g, 1.07 mmol, 0.33 mL), DCC (0.22 g, 1.07 mmol), DMAP (0.13 g, 1.07 
mmol) and (R)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (0.14 g, 1.07 mmol, 0.1
R
3 mL) 
in CH2Cl2 (3.5 mL), afforded after purification by flash chromatography (85:15 
hexane/EtOAc), 0.34 g (81%) of the titled compound as a colourless oil. The enantiomeric 
excess (>99% ee) was determined using Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 99:1 
hexane/iPrOH, 1.0 mL/min, tR= 7.2 min). 
(9Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Hexadeca-9-enoate (R)-3a. 
Following the general procedure described above for ester formation, the reaction of 
palmitoleic acid (0.2 g, 0.79 mmol, 0.9 mL), DCC (0.16 g, 0.79 mmol), DMAP (0.
R
10 g, 0.79 
mmol) and (S)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (0.10 g, 0.79 mmol, 0.1 mL) in 
CH2Cl2 (2.5 mL), afforded after purification by flash chromatography (85:15 hexane/EtOAc), 
0.19 g (65%) of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 
5.4-5.3 (m, 2H, H9 + H10), 4.3-4.2 (m, 1H, H2’), 4.13 (dd, J = 11.5, 4.7 Hz, 1H, H1’), 4.1-4.0 
(m, 2H, H1’ + H3’), 3.71 (dd, J = 8.4, 6.2 Hz, 1H, H3’), 2.31 (t, J = 7.6 Hz, 2H, 2H2), 2.0-1.9 
(m, 4H, 2H8 + 2H11), 1.65-1.55 (m, 2H, 2H3), 1.40 (s, 3H), 1.34 (s, 3H) 1.3-1.2 (m, 16H), 0.85 
(t, J = 6.6 Hz, 3H, 3H16) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 173.5 (s, C1), 129.9 (d), 
129.6 (d), 109.7 (s, C1’’), 73.6 (d, C2’), 66.2 (t), 64.4 (t), 34.0 (t), 31.7 (t), 29.6 (t), 29.6 (t), 29.1 
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(t), 29.0 (t, 2x), 28.9 (t), 27.1 (t), 27.0 (t), 26.6 (q), 25.3 (q), 24.8 (t), 22.6 (t), 14.0 (q, C18) ppm. 
HRMS (ESI+): Calcd for C22H41O4, 369.29994; found, 369.30105. IR (NaCl): ν 2927 (s, C-
H), 2857 (m, C-H), 1742 (s, C=O), 1459 (w), 1375 (w), 1216 (w), 1164 (w), 1085 (w),  1059 
(w) cm-1. The enantiomeric excess (>99% ee) was determined by Chiral HPLC (Chiralpak® 
IC, 250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 8.0 min). 
 (9Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Hexadeca-9-enoate (S)-3a. 
Following the general procedure described above for e
R
ster formation, the reaction of 
palmitoleic acid (0.2 g, 0.79 mmol, 0.9 mL), DCC (0.16 g, 0.79 mmol), DMAP (0.10 g, 0.79 
mmol) and (R)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (0.10 g, 0.79 mmol, 0.1 mL) 
in CH2Cl2 (2.5 mL), afforded after purification by flash chromatography (85:15 
hexane/EtOAc), 0.21 g (73%) of the titled compound as a colourless oil. The enantiomeric 
excess (>99% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 99:1 
hexane/iPrOH, 1.0 mL/min, tR= 7.1 min). 
(13Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Docosa-13-enoate (R)-
R
4a. 
Following the general procedure described above for ester formation, the reaction of erucic 
acid (0.3 g, 0.89 mmol), DCC (0.18 g, 0.89 mmol), DMAP (0.11 g, 0.89 mmol) and (R)-2,3-O-
isopropylidene-2,3-dihydroxy-1-propanol (0.12 g, 0.89 mmol, 0.11 mL) in CH2Cl2 (3.5 mL), 
afforded after purification by flash chromatography (85:15 hexane/EtOAc), 0.33 g (82%) of 
the titled compound as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 5.35-5.25 (m, 2H, 
H13 + H14), 4.3-4.2 (m, 1H, H2’), 4.2-4.1 (m, 1H, H1’)  4.1-4.0 (m, 1H, H1’ + H3’), 3.70 (t, J = 
7.3 Hz, 1H, H3’), 2.30 (t, J = 7.5 Hz, 2H, 2H2), 2.0-1.9 (m, 4H, 2H12+ 2H15), 1.6-1.5 (m, 2H, 
2H3), 1.39 (s, 3H), 1.33 (s, 3H), 1.3-1.2 (m, 28H), 0.84 (t, J = 6.3 Hz, 3H, 3H22) ppm. 13C-
NMR (100.62 MHz, CDCl3): δ 173.5 (s, C1), 129.8 (d, 2x), 109.7 (s, C1’’), 73.6 (d, C2’), 66.3 
(t), 64.4 (t), 34.0 (t), 32.5 (t), 31.8 (t), 29.7 (t), 29.6 (t, 2x), 29.5 (t, 4x), 29.4 (t), 29.2 (t, 2x), 
29.1 (t), 27.1 (t, 2x), 26.6 (q), 25.3 (q), 24.8 (t), 22.6 (t), 14.0 (q, C22) ppm. HRMS (ESI+): 
Calcd for C28H53O4, 453.39384; found, 453.39324. IR (NaCl): ν 2925 (s, C-H), 2855 (m, C-
H), 1743 (m, C=O), 1460 (w), 1375 (w), 1216 (w), 1164 (w), 1088 (w),  1060 (w) cm-1. The 
enantiomeric excess (>99% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 
99:1 hexane/iPrOH, 1.0 mL/min, tR= 6.9 min). 
 (13Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Docosa-13-enoate (S)-4a. 
Following the general procedure described above for ester formation, the reaction of erucic 
acid (0.3 g, 0.89 mmol), DCC (0.18 g, 0.89 mmol), DMAP (0.1
R
1 g, 0.89 mmol) and (R)-2,3-O-
isopropylidene-2,3-dihydroxy-1-propanol (0.12 g, 0.89 mmol, 0.11 mL) in CH2Cl2 (3.5 mL), 
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afforded after purification by flash chromatography (85:15 hexane/EtOAc), 0.34 g (85%) of 
the titled compound as a colourless oil. The enantiomeric excess (>99% ee) was determined by 
Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 6.3 min). 
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Hexadecanoate (R)-5a. Following the 
general procedure described above for ester formation, the reaction of palmitic acid (0.2 g, 0.78 
mmol), DCC (0.16 g, 0.78 mmol), DMAP (0.10 g, 0.78 mmol) and (S)-2,3-O-isopropylidene-
2,3-dihydroxy-1-propanol (0.10 g, 0.78 mmol, 0.10 m
R
L) in CH2Cl2 (2.5 mL), afforded after 
+
purification by flash chromatography (85:15 hexane/EtOAc), 0.25 g (86%) of the titled 
compound as a yellow solid. m.p. 36-37 ºC 1H-NMR (400.13 MHz, CDCl3): δ 4.3-4.2 (m, 
1H, H2’), 4.09 (dd, J = 11.5, 4.8 Hz,1H, H1’), 4.05-3.95 (m, 2H, H1’ + H3’), 3.66 (dd, J = 8.4, 
6.2 Hz, 1H, H3’), 2.27 (t, J = 7.5 Hz, 2H, 2H2), 1.6-1.5 (m, 2H, 2H3), 1.36 (s, 3H), 1.29 (s, 
3H), 1.25-1.1 (m, 24H), 0.81 (t, J = 6.8 Hz, 3H, 3H16) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ 173.3 (s, C1), 109.6 (s, C1’’), 73.5 (d, C2’), 66.2 (t), 64.3 (t), 33.9 (t), 31.8 (t), 29.6 (t, 4x), 
29.5 (t, 2x), 29.3 (t), 29.2 (t), 29.1 (t), 29.0 (t), 26.5 (q), 25.2 (q), 24.7 (t), 22.6 (t), 14.0 (q, C16) 
ppm. HRMS (ESI ): Calcd for C22H42O4Na, 393.29753; found, 393.29720. IR (NaCl): 
ν 2986 (w), 2925 (s, C-H), 2854 (m, C-H), 1743 (m, C=O), 1465 (w), 1371 (w), 1212 (w), 
1161 (w), 1087 (w),  1058 (w) cm-1. The enantiomeric excess was determined by Chiral HPLC 
(Chiralpak® IC, 250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 7.6 min; > 99% ee). 
 (2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Hexadecanoate (S)-5a. Following the 
general procedure described above for ester formation, the reaction of palmitic acid (0.2 g, 0.78 
mmol), DCC (0.16 g, 0.78 mmol), DMAP (0.10 g, 0.78 mmol) and (R)-2,3-O-isopropylidene-
2,3-dihydroxy-1-propanol (0.10 g, 0.78 mmol, 0.10 mL) in CH
R
) of the titled 
2Cl2 (2.5 mL), afforded after 
purification by flash chromatography (85:15 hexane/EtOAc), 0.23 g (81%
compound as a yellow solid. The enantiomeric excess (>99% ee) was determined by Chiral 
HPLC (Chiralpak® IC, 250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 6.9 min). 
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Eicosanoate (R)-6a. Following the 
general procedure described above for ester formation, the reaction of arachidic acid (0.2 g, 
0.64 mmol), DCC (0.13 g, 0.64 mmol), DMAP (0.08 g, 0.64 mmol) and (S)-2,3-O-
isopropylidene-2,3-dihydroxy-1-propanol (0.085 g, 0.64 mmol, 0.08 mL) in CH
R
/EtOAc), 0.18 g (67%) of 
2Cl2 (2.5 mL), 
afforded after purification by flash chromatography (85:15 hexane
the titled compound as a yellow solid. m.p. 51-52 ºC 1H-NMR (400.13 MHz, CDCl3): δ 4.3-
4.2 (m, 1H, H2’), 4.12 (dd, J = 11.5, 4.8 Hz,1H, H1’), 4.1-4.0 (m, 2H, H1’ + H3’), 3.70 (dd, J = 
8.4, 6.2 Hz, 1H, H3’), 2.30 (t, J = 7.6 Hz, 2H, 2H2), 1.6-1.5 (m, 2H, 2H3 ), 1.39 (s, 3H), 1.33 (s, 
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3H), 1.3-1.2 (m, 32H), 0.84 (t, J = 6.8 Hz, 3H, 3H20) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ 173.4 (s, C1), 109.7 (s, C1’’), 73.6 (d, C2’), 66.3 (t), 64.4 (t), 34.0 (t), 31.8 (t), 29.6 (t), 29.5 (t), 
29.4 (t), 29.3 (t), 29.2 (t), 29.0 (t), 26.6 (q), 25.3 (q), 24.8 (t), 22.6 (t), 14.0 (q, C20) ppm. 
HRMS (ESI+): Calcd for C26H50O4Na, 449.36013; found, 449.36000. IR (NaCl): ν 2919 (s, 
C-H), 2849 (m, C-H), 1738 (w, C=O), 1465 (w), 1373 (w), 1173 (w), 1082 (w),  1051 (w) cm-
1. The enantiomeric excess (>99% ee) was determined by Chiral HPLC (Chiralpak® IC, 
250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 6.8 min). 
(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl Eicosanoate (S)-6a. Following the 
general procedure described above for ester formation, the reaction of arachidic acid (0.2 g, 
0.64 mmol), DCC (0.13 g, 0.64 mmol), DMAP (0.08 g, 0.64 mmol) and (R)-2,3-O-
isopropylidene-2,3-dihydroxy-1-propanol (0.085 g, 0.64 mmol, 0.08 mL) in CH
R
ed compound as a yellow solid. The enantiomeric excess (>99% ee) was determined by 
2Cl2 (2.5 mL), 
afforded after purification by flash chromatography (85:15 hexane/EtOAc), 0.21 g (78%) of 
the titl
Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 99:1 hexane/iPrOH, 1.0 mL/min, tR= 6.1 min). 
General procedure for ketal deprotection. (9Z)-(2’R)-2,3-dihydroxyprop-1-yl Octadeca-
9-enoate (R)-2b. A stirred solution of (9Z)-(2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-
yl octadeca-9-enoate (0.06 g, 0.15 mmol) in acetonitrile/water (1.0 mL, 1:1 v/v) was heated to 
70 ºC and solid CAN (2.5 mg, 4.5 μmol) was added. The resulting colourless solution was 
stirred for 4 hours at this temperature. After cooling to room temperature, the reaction mixture 
was extracted with ether (3x). The combined orga
R
nic layers were dried over Na2SO4 and the 
solvents were removed in vacuo. The residue was purified by flash chromatography (silica gel, 
50:50 hexane/EtOAc) to give 56 mg (quantitative) of the titled compound as a white solid. 1H-
NMR (400.13 MHz, C6D6): δ 5.55-5.45 (m, 2H, H9 + H10), 4.14 (dd, J = 11.5, 6.2 Hz, 1H, 
H1’), 4.08 (dd, J = 11.5, 4.9 Hz, 1H, H1’), 3.8-3.7 (m, 1H, H2’), 3.50 (dd, J = 11.4, 3.9 Hz, 1H, 
H3’), 3.42 (dd, J = 11.4, 5.9 Hz, 1H, H3’), 2.2-2.0 (m, 6H, 2H2 + 2H8 + 2H11), 1.6-1.5 (m, 2H, 
2H3), 1.4-1.1 (m, 20H), 0.90 (t, J = 6.8 Hz, 3H, 3H18) ppm. 13C-NMR (100.62 MHz, C6D6): 
δ 173.9 (s, C1), 130.3 (d), 130.1 (d), 70.6 (d, C2’), 65.4 (t), 63.6 (t), 34.2 (t), 32.3 (t), 30.2 (t), 
30.1 (t), 30.0 (t), 29.7 (t, 2x), 29.6 (t), 29.5 (t), 29.4 (t), 27.7 (t), 27.6 (t), 25.2 (t), 23.1 (t), 14.3 
(q, C18) ppm. HRMS (ESI+): Calcd for C21H41O4, 357.29994; found, 357.29949. IR (NaCl): 
ν 3600-3200 (br), 2925 (s, C-H), 2857 (m, C-H), 1735 (m, C=O), 1458 (w), 1178 (w), 1050 
(w) cm-1. The enantiomeric excess (80% ee) was determined by Chiral HPLC (Chiralpak® IC, 
250x4.6 mm, 90:10 hexane/iPrOH, 1.0 mL/min, tR= 14.4 min). R
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(9Z)-(2’S)-2,3-dihydroxyprop-1-yl Octadeca-9-enoate (S)-2b. Following the general 
procedure described above the reaction of (9Z)-(2’S)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl octadeca-9-enoate (0.06 g, 0.15 mmol) and CAN (2.5 mg, 4.5 μmol) in 
acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography 
(silica gel, 50:50 hexane/EtOAc), 56 mg (quantitative) of the titled compound as a white solid. 
The enantiomeric excess (94% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 
mm, 90:10 hexane/iPrOH, 1.0 mL/min, tR= 12.9 min). 
(9Z, 12Z)-(2’R)-2,3-dihydroxyprop-1-yl Octadeca-9,12-dienoate (R)-1b. Following the 
general procedure described above the reaction o
R
f (9Z, 12Z)-(2’R)-2,3-O-isopropylidene-2,3-
, 250x4.6 mm, 90:10 hexane/iPrOH, 1.0 mL/min, tR= 16.8 min). 
L/min, tR= 15.0 min).  
dihydroxyprop-1-yl octadeca-9,12-dienoate (0.06 g, 0.15 mmol) and CAN (2.5 mg, 4.6 μmol) 
in acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash 
chromatography (silica gel, 50:50 hexane/EtOAc), 49 mg (91%) of the titled compound as a 
white solid. 1H-NMR (400.13 MHz, C6D6): δ 5.48 (m, 4H, H9 + H10 + H12 + H13), 4.18 (dd, J 
= 11.5, 6.2 Hz, 1H, H1’), 4.12 (dd, J = 11.5, 4.9 Hz, 1H, H1’), 3.9-3.8 (m, 1H, H2’), 3.57 (dd, J 
= 11.4, 3.8 Hz, 1H, H3’), 3.48 (dd, J = 11.4, 6.0 Hz, 1H, H3’), 2.88 (t, J = 5.9 Hz, 2H, 2H11), 
2.17 (t, J = 7.5 Hz, 2H, 2H2), 2.1-2.0 (m, 4H, 2H8 + 1H14), 1.6-1.5 (m, 2H, 2H3), 1.4-1.1 (m, 
14H), 0.88 (t, J = 6.9 Hz, 3H, 3H18) ppm. 13C-NMR (100.62 MHz, C6D6): δ 173.9 (s, C1), 
130.4 (d), 130.3 (d), 128.5 (d), 128.4 (d), 70.7 (d, C2’), 65.4 (t), 63.7 (t), 34.2 (t), 31.8 (t), 30.0 
(t), 29.7 (t), 29.6 (t), 29.5 (t), 29.4 (t), 27.6 (t, 2x), 26.1 (t), 25.2 (t), 23.0 (t), 14.3 (q, C18) ppm. 
HRMS (ESI+): Calcd for C21H38O4Na, 377.26623; found, 377.26552. IR (NaCl): ν 3600-
3200 (br), 3007 (w, C=C-H), 2926 (s, C-H), 2858 (m, C-H), 1735 (m, C=O), 1457 (w), 1178 
(w), 1050 (w) cm-1. The enantiomeric excess (92% ee) was determined by Chiral HPLC 
(Chiralpak® IC
 (9Z, 12Z)-(2’S)-2,3-dihydroxyprop-1-yl Octadeca-9,12-dienoate (S)-1b. Following the 
general procedure described above the reaction of (9Z, 12Z)-(2’S)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl octadeca-9,12-dienoate (0.06 g, 0.15 mmol) and CAN (2.5 mg, 4.6 μmol) 
in acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash 
chromatography (silica gel, 50:50 hexane/EtOAc), 38 mg (71%) of the titled compound as a 
white solid. The enantiomeric excess (98% ee) was determined by Chiral HPLC (Chiralpak® 
IC, 250x4.6 mm, 90:10 hexane/iPrOH, 1.0 m
(9Z)-(2’R)-2,3-dihydroxyprop-1-yl Hexadeca-9-enoate (R)-3b. Following the general 
procedure described above the reaction of (9Z)-(2’R)-2,3-O-Isopropylidene-2,3-
dihydroxyprop-1-yl hexadeca-9-enoate (0.05 g, 0.14 mmol) and CAN (2.2 mg, 4.1 μmol) in 
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acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography 
(silica gel, 50:50 hexane/EtOAc), 40 mg (90%) of the titled compound as a colourless oil. 1H-
NMR (400.13 MHz, C6D6): δ 5.55-5.45 (m, 2H, H9 + H10), 4.19 (dd, J = 11.4, 6.2 Hz, 1H, 
H1’), 4.12 (dd, J = 11.5, 4.9 Hz, 1H, H1’), 3.9-3.8 (m, 1H, H2’), 3.57 (dd, J = 11.4, 3.7 Hz, 1H, 
H3’), 3.49 (dd, J = 11.5, 6.0 Hz, 1H, H3’), 2.17 (t, J = 7.5 Hz, 2H, 2H2), 2.1-2.0 (m, 4H, 2H8 + 
2H11), 1.6-1.5 (m, 2H, 2H3), 1.4-1.2 (m, 16H), 0.90 (t, J = 6.8 Hz, 3H, 3H16) ppm. 13C-NMR 
(100.62 MHz, C6D6): δ 174.0 (s, C1), 130.3 (d), 130.1 (d), 70.6 (d, C2’), 65.3 (t), 63.7 (t), 34.2 
(t), 32.2 (t), 30.1 (t), 30.2 (t), 29.6 (t), 29.5 (t), 29.4 (t), 29.4 (t), 27.7 (t), 27.6 (t), 25.2 (t), 23.0 
(t), 14.3 (q, C18) ppm. HRMS (ESI+): Calcd for C19H36O4Na, 351.25058; found, 351.25031. 
IR (NaCl): ν 3600-3200 (br), 3002 (w, C=C-H), 2926 (s, C-H), 2858 (m, C-H), 1738 (m, 
C=O), 1459 (w), 1177 (w), 1050 (w) cm-1. The enantiomeric excess (90% ee) was determined 
by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 90:10 hexane/iPrOH, 1.0 mL/min, tR= 16.5 
min). 
 (9Z)-(2’S)-2,3-dihydroxyprop-1-yl Hexadeca-9-enoate (S)-3b. Following the general 
procedure described above the reaction of (9Z)-(2’S)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl hexadeca-9-enoate (0.05 g, 0.14 mmol) and CAN (2.2 mg, 4.1 μmol) in 
acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography 
(silica gel, 50:50 hexane/EtOAc), 41 mg (9
R
2%) of the titled compound as a colourless oil. The 
nantiomeric excess (70% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 
0:10 hexane/iPrOH, 1.0 mL/min, tR= 14.5 min).  
3Z)-(2’R)-2,3-Dihydroxyprop-1-yl Docosa-13-enoate (R)-4b. Following the general 
rocedure described above the reaction of (13Z)-(2’R)-2,3-O-isopropylidene-2,3-
ihydro yprop-1-yl docosa-13-enoate (0.05 g, 0.11 mmol) and CAN (2.0 mg, 3.3 μmol) in 
acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography 
(silica gel, 40:60 hexane/EtOAc), 41 mg (90%) of the titled compound as a white solid. 1H-
NMR (400.13 MHz, C6D6): δ 5.55-5.45 (m, 2H, H13 + H14), 4.11 (dd, J = 11.5, 6.2 Hz,1H, 
H1’), 4.06 (dd, J = 11.5, 4.8 Hz, 1H, H1’), 3.75-3.65 (m, 1H, H2’), 3.44 (dd, J = 11.4, 4.0 
Hz,1H, H3’), 3.37 (dd, J = 11.4, 5.8 Hz,1H, H3’), 2.2-2.0 (m, 6H, 2H2 + 2H12 + 2H15), 1.6-1.5 
(m, 2H, 2H3) 1.4-1.1 (m, 28H),0.90 (t, J = 6.8 Hz, 3H, 3H22) ppm. 13C-NMR (100.62 MHz, 
C6D6): δ 173.8 (s, C1), 130.2 (d), 130.2 (d), 70.6 (d, C2’), 65.3 (t), 63.6 (t), 34.2 (t), 32.3 (t), 
30.3 (t), 30.2 (t), 30.1 (t), 30.1 (t, 2x), 30.0 (t), 29.9 (t), 29.8 (t, 2x), 29.7 (t, 2x), 29.5 (t), 27.7 (t, 
2x), 25.2 (t), 23.1 (t), 14.4 (q, C22) ppm. HRMS (ESI+): Calcd for C25H48O4Na, 435.34448; 
found, 435.34479. IR (NaCl): ν 3600-3200 (br), 2924 (s, C-H), 2856 (m, C-H), 1733 (m, 
e
9
(1
p
d x
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C=O), 1518 (w), 1458 (w), 1177 (w), 1047 (w) cm-1. The enantiomeric excess (96% ee) was 
determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 90:10 hexane/iPrOH, 1.0 mL/min, 
tR= 13.4 min).  
(13Z)-(2’S)-2,3-Dihydroxyprop-1-yl Docosa-13-enoate (S)-4b. Following the general 
procedure described above the reaction of (13Z)-(2’S)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl docosa-13-enoate (0.05 g, 0.11 mmol) and CAN (2.0 mg, 3.3 μmol) in 
acetonitrile-water (1 ml, 1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography 
(silica gel, 40:60 hexane/EtOAc), 45 mg (99%) of the titled compound as a white solid. The 
enantiomeric excess (96% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 
90:10 hexane/iPrOH, 1.0 mL/min, tR= 11.8 min). 
 (2’R)-2,3-Dihydroxyprop-1-yl Hexadecanoate (R)-5b. Following the general procedure 
described above the reaction of  (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 
hexadecanoate (0.10 g, 0.27 mmol) and CAN (4.4 mg, 8.1 μmol) in acetonitrile-water (1.6 mL, 
1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography (silica gel, 40:60 
hexane/EtOAc), 85 mg (96%) of the titled compound as a white solid. 1H-NMR (400.13 MHz, 
CDCl3): δ 4.2-4.1 (m, 2H, 2H1’), 4.0-3.9 (m, 1H, H2’), 3.69 (dd, J = 11.6, 3.7 Hz, 1H, H3’), 
3.59 (dd, J = 11.6, 6.0 Hz, 1H, H3’), 2.35 (t, J = 7.6 Hz, 2H, 2H2), 1.7-1.6 (m, 2H, 2H3), 1.4-
1.2 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H, 3H16) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 174.4 (s, 
C1), 70.2 (d, C2’), 65.0 (t), 63.3 (t), 34.1 (t), 31.9 (t), 29.6 (t, 6x), 29.4 (t), 29.3 (t), 29.2 (t), 29.1 
(t), 24.8 (t), 22.6 (t), 14.0 (q, C16) ppm. HRMS (ESI+): Calcd for C19H38O4Na, 353.26623; 
found, 353.26589. IR (NaCl): ν 3600-3200 (br), 2954 (w), 2919 (s, C-H), 2850 (m, C-H), 1736 
(m, C=O), 1468 (w), 1179 (w), 1116 (w), 1050 (w) cm-1. The enantiomeric excess (96% ee) 
was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 90:10 hexane/iPrOH, 1.0 
mL/min, tR= 15.6 min). 
 (2’S)-2,3-Dihydroxyprop-1-yl Hexadecanoate (S)-5b. Following the general procedure 
described above the reaction of  (2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 
hexadecanoate (0.10 g, 0.27 mmol) and CAN (4.4 mg, 8.1 μmol) in acetonitrile-water (1.6 mL, 
1:1 v/v) at 70 ºC, afforded, after purification by flash chromatography (silica gel, 40:60 
hexane/EtOAc), 73 mg (82%) of the titled compound as a white solid. The enantiomeric 
excess (72% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 90:10 
hexane/iPrOH, 1.0 mL/min, tR= 13.6 min). 
(2’R)-2,3-Dihydroxyprop-1-yl Eicosanoate (R)-6b. Following the general procedure 
described above the reaction of  (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 
140 
Separation of Regioisomers and Enantiomers of MAGs 
141 
eicosanoate (0.10 g, 0.23 mmol) and CAN (4.0 mg, 7.0 μmol) in acetonitrile-water (1.4 mL, 
1:1 v/v) at 80 ºC, afforded, after purification by flash chromatography (silica gel, 96:4 
CH2Cl2/MeOH), 74 mg (99%) of the titled compound as a white solid. 1H-NMR (400.13 
MHz, CDCl3): Hz, 1H, H1’), 
3.95-3.85 (m, 1 , 5.8 Hz, 1H, 
63.3 (t), 34 ), 24.9 (t), 
22.7 (t), 1 3; found, 
409.32860. IR (NaC m, C-H), 1736 (m, 
C=O), 1463 (w), 121 xcess (82% ee) was 
determined by Chiral HP ane/iPrOH, 1.0 mL/min, 
tR= 13.4 min). 
(2’S)-2,3-Dihydroxyprop-1-yl Eicosanoate (S)-6b. Following the general procedure 
described above the reaction of  (2’S 2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 
eicosanoate (0.06 g, 0.13 mmol) and CAN (2.2 mg, 4.0 μmol) in acetonitrile-water (1.0 mL, 
1:1 v/v) at 80 ºC, afforded, after purification by flash chromatography (silica gel, 96:4 
 δ 4.17 (dd, J = 11.6, 4.8 Hz, 1H, H1’), 4.12 (dd, J = 11.6, 6.1 
H, H2’), 3.67 (dd, J = 11.5, 3.9 Hz, 1H, H3’), 3.57 (dd, J = 11.5
H3’), 2.32 (t, J = 7.6 Hz, 2H, 2H2), 1.65-1.55 (m, 2H, 2H3), 1.3-1.2 (m, 32H), 0.85 (t, J = 6.8 
Hz, 3H, 3H20) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 174.4 (s, C1), 70.2 (d, C2’), 65.1 (t), 
.1 (t), 31.9 (t), 29.7 (t, 8x), 29.6 (t, 2x), 29.4 (t), 29.3 (t), 29.2 (t), 29.1 (t
4.1 (q, C20) ppm. HRMS (ESI+): Calcd for C23H46O4Na, 409.3288
l): ν 3600-3200 (br), 3020 (w), 2920 (s, C-H), 2850 (
5 (m), 1010 (w), 1052 (w) cm-1. The enantiomeric e
LC (Chiralpak® IC, 250x4.6 mm, 90:10 hex
)-
CH2Cl2/MeOH), 42 mg (81%) of the titled compound as a white solid. The enantiomeric 
excess (86% ee) was determined by Chiral HPLC (Chiralpak® IC, 250x4.6 mm, 90:10 
hexane/iPrOH, 1.0 mL/min, tR= 11.9 min). 
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e. Therefore, this 
compound interferes in a very specific manner with signaling pathways that are differently 
ulated by 8 but not by the DNMT inhibitor SGI-1027.  
5. A NOVEL DNA METHYL 
TRANSFERASE INHIBITOR INSPIRED 
IN THE STRUCTURE OF THE 
NATURAL PRODUCT 
PEYSSONENYNE 
 
A novel epigenetic modulator that displays DNMT1 inhibition and DNMT3a activation 
profile has been characterized. This compound is a derivative of palmitic acid that 
incorporates the putative reactive functional group (a diynone) of the natural product 
peyssonenyne. Other analogues containing an acetoxyenediyne or a diynone functional 
group did not exhibit the same biological profile. In U937 human leukemia cells diynone 8 
induced cell differentiation and apoptosis, which correlated with the expression of Fas 
protein. Very surprisingly, diynone 8 was toxic to normal human fibroblasts (BJ) and 
mouse embryo fibroblasts (MEF), but not to immortalized human fibroblasts (BJEL), a 
unique effect not observed with the DNMT inhibitor azacytidin
active in the normal and immortalized cell types. This toxicity is reminiscent of the effects 
of Dnmt1 ablation on mouse fibroblasts. In fact, some of the genes deregulated by loss of 
Dnmt1 are similarly dereg
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5.1 Introduction 
Methylation of DNA at the C5 position of cytosine in CpG nucleotide islands (and 
the so called DNA shores1) is the most widely studied epigenetic modification in humans.2 
This molecular signature fulfils the criteria of an epigenetic molecular signal, namely 
propag 3
riptional 
ation, transmission and effects on gene expression.  Symmetrical methylation on 
both DNA strands generates two hemi-methylated double strands upon replication, which 
are then transformed into fully methylated ones by maintenance DNA methyltransferases 
(DNMT1). Moreover, methylation remains stable after several rounds of DNA replication 
in vivo. Finally, DNA methylation causes transcriptional responses by either preventing or 
promoting the recruitment of transcription factors to target-binding sites.3 Some CpG 
island promoters get methylated during development, resulting in long-term transc
silencing.  DNA methylation is also important in X-chromosome inactivation in females to 
compensate for its single dose in males, and in the parent-specific monoallelic expression 
4
of genes known as genomic imprinting.5  
The family of DNMT enzymes catalyzes the transfer of the methyl group of S-
adenosyl-L-methionine ((S)-AdoMet, SAM) to DNA.6 Five DNMTs have been reported in 
mammals: DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L, but only DNMT1, 
DNMT3A and DNMT3B possess methyltransferase activity. DNMT3A and DNMT3B are 
de novo methyltransferases that establish embryonic methylation patterns which are then 
copied to daughter cells during S phase by the maintenance DNMT1.7 DNMT3L lacks 
intrinsic catalytic activity, but modulates the activity of DNMT3a and DNMT3b, to which 
it is physically associated, and is required for establishing maternal genomic imprinting. 
DNMT1 is the most abundant DNMT in the cell and, although it also has de novo activity, 
maintains the methylation pattern in DNA and its copy in the replicated strand.2 DNMT 
enzymes contribute to keep the genome in the "epimutated" state and are also found 
overexpressed in several tumors.2,8   
                                                 
1 Irizarry, R. A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montano, C.; Onyango, P.; Cui, H.; Gabo, K.; Rongione, 
M.; Webster, M.; Ji, H.; Potash, J. B.; Sabunciyan, S.; Feinberg, A. P. Nat. Genet. 2009, 41, 178. 
2 a. Kelly, T. K.; De Carvalho, D. D.; Jones, P. A. Nat. Biotech. 2010, 28, 1069 . b. Portela, A.; Esteller, M. 
Nat. Biotech. 2010, 28, 1057. 
, 5427. b. Rodriguez-Paredes, M.; Esteller, M. Nat. Med. 2011, 17, 330. 
3 Bonasio, R.; Tu, S.; Reinberg, D. Science 2010, 330, 612. 
4 Ooi, S. K. T.; Bestor, T. H. Cell 2008, 133, 1145. 
5 Reik, W.; Lewis, A. Nat. Rev. Genet. 2005, 6, 403. 
6 Jurkowska, R. Z.; Jurkowski, T. P.; Jeltsch, A. ChemBioChem 2011, 12, 206. 
7 Brown, R.; Strathdee, G. Trends Mol. Med. 2002, 8, S43. 
8 a. Esteller, M. Oncogene 2002, 21
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Cancer cells are characterized by a global loss of DNA methylation 
(hypomethylation) and genomic instability,2a which is usually accompanyied by increased 
de novo methylation (hypermethylation) of a subset of promoters of tumor suppressor 
genes contained within normally unmethylated CpG nucleotide islands.2,8 Mice carrying a 
hypomorphic DNA methyltransferase 1 (Dnmt1) allele, which reduces Dnmt1 expression 
to 10% of wild-type levels, results in substantial genome-wide hypomethylation in all 
tissues.9 At 4 to 8 months of age the mutant mice develop aggressive T cell lymphomas 
that display a high frequency of trisomic chromosome 15. These results indicate that DNA 
hypomethylation plays a causal role in tumor formation, possibly by promoting 
chromosomal instability. Similarly, loss of imprinting in embryonic stem cells predisposes 
them to tumorigenesis.10 However, the effects of DNA hypomethylation can be opposite at 
different stages of tumorigenesis11 and deletion of DNMT3b has even been reported to 
exert a tumor suppressive effect.12  
While the enzymatic reversal of this epigenetic modification, DNA demethylation, 
remains to be demonstrated - oxidation of 5-methylcytosine to 5-hydroxymethylcytosine 
catalyzed by TET1-3 has been shown,13 but the mechanism of its further conversion to 
unmethylated cytosine remains still unknown - current therapeutic intervention protocols 
focus on inhibition of DNMT enzymes.  
DNMT inhibitors (DNMTis) can be broadly divided in two groups, nucleoside and 
non-nucleoside inhibitors.14 The first is formed by 5-azacytidine 1 (5-aza-CR, azacitidine, 
Vidaza®), 5-aza-2´-deoxycytidine 2 (5-aza, 5-aza-CdR, decitabine, Dacogen®), and their 
deoxyribonucleoside analogues, such as 5-fluoro-2’-deoxycytidine (FCDR) and 
zebularine 3. These drugs function as suicide inhibitors after their phosphorylation and 
incorporation into DNA (also RNA for 5-azacytidine 1), and undergo attack of the 
DNMTs’ invariant active-site Cys residue after base-flipping.15 However, the 
                                                 
9 Gaudet, F.; Hodgson, J. G.; Eden, A.; Jackson-Grusby, L.; Dausman, J.; Gray, J. W.; Leonhardt
Jaenisch, R. Science 2003, 300, 489. 
, H.; 
10 Holm, T. M.; Jackson-Grusby, L.; Brambrink, T.; Yamada, Y.; Rideout, W. M., 3rd; Jaenisch, R. Cancer 
Cell 2005, 8, 275. 
11 Yamada, Y.; Jackson-Grusby, L.; Linhart, H.; Meissner, A.; Eden, A.; Lin, H.; Jaenisch, R. Proc. Natl. 
Acad. Sci. U. S. A. 2005, 102, 13580. 
etis, K.; Lo, G.; 
sio, A. C.; Taranova, O. V.; Hong, K.; Sowers, L. C.; Zhang, Y. Nature 2010, 466, 1129. 
, L. M.; 
12 Lin, H.; Yamada, Y.; Nguyen, S.; Linhart, H.; Jackson-Grusby, L.; Meissner, A.; Mel
Jaenisch, R. Mol. Cell Biol. 2006, 26, 2976. 
13 a. Ito, S.; D/'Ales
b. Tahiliani, M.; Koh, K. P.; Shen, Y.; Pastor, W. A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer
Liu, D. R.; Aravind, L.; Rao, A. Science 2009, 324, 930. 
14 Álvarez, R.; Gronemeyer, H.; Altucci, L.; de Lera, A. R. Curr. Top. Med. Chem. 2011, 11, 2749. 
15 Roberts, R. J.; Cheng, X. Ann. Rev. Biochem. 1998, 67, 181. 
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azanucleosides also act through non-specific mechanisms, which contributes to their 
effectiveness in the clinic. They are approved for the treatment of patients with high-risk 
myelodisplastic syndromes (MDS) and are in clinical trials for other indications alone 
(AML, CMML) or in combination (advanced solid cancer, refractory solid tumors) with 
HDAC inhibitors.2a  
The second, more diverse group includes the local anesthetic procaine and 
antiarrythmic procainamide, hydralazine and other small molecules (Figure 5.1), as well as 
natural products (Figure 5.1). RG108 416 was discovered by virtual ligand screening using 
the homology-built DNMT1 model. A more potent and selective (DNMT1 vs DNMT3B) 
analogue is the diarylmethane NSC 14778 5.17 The quinoline-based SGI-1027 6, functions 
as a SAM competitor, and was found to reactivate tumor suppressor genes by blocking 
DNMT1 activity (also DNMT3A and DNMT3B) and inducing its degradation.18  
                                                 
16 a. Brueckner, B.; Boy, R. G.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; 
eckner, B.; 
y, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, 
Wiessler, M.; Lyko, F. Cancer Res. 2005, 65, 6305. b. Siedlecki, P.; Boy, R. G.; Musch, T.; Bru
Suhai, S.; Lyko, F.; Zielenkiewicz, P. J. Med. Chem. 2006, 49, 678. 
17 Kuck, D.; Singh, N.; Lyko, F.; Medina-Franco, J. L. Bioorg.  Med. Chem. 2010, 18, 822. 
18 Datta, J.; Ghoshal, K.; Denn
S. T. Cancer Res. 2009, 69, 4277. 
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Figure 5.1. Adenosine analogs and other small-molecule DNMTis. 
Among the natural compounds, DNMT inhibitory activities have been reported for 
epi-gallocatechin-3-gallate (EGCG) a green tea polyphenol, nanaomycin (selective 
DNMT3B inhibitor)  from Streptomyces and several marine natural products: the 
pyridoacridine dercitin , the halogenated monoterpene halomon from the red alga 
Portieria hornemannii,  several psammaplins and
19
20
21  bisaprasin from Verongida sponges22 
and the glycerol fatty acid peyssonenynes 7 from the red alga Peyssonelia caulifera.23  
                                                 
19 Kuck, D.; Caulfield, T.; Lyko, F.; Medina-Franco, J. L. Mol. Cancer Ther. 2010, 9, 3015. 
ock, Y. Pharm. 
utschi, J. T.; Wang, G. Y. S.; Sanders, M. L.; Schmitz, F. J.; France, D.; Cornell-Kennon, S.; 
od. 2004, 67, 1010. 
20 Crews, P.; Gerwick, W. H.; Schmitz, F. J.; France, D.; Bair, K. W.; Wright, A. E.; Hall
Biol. 2003, 41, 39. 
21 Andrianasolo, E. H.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J.  Nat. Prod. 2006, 69, 576. 
22 Piña, I. C.; Ga
Sambucetti, L. C.; Remiszewski, S. W.; Perez, L. B.; Bair, K. W.; Crews, P. J. Org. Chem. 2003, 68, 3866. 
23 McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J. Nat. Pr
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The mechanism of inhibition of these structurally diverse ligands is unclear, but 
might involve either binding to CpG-rich DNA sequences, thus perturbing the interactions 
between DNMTs and their target sequences, or binding to the target enzyme. In addition, 
for those inhibitors with electrophilic groups inactivation of the invariant Cys residue is 
also likely. Binding modes have been proposed for EGCG24 and also for hydralazine, 
procainamide and procaine25 using a DNMT1 enzyme model built by homology. In the 
latter case, the binding poses proposed are the same previously suggested for 5-azacytidine 
1 and 5-aza-2’-deoxycytidine 2, in which the deoxyribose oxygen stabilizes the 
intermediate formed after the nucleophilic attack to AdoMet.25 RG108 4 is considered to 
selectively block the active domain of DNMT1, occupying the pocket of the native 
cytosine and close to the Cys residue without covalent binding.16b More accurate insights 
will be obtained from docking studies using the recently reported crystal structure of the 
complex with DNA of both human and mouse DNMT1 bound to (S)-adenosyl-L-
homocysteine.26
th Z geometry. All four 
compo
Upon reflecting on the mechanism of DNMT1 inhibition by these oxylipin natural 
products, we reasoned that compounds 7 might act as pro-drugs of a highly reactive 
diynone that is disguised in the structure of the enol acetate.28 In vivo saponification by 
hydrolases would release the Michael acceptor diynone that could then react with the 
DNMT enzyme, perhaps capturing the invariant Cys residue. The thiol addition process, 
                                                
  
We have recently reported the total synthesis of the purported structures of the 
peyssonenyne A and B (compounds 7, E or Z geometric isomers) in both enantiomeric 
forms, determined the configuration of the enolacetate conjugated to the diyne functional 
group, and corrected the structure of peyssonenyne B 7b, which was shown to correspond 
to the sn-2 positional isomer of the sn-1/3 counterpart wi
unds are roughly equipotent DNA methyl transferase 1 (DNMT1) inhibitors as 
determined by a radioactive methyl transfer assay,27 and therefore neither the absolute 
configuration nor the geometry of the enolacetate appear to play a significant biological 
role on this epigenetic inhibitory activity. 
 
24 Fang, M. Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C. S. Cancer Res 2003, 63, 
7563. 
25 Singh, N.; Dueñas-González, A.; Lyko, F.; Medina-Franco, J. L. ChemMedChem 2009, 4, 792. 
26 Song, J.; Rechkoblit, O.; Bestor, T. H.; Patel, D. J. Science 2011, 331, 1036. 
27 García-Domínguez, P.; Lepore, I.; Erb, C.; Gronemeyer, H.; Altucci, L.; Álvarez, R.; de Lera, A. R. Org. 
. 
Biomol. Chem. 2011, 9, 6979. 
28 Kwan, J. C.; Luesch, H. Chem. Eur. J. 2010, 16, 13020
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which we have mimicked in a model experiment in the present study, might be reversible 
in vivo and therefore transient.29  
 the putative diynones corresponding to 
 as additional synthetically more accessible 
analogues that differ in the nature of the group (alkyl, aryl or heteroaryl) attached to either 
the diy
Based on these assumptions, we prepared
the structure of the natural products as well
ne enolacetate or the diynone and also in the carboxylate group. Notably among 
those is DNMT1 inhibitor 8, derived from palmitic acid, which exhibited remarkable 
biological activities and may correspond to a lead compound for the treatment of fibrosis.  
5.2 Results 
5.2.1 Synthesis 
Weinreb amide 930 prepared from palmitic acid by treatment with N,O-
dimethylhydroxylamine hydrochloride, EDC and DMAP,31 was transformed into the 
propargylic ketone 10 by addition of the anion of TIPS-acetylene. Reduction of the ketone 
to the corresponding alcohol 11 using sodium borohydride in MeOH was required for a 
successful Cadiot-Chodkiewicz coupling using CuI and piperidine32 after TBAF 
deprotection of the TIPS-protected alkyne. Condensation of propargylic alcohol 12 and 
previously described iodoalkyne 1327 provided diynol 14, which was oxidized to 
diynylketone 15 using the Swern conditions. Ketal hydrolysis in the presence of catalytic 
quantities of cerium (IV) ammonium nitrate (CAN) at 70 ºC gave in good yield diynone 
8.33 In addition, enol acetate formation from the unsaturated ketone 15 using Et3N, DMAP 
and Ac2O34 provided a mixture of E/Z isomers 16 in 88% yield. Deprotection of the 
dioxolane as described for 8,33 afforded the mixture of geometric isomers of the glycerol 
derived fatty acid 17. These acetoxyendiyne isomers 17A and 17B were separated using 
RP-HPLC (Nova-Pak HR C18, 6 μm, 300 x 19 mm, 80:20 acetonitrile/H2O, 20 mL/min) 
                                                 
29 Sun, A.; Lu, Y. J.; Hu, H.; Shoji, M.; Liotta, D. C.; Snyder, J. P. Bioorg. Med. Chem. Lett. 2009, 19, 6627. 
30 Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815. 
31 Aoki, S.; Matsui, K.; Wei, H.; Murakami, N.; Kobayashi, M. Tetrahedron 2002, 58, 5417. 
32 Alami, M.; Ferri, F. Tetrahedron Lett. 1996, 37, 2763. 
33 Ates, A.; Gautier, A.; Leroy, B.; Plancher, J.-M.; Quesnel, Y.; Vanherck, J.-C.; Markó, I. E. Tetrahedron 
2003, 59, 8989. 
34 Compernolle, F.; Toppet, S.; Brossette, T.; Mao, H.; Koukni, M.; Kozlecki, T.; Medaer, B.; Guillaume, M.; 
Lang, Y.; Leurs, S.; Hoornaert, G. J. Eur. J.  Org. Chem. 2006, 2006, 1586. 
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and identified as E and Z, respectively, based on the magnitude of the 3JH-C coupling 
constants determined on an EXSIDE NMR experiment.35  
 
Scheme 5.1. Synthesis of acetoxyenediynes 17A, 17B and diynone 8. 
Following a similar synthetic sequence, the tert-butyl ester analogues of 17 that 
replace the fatty acid by a thiophene (18), a benzene (19) or a naphtalene (20) ring were 
also prepared (see Scheme SI5.2 for the synthesis). In these cases, the extended 
conjugation of the acetoxyenediyne favored the exclusive formation of the more stable Z 
isomers (Figure 5.2), as confirmed by EXSIDE experiments.35b 
The diynones 21 and 22 (Figure 5.2) corresponding to the natural products (the S 
and R enantiomers, respectively) were also included in the biological screening, since they 
are readily available by deprotection of the previously described dioxolanes27 similarly to 
the 15 to 8 transformation (Scheme 5.1).  
 
                                                 
35 a. García-Domínguez, P.; Martín-Pastor, M.; de Lera, Á. R.; Álvarez, R. Mag. Res. Chem. 2010, 48, 543. 
b. Krishnamurthy, V. V. J. Magn. Res. A 1996, 121, 33. 
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Figure 5.2. Structure of analogues 18-22.  
5.3 Biological evaluation 
5.3.1 Activity on human DNMT enzymes 
The ability of acetoxyenediynes 17A and 17B, 18-20 and diynones 8, 21 and 22 to 
influence human DNMT1 activity was studied using a radioactive methyl transfer assay 
after immunoprecipitation of K562 human cells treated with anti-DNMT1 antibodies. At 
50 µM
ns up to 2.5-fold. 
Analogues 18-20 were considerably less potent in this assay. A more moderate activating 
effect was also noticed in DNMT3B (Figure 5.3C).   
 these compounds inhibited DNMT1 activity (Figure 5.3A), at least as efficiently as 
RG108 416a but less potently than SGI-1027 6 when used at the same concentration.18 
Surprinsingly, in contrast to RG108, which did not exert a significant effect, compounds 
17A and 17B, and diynones 8, 21 and 22 stimulated the intrinsic methyltransferase 
activities of human DNMT3A (Figure 5.3B) under identical conditio
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Figure 5.3. In vitro radioactive assays to evaluate the effect of compounds on DNMT1 (A), DNMT3A (B) 
and DNMT3B (C) activity relative to reference compounds RG108 4 and SGI-1027 6.  
As 17, 8, 21 and 22 exerted unexpected stimulatory effects on the activities of 
DNMT
5.3.2 Effect on U937 cell cycle and differentiation 
1 and DNMT3A, which appeared to be related to the long carbon chain, we decided 
to study the characteristics of these compounds in cell-based assays. 
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We analyzed the U937 cell cycle by FACS after exposure to the compounds. As 
reference compounds, two HDAC inhibitors, SAHA36 and MS-27537 both at 5 µM were 
selected, since these compounds have a well characterized activity on U937 cells. After 
treatment for 24 hours compounds 17A and 21 at 50 µM induced a slight increase of pre-
G1 peak, whereas 8 produced a massive apoptosis, which was also noticed at lower 
r (Figure 5.4 and data not shown). 
terminal 
differentiation, we measured the expression of the CD11c differentiation marker by FACS 
(Figure
concentration, while 17B and 22 did not induce sub-G1 particles indicative of nuclear 
fragmentation; note that the pro-apoptotic compounds increased U937 cell death in a dose-
dependent manne
To assess if the induction of apoptosis was a consequence of 
 5.5). After treating U937 cells for 24 hours with the compounds at 5 and 50 µM 
only dienones at 50 µM showed an increase of CD11c positive cells in comparison with 
the untreated control and the reference compound MS-275 (Figure 5.5). 
 
Figure 5.4. Cell cycle analysis by FACS after stimulation of U937 cells with the indicated compounds for 24 
hours. MS-275 was used as control. 
                                                 
36 Marks, P. A. Oncogene 2007, 26, 1351. 
37 Rosato, R. R.; Grant, S. Cancer Biol. Ther. 2003, 2, 30. 
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Figure 5.5. U937 differentiation analysis. CD11c expression of U937 cells treated with the indicated 
compounds for 24 hours.  
Note that the apoptogenic activity of 8 was not confined to U937 cells. Indeed, 
compound 8 was cytotoxic to several normal human cells (fetal amniocytes from amniotic 
fluid and CD34+ hematopoietic progenitors) even when used at 25 μM (data not shown). 
5.3.3 Effect on regulators of cell cycle and apoptosis  
In contrast to the effect seen with SAHA or MS-275, a 24 h treatment of U937 cells 
with the compounds at 5 and 50 µM did not affect the levels of p16, a protein often 
silenced in leukaemia38 (data not shown). We have also evaluated the impact of the 
apoptotic effect of these substances on the expression of p21, Bcl-2 and Fas by 
immunoblotting (Figure SI5.1A, SI5.1B and Figure 5.6). At the highest used concentration 
compound 8 induces Fas expression while induction of p21 was already seen at 5 µM 
(Figure 5.6 and Figure SI5.1A). These effects may account for the apoptogenic action of 8.  
To study if these compounds may exert additional epigenetic activities, we 
performed different tubulin (Figure SI5.2A) and histone H3 (Figure SI5.2B) acetylation 
assays, which would reveal HDAC class I and class II inhibition, with negative results.  
                                                 
38 Chim, C. S.; Wong, A. S.; Kwong, Y. L. Ann. Hematol. 2003, 82, 738. 
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Figure 5.
veloped by 
Hahn and Weinberg.40 In this model human primary BJ fibroblasts have been immortalized 
by introduction of the early region of SV40, which encompasses large T, resulting in the 
repression of p53.  
Monitoring viable [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
positive; MTT+] cells revealed that at 10 µM compound 8 killed normal BJ but not the 
immortalized BJEL fibroblasts. In contrast the DNA methylation inhibitor 5-aza-2’-
deoxycitidine (5-aza) 1, rather inhibited growth of the immortalized cells with little, if any 
effect on normal BJ cells. At higher concentration, compound 8 displayed high toxicity and 
killed both normal and immortalized cells (Figure 5.7B).  
The effect on human fibroblasts was reproduced with mouse embryo fibroblasts 
(MEFs). Indeed, diynone 8 completely inhibited the viability of normal primary MEFs, 
while 5-aza affected immortalized MEFs more than normal ones (Figure 5.7C). Phase 
contrast views of the corresponding cultures are shown in Figure SI5.3. A comparison with 
                                                
6. Western Blot analysis of U937 cells treated with the compounds or controls for 24 hours. Fas 
expression in total cell lysates from U937 cells stimulated with the indicated compounds. ERK1 is used to 
normalize loading. 
5.3.4 Differential effect on the viability of normal and immortalized fibroblasts 
With the aim of establishing a cellular readout of the activities of acetoxyenediynes 
17 and dienones 8, 21 and 22 we used an assay based on the report that Cre-mediated 
deletion of DNMT1 causes demethylation of cultured primary fibroblasts and p53-
dependent cell death, which could be blocked by inactivation of p53.39 For this we tested 
the effects of the various compounds on the viability of normal (BJ) and immortalized 
(BJEL) human fibroblasts, using the stepwise cellular tumorigenesis model de
 
39 Jackson-Grusby, L.; Beard, C.; Possemato, R.; Tudor, M.; Fambrough, D.; Csankovszki, G.; Dausman, J.; 
Lee, P.; Wilson, C.; Lander, E.; Jaenisch, R. Nat. Genet. 2001, 27, 31. 
40 Hahn, W. C.; Counter, C. M.; Lundberg, A. S.; Beijersbergen, R. L.; Brooks, M. W.; Weinberg, R. A. 
Nature 1999, 400, 464. 
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SGI-1027 618 revealed that a significant differential toxic effect for normal fibroblasts was 
seen only for diynone 8. 
 
Figure 5.7. Diynone 8 shows the greatest impact on the viability of normal human and mouse 
fibroblasts. Effect on cell viability by treatment with the synthetic compound and 5-aza-2’-deoxycytidine (5-
aza) compared to the vehicle control (DMSO) on normal (BJ) and immortalized (BJEL) human fibroblast cell 
ding 
compounds. (C). Effect on cell viability by treatment with compound 8 and 5-aza-2’-deoxycytidine 1 (5-aza) 
lines (A, B). Determination of the cell viability by MTT-assay after 72h treatment with the correspon
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compare
c demethylation induced by Cre-mediated Dnmt1 ablation in MEFs induces 
a set of 66 genes that showed a significant change of expression.39
 and Scya2 (data not 
shown), while expression of 
d to the vehicle control (DMSO) on normal ("MEF CD1") or immortalized ("MEF immo") mouse 
fibroblasts. Determination of the cell viability was performed by MTT-assay 6 days post-treatment with the 
indicated compounds. 
5.3.5 Diynone 8 induces genes that are induced by genomic demethylation 
Genomi
 Given that 8 
recapitulates some of the features of DNMT1 ablation we asked if the same set of genes 
would be deregulated. Notably, a comparative analysis of the expression of a set of genes 
strongly induced by DNMT1 ablation (Iap, Dnmt3a, Csk, Gjb2, Nmyc, Slpi) revealed that 
the same genes were also deregulated by 1µM or 5µM 8, but not by SGI-1027 6 at the 
same concentrations (Figure 5.8). However, while Iap, Csk and Slpi were similarly induced 
by Dnmt1 ablation and exposure to 8, Gjb2 and Nmyc were upregulated by 8, while Dnmt1 
ablation resulted in strong suppression of expression from these genes. No significant 
effects of 8 were seen for the Dnmt1 ablation-regulated genes Pea3
Dnmt3a was increased by diynone 8 (Figure 5.8).  
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Figure 8. Diynone 8 induces some of the genes that are induced by Dnmt1 ablation. The expression of 
the indicated genes in primary MEFs in presence of vehicle or of the indicated compounds was determined 
by RT-qPCR and normalized to β-actin. The compound-induced induction relative to vehicle is plotted. The 
data are derived from experiments done in duplicate.  
5.3.6 Mechanistic insights into the possible mechanism of DNMT1 inhibition by 8  
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In principle, both ester functionalities of the natural products peyssonenynes 7 (and 
by analogy of compound 17) are expected to undergo in vivo hydrolysis, followed by 
tautomerization of the enol group to generate a diynone Michael acceptor.28 The active 
diynone species (8 in the case of the acetoxyenediyne 17) could then react with the thiol41 
upporting such a mechanism of action of these 
compo
methyl ester analogue of 8 (see 
Scheme SI5.3 for the synthesis), yielded a mixture of products when treated with the same 
thiol and D
-
i is the first report on the isolation and full characterization of 
adducts
 
of the invariant DNMT cysteine residue  thus leading to irreversible covalent attachment 
to the enzyme. 
In order to provide evidence s
15
unds, diynone 8 was treated with N-Boc-L-cysteine methyl ester in the presence of 
catalytic quantities of either p-TSA or DBU. Whereas no reaction took place in the 
presence of acid, substrate 8 underwent extensive decomposition when DBU (0.1 equiv) 
was added together with the trapping agent in a toluene/THF solvent mixture. The 
synthetically more accessible compound 23, which was the 
BU (10 mol%) in toluene at 0 ºC or -20 ºC, or with benzenethiol in the same 
conditions or upon heating at 37 ºC in a CH3CN/H2O mixture.29  
Since some of the products in the above mixture could correspond to 
thioesterification reactions, the silyl-protected alcohol 24 (Scheme 5.2) with the same 
reactive diynone was synthesized (see Scheme SI5.4 for the synthesis). Treating 24 with N
Boc-L-cysteine methyl ester and Et3N in CH2Cl2 gave a mixture of products that, after 
separation by HPLC, were identified and characterized as the highly labile 1,4- and 1,6-
Michael type adducts 25 and 26 (9% and 5% yield, respectively). The geometry of the 
vinylsulfide in 25 and 26 was assigned as E in both cases by analysis of NOE experiments. 
To our knowledge th s 
 resulting from the irreversible addition of thiols to a diynone and indirectly 
confirm the anticipated reactive nature of the 2,4-diynone (Scheme 5.2). 
                                                 
41 Yadav, J. S.; Reddy, B. V. S.; Baishya, G. J. Org. Chem. 2003, 68, 7098. 
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Scheme 5.2.  Reactivity of diynones with N-Boc-L-cysteine methyl ester. 
5.4 Discussion 
Epigenetic aberrations have been well established in different types of cancer42 but 
43 44 45also in an increas
methylation (in gene bodies and intergenic regions) can lead to 
genomic i
hyperm
ing number of different diseases such as diabetes , lupus,  asthma,  
multiple neurological disorders,46 cardiovascular disease47 and fibrogenesis.48 Best studied 
so far is the involvement of epigenetic marks in cancer. For example in tumor cells a 
global loss of DNA 
nstability. This global hypomethylation is accompanied by local 
ethylation of promoters of tumor suppressor genes, resulting in their stable 
silencing. Also histone modifications are altered, in particular H4K16 acetylation and 
H4K20me3 are globally lost, and members of the PRC complexes, such as Bmi1 or Ezh2 
are upregulated.49 Furthermore, histone modifying enzymes have been found to be 
rearranged, mutated or deleted in cancer cells.2b  
                                                 
42 a. Johnstone, S. E.; Baylin, S. B. Nat. Rev. Genet. 2010, 11, 806. b. Jones, P. A.; Baylin, S. B. Cell 2007, 
128, 683. 
43 a. Ling, C.; Groop, L. Diabetes 2009, 58, 2718. b. Villeneuve, L. M.; Natarajan, R. Am. J. Physiol. Renal. 
Physiol.  2010, 299, F14. 
44 Javierre, B. M.; Fernandez, A. F.; Richter, J.; Al-Shahrour, F.; Martin-Subero, J. I.; Rodriguez-Ubreva, J.; 
Berdasco, M.; Fraga, M. F.; O'Hanlon, T. P.; Rider, L. G.; Jacinto, F. V.; Lopez-Longo, F. J.; Dopazo, J.; 
Forn, M.; Peinado, M. A.; Carreno, L.; Sawalha, A. H.; Harley, J. B.; Siebert, R.; Esteller, M.; Miller, F. W.; 
Ballestar, E. Genome Res. 2010, 20, 170. 
45 Adcock, I. M.; Ito, K.; Barnes, P. J. COPD 2005, 2, 445. 
, 31, 27. 
46 Urdinguio, R. G.; Sanchez-Mut, J. V.; Esteller, M. Lancet Neurol. 2009, 8, 1056. 
47 Hang, C. T.; Yang, J.; Han, P.; Cheng, H. L.; Shang, C.; Ashley, E.; Zhou, B.; Chang, C. P. Nature 2010, 
466, 62. 
48 Bechtel, W.; McGoohan, S.; Zeisberg, E. M.; Muller, G. A.; Kalbacher, H.; Salant, D. J.; Muller, C. A.; 
Kalluri, R.; Zeisberg, M. Nat. Med. 2010, 16, 544. 
49 Sharma, S.; Kelly, T. K.; Jones, P. A. Carcinogenesis 2010
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Currently four “epigenetic drugs” (DNMT inhibitors: 5-aza-cytidine, Vidaza® and 
5-aza-2’-deoxycytidine, Dacogen®; HDAC inhibitors: Vorinostat, Zolinza® and 
Romidepsin, Istodax®) have been approved by the FDA for the treatment of cancer and 
seizure disorders and several novel compounds are in clinical trials.2a,49 Although the 
mechan
 tumor suppressor genes in a wide 
range o
enes which are important for growth control and 
genetic integrity, such as p16INK4a, BRCA1, RARβ2, IRF1 and hMLH1 and is maintained 
isms underlying the therapeutic benefit of these drugs remain largely unknown, 
future studies that combine genome-wide mapping analysis with expression profiling will 
provide the key to their understanding. 
Several experiments have demonstrated that global DNA hypomethylation induced 
by hypomorphic Dnmt1 alleles significantly suppresses intestinal tumorigenesis in ApcMin/+ 
mice.11,50 In contrast, global DNA hypomethylation promotes chromosomal instability in 
ES cells and mice, which results in the development of T cell lymphoma9 and also 
accelerates tumor formation in a murine sarcoma model.51  
The underlying rationale for the therapeutic use of DNA methylation inhibitors2a is 
rather well understood and linked to the observation that hypermethylation of DNA 
promoter and coding sequences is a major epigenetic mechanism that contributes to cancer 
progression by causing the inactivation of a number of
f tumor types,42b which is the most common molecular lesion of cancer cells.2b 
Epigenetic silencing is caused by cytosine methylation in CpG clusters or islands (and also 
other regions in the genome)52 in the corresponding promoters/regulatory region(s) and 
affects multiple tumor suppressor g
through cell divisions.2a 
The azanucleoside drugs (5-aza-cytidine 1 and 5-aza-2’-deoxycytidine 2) approved 
for treatment of myelodysplastic syndrome sequester DNMTs at low doses leading to 
global demethylation as cell divide and DNA is repaired, but at higher doses they are 
cytotoxic. Other limitations of these drugs are the requirement for metabolic 
transformation into the corresponding triphosphates and the lack of specificity of 1, which 
is also incorporated into RNA and affects protein synthesis. Both compounds 1 and 2 are 
                                                 
50 a. Cormier, R. T.; Dove, W. F. Cancer Res 2000, 60, 3965. b. Eads, C. A.; Nickel, A. E.; Laird, P. W. 
Cancer Res 2002, 62, 1296. c. Laird, P. W.; Jackson-Grusby, L.; Fazeli, A.; Dickinson, S. L.; Jung, W. E.; 
Li, E.; Weinberg, R. A.; Jaenisch, R. Cell 1995, 81, 197. 
51 Eden, A.; Gaudet, F.; Waghmare, A.; Jaenisch, R. Science 2003, 300, 455. 
ery, J. R.; Lee, L.; 
ature 2009, 462, 315. 
52 Lister, R.; Pelizzola, M.; Dowen, R. H.; Hawkins, R. D.; Hon, G.; Tonti-Filippini, J.; N
Ye, Z.; Ngo, Q.-M.; Edsall, L.; Antosiewicz-Bourget, J.; Stewart, R.; Ruotti, V.; Millar, A. H.; Thomson, J. 
A.; Ren, B.; Ecker, J. R. N
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highly unstable in neutral aqueous solutions complicating the treatment regimens. 
Zebularine 3 (Figure 5.1) is a cytidine analogue that acts similarly to 1, but has greater 
stability at acidic and neutral pHs and in aqueous solution, lower toxicity in cultured cells, 
that makes it possible for oral administration, and greater selectivity for tumour cells.53 5-
aza-cytidine 1 and 5-aza-2’-deoxycytidine 2 are deaminated by cytidine deaminase and 
deoxycytidine deaminase, respectively, which makes them inactive, whereas zebularine 
has the ability to inhibit the enzyme cytidine deaminase evading this deactivation 
mechanism. The phosphoramidate of deoxycytidine has been prepared, and found to 
activate p16 silenced by DNA methylation in cancer cells.54 S110, a dinucleotide of 5-aza-
2´-deoxycytidine and deoxyguanosine, is an effective DNMT inhibitor that is moreover 
less susceptible to deamination by cytidine deaminase than nucleoside 2.  In vivo 
evaluation of S110 in mice (i.p. and s.c. injections) showed a better stability and lower 
toxicity profiles than 2, while being as effective in inducing p16 expression, reducing 
methylation at the p16 promoter region and retarding tumor growth in tumor xenografts.55  
Given the limitations of current therapies, novel inhibitors with alternative 
mechanisms of action, such as direct inhibition of DNMT enzymes as proposed for RG108 
453,56 or induction of DNMT degradation as demonstrated for SGI-1027 6,18 are actively 
sought. 
Inspired on the structure of the natural products peyssonenynes 7 (Figure 5.1) we 
have generated a series of derivatives, (some of) which display DNMT1-selective 
inhibitory activity (see Scheme 5.1 and Figure 5.2). Notably among them is diynone 8, a 
DNMT1 inhibitor with greater potency than RG108 4, which at the same time displays 
DNMT3a activation, a profile that is not shared by RG108 4, inactive in the same assay. 
of the thiol group of N-protected-L-cysteine 
methyl ester in both the 1,4 and 1,6 modes (Scheme 5.2). This experiment provides indirect 
This diynone 8 derived from palmitic acid induced U937 cell differentiation and apoptosis, 
which correlated with the expression of Fas protein. Trapping experiments using a model 
system 2,4-diynone 24 led to the isolation and characterization of unstable adducts 25 and 
26, which correspond to the conjugate addition 
evidence about the mechanism of inhibition of DNMT1 by diynone 8 and, by inference, of 
                                                 
53 Stresemann, C.; Brueckner, B.; Musch, T.; Stopper, H.; Lyko, F. Cancer Res. 2006, 66, 2794. 
54 Yoo, C. B.; Valente, R.; Congiatu, C.; Gavazza, F.; Angel, A.; Siddiqui, M. A.; Jones, P. A.; McGuigan, 
C.; Marquez, V. E. J. Med. Chem. 2008, 51, 7593. 
55 Chuang, J. C.; Warner, S. L.; Vollmer, D.; Vankayalapati, H.; Redkar, S.; Bearss, D. J.; Qiu, X.; Yoo, C. 
B.; Jones, P. A. Mol. Cancer Ther. 2010, 9, 1443. 
56 Lyko, F.; Brown, R. J. Natl. Cancer Inst. 2005, 97, 1498. 
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the precursor acetoxyenediynes present in both 17 and the natural product peyssonenyne 7. 
The latter is yet another example of a natural product which serves as a stable precursor of 
a disguised highly reactive functional group28 that would favor the entry into the cells 
before the release of the chemical weapon.57  
Our studies reveal a potent toxic activity of diynone 8 on normal human and mouse 
fibroblast which is alleviated in immortalized cells, a step that is commonly believed to 
precede the final tumorigenic step in human cancer.58 The fact that 8 is fully toxic for 
normal human fibroblasts at concentrations where it does not exhibit significant toxicity 
for immortalized cells shows that this compound does not display a general toxicity but 
interferes in a very specific manner with pathways that are differently active in the two cell 
types, most likely p53 and/or Rb signaling. This toxicity is reminiscent of the effects of 
Dnmt1 ablation on mouse fibroblasts and we observe that some of the genes deregulated by 
loss of DNMT1 are similarly deregulated by 8. However, several of the genes are 
divergently regulated suggesting that compound 8 does not mimic DNMT1 ablation. 
Global coupled DNA methylation and transcription profiling studies may reveal which 
pathways are affected by the peyssonenyne derivative.  
Based on the toxicity for normal cells we do not believe that 8 holds potential for 
long-term therapies targeting neoplastic diseases. However, diseases based on 
hyperproliferation of fibroblasts, such as fibrogenesis,48 may potentially be treated using 
short-term or local drug application. 
5.5 Materials and methods 
General procedures. Solvents (acetone and benzene) were dried according to published 
methods and distilled before use. THF, CH Cl , CH CN and MeOH were dried using a 
Puresolv
2 2 3
fication system. Et N and piperidine were dried by distillation with TM solvent puri 3
CaH2. All other reagents were commercial compounds of the highest purity available. All 
reactions were carried out under argon atmosphere, and those not involving aqueous reagents 
were carried out in oven-dried glassware. All solvents and anhydrous solutions were 
transferred through syringes and cannulae previously dried in the oven for at least 12 h and 
kept in a dessicator with KOH. For reactions at low temperature, icewater or CO2/acetone 
                                                 
57 Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. Nat. Rev. Drug Discov. 2011, 10, 307. 
58 a. Hahn, W. C.; Weinberg, R. A. Nat. Rev. Cancer 2002, 2, 331. b. Hahn, W. C.; Weinberg, R. A. N. Engl. 
J. Med. 2002, 347, 1593. 
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systems were used. Analytical thin layer chromatography (TLC) was performed on aluminium 
plates with Merck Kieselgel 60F254 and visualised by UV irradiation (254 nm) or by staining 
with an ethanolic solution of phosphomolibdic acid or an ethanolic solution of anisaldehyde. 
Flash column chromatography was carried out using Merck Kieselgel 60 (230-400 mesh) 
under pressure. UV/Vis spectra were recorded with a Cary 100 Bio spectrophotometer in 
MeOH. IR spectra were obtained on a JASCO IR 4200 spectrophotometer from a thin film 
deposited onto NaCl glass. Mass spectra were obtained on a Hewlett-Packard HP59970 
nd C6D6 at ambient temperature on the same 
T
instrument operating at 70 eV by electron ionisation and APEX III FT-ICR MS (Bruker 
Daltonics, Billerica, MA), equipped with a 7T actively shielded magnet. Ions were generated 
using an Apollo API electrospray ionization (ESI) source, with a voltage between 1800 and 
2200 V (to optimize ionisation efficiency) applied to the needle, and a counter voltage of 450 
V applied to the capillary. Samples were prepared by adding a spray solution of 70:29.9:0.1 
(v/v/v) CH3OH/water/formic acid to a solution of the sample at a v/v ratio of 1 to 5% to give 
the best signal-to-noise ratio. High-resolution mass spectra were taken on a VG Autospec 
instrument. 1H NMR spectra were recorded in CDCl3 and C6D6 at ambient temperature on a 
Bruker AMX-400 spectrometer at 400 MHz with residual protic solvent as the internal 
reference [CDCl3, δH = 7.26 ppm and C6D6, δH = 7.16 ppm]; chemical shifts (δ) are given in 
parts per million (ppm), and coupling constants (J) are given in Hertz (Hz). The proton spectra 
are reported as follows: δ (multiplicity, coupling constant J, number of protons, assignment). 
13C NMR spectra were recorded in CDCl3 a
spectrometer at 100 MHz, with the central peak of CDCl3 (δC = 77.16 ppm) or C6D6 (δC = 
128.06 ppm) as the internal reference. The DEPT135 pulse sequence was used to aid in the 
assignment of signals in the 13C NMR spectra. 
All tested compounds were purified by RP-HPLC (Nova-Pak HR C18 6 μm, 19x300 mm, 
80:20 acetonitrile/H2O for (R)-17, SunfireTM C18 5 μm, 46x250 mm, acetonitrile for 8 and 
Sunfire M C18 5 μm, 46x250 mm, acetonitrile/H2O gradient from 70:30 to 100:0 for 18, 19 and 
20) and shown to have >95% purity. 
 
N-methoxy-N-methylhexadecanamide (9).a To a solution of palmitic acid (3.0 g, 11.79 
mmol) in CH2Cl2 (5 mL) was added N,O-dimethylhydroxylamine hydrochloride (1.71 g, 
17.55 mmol), EDCI (3.36 g, 17.55 mmol) and DMAP (2.14 g, 17.55 mmol) and the reaction 
was stirred overnight at room temperature. A saturated aqueous NaCl solution was added and 
the mixture was extracted with EtOAc (3x). The combined organic layers were washed with an 
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aqueous HCl solution (5%) and brine, dried over Na2SO4 and the solvent was evaporated to 
afford 3.33 g (95%) of the titled compound as a white solid, m.p.: 62-64 ºC (hexane/ether). 1H-
NMR (400.13 MHz, CDCl3): δ 3.66 (s, 3H, OCH3), 3.16 (s, 3H, NCH3), 2.39 (t, J = 7.6 Hz, 
2H, 2H2), 1.68-1.52 (m, 2H, 2H3), 1.37-1.18 (m, 24 H, 12 x -CH2-), 0.86 (t, J = 6.8 Hz, 3H, 
1
nd, 
l3): δ 4.38 (dd, J = 12.4, 6.4 Hz, 1H, H3), 1.77-1.63 (m, 3H, 2H4 + 
CH3) pm. 13C-NMR (100.62 MHz, CDCl3): δ 174.4 (s, C1), 60.7 (q, OMe), 31.7 (t), 31.5 (t), 
29.4 (t, 5x), 29.2 (t, 3x), 29.1 (t), 29.1 (t), 26.8 (q, NCH3), 24.3 (t), 22.4 (t), 13.8 (q, C16) ppm. 
MS (FAB+): m/z (%) 300 ([M+1]+, 100). HRMS (FAB+): Calcd for C18H38NO2 ([M+1]+, 
300.2903; found, 300.2910. IR (NaCl): ν 2925 (s, C-H), 2855 (m, C-H), 1674 (m, C=O) cm-1.  
1-(Triisopropylsilyl)-octadec-1-yn-3-one (10).35a To a stirred solution of triisopropylsilyl 
acetylene (6.09 g, 33.41 mmol, 7.4 mL) in THF (0.2 mmol/mL) at -40 ºC, was added n-BuLi 
(14.20 mL, 1.57M in THF, 22.28 mmol) dropwise and the solution was stirred for 1 h. 
Subsequently, a solution of N-methoxy-N-methylhexadecanamide 9 (3.33 g, 11.14 mmol) in 
THF (0.84 mmol) was added dropwise at -10 ºC and the reaction was further stirred for 1 h at -
10 ºC and for 1 h at room temperature. A saturated aqueous solution of NH4Cl was added and 
the mixture was extracted with Et2O (3x). The combined organic layers were washed with 
brine, dried over Na2SO4 and the solvent was evaporated. The residue was purified by flash 
chromatography (reverse phase, 10:90 CH2Cl2/acetonitrile) to afford 4.31 g (92%) of the titled 
product as a colourless oil. H-NMR (400.13 MHz, CDCl3): δ 2.54 (t, J = 7.4 Hz, 2H, 2H2), 
1.74-1.63 (m, 2H, 2H3), 1.36-1.18 (m, 24H, 12 x -CH2-), 1.17-1.03 (m, 21H, i-Pr3-Si), 0.88 (t, 
J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 188.1 (s), 104.4 (s, C2), 95.4 
(s), 45.8 (t), 32.1 (t), 29.8 (t, 6x), 29.6 (t), 29.5 (t, 2x), 29.1 (t), 24.4 (t), 22.8 (t), 18.6 (q, 6x, i-
Pr3-Si), 14.2 (q), 11.1 (d, 3x, i-Pr3-Si) ppm. MS (EI): m/z (%) 421 ([M+1]+, 0.2), 420 (M+, 
0.6), 378 (19), 377 (100), 167 (15). HRMS (EI): Calcd for C27H52OSi, 420.3787; fou
420.3795. IR (NaCl): ν 2925 (s, C-H), 2855 (m, C-H), 1681 (m, C=O), 1460 (m) cm-1. UV 
(MeOH): λmax 234 nm. 
1-(Triisopropylsilyl)-octadec-1-yn-3-ol (11). NaBH4 (0.09 g, 2.43 mmol) was added 
portionwise to a solution of 1-triisopropylsilyloctadec-1-yn-3-one 10 (1.50 g, 3.58 mmol) in 
MeOH (4 mL) at 0 ºC and the mixture was stirred for 1.5 h. The reaction was poured into an 
aqueous HCl solution (1N) and the mixture was extracted with Et2O (3x). The combined 
organic layers were washed with a saturated aqueous NaHCO3 solution, dried over Na2SO4 
and the solvent was evaporated. The residue was purified by flash chromatography (silica gel, 
95:5 hexane/EtOAc) to afford 1.51 g (80%) of the titled compound as a colourless oil. 1H-
NMR (400.13 MHz, CDC
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OH), 1.52-1.40 (m, 2H, 2H5), 1.37-1.20 (m, 24H, 12 x -CH2-), 1.12-1.01 (m, 21H, i-Pr3Si), 
0.88 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 109.2 (s), 85.3 (s), 
63.1(d), 38.1 (t), 32.1 (t), 29.9 (t, 5x), 29.8 (t), 29.7 (t, 2x), 29.5 (t), 29.4 (t), 25.3 (t), 22.8 (t), 
18.7 (q, 6x, i-Pr3-Si), 14.2 (q), 11.3 (d, 3x, i-Pr3-Si) ppm. MS (FAB+): m/z (%) 422 ([M+1]+, 
3), 421 (M+, 7), 405 (16), 363 (32), 181 (18), 158 (16), 157 (100). HRMS (FAB+): Calcd for 
C27H53OSi, 421.3866; found, 421.3858. IR (NaCl): ν 3600−3300 (br, ΟΗ), 2926 (s, C-H), 
2858 (s, C-H), 1462 (m) cm-1. 
Octadec-1-yn-3-ol (12). To a stirred solution of 1-triisopropylsilyloctadec-1-yn-3-ol 11 (0.94 
g, 2.21 mmol) in THF (58 mL) was added n-Bu4NF (2.44 mL, 1M in THF, 2.44 mmol) and 
the reaction was stirred for 30 minutes at 25 ºC. A saturated aqueous solution of NaHCO3 was 
added and the mixture was extracted with Et2O (3x). The combined organic layers were 
dihydroxyprop-1-yl 8-Hydroxy-tetracosa-4,6-diynoate 
, 5H, CH3 + 2H10), 
washed with brine, dried over Na2SO4 and the solvent was evaporated. The residue was 
purified by flash chromatography (silica gel, 90:8:2 hexane/EtOAc/Et3N) to afford 1.51 g 
(82%) of the titled compound as a white solid, m. p.: 54-56 ºC (hexane/ether). 1H-NMR 
(400.13 MHz, CDCl3): δ 4.36 (td, J = 6.6, 1.9 Hz, 1H, H3), 2.46 (d, J = 2.1 Hz, 1H, H1), 1.92 
(s, 1H, OH), 1.76-1.63 (m, 2H, 2H4), 1.50-1.38 (m, 2H, 2H5), 1.36-1.17 (m, 24H, 12 x -CH2-), 
0.87 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 85.2 (s), 72.9 (d), 62.5 
(d), 37.8 (t), 32.1 (t), 29.8 (t, 6x), 29.7 (t, 2x), 29.5 (t), 29.4 (t), 25.2 (t), 22.8 (t), 14.3 (q) ppm. 
HRMS (ESI+): Calcd for C18H34ONa, 289.24897; found 289.25019. IR (NaCl): ν 3600-3300 
(br, ΟΗ), 2918 (s, C-H), 2850 (m, C-H) cm-1.  
(2’R)-2,3-O-Isopropylidene-2,3-
(14). To a stirred solution of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 5-iodopent-4-
ynoate 13 (0.88 g, 2.61 mmol) and octadec-1-yn-3-ol 12 (1.82 g, 6.85 mmol) in degassed 
piperidine (5 mL), at 0 ºC, was added copper chloride (0.03 g, 0.26 mmol). After stirring for 2 
hours, a saturated aqueous NH4Cl solution was added and the mixture was extracted with 
CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and the solvent was 
removed under vacuum. The residue was purified by flash chromatography (silica gel, 80:20 
hexane/EtOAc) to provide 0.8 g (64%) of the titled compound as a white solid, m.p.: 36-38 ºC 
(hexane/ether). 1H-NMR (400.13 MHz, CDCl3): δ 4.37 (dd, J = 11.5, 5.9 Hz, 1H, H8), 4.31 
(dd, J = 11.6, 5.7 Hz, 1H, H2’), 4.2-4.0 (m, 3H, 2H1’ + 1H3’), 3.75 (dd,  J = 8.4, 6.2 Hz, 1H, 
H3’), 2.65-2.52 (m, 4H, 2H2 + 2H3), 1.74-1.60 (m, 2H, 2H9), 1.47-1.38 (m
1.36 (s, 3H, CH3), 1.33-1.17 (m, 24H, 12 x -CH2-), 0.87 (t, J = 6.7 Hz, 3H, CH3) ppm. 13C-
NMR (100.62 MHz, CDCl3): δ 171.3 (s), 110.0 (s), 79.0 (s), 77.7 (s), 73.6 (d), 69.6 (s), 66.4 
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(t), 65.5 (s), 65.1 (t), 62.9 (d), 37.7 (t), 32.9 (t), 32.0 (t), 29.8 (t, 6x), 29.7 (t), 29.6 (t), 29.5 (t), 
29.4 (t), 26.8 (q), 25.5 (q), 25.2 (t), 22.8 (t), 15.4 (t), 14.2 (q) ppm. HRMS (ESI+): Calcd for 
C29H48O5Na, 499.3379; found, 499.3394. IR (NaCl): ν 3600-3300 (br, ΟΗ), 2925 (s, C-H), 
2854 (m, C-H), 2255 (w, C≡C), 1742 (m, CO) cm-1.  
(2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 8-Oxo-tetracosa-4,6-diynoate (15). To 
a stirred solution of oxalyl chloride (13 μL, 0.02 g, 0.15 mmol) in CH2Cl2 (1 mL) at – 60 ºC, 
DMSO (18 μL, 0.02 g, 0.25 mmol) was added dropwise and the reaction was stirred for 5 min 
at this temperature. Then, a solution of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 8-
hydroxy-tetracosa-4,6-diynoate 14 (0.47 g, 0.98 mmol) in CH2Cl2 (1 mL) was added. After 
stirring for 30 min, Et3N (97 μL, 0.07 g, 0.69 mmol) was added and the reaction was stirred for 
10 min at -60 ºC. The mixture was allowed to warm to room temperature, poured into water 
and extracted with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and the 
dd, 
diynoate 
solvent was evaporated. The residue was purified by flash chromatography (silica gel, 80:20 
hexane/EtOAc) to afford 0.05 g (99%) of the titled compound as a yellow oil. 1H-NMR 
(400.13 MHz, CDCl3): δ 4.34-4.26 (m, 1H, H2’), 4.19 (dd, J = 11.5, 4.6 Hz, 1H, H1’), 4.11 (
J = 11.5, 6.1 Hz, 1H, 1H1’), 4.07 (dd, J = 8.5, 6.5 Hz, 1H, H3’), 3.73 (dd, J = 8.5, 6.0 Hz, 1H, 
H3’), 2.71-2.65 (m, 2H, 2H2 or 2H3), 2.64-2.58 (m, 2H, 2H2 or 2H3), 2.52 (t, J = 7.4 Hz, 2H, 
2H9), 1.68-1.57 (m, 2H, 2H10), 1.41 (s, 3H, CH3), 1.35 (s, 3H, CH3), 1.31-1.17 (m, 24H, 12 x -
CH2-), 0.86 (t, J =  6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 187.2 (s), 
170.9 (s), 110.0 (s), 87.6 (s), 75.4 (s), 73.6 (d), 72.9 (s), 66.3 (t),  65.3 (t), 64.6 (s), 45.6 (t), 32.3 
(t), 32.0 (t), 29.8 (t, 4x), 29.7 (t, 2x), 29.5 (t), 29.4 (t, 2x), 29.0 (t), 26.8 (q), 25.4 (q), 24.0 (t), 
22.8 (t), 15.6 (t), 14.2 (q) ppm. HRMS (ESI+): Calcd for C29H46O5, 475.34129; found, 
475.34180. IR (NaCl): ν 2925 (s, C-H), 2854 (m, C-H), 2236 (w, C≡C), 1743 (m, CO), 1673 
(s) cm-1.  
(8Z,2’R)- and (8E,2’R)-2,3-Dihydroxyprop-1-yl 8-Acetoxytetracosa-8-en-4,6-
((R)-17). To a stirred solution of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 8-oxo-
tetracosa-4,6-diynoate 15 (0.37 g, 0.77mmol) in CH2Cl2 (20 mL) at 0 ºC were added Et3N 
(0.54 mL, 0.39 mg,  3.87 mmol), DMAP ( 47 mg,  0.39 mmol) and acetic anhydride (0.44 mL, 
0.47 g, 4.64 mmol) and the reaction mixture was stirred for 2h at room temperature. A 
saturated NH4Cl aqueous solution was added and the mixture was extracted with CH2Cl2 (3x). 
The combined organic layers were dried over Na2SO4 and the solvent was evaporated. The 
residue was purified by flash chromatography (silica gel, 80:20:10 hexane/CH2Cl2/EtOAc) to 
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afford 0.35 g (88%) of a colourless oil, identified as a 70:30 mixture of E/Z isomers, which 
was used in the next step.  
A stirred solution of (2’R)-2,3-O-methylidene-2,3-dihydroxyprop-1-yl  8-acetoxytetracosa-8-
en-4,6-diynoate 16 (0.19 g, 0.36 mmol) in 1:1  acetonitrile/water (2 mL, 1:1  v/v) was heated to 
70 ºC and solid CAN (6 mg, 0.01 mmol) was added. The resulting slightly yellow solution was 
stirred for 24 hours at this temperature. After cooling to room temperature, the reaction mixture 
was extracted with ether (3x). The combined organic layers were dried over Na2SO4 and the 
solvents were removed in vacuo. The residue was purified by flash chromatography (silica gel, 
60:38:2 hexane/EtOAc/Et3N) to give 0.13 g (74%) of a colourless oil that was identified as a 
70:30 mixture of E/Z isomers. This mixture was separated by RPHPLC (Nova-Pak HR C18 6 
μm, 19x300 mm, 80:20 acetonitrile/H2O, 20 mL/min) to yield 21.5 mg (29%) of the E isomer 
(tR = 22.7 min) and 53.2 mg (71%) of the Z isomer (tR RR = 27.0 min) of (2R’)-2,3-
dihydroxyprop-1-yl 8-acetoxytetracosa-8-en-4,6-diynoate (R)-17. 
Data for (8E,2’R)-17 (17A):  1H-NMR (400.13 MHz, C6D6): δ  5.67 (t, J = 8.0 Hz, 1H, H9), 
4.02 (dd, 1H, J = 11.5, 6.1 Hz, 1H, H1’), 3.98 (dd, J = 11.5, 5.0 Hz, 1H, H1’), 3.72-3.63 (m, 
1H, H2’), 3.45 (dd, J = 11.3, 4.0 Hz, 1H, H3’), 3.37 (dd, J = 11.3, 6.0 Hz, 1H, H3’), 2.25-2.14 
(m, 4H, 2H10 + 2H2 or 2H3), 2.03 (t, J = 6.9 Hz, 2H, 2H2 or 2H3), 1.63 (s, 3H, CO2CH3), 
1.41-1.15 (m, 24H, 12 x -CH2-),  0.91 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, 
C6D6): δ 171.2 (s), 168.4 (s), 132.4 (d), 130.4 (s), 85.5 (s), 79.4 (s), 70.4 (d), 68.6 (s), 66.0 (s), 
65.8 (t), 63.6 (t), 32.5 (t), 32.4 (t), 30.2 (t, 5x), 30.0 (t), 29.9 (t, 2x), 29.4 (t), 29.2 (t), 28.4 (t), 
23.1 (t), 20.1 (q), 15.5 (t), 14.4 (q) ppm. HRMS (ESI+): Calcd for C28H44O6Na, 499.30218; 
found, 499.30301. IR (NaCl): ν 3600−3300 (br, ΟΗ), 2923 (s, C-H), 2853 (m, C-H), 2235 (w, 
C≡C), 1740 (m, C=O), 1204 (m) cm-1.  
Data for (8Z,2’R)-17 (17B): 1H-NMR (400.13 MHz, C6D6): δ 5.65 (t, J = 7.7 Hz, 1H, H9), 
, J = 11.4, 6.1 Hz, 1H, H1’), 4.01 (dd, J = 11.5, 4.9 Hz, 1H, H1’), 3.74-3.67 (m, 4.05 (dd, 1H
1H, H2’), 3.47 (dd, J = 11.3, 4.0 Hz, 1H, H3’), 3.40 (dd, J = 11.3, 6.0 Hz, 1H, H3’), 2.20 (t, J = 
7.2 Hz, 2H, 2H2 or 2H3), 2.07 (t, J = 7.0 Hz, 2H, 2H2 or 2H3), 1.99-1.88 (m, 2H, 2H10), 1.64 
(s, CO2CH3), 1.38-1.08 (m, 24H, 12 x -CH2-), 0.92 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, C6D6): δ 171.4 (s), 167.7 (s), 131.9 (d), 130.0 (s), 84.3 (s), 74.6 (d), 70.8 (s), 
70.4 (d), 66.1 (s), 65.8 (t), 63.6 (t), 32.6 (t), 32.4 (t), 30.2 (t, 4x), 30.1 (t), 30.0 (t), 29.8 (t, 2x), 
t), 26.6 (t), 23.1 (t), 19.9 (q), 15.5 (t), 14.4 (q) ppm. HRMS (ESI+): Calcd for 
C28H45O6, 477.32211; found, 477.32107. IR (NaCl): ν 3600-3300 (br, ΟΗ), 2922 (s, C-H), 
2853 (m, C-H), 2359 (m), 2233 (w, C≡C), 1736 (w, C=O), 1197 (w) cm-1.  
29.5 (t), 28.7 (
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(2’R)-2,3-Dihydroxyprop-1-yl 8-Oxo-4,6-tetracosadiynoate ((R)-8). Following the general 
procedure described above for the deprotection of ketals, the reaction of (2’R)-2,3-O-
isopropylidene-2,3-dihydroxy-1-prop-1-yl 8-oxo-tetracosa-4,6-diynoate 15 (80.2 mg, 0.17 
Cl3): δ 187.6 (s), 171.5 (s), 87.7 (s), 75.5 (s), 
), 63.4 (t), 45.6 (t), 32.4 (t), 32.0 (t), 29.8 (t, 5x), 29.7 (t), 29.5 
(t, 2x), 29.4 (t), 29.0 (t), 24.0 (t), 22.8 (t), 15.6 (t), 14.2 (q) ppm. HRMS (ESI+): Calcd for 
d by HPLC (Waters Spherisorb® 5 μm silica gel, 
 EtOAc, 2.0 mL/min) to yield 6.2 mg (5%) of the (Z)-1,6-Michael 
adduct (tR= 30.5 min) and 11 mg (9%) of the (Z)-1,4-Michael adduct (tR= 33.0 min). 
7
mmol) and CAN (3 mg, 5.1 μmmol) in acetonitrile-water  (1 mL, 1:1 v/v) at 70 ºC afforded, 
after purification by flash chromatography (silica gel, 70:30 hexane/EtOAc), 37 mg (78%) of 
the titled product as a white solid. 1H-NMR (400.13 MHz, CDCl3): δ 4.23 (dd, J = 11.6, 4.8 
Hz, 1H, H1’), 4.19 (dd, J = 11.6, 6.2 Hz, 1H, H1’), 3.99-3.90 (m, 1H, H2’), 3.71 (dd, J = 11.3, 
3.7 Hz, 1H, H3’), 3.60 (dd, J = 11.3, 5.9 Hz, 1H, H3’), 2.75-2.59 (m, 4H, 2H2 + 2H3), 2.54 (t, J 
=  7.4 Hz, 2H, 2H9), 1.70-1.57 (m, 2H, 2H10), 1.35-1.12 (m, 24H, 12 x -CH2-), 0.87 (t, J = 6.6 
Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CD
72.9 (s), 70.2 (d), 65.9 (t), 64.7 (s
C26H43O5, 435.31192; found, 435.31050. IR (NaCl): ν 3400-3100 (br), 2919 (s, C-H), 2850 
(m, C-H), 2239 (w, -C≡C-), 1727 (m, CO), 1668 (m, CO), 1173 (m) cm-1.  
Methyl (2R,6’Z/E)-2-(tert-Butoxycarbonylamino)-3-(1’-(tert-butyldiphenylsilyloxy)-8’-
oxotricosa-6’-en-4’-yn-6’-ylthio)propanoate (23) and Methyl (2R,4’Z/E)-2-(tert-
Butoxycarbonylamino)-3-(1’-(tert-butyldiphenylsilyloxy)-8’-oxotricosa-4’-en-6’-yn-4’-
ylthio)propanoate (24). To a solution of 1-(tert-butyldiphenylsilyloxy)-tricosa-4,6-diyn-8-one 
(84 mg, 0.14 mmol) in CH2Cl2 (1.7 mL), were successively added Et3N (20 μL, 14.6 mg, 0.14 
mmol) and N-(tert-butoxycarbonyl)-L-cysteine methyl ester (30 μL, 34 mg, 0.14 mmol). The 
reaction was stirred at room temperature for 72 h, diluted with water and the mixture was 
extracted with CH2Cl2 (3x). The combined organic layers were dried and the solvent was 
evaporated. The residue was purified by flash chromatography (silica gel, 80:20 
hexane/EtOAc) to afford 27 mg (27%) of the titled compounds as yellow oils. The mixture of 
1,4- and 1,6-Michael adducts were separate
10 x 250 mm, 90:10 hexane/
(2R,6’Z/E)-Methyl 2-(tert-Butoxycarbonylamino)-3-(1’-(tert-butyldiphenylsilyloxy)-8’-
oxotricosa-6’-en-4’-yn-6’-ylthio)propanoate (25). 1H-NMR (400.13 MHz, C6D6): δ 7.79 – 
.74 (m, 4H, ArH), 7.28 – 7.23 (m, 6H, ArH), 6.50 (s, 1H, H7’), 5.08 (d, J = 8.4 Hz, 1H, 
NHCO2(CH3)3), 4.80 (dd, J = 13.3, 7.7 Hz, 1H, H2), 3.67 (t, J = 5.9 Hz, 2H, 2H1’), 3.47 (dd, J 
= 14.0, 5.2 Hz, 1H, H3A), 3.19 (s, 3H, CO2Me), 3.02 (dd, J = 14.0, 7.3 Hz, 1H, H3B), 2.48 (t, J 
= 7.1 Hz, 2H, 2H ), 2.13 (t, J = 7.4 Hz, 2H, 2H ), 1.72 (q, J = 7.0 Hz, 2H, 2H ), 1.61 – 1.50 9’ 3’ 2’
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(m, 2H, 2H10’), 1.38 (s, 9H, NHCO2(CH3)3), 1.36 – 1.18 (m, 24H, 12 x -CH2-), 1.17 (s, 9H, 
SiC(CH3)), 0.92 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 197.2 (s, 
C ), 171.2 (s, C ), 155.3 (s, NHC8’ 1 O C(CH ) ), 139.7 (s), 136.0 (d, 4x), 134.0 (s, 2x), 130.1 (d, 
CO2C
2 3 3
2x), 128.2 (d, 4x), 126.0 (d), 101.6 (s), 79.6 (s), 77.2 (s, NH (CH3)3), 62.7 (t), 54.0 (d, 
C2), 52.0 (q, CO2CH3), 43.2 (t), 35.7 (t), 32.4 (t), 31.4 (t), 30.2 (t, 6x), 30.0 (t, 2x), 29.9 (t), 
29.7 (t), 28.3 (q, NHCO2C(CH3)3), 27.1(q, SiC(CH3)3), 24.8 (t), 23.2 (t), 19.5 (s, SiC(CH3)3), 
16.5 (t), 14.4 (q) ppm. HRMS (ESI+): Calcd for C48H74NO6SSi ([M + 1]+), 820.50006; found, 
820.49937. IR (NaCl): ν 3400-3200 (br, N-H), 2952 (m, C-H), 2925 (s, C-H), 2854 (m, C-H), 
2215 (w, C≡C), 1748 (m, C=O), 1719 (m, C=O), 1658 (w, C=O), 1522 (m), 1167 (m), 1110 
(m), 703 (m) cm-1. UV (MeOH): λmax  264, 326 nm. 
(2R,4’Z/E)-Methyl 2-(tert-Butoxycarbonylamino)-3-(1’-(tert-butyldiphenylsilyloxy)-8’-
oxotricosa-4’-en-6’-yn-4’-ylthio)propanoate (26). 1H-NMR (400.13 MHz, C6D6): 7.81 – 
3 (m, 6H, ArH), 5.27 (s, 1H, H7’), 5.15 (d, J = 8.4 Hz, 1H, 
NH
7.72 (m, 4H, ArH), 7.32 – 7.2
CO2(CH3)3), 4.54 (dd, J = 12.8, 5.5 Hz, 1H, H2), 3.66 (t, J = 6.2 Hz, 2H, 2H1’), 3.17 (s, 
3H, CO2Me), 2.94 (dd, J = 13.6, 4.9 Hz, 1H, H3), 2.73-2.63 (m, 3H, 2H9’ + H3), 2.42 (t, J = 
7.4 Hz, 2H, 2H3’), 1.91 – 1.81 (m, 2H, 2H2’), 1.71 – 1.62 (m, 2H, 2H10’), 1.41 (s, 9H, 
NHCO2(CH3)3), 1.37 – 1.13 (m, 33H, 12 x -CH2- + SiC(CH3)), 0.92 (t, J = 6.8 Hz, 3H, CH3).
C-NMR (100.62 MHz, C
 
13
6D6): δ 186.4 (s, C10’), 170.5 (s, C1), 160.9 (s, C4’), 155.1 (s, 
NHCO2C(CH3)3), 136.0 (d, 4x), 134.2 (s, 2x), 130.0 (d, 2x), 128.2 (d, 4x), 98.7 (d, C5’), 94.2 
(s), 87.4 (s), 80.1 (s, NHCO2C(CH3)3), 63.5 (t), 52.7 (d, C2), 52.2 (q, CO2CH3), 45.7 (t), 33.6 
(t), 32.4 (t, 2x), 30.2 (t, 6x), 30.1 (t), 30.0 (t), 29.9 (t, 2x), 29.4 (t), 28.3 (q, NHCO2C(CH3)3), 
27.2 (q, SiC(CH3)3), 24.6 (t), 23.2 (t), 19.5 (s, SiC(CH3)3), 14.4 (q) ppm. HRMS (ESI+): Calcd 
for C48H74NO6SSi ([M + 1] ), 820.50006; found, 820.49950. IR (NaCl): ν 3400-3200 (br, N-
 
Cell cultures 
+
H), 2925 (s, C-H), 2854 (m, C-H), 2166 (m, C≡C), 1750 (w, C=O), 1718 (m, C=O), 1663 (m, 
C=O), 1522 (m), 1166 (m), 1110 (m), 703 (m) cm-1. UV (MeOH): λmax  324 nm. 
Chemicals 
All chemicals used in these experiments were dissolved in DMSO (Sigma-Aldrich): the 
reference HDACis SAHA (Alexis) and MS 275 (Schering AG) were utilized at 5 μM, whereas 
the DNMTis 5-AZA, RG108 and SGI-1027 were instead used at 50 μM. The peyssonenynes
derivatives were also dissolved in DMSO and used at 5 μM and at 50 μM. 
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K562 and U937 human leukaemia cell lines were grown in RPMI 1640 medium (Euroclone) 
supplemented with heat-inactivated FBS, 1% glutamine, 1% penicillin/streptomycin and 0,1% 
gentamycin, at 37 °C in air and 5% CO2.  
BJ cells were grown in DMEM; BJEL were in DMEM/199 (4:1) plus hygromycin and G418; 
DMEM was supplemented with 10% FCS, sodium pyruvate, non-essential amino acids and 
gentamycin. Cells were exposed to 1µm, 5µM or 10µm of the synthetic compounds, SGI-
1027, 5-aza-2’-deoxycitidine; stock solutions were in 10mM DMSO. MEFs were grown in 
ith GLUTAMAX1, supplemented with 10%FCS, sodium 
 
The supernatant was transferred to a new tube and 3.25 μg of antibody against DNMT1 
ed and IP was allowed to proceed overnight at 4 °C on a rocking table. As 
roceed with the radioactive assay. 
mixture composed of 10 µL of DNMT1-bound resin, 5 µCi of (S)-adenosyl-L-[methyl-
 (radioactive methyl donor; 12-18 Ci/mmol), 0.1 µg of poly dI-dC (methyl 
DMEML (4.5g/L glucose) w
pyruvate and gentamycin. All experiments with primary MEFs were done with cultures that 
were maximally at passage 3.  
DNMT1 Immunoprecipitation 
The K562 cells were lysed in TAP buffer pH 7-7.5 (50 mM Tris pH 7.0, 180 mM NaCl, 0.15% 
NP40 v/v, 10% glycerol v/v, 1.5 mM MgCl2, 1 mM NaMnO4, 0.5 mM NaF, 1 mM DTT, 0.2 
mM PMSF and protease inhibitor cocktail) for 10 minutes in ice and centrifuged at 13000 rpm 
for 30 minutes. 650 µg of extracts were diluted in TAP buffer up to 1 mL and pre-cleared by 
incubating with 20 µL A/G plus Agarose (Santa Cruz) for 1 hour on a rocking table at 4 °C.
(Abcam) was add
negative control the same amount of protein extracts were immunoprecipitated with purified 
rabbit IgG (Santa Cruz). The following day 50 µL A/G plus Agarose were added and 
incubation was continued for 2 hours. The beads were recovered by brief centrifugation and 
washed with cold TAP buffer several times. At this point the resin was resuspended in 10 µL 
of DNMT buffer (5 mM EDTA, 0.2 mM DTT, 26 mM NaCl, 20 mM Tris HCl pH 7.4) in 
order to p
DNMT1 radioactive assay 
DNMT1 assays were performed in the presence of the analogues at 50 µM plus a reaction 
3H]methionine
acceptor), and DNMT buffer. The reaction was carried out for 2 hours at 37 °C with gently 
stirring and the experiment was performed in duplicate. Subsequently each sample was spread 
on Whatman DE-81 paper (in quadruplicate) and the papers were washed three times with 5% 
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Na2HO4P and once with distilled water. An the end the papers were transferred in the 
ix 
containing: DNMTbuffer (5 mM EDTA; 0.2 mM DTT; 26 mM NaCl, 20 mM TRIS HCl pH 
7.4), Po γ/λ, adenosyl-L-methionine [ H] 1 µCi, DN
carried out at 37 ˚C for i than put on E81 paper 
and wa llows um te 5 or 5 minutes and 1x with 
sterile w or 2 minu e  sci tion vial containing 5 mL 
scintilla cocktail. E arrie ndent icates. 
Cell cy alysis by
2.5 x 105 U937 cells were collected by centrifugation after 24 hours stimulation with reference 
yne analogues. Then the cells were resuspended in 500 µL of a 
hypotonic buffer (0.1% NP-40, 0.1% sodium citrate, 50 µg/mL PI, RNAse A) and incubated in 
the dark for 30 minutes. The analysis was performed with a FACS-Calibur (Becton Dickinson) 
using the Cell Quest Pro software (Becton Dickinson) and ModFit LT version 3 software 
(Verity). The experiment was performed in duplicate. 
 
r t
 
t P
scintillation vials containing 5 mL of scintillation fluid in order to read the DPM values.  
DNMT3A and DNMT3B radioactive assays 
DNMT3A and DNMT3B were expressed in bacteria (E.coli BL21) and purified following 
standard procedures. The DNMT radioactive assay was performed in a reaction m
ly dI-dC 0.1 3 MT3A (30 ng). Reaction was 
 2 hours on a shaker. The radioactive m x is  a D
shed as fo : 3x with di-sodi hydrogenphospha % f
ater f tes. Once dried, th paper is put into a ntilla
tion xperiments are c d out as indepe  tripl
cle an  FACS 
compounds or peyssonen
Granulocytic differentiation analysis 
2.5 x 105 U937 cells were collected by centrifugation after 24 hours stimulation with reference 
compounds or peyssonenyne analogues. Then the cells were washed with PBS and incubated 
in the dark at 4 °C for 30 minutes with 10 µL of PE-conjugated anti-CD11c surface antigen 
antibody; there was included also a PE control, so a sample incubated with 10 µL of PE-
conjugated IgG, in orde o remove the background signal in the following analysis. At the end 
of incubation the samples were washed again and then resuspended in 500 µL of PBS 
containing 0.25 μg/mL protease inhibitors (PI). The analysis was performed with a FACS-
Calibur (Becton Dickinson) using the Cell Ques ro software (Becton Dickinson). The 
experiment was performed in duplicate and PI positive cells were excluded from the analysis.  
Protein extraction 
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U937 cells were treated with reference compounds or peyssonenyne derivatives and harvested 
by centrifugation. After PBS wash the samples were resuspended in a lysis buffer (50 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 10 mM NaF, 1 mM PMSF and PI) and the lysis 
reaction was carried out for 15 minutes at 4 °C. At the end the samples were centrifuged at 
13000 rpm for 30 minutes at 4 °C and the proteins were quantified by Bradford assay (Bio-
Rad). 
Histone extraction 
Histone extraction was performed according to the Abcam protocol. Briefly, after stimulation 
with the same compounds the cells were collected by centrifugation and washed two times 
with PBS. Then the samples were resuspended in Triton Extraction Buffer (PBS containing 
0.5% Triton X 100 (v/v), 2 mM PMSF, 0.02% (w/v) NaN3) and the lysis was performed for 10 
minutes at 4 °C. Then the samples were centrifuged at 2000 rpm for 10 minutes at 4 °C and the 
pellets were washed in TEB again (but this time in half the volume of buffer). After a new 
centrifugation in the same conditions the sample were resuspended in 0.2 N HCl and the acid 
histone extraction was carried out overnight at 4 °C. The following day the supernatant was 
recovered by centrifugation and the protein content was ensured by Bradford assay (Bio ). 
rylamide gel in order to 
evaluate acetyl-tubulin expression (Sigma Aldrich, dilution 1:500), while the same amount of 
proteins but on 15% polyacrylamide gels were used for p21Cip1/WAF1 (Transduction 
Laboratories, dilution 1:500), Fas (Cell Signaling, dilution 1:500) and Bcl-2 (Cell Signaling, 
dilution 1:500) analysis. ERK1 antibody (Santa Cruz, dilution 1:1000) was used as loading 
control. 
10 μg of histonic extracts were loaded on 15% polyacrylamide gel and the histone H3 
acetylation was assessed with 
Ponceau Red (Sigma) was used to color nitrocellulose filter and check the equal loading. 
-Rad
Western Blots 
50 μg of total protein for each sample were loaded on 10% polyac
anti-acetyl-histone H3 antibody (Abcam, dilution 1:500). 
MTT assays 
Cells were treated with compounds in 96 well plates for the times indicated, washed and 
exposed to 0.5mg/mL MTT (Sigma) for 4h at 37 °C. Medium was removed and 100µL 
DMSO added. After shaking plates were read at 550 nm absorbance using an EL800 (Biotek).  
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Real time PCR 
Total RNA was extracted (DNA & RNA purification kit, Sigma-Aldrich) according to the 
instructions provided by the manufacturer and cDNA was synthesized from 2µg RNA using 
SuperScript II (Invitrogen) using the following conditions: 1h 42°C, 10 min, 95°C, 4°C. The 
cDNA was used for PCR amplification using SYBR Green I (Qiagen) according to standard 
procedures using ABI770 (Applied Biosystems). PCR primers are given below. 
Oligonucleotides sense (5'→3') antisense (5→3') PCR product (pb) tm (°C)'
CSK aactatgtccagaagcgtgagg cacagtgtgtagtctccagggtagt 170 60 
DNMT1 agcactaccgcaagtattctgact gtagaacttgtagagcctcagcttg 152 60 
DNMT3A gccagaactgtaagaactgc aagagatccacacactcgac 157 55 
GJB2 gcctaccggagacatgaaaa tcaaagatgacccggaagaa 155 60 
IAP cttcacttaggacgcatcac gcgttgacatcctgtgtt 149 55 
NMYC1 gtcactagtgtgtctgttccagctac gatttcctcctcttcatcttcctc 168 60 
SLPI aagtgcgtgaatcctgttcc cacatataccctcacagcacttgt 157 60 
 
Synthesis of Analogues 
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O
O
R2 =
O
O
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H2O-CH3CN, 60 ºC
O
3
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(12Z,15Z)-(2’R)-2,3-Dihydroxyprop-1-yl 8-Oxooctadeca-12,15-dien-4,6-diynoate (22). A 
stirred solution of (12Z,15Z)-(2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 8-
oxooctadeca-12,15-dien-4,6-diynoate (0.06 g, 0.15 mmol) in acetonitrile/water (0.8 ml, 1:1 
v/v) was heated to 60 ºC and CAN (2.4 mg, 4.4 mmol) was added. The resulting slightly 
yellow solution was stirred for 4 hours at this temperature. After cooling down to room 
temperature, the reaction mixture was extracted with ether (3x). The combined organic layers 
were dried over Na2SO4 and the solvents were removed in vacuo. The residue was purified by 
flash chromatography (silica gel, 30:70 hexane/EtOAc) to afford 0.038 g (72%) of the title 
compound as a yellow oil. 1H-NMR (400.13 MHz, C6D6): δ  5.51-5.31 (m, 3H), 5.28-5.15 (m, 
1H), 4.20-4.05 (m, 2H, 2H1’), 3.91-3.76 (m, 1H, H2’), 3.59 (dd, J = 11.4 and 3.7 Hz, 1H, H3’),  
3.51 (dd, J = 11.4, 6.0 Hz, 1H, H3’), 2.74 (t, J = 6.5 Hz, 2H, 2H14), 2.30-2.12 (m, 6H, 2H3 + 
2H11 + 2H17), 2.08-2.96 (m, 2H, 2H2), 1.93-1.84 (m, 2H, 2H9), 1.60-1.49 (m, 2H, 2H10), 0.94 
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(t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 186.3 (s), 171.3 (s), 132.2 
(d), 129.6 (d), 128.9 (d), 127.9 (d), 88.4 (s), 75.1 (s), 73.6 (s), 70.5 (d), 65.9 (t), 64.8 (s), 63.7 
(t), 44.8 (t), 32.2 (t), 26.5 (t), 25.9 (t), 23.9 (t), 21.0 (t), 15.4 (t), 14.5 (q) ppm. IR (NaCl): 
ν 3600−3300 (br, ΟΗ), 2925 (s, C-H), 2855 (m, C-H), 2234 (w, -C≡C-), 1735 (m, CO), 1668 
(m. CO), 1458 (w) cm-1. HRMS (ESI+): Calcd for C21H28O5Na, 383.18300; found, 
383.18290. 
(12Z,15Z)-(2’S)-2,3-Dihydroxyprop-1-yl 8-Oxooctadeca-12,15-dien-4,6-diynoate (21). 
Following the general procedure described above for the deprotection of  the isopropylidene 
ketal, the reaction of (12Z,15Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-
oxooctadeca-12,15-dien-4,6-diynoate (0.04 g, 0.10 mmol) and CAN (1.6 mg, 3.0 mmol) in 
acetonitrile-water (0.6 ml, 1:1 v/v) afforded, after purification by flash chromatography (silica 
gel, 30:70 hexane/EtOAc), 0.02 g (54%) of the title compound. 
 
Scheme SI5.1 Retrosynthetic analysis for the synthesis of peyssonenynes analogues 18, 19 and 20. A Ni/Cu 
co-catalyzed coupling reaction (alkyne-alkyn ) or a Cadiot-Chodkiewicz coupling (iodoalkyne-alkyne) were 
selected as key step of the synthesis to form the basic skeleton of the analogues. 
e
Scheme SI5.2 General scheme for the synthesis of analogues 18, 19 and 20. 
OtBu
O
SI-1
 
tert-Butyl Pent-4-ynoate (SI-1). To a cooled (-40 ºC) stirred solution of diisopropylamine 
(0.52 g, 5.16 mmol, 0.83 mL) in THF (0.5 mmol/mL), n-BuLi (3.0 mL, 1.45 M in THF, 4.30 
mmol) was added dropwise and the solution was stirred for 30 minutes. Subsequently, it was 
cooled down to -78 ºC, a solution of tert-butyl acetate (0.5 g, 4.30 mmol, 0.58 mL) and DMPU 
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(2.28 g, 17.22 mmol, 2.1 mL) in THF (0.1 mmol/mL) was added dropwise and the reaction 
mixture was stirred for a further 1 h at -78 ºC. Then propargylic bromide (0.51 g, 4.30 mmol, 
0.32 mL) was added and the solution was further stirred for 1h. The mixture was poured into a 
saturated aqueous solution of NaHCO3 and extracted with Et2O (3x). The combined organic 
layers were dried over Na2SO4 and the solvent was evaporated. The residue was purified by 
column chromatography (silica gel, 92:8 hexane/EtOAc) to afford 0.64 g (96%) of the titled 
 1compound as a colourless oil. H-NMR (400.13 MHz, C6D6): δ 2.47-2.44 (m, 4H, 2H2 + 
2H3), 1.97-1.95 (m, 1H, H5), 1.45 (s, 9H, C(CH3)3) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ 171.0 (s), 82.7 (s), 80.8 (s, C(CH3)3), 68.9 (d), 34.5 (t), 28.1 (q, C(CH3)3), 14.5 (t) ppm. 
HRMS (ESI+): Calcd for C9H14O2Na ([M + Na]+), 177.08860; found, 177.08795. IR (NaCl): 
ν  3303 (m, C≡C-H), 2978 (m, C-H), 2931 (w, C-H), 1732 (s, C=O), 1367 (m), 1252 (m), 1154 
(s) cm-1.  
 
tert-Butyl 5-Iodopent-4-ynoate (SI-2). To a stirred solution of tert-butyl pent-4-ynoate ( ) (0.2 
g, 1.30 mmol) in acetone (2 mL), were added sequentially NIS (0.35 g, 1.56 mmol) and AgNO
SI-1
 gel, 92:8 
hexane/EtOAc) to afford 0.22 g (61%) of the titled compound as a colourless oil. 1H-NMR (400.13 
MHz, CDCl3): δ  2.56 (t, J = 7.5 Hz, 2H, 2H2), 2.38 (t, J = 7.3 Hz, 2H, 2H3), 1.40 (s, 9H, t-Bu) 
3 
(0.22 g, 1.30 mmol) and the reaction mixture was stirred overnight at room temperature. The 
solvent was evaporated and the residue was purified by column chromatography (silica
ppm. 13C-NMR (100.62 MHz, CDCl3): δ  170.9 (s, C1), 92.6 (s, C4), 80.8 (s, C(CH3)3), 34.4 (t), 
28.1 (s, C(CH3)3), 16.9 (t), -5.4 (s, C5) ppm. HRMS (ESI+): Calcd for C9H13IO2Na ([M + Na]+), 
302.98524; found, 302.98517. IR (NaCl): ν 2978 (m, C-H ), 2927 (w, C-H), 1732 (s, C=O), 1366 
(s), 1250 (m), 1146 (s) cm-1.  UV (MeOH): λmax  234 nm. 
 
synthesis of Weinreb amides. To a solution of 2-(benzothiophen-3-yl)acetic acid (1.0 g, 5.20 
mmol) in CH
2-(Benzothiophen-3-yl)-N-methoxy-N-methylacetamide (SI-3). General procedure for the 
oc
th CH 2
2Cl2 (30 mL) was added N,O-dimethylhydroxylamine hydr hloride (0.76 g, 
7.80 mmol), EDCI (1.50 g, 7.80  mmol) and DMAP (0.95 g, 7.80 mmol) and the reaction was 
stirred overnight at room temperature. A saturated aqueous solution of NaCl was added and the 
mixture was extracted wi 2Cl  (3x). The combined organic layers were washed with a 
5% aqueous solution of HCl (1x) and brine (1x), dried over Na2SO4 and the solvent was 
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evaporated to afford 1.20 g (98%) of the titled compound as a yellow solid, which was used in 
the next step without further purification. 1H-NMR (400.13 MHz, CDCl3): δ 7.94-7.75 (m, 
2H, ArH), 7.43–7.34 (m, 2H, ArH), 7.33 (s, 1H, H2’), 4.00 (s, 2H, 2H2), 3.63 (s, 3H, OCH3),  
3.22 (s, 3H, NCH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ  171.3 (s), 140.1 (s), 138.8 (s), 
129.2 (s), 124.3 (d), 124.1 (d, 2x), 122.8 (d), 121.9 (d), 61.3 (q), 32.5 (t),  32.3  (q)  ppm. MS 
(EI+): m/z (%) 236 (M+ + 1, 2), 235 (M+, 21), 174 (21), 148 (24), 147 (100). HRMS (EI+): 
Calcd for C12H13NO2S ([M+]), 235.0667; found, 235.0666. IR (NaCl): ν 2924 (s, C-H), 2854 
(m, C-H), 1653 (s, C=O), 1456 (m), 1418 (m), 1373 (m) cm-1. UV (MeOH): λmax 228, 261, 
290, 299 nm. 
 
N-Methoxy-N-methyl-2-(thiophen-3-yl)acetamide (SI-4). Following the general procedure
described above for the synthesis of Weinreb amides, the reaction of 2-(thiophen-3-yl)acetic 
acid (1.0 g, 7.03 mmol), N,O-dimethylhydroxylamine hydrochloride 
 
(1.03 g, 10.55 mmol), 
EDCI (2.02 g, 10.55 mmol) and DMAP (1.29 g, 10.05  mmol) in CH2Cl2 (41  mL) afforded 
1.22  g (94%) of the titled compound as a brown oil, which was used in the next step without 
further purification. 1H-NMR (400.13 MHz, CDCl3): δ  7.20 (dd, J = 4.0, 2.4 Hz,  1H, ArH), 
6.98 – 6.92 (m 2H, ArH), 3.98 (s, 2H, 2H2),  3.69 (s, 3H, OCH3),  3.21 (s, 3H, NCH3) pm. , 
13C-NMR (100.62 MHz, CDCl3): δ  171.0 (s), 136.0 (s), 126.7 (d), 126.6 (d), 124.8 (d), 61.4 
(q), 33.2 (t), 32.2 (q) ppm. MS (EI+): m/z (%) 186 (M+ + 1, 1), 185 (M+, 8), 124 (18), 98 (8), 
97 (100) HRMS (EI+): Calcd for C8H11NO2S ([M+]), 185.0511; found, 185.0510. IR (NaCl): 
ν 3100 (w,   -C=C-H),  2934 (w, C-H), 1665 (s, C=O), 1428 (m), 1384 (m), 1174 (m), 1000 
(m) cm-1. UV (MeOH): λmax 234 nm. 
 
2-Phenylacetic Acid (SI-5). To a solution of 2-phenylethanol (1.0 g,  8.18 mmol) in acetone 
(14 mL) at 0 ºC was added dropwise a 2 N solution of Jones reagent (1.46  g CrO3, 1.26 mL 
H2SO4, 14.76  mL H2O), the mixture was allowed to warm to room temperature and was 
stirred for  2 hours. Water was added, the resulting mixture was extracted with Et2O (3x), and 
the combined organic layers were washed successively with water (3x) and brine (3x), dried 
over Na2SO4 and the solvent was evaporated. The residue was purified by recristalization 
(Et2O-hexane) to afford 0.45 g (40%) of the titled compound as a white solid. M.p.: 74-75 ºC 
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(hexane/ether). Elem. Anal. Calcd for C8H8O2: C, 70.57%; H, 5.92%; found: C, 70.86%; H, 
5.91%.  1H-NMR (400.13 MHz, CDCl3): δ  7.38-7.24 (m, 5H, ArH), 3.66 (s, 2H, 2H2) ppm. 
13C-NMR (100.62 MHz, CDCl3): δ  177.9 (s), 133.4 (s), 129.5 (d, 2x), 128.8 (d, 2x), 127.5 
(d), 41.2 (t) ppm. MS (EI+): m/z (%) 137 (M+ + 1, 3), 136 (M+, 31), 92 (22), 91 (100), 85 (20), 
84 (34) HRMS (EI+): Calcd for C8H8O2 ([M+]), 136.0524; found, 136.0524. IR (NaCl): ν  
3300-2800 (br, O-H), 1702 (s, C=O), 1408 (w) cm-1.  
 
N-Methoxy-N-methyl-2-phenylacetamide (SI-6). Following the general procedure described 
above for the synthesis of Weinreb amides, the reaction of 2-phenylacetic acid (SI-5) (0.38 g, 
2.82 mmol), N,O-dimethylhydroxylamine hydrochloride (0.41 g, 4.23 mmol), EDCI (0.81 g, 
4.23 mmol) and DMAP (0.52 g, 4.23  mmol) in CH2Cl2 (16  mL) afforded 0.47 g (94%) of the 
titled compound as a yellow oil, which was used in the next step without further purification. 
1H-NMR (400.13 MHz, CDCl3): δ  7.35-7.21 (m, 5H), 3.78 (s, 2H, 2H2), 3.60 (s, 3H, OCH3),  
3.19 (s, 3H, NCH3) pm. 13C-NMR (100.62 MHz, CDCl3): δ  172.3 (s), 134.9 (s), 129.2 (d, 
2x), 128.4 (d, 2x), 126.7 (d), 61.2 (q), 39.4 (t), 32.6 (q) ppm. MS (EI+): m/z (%) 179 (M+, 2), 
118 (23), 92 (24), 91 (100), 65 (14). HRMS (EI+): Calcd for C10H13NO2 ([M+]), 179.0946; 
found, 179.0943. IR (NaCl): ν  3060 (w, -C=C-H), 3029 (w, -C=C-H), 2924 (s, C-H), 
2855 (m, C-H), 1662 (m, C=O), 1457 (m), 1414 (m), 1378 (m), 1170 (w), 1101 (w), 1003 (m) 
cm-1.  
 
N-Methoxy-N-methyl-2-(naphthalen-2-yl)acetamide (SI-7). Following the general 
procedure described above for the synthesis of Weinreb amides, the reaction of 2-(naphthalen-
2-yl)acetic acid (1.0 g, 5.38  mmol), N,O-dimethylhydroxylamine hydrochloride (0.79 g, 8.06 
mmol), EDCI (1.54 g, 8.06  mm and DMAP (0.98  g, 8.06  mmol) in CHol) 
ArH), 3.94 (s, 2H, 2H ), 3.62 (s, 3H, OCH ), 3.22 (s, 3H, NCH ) ppm. C-NMR (100.62 
MHz, CDCl ):  172.2 (s, C ), 133.4 (s), 132.5 (s), 132.3 (s), 128.0 (d), 127.8 (d), 127.6 (d, 
2Cl2 (31  mL) 
afforded 1.18 g (96%) of the titled compound as a white solid, which was used in the next step 
without further purification. M.p.: 59-61 ºC (hexane/CH2Cl2). Elem. Anal. Calcd for 
C14H15NO2: C, 73.34%; H, 6.59%; N, 6.11%; found: C, 73.09%; H, 6.79%; N, 6.18%. H-
NMR (400.13 MHz, CDCl3): δ  7.85-7.77 (m, 3H, ArH), 7.75 (s, 1H, ArH), 7.54-7.38 (m, 3H, 
1
2 3 3
13
3 δ 1
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3x), 126.0 (d), 125.6 (d), 61.2 (q, OMe), 39.5 (t, C2), 32.2 (q, NCH3) ppm. MS (EI+): m/z (%) 
230 (M+ + 1, 2), 229 (M+, 14), 199 (16), 168 (28), 142 (62), 141 (100), 139 (29), 115 (63). 
HRMS (EI+ : Calcd for C14H15NO2 ([M+]), 229.1103; found, 229.1105. IR (NaCl): 
, 
)
ν 3049 (w, -C=C-H), 2924 (s, C-H), 2854 (m, C-H), 1656 (m, C=O) (m), 1459 (w), 1412 (w), 
1374 (w) cm-1. UV (MeOH): λmax 224 nm.  
N
N
O
Me
OMe
SI-8  
N-Methoxy-N-methyl-2-(pyridin-3-yl)acetamide (SI-8). Following the general procedure 
described above for the synthesis of Weinreb amides, the reaction of 2-(pyridin-3-yl)acetic 
acid (0.5 g, 2.88  mmol),  N,O-dimethylhydroxylamine hydrochloride (0.42 g, 4.32 mmol), 
EDCI (0.83 g, 4.32  mmol) and DMAP (1.06  g, 8.64  mmol) in CH2Cl2 (17  mL) afforded 
0.41 g (80%) of the titled compound as a yellow solid, which was used in the next step without 
further purification. 1H-NMR (400.13 MHz, CDCl3): δ  8.58-8.42 (m, 2H, H2’ + H6’), 7.67 (d, 
J = 7.8 Hz, 1H, H4’), 7.33-7.17 (m, 1H, H5’), 3.77 (s, 2H, 2H2), 3.68 (s, 3H, OCH3), 3.20 (s, 
3H, NCH3) pm. 13C-NMR (100.62 MHz, CDCl3): δ  171.2 (s), 150.4 (d), 148.1 (d), 137.0 (d), 
130.6 (s), 123.3 (d), 61.3 (q), 36.2 (t), 32.2 (q) ppm. HRMS (ESI+): Calcd for C9H13N2O2 
([M+]), 181.09715; found, 181.09754. IR (NaCl): ν 2934 (w, C-H), 1664 (s, C=O), 1424 (w), 
1384 (w), 1102 (w) cm-1. UV (MeOH): λmax 261 nm.  
 
4-(Benzothiophen-3-yl)-1-(triisopropylsilyl)but-1-yn-3-ol (SI-9). General procedure for 
e
r 1 h at -10 ºC and for 1 h at room temperature. A saturated aqueous 
 
the addition of alkynyllithium to Weinreb amides. To a cooled (-40 ºC) stirr d solution of 
triisopropylsilyl acetylene (1.37 g, 7.5 mmol, 1.67 mL) in THF (0.2 mmol/mL), n-BuLi (5 mL, 
1.30M in THF, 6.5 mmol) was added dropwise and the solution was stirred for 1 h. 
Subsequently, a solution of 2-(benzothiophen-3-yl)-N-methoxy-N-methylacetamide (SI-3),  
(1.18 g, 5.0 mmol) in THF (0.84 mmol/mL) was added dropwise at -10 ºC and the reaction 
was further stirred fo
solution of NH4Cl was added and the mixture was extracted with Et2O (3x). The combined
organic layers were washed with brine (2x), dried over Na2SO4 and the solvent was 
evaporated. The residue was used in the next step without further purification.  
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General procedure for the reduction of ketones to alcohols using sodium borohydride. 
NaBH4 (0.13 g, 3.4 mmol) was added portionwise to a solution of 4-(benzothiophen-3-yl)-1-
(triisopropylsilyl)but-2-yn-3-one (5 mmol) in MeOH (6 mL) at 0 ºC and the mixture was 
stirred  for 1.5 h. The reaction mixture was poured into a 1N aqueous solution of HCl and it 
was extracted with Et2O (3x). The combined organic layers were washed with a saturated 
aqueous solution of NaHCO3 (3x), dried over Na2SO4 and the solvent was removed under 
vacuum.  The residue was purified by column chromatography (silica gel, 90:10 
hexane/EtOAc) to afford pure 4-(benzothiophen-3-yl)-1-(triisopropylsilyl)but-2-yn-3-ol (SI-9) 
(1.03 g, 58%) as a yellow oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.94-7.74 (m, 2H, ArH), 
7.47-7.30 (m, 3H ArH), 4.76 (t, J = 6.3 Hz, 1H, H ), 3.30 (d, J = 6.3 Hz, 2H, 2H ), 1.05-1.00 , 3 4
(m, 21H, i-Pr3Si) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 140.4 (s), 139.2 (s), 131.3 (s), 
124.4 (d, 2x), 124.1 (d), 123.0 (d), 122.0 (d), 107.9 (s), 86.8 (s), 62.7 (d, C3), 37.0 (t, C4), 18.7 
(q, 6x, SiCH(CH3)2), 11.2 (d, 3x, SiCH(CH3)2) ppm. MS (EI+): m/z (%) 359 (M+ + 1, 1), 358 
(M+, 4), 176 (12), 148 (50), 147 (100), 139 (26), 111 (27), 103 (21), 97 (11), 83 (39), 75 (18). 
HRMS (EI+)  + IR ν : Calcd for C21H30OSSi ([M ]), 358.1787; found, 358.1792. (NaCl):  3600-
-13100 (br, O-H), 2926 (s, C-H), 2860 (s, C-H), 1462 (w), 1026 (w) cm . UV (MeOH): λmax 230 
nm. 
 
4-(Thiophen-3-yl)-1-(triisopropylsilyl)but-2-yn-3-ol (SI-10). Following the general 
procedure described above for the addition of alkynyllithium reagents to Weinreb amides, the 
reaction of 2-(thiophen-3-yl)-N-methoxy-N-methylacetamide (SI-4) (0.96 g, 5.16 mmol), 
triisopropylsilyl acetylene (1.41 g, 7.74 mmol, 1.72 mL) and n-BuLi (4.63 mL, 1.45M in THF, 
6.71 mmol) in THF (45 mL) afforded 1.82 g of a residue which was used in the next step 
without further purification.  
Following the general procedure described above, the reaction of 4-(thiophen-3-yl)-1-
(triisopropylsilyl)but-2-yn-3-one (1.82 g) and NaBH4 (0.13 g, 3.51 mmol) in MeOH (6 mL) 
afforded, after purification by column chromatography (silica gel, 85:15 hexane/EtOAc), 0.78 
g (49%, over two steps) of the titled product as a brown oil. 1H-NMR (400.13 MHz, CDCl3): 
δ 7.18 (dd, J = 4.1, 2.3 Hz, 1H, H5’), 6.98-6.92 (m, 2H, H2’ + H4’), 4.61 (t, J = 6.0 Hz, 1H, H3), 
3.34-3.12 (m, 2H, 2H4), 1.17-0.94 (m, 21H, i-Pr3Si) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ 138.3 (s), 126.9 (d, 2x), 124.7 (d), 107.5 (s), 86.9 (s), 63.4 (d), 38.6 (t), 18.7 (q, 6x, 
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SiCH(CH3)2), 11.2 (d, 3x, SiCH(CH3)2) ppm. MS (EI+): m/z (%) 308 (M+, 1), 265 (10), 143 
(20), 139 (12), 131 (38), 127 (52), 111 (20), 103 (73), 99 (12), 98 (100), 97 (90). HRMS (EI+): 
Calcd for C17H28OSSi ([M+]), 308.1630; found, 308.1635. IR (NaCl): ν  3600-3100 (br, O-H), 
2935 (s, C-H), 2864 (s, C-H), 1463 (m), 1382 (w), 1044 (m) cm-1. UV (MeOH): λmax 234 nm. 
 
4-Phenyl-1-(triisopropylsilyl)but-2-yn-3-ol (SI-11). Following the general procedure 
described above for the addition of alkynyllithium reagents to Weinreb amides, the reaction of 
N-methoxy-N-methyl-2-phenylacetamide (SI-6) (1.0 g, 5.55 mmol), triisopropylsilyl acetylene 
(1.52 g, 8.33 mmol, 1.85 mL) and n-BuLi (4.51 mL, 1.6 M in THF, 7.22  mmol) in THF (49 
mL) afforded a residue which was used in the next step without further purification.  
Following the general procedure described above,
 
 the reaction of 4-phenyl-1-
(triisopropylsilyl)but-2-yn-3-one (5.55  mmol) and NaBH4 (0.14 g, 3.78 mmol) in MeOH (6.4 
mL) afforded, after purification by column chromatography (silica gel, 90:10 hexane/EtOAc), 
1.35 g (80%, over two steps) of the titled product as a colourless oil. 1H-NMR (400.13 MHz, 
CDCl3): δ 7.39-7.23 (m, 5H, ArH), 4.71-4.57 (m, 1H, H3), 3.05 (d, J = 6.4 Hz 2H, 2H4), 2.04 
(d, J = 5.9 Hz, 1H, OH) 1.18-0.99 (m, 21H, i-Pr3Si) ppm. 13C-NMR (100.62 MHz, CDCl3): 
δ 136.6 (s), 130.0 (d, 2x), 128.4 (d, 2x), 126.9 (d), 108.0 (s), 86.7 (s), 63.8 (d), 44.3 (t), 18.7 (q, 
6x, SiCH(CH3)2), 11.3 (d, 3x, SiCH(CH3)2) ppm. MS (EI+): m/z (%) 302 (M+, 0.3), 210 (27), 
139 (12), 131 (81), 128 (12), 127 (60), 111 (20), 103 (100), 92 (11), 91 (79), 89 (13), 85 (27), 
83 (24), 75 (96), 65 (13), 61 (51). HRMS (EI+): Calcd for C19H30OSi ([M+]), 302.2066; 
found, 302.2078. IR (NaCl): ν  3600-3100 (br, O-H), 2940 (s, C-H), 2865 (s, C-H), 1462 (m), 
1382 (w), 1031 (m) cm-1.  
 
4-(Naphthalene-2-yl)-1-(triisopropylsilyl)but-1-yn-3-ol (SI-12). Following the general 
procedure described above for the addition of alkynyllithium reagents to Weinreb amides, the 
reaction of N-methoxy-N-methyl-2-(naphthalen-2-yl)acetamide (SI-7) (1.06 g, 4.62  mmol), 
triisopropylsilyl acetylene (1.26 g, 6.92 mmol, 1.54 mL) and n-BuLi (4.14 mL, 1.45 M in 
THF, 6.0  mmol) in THF (41 mL) afforded a residue which was used in the next step without 
further purification.  
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Following the general procedure described above, the reaction of 4-(naphthalene-2-yl)-1-
(triisopropylsilyl)but-2-yn-3-one (4.62 mmol) with NaBH4 (0.12 g, 3.14 mmol) in MeOH (5.3 
mL) afforded, after purification by column chromatography (silica gel, 90:10 hexane/EtOAc), 
1.35 g (83%, over two steps) of the titled product as a colourless oil. 1H-NMR (400.13 MHz, 
CDCl3): δ 7.91-7.68 (m, 4H, ArH), 7.54-7.37 (m, 3H, ArH), 4.73 (t, J = 6.3 Hz, 1H, H3), 3.21 
(d, J = 6.3 Hz, 2H, 2H4), 2.08 (s, 1H, OH), 1.08-1.02 (m, 21H, i-Pr3Si) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 134.1 (s), 133.5 (s), 132.6 (s), 128.6 (d), 128.2 (d), 128.0 (d), 127.7 
(d, 2x), 126.0 (d), 125.6 (d), 108.0 (s), 86.9 (s), 63.7 (d), 44.4 (t), 18.6 (q, 6x, SiCH(CH3)2), 
11.2 (d, 3x, SiCH(CH3)2) ppm. MS (EI+): m/z (%) 353 (M+ + 1, 1), 352 (M+, 4), 170 (15), 142 
(43), 141 (100), 139 (40), 115 (38), 111 (27), 103 (24), 83 (35), 75 (21). HRMS (EI+): Calcd 
for C23H32OSi ([M+]), 352.2222; found, 352.2220. IR (NaCl): ν  3600-3100 (br, O-H), 
2937 (s, C-H), 2864 (s, C-H), 1463 (m), 1376 (w), 1038 (m) cm-1. UV (MeOH): λmax 226 nm. 
 
4-(Pyridin-3-yl)-1-(triisopropylsilyl)but-2-yn-3-ol (SI-13). Following the general procedure 
described above for the addition of alkynyllithium reagents to Weinreb amides, the reaction of 
N-methoxy-N-methyl-2-(pyridin-3-yl)acetamide (SI-8) (1.34 g, 7.45  mmol), triisopropylsilyl 
acetylene (2.04 g, 11.18  mmol, 2.48 mL) and n-BuLi (6.42 mL, 1.51 M in THF, 9.69  mmol) 
in THF (65 mL) afforded a residue which was used in the next step without further 
purification.  
Following the general procedure described above, the reaction of 4-(pyridin-3-yl)-1-
(triisopropylsilyl)but-2-yn-3-one (7.45 mmol) with NaBH4 (0.19 g, 5.07 mmol) in MeOH (9 
mL) afforded, after purification by column chromatography (silica gel, 95:5 CH2Cl2/MeOH), 
1.21 g (53%, over two steps) of the titled product as a colourless oil. 1H-NMR (400.13 MHz, 
CDCl3): δ 8.47 (d, J = 1.6 Hz, 1H, H2’), 8.41 (dd, J = 4.8, 1.4 Hz, 1H, H6’), 7.65 (td, J = 7.8, 
1.9 Hz, 1H, H4’), 7.18 (dd, J = 7.6, 5.0 Hz, 1H, H5’), 4.65 (t, J = 6.2 Hz, 1H, H3), 3.00 (d, J = 
6.2 Hz, 2H, 2H , 21H, i-Pr3Si) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 150.8 4), 1.07-0.92 (m
(d), 147.8 (d), 137.8 (d), 132.7 (s), 123.2 (d), 107.7 (s), 87.1 (s), 63.0 (d), 41.3 (t), 18.6 (q, 6x, 
SiCH(CH3)2), 11.2 (d, 3x, SiCH(CH3)2) ppm. HRMS (ESI+): Calcd for C18H30NOSi ([M+]), 
304.20912; found, 304.21008. IR (NaCl): ν  3400-3000 (br, O-H), 2944 (s, C-H), 2866 (s, C-
H), 1463 (m), 1048 (m) cm-1. UV (MeOH): λmax 261 nm. 
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4-(Benzothiophen-3’-yl)-but-1-yn-3-ol (SI-14). General procedure for the deprotection of 
silylethers. To a stirred solution of 4-(benzothiophen-3-yl)-1-(triisopropylsilyl)but-1-yn-3-ol  
(SI-9) (1.03 g, 2.88 mmol) in THF (74 mL) was added n-Bu4NF (3.2 mL, 1M in THF, 3.20 
mmol) and the reaction was stirred for 30 minutes at 25 ºC. A saturated aqueous solution of 
NaHCO3 was added and the mixture was extracted with Et2O (3x). The combined organic 
layers were washed with brine, dried over Na2SO4 and the solvent was evaporated. The 
residue was purified by column chromatography (silica gel, 75:25 hexane/EtOAc) to afford 
0.41 g (81%) of the titled compound as a white solid. 1H-NMR (400.13 MHz, C6D6): δ 7.57-
7.54 (m, 1H, ArH), 7.51-7.47 (m, 1H, ArH), 7.15-7.11 (m, 1H, ArH), 7.07 (td, J = 7.6, 1.1 Hz, 
1H, ArH), 6.92 (s, 1H, H2’),  4.44-4.24 (m, 1H, H3), 3.02-2.92 (m, 2H, 2H4), 1.99 (d, J = 2.1 
Hz, 1H, H1), 1.52 (d, J = 5.5 Hz, 1H, OH) ppm. 13C-NMR (100.62 MHz, C6D6): δ 140.7 (s), 
139.5 (s), 131.7 (s), 124.5 (d), 124.4 (d), 124.2 (d), 123.0 (d), 122.2 (d), 84.9 (s), 73.5 (d), 61.8 
(d), 36.9 (t) ppm. MS (EI+): m/z (%) 203 (M+ + 1, 4), 202 (M+, 59), 173 (16), 148 (27), 147 
(100), 115 (17), 103 (25). HRMS (EI+): Calcd for C12H10OS ([M+]), 202.0452; found, 
202.0447. IR (NaCl): ν  3600-3100 (br, O-H), 3289 (s, C≡C-H), 3067 (w, C=C-H), 2924 (s, C-
H), 2857 (m, C-H), 1427 (m), 1029 (s) cm-1. UV (MeOH): λmax 229 nm. 
 
4-(Thiophen-3-yl)-but-1-yn-3-ol (SI-15). Following the general procedure described above 
for the deprotection of silylethers, the reaction of 4-(thiophen-3-yl)-1-(triisopropylsilyl)but-2-
yn-3-ol (SI-10) (0.73 g, 2.36 mmol) and n-Bu4NF (2.6 mL, 1M in THF, 2.60 mmol) in THF 
(61 mL) afforded, after purification by column chromatography (silica gel, 75:25 
hexane/EtOAc), 0.31 g (86%) of the titled compound as a colourless oil. 1H-NMR (400.13 
MHz, C6D6): δ 6.84 (d, J = 4.9 Hz, 1H, H5’), 6.79-6.62 (m, 2H, H2’ + H4’), 4.34 (t, J = 6.0 Hz, 
1H, H3), 3.01 (app d, J = 6.3 Hz, 2H, 2H4), 2.80 (br s, 1H, OH), 2.12 (d, J = 1.9 Hz, 1H, H1) 
ppm. 13C-NMR (100.62 MHz, C6D6): δ 138.7 (s), 127.0 (d, 2x), 124.7 (d), 84.5 (s), 74.1 (d), 
62.9 (d), 38.3 (t)  ppm. MS (EI+): m/z (%) 153 (M+ + 1, 1), 152 (M+, 4), 124 (6), 123(5), 98 
(7), 97 (100). HRMS (EI+): Calcd for C12H8OS ([M+]), 152.0296; found, 152.0303. IR 
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(NaCl): ν  3600-3100 (br, O-H), 3289 (s, C≡C-H), 2924 (s, C-H), 2857 (m, C-H), 1429 (w), 
1386 (w), 1278 (m), 1131 (w), 1040 (s) cm-1. UV (MeOH): λmax 234 nm. 
 
4-Phenyl-but-1-yn-3-ol (SI-16). Following the general procedure described above for the 
deprotection of silylethers, the reaction of 4-phenyl-1-(triisopropylsilyl)but-2-yn-3-ol (SI-11) 
(0.30 g, 1.0 mmol) and n-Bu4NF (1.12 mL, 1M in THF, 1.12 mmol) in THF (26 mL) afforded, 
after purification by column chromatography (silica gel, 75:25 hexane/EtOAc), 0.14 g (94%) 
of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.35-7.23 (m, 
5H, ArH), 4.59 (td, J = 6.4, 2.1 Hz, 1H, H3), 3.07-2.97  (m, 2H, 2H4),  2.48 (d, J = 2.1 Hz, 1H, 
H1) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 136.4 (s), 129.9 (d, 2x), 128.6 (d, 2x), 127.2 (d), 
84.2 (d), 74.0 (d), 63.1 (d), 44.0 (t) ppm. MS (EI+): m/z (%) 146 (M+, 1), 145 (5), 117 (13), 92 
(27), 91 (100), 65 (14). HRMS (EI+): Calcd for C10H10O ([M+]), 146.0732; found, 146.0727. 
IR (NaCl): ν  3600-3100 (br, O-H), 3292 (m, C≡C-H), 2924 (s, C-H), 2854 (m, C-H), 1456 
(w), 1034 (s) cm-1. 
 
4-(Naphthalene-2’-yl)-but-1-yn-3-ol (SI-17). Following the general procedure described 
above for the deprotection of silylethers, the reaction of 4-(naphthalene-2-yl)-1-
(triisopropylsilyl)but-1-yn-3-ol (SI-12) (1.14 g, 3.25 mmol) and n-Bu4NF (3.57 mL, 1M in 
THF, 3.57 mmol) in THF (84 mL) afforded, after purification by column chromatography 
(silica gel, 75:25 hexane/EtOAc), 0.58 g (91%) of the titled compound as a yellow solid. M.p.: 
49-51 ºC (hexane/CH2Cl2).  1H-NMR (400.13 MHz, CDCl3): δ 7.87-7.80 (m, 3H, ArH), 7.75 
(s, 1H, H1’), 7.52-7.45 (m, 2H, ArH), 7.44 (dd, J = 8.4, 1.7 Hz, 1H, H3’), 4.69 (dt, J = 6.4, 2.1 
Hz, 1H, H3), 3.24-3.15 (m, 2H, 2H4), 2.51 (d, J = 2.1Hz, 1H, H1) ppm. 13C-NMR (100.62 
MHz, CDCl3): δ 133.9 (s), 133.5 (s), 132.6 (s), 128.6 (d), 128.1 (d), 128.0 (d), 127.8 (d, 2x), 
126.2 (d), 125.8 (d), 84.3 (s), 74.1 (s), 63.0 (s), 44.1 (t) ppm. MS (EI+): m/z (%) 197 (M+ + 1, 
2), 196 (M+, 14), 142 (18), 141 (100), 139 (15), 115 (62). HRMS (EI+): Calcd for C12H12O 
([M+]), 196.0888; found, 196.0890. IR (NaCl): ν  3600-3100 (br, O-H), 3291 (s, C≡C-H), 
3053 (w, C=C-H), 2924 (w, C-H), 1637 (w), 1599 (w), 1505 (w), 1373 (w), 1270 (w), 1038 (s) 
cm-1. UV (MeOH): λmax 225 nm. 
185 
A novel DNA methyltransferase inhibitor 
 
4-(Pyridin-3-yl)-but-1-yn-3-ol (SI-18). Following the general procedure described above for 
the deprotection of silylethers, the reaction of 4-(pyridin-3-yl)-1-(triisopropylsilyl)but-2-yn-3-
ol (SI-13) (0.31 g, 1.03 mmol) and n-Bu4NF (1.13 mL, 1M in THF, 1.13 mmol) in THF (26 
mL) afforded, after purification by column chromatography (silica gel, 95:5 CH2Cl2/MeOH), 
0.14 g (94%) of the titled compound as a yellow solid. 1H-NMR (400.13 MHz, C6D6): δ 8.44 
(d, J = 1.8 Hz, 1H, H2’), 8.26 (dd, J = 4.8, 1.6 Hz, 1H, H6’), 7.22-7.06 (m, 1H, H4’),  6.65 (ddd, 
J = 7.8, 4.8, 0.7 Hz, 1H, H5’), 4.36 (td, J = 6.2, 2.1 Hz, 1H, H3), 2.69 (app d, J = 6.2 Hz, 2H, 
2H4), 2.08 (d, J = 2.1 Hz, 1H, H1) ppm. 13C-NMR (100.62 MHz, C6D6): δ 151.1 (d), 147.8 
(d), 137.6 (d), 133.1 (s), 123.1 (d), 85.1 (s), 73.6 (d), 62.2 (d), 41.3 (t) ppm. MS (EI+): m/z (%) 
148 (M+ + 1, 1), 147 (M+, 9), 118 (12), 93 (100), 92 (62), 65 (34). HRMS (EI+): Calcd for 
C9H9NO ([M+]), 147.0684; found, 147.0686. IR (NaCl): ν  3600-3100 (br, O-H), 3286 (s, 
C≡C-H), 2848 (w, C-H), 1583 (w), 1428 (m), 1322 (w), 1048 (s) cm-1. UV (MeOH): λmax 261 
nm. 
 
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxy-1-prop-1-yl 11-Hydroxyundeca-4,6-
diynoate (Model system for the Ni/Cu co-catalyzed cross-coupling of terminal 
alkynes). General procedure for the synthesis of 1,3-diynes. CuI (5 mol%) and 
NiCl2 .6H2O (5 mol%) were dissolved in THF (1 mL). After addition of TMEDA (7 μL), 
the reaction mixture was stirred for 2 minutes at room temperature. 5-Hexyn-1-ol (0.12g, 
1.18 mmol, 0.13 mL) and (2 )-2,3-O-isopropylidene-2,3-dihydroxy-1-prop-1-yl pent-4-
δ 170.8 (s), 109.7 (s), 78. 3 (s), 75.6 (s), 73.8 (d), 67.2 (s), 66.5 (s, 2x), 65.0 (t), 61.9 (t), 
’R
ynoate (13) (0.05g, 0.24 mmol) were subsequently added and the mixture was stirred under 
air for 24 hours at room temperature. After completion of the reaction the solvent was 
evaporated and the residue was purified by column chromatography (95:5 CH2Cl2/MeOH) 
to afford 0.048 g (65%) of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, 
C6D6): δ 4.02-3.84 (m, 3H, H2’ + 2H1’), 3.66 (dd, J = 8.5, 6.4 Hz, 1H, H3’), 3.44 (dd, J = 
8.4, 5.9 Hz, 1H, H3’), 3.21 (t, J = 5.8 Hz, 2H, 2H11), 2.21 (t, J = 7.1 Hz, 2H, 2H2 or 2H3), 
2.13-2.04 (m, 2H, 2H2 or 2H3), 1.90 (t, J = 6.7 Hz, 2H, 2H8), 1.35 (s, 3H, CH3), 1.33-1.26 
(m, 7H, CH3 + 2H9 + 2H10), 1.25 (s, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): 
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33.0 (t), 32.0 (t), 26.9 (q), 25.6 (q), 24.9 (t), 19.1 (t), 15.3 (t)  ppm. HRMS (ESI+): Calcd 
for C17H25O5 ([M +1]+), 309.16965; found, 309.16937. IR (NaCl): ν  3600-3100 (br, O-
H), 2925 (s, C-H), 2858 (m, C-H), 1738 (s, C=O), 1455 (w), 1375 (m), 1211 (m), 1162 (s), 
1055 (s) cm-1. UV (MeOH): λmax 225 nm. 
 
tert-Butyl 9-(Benzothiophen-3’-yl)-8-hydroxynona-4,6-diynoate (SI-19). Following the 
general procedure described above for the synthesis of 1,3-diynes, the reaction of tert-butyl 
pent-4-ynoate (SI-1) (1.80 g, 11.65  mmol), 4-(benzothiophen-3-yl)-but-1-yn-3-ol (SI-14) 
 
(0.47 g, 2.33 mmol), CuI (5 mol%), NiCl2.6H2O (5 mol%) and TMEDA (70 μL) in THF (10 
mL) afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 
0.39 g (48%) of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, C6D6): δ  
7.75 (dt, J = 7.9, 0.8 Hz, 1H, ArH), 7.70 (app d, J = 7.9 Hz, ArH), 7.39-7.33 (m, 2H, ArH), 
7.30-7.25 (m, 1H, ArH), 4.66-4.57 (m, 1H, H8), 3.18 (d, J = 6.6 Hz, 2H, 2H9), 2.40 (t, J = 7.2 
Hz, 2H, 2H2 or 2H3), 2.26 (t, J = 7.1 Hz, 2H2 or 2H3), 2.20 (br s, 1H, OH), 1.52 (s, 9H, 
C(CH3)3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 170.5 (s), 140.7 (s), 139.5 (s), 131.5 (s), 
124.5 (d, 2x), 124.2 (d), 123.0 (d), 122.2 (d), 80.5 (s, C(CH3)3), 80.2 (s), 77.6 (s), 70.8 (s), 65.9 
(s), 62.4 (d), 36.8 (t), 34.0 (t), 28.0 (q, C(CH3)3), 15.5 (t)  ppm. HRMS (ESI+): Calcd for 
C21H23O3S ([M+1]+), 355.13624; found, 355.13601. IR (NaCl): ν  3600-3200 (br, O-H), 
2969 (m, C-H), 2925 (s, C-H), 2855 (m, C-H), 2253 (w, C≡C), 1726 (s, C=O), 1462 (w), 1426 
(w), 1366 (m), 1252 (m), 1151 (s) cm-1.  UV (MeOH): λmax 229, 262, 290, 299 nm. 
  
tert-Butyl 8-hydroxy-9-(thiophen-3’-yl)-nona-4,6-diynoate (SI-20). Method A. General 
procedure for Cadiot-Chodkiewicz cross-coupling reaction. To a cooled (0 ºC) stirred solution 
of tert-butyl 5-iodopent-4-ynoate (SI-2) (0.57  g, 2.04  mmol) and 4-(thiophen-3-yl)-but-1-yn-
3-ol (SI-15) (0.31 g, 2.04 mmol) in degassed piperidine (3.7 mL), at 0 ºC, was added copper 
chloride (20 mg,  0.20 mmol). After stirring overnight, a saturated aqueous NH4Cl solution 
was added and the mixture was extracted with CH2Cl2 (3x). The combined organic layers were 
dried over Na2SO4 and the solvent was removed under vacuum. The residue was purified by 
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column chromatography (silica gel, 80:20 hexane/EtOAc) to provide 0.44 g (71%) of the titled 
compound as a colourless oil. 
 Method B. Following the general procedure described above for the synthesis of 1,3-diynes, 
the reaction of tert-butyl pent-4-ynoate (SI-1) (1.01 g, 6.57 mmol), 4-(thiophen-3-yl)-but-1-yn-
3-ol (SI-15) (0.2 g, 1.32 mmol), CuI (5 mol%), NiCl2.6H2O (5 mol%) and TMEDA (40 μL) in 
THF (6 mL) afforded, after purification by column chromatography (silica gel, 80:20 
hexane/EtOAc), 0.23 g (57%) of the titled compound as a colourless oil. 1H-NMR (400.13 
MHz, C6D6): δ 6.87-6.76 (m, 1H, H5), 6.75-6.64 (m, 2H, H2 + H4), 4.25 (t, J = 6.2 Hz, 1H, 
H8), 2.95-2.85 (m, 2H, 2H9), 2.19 (t, J = 7.2 Hz, 2H, 2H2 or 2H3), 2.09-2.01 (t, J = 7.1 Hz, 2H, 
2H2 or 2H3), 1.32 (s, 9H, C(CH3)3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 170.4 (s), 138.5 
(s), 127.0 (d), 126.9 (d), 124.8 (d), 80.5 (s, C(CH3)3), 80.2 (s), 77.0 (s), 71.1 (s), 65.9 (s), 63.4 
(d), 38.2 (t), 34.0 (t), 28.0 (q, C(CH3)3), 15.5 (t)  ppm. HRMS (ESI+): Calcd for C17H21O3S 
([M + 1]+), 305.12059; found, 305.12202. IR (NaCl): ν  3600-3100 (br, O-H), 2978 (w, C-H), 
2926 (w, C-H), 2253 (w, C≡C), 1724 (s, C=O), 1367 (m), 1252 (m), 1152 (s), 1038 (m) cm-1.  
UV (MeOH): λmax 234 nm. 
  
tert-Butyl 8-Hydroxy-9-phenylnona-4,6-diynoate (SI-21). Following the general procedure 
described above for the synthesis of 1,3-diynes, the reaction of tert-butyl pent-4-ynoate (SI-1) 
(1.05 g, 6.84 mmol), 4-phenyl-but-1-yn-3-ol (SI-16) (0.2 g, 1.37 mmol), CuI (5 mol%), 
NiCl2.6H2O (5 mol%) and TMEDA (41 μL) in THF (6 mL) afforded, after purification by 
column chromatography (silica gel, 80:20 hexane/EtOAc), 0.24 g (59%) of the titled 
compound as a colourless oil. 1H-NMR (400.13 MHz, C6D6): δ 7.14-7.01 (m, 5H, ArH), 4.31-
4.21 (m, 1H, H8), 2.80-2.70 (m, 2H, 2H9), 2.24-2.13 (m, 2H, 2H2), 2.04 (td, J = 7.2, 0.6 Hz, 
2H, 2H3), 1.43 (d, J = 6.0 Hz, 1H, OH), 1.32 (s, 9H, C(CH3)3)  ppm. 13C-NMR (100.62 MHz, 
C6D6): δ 170.3 (s), 136.9 (s), 130.1 (d, 2x), 128.6 (d, 2x), 127.0 (d), 80.4 (s, C(CH3)3), 80.1 
(s), 77.4 (s), 71.0 (s), 66.0 (s), 63.8 (d), 44.1 (t), 34.0 (t), 28.0 (q, C(CH3)3), 15.5 (t) ppm. 
HRMS (ESI+): Calcd for C19H22O3Na ([M + Na]+), 321.14612; found, 321.14638. IR (NaCl): 
ν  3600-3100 (br, O-H), 2978 (w, C-H), 2928 (w, C-H), 2254 (w, C≡C), 1724 (s, C=O), 1367 
(m), 1252 (m), 1152 (s), 1034 (m) cm-1.  
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tert-Butyl 8-Hydroxy-9-(naphtalen-2’-yl)nona-4,6-diynoate (SI-22). Following the general 
procedure described above for the synthesis of 1,3-diynes, the reaction of tert-butyl pent-4-
ynoate (SI-1) (0.78 g, 5.1 mmol), 4-(naphthalene-2-yl)-but-1-yn-3-ol (SI-17) (0.2 g, 1.02 
mmol), CuI (5 mol%), NiCl2.6H2O (5 mol%) and TMEDA (31 μL) in THF (4 mL) afforded, 
after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 0.20 g (56%) 
of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, C6D6): δ 7.65-7.59 (m, 2H, 
ArH), 7.57 (d, J = 8.4 Hz, 1H, H4’), 7.48 (s, 1H, H1’), 7.29-7.19  (m, 3H, ArH), 4.44-4.32 (m, 
1H, H8), 2.94-2.89 (m, 2H, 2H9), 2.18 (t, J = 7.2 Hz, 2H, 2H2), 2.04 (td, J = 7.1, 0.9 Hz, 2H, 
2H3), 1.79 (d, J = 5.4 Hz, 1H, OH), 1.31 (s, 9H, C(CH3)3)  ppm. 13C-NMR (100.62 MHz, 
C6D6): δ 170.4 (s), 134.5 (s), 134.0 (s), 133.0 (s), 128.8 (d), 128.4 (d), 128.2 (d), 128.1 (d), 
128.0 (d), 126.2 (d), 125.8 (d), 80.4 (s, C(CH3)3), 80.2 (s), 77.5 (s), 71.1 (s), 65.9 (s), 63.7 (d), 
44.3 (t), 34.0 (t), 28.0 (q, C(CH3)3), 15.5 (t) ppm. HRMS (ESI+): Calcd for C23H24O3Na ([M 
+ Na]+), 371.16177; found, 371.16294. IR (NaCl): ν  3600-3100 (br), 3053 (w, aromatic C-H 
), 2976 (w, C-H), 2927 (w, C-H), 1726 (s, C=O), 1367 (m), 1252 (m), 1151 (s), 1038 (m) cm-1.  
UV (MeOH): λmax 226 nm. 
  
tert-Butyl 8-Hydroxy-9-(pyridin -3’-yl)nona-4, 6-diynoate (SI-23). Following the general 
in
procedure described above for the synthesis of 1,3-diynes, the reaction of tert-butyl pent-4-
ynoate (SI-1) (0.52 g, 3.4  mmol), 4-(pyrid -3’-yl)-but-1-yn-3-ol (SI-18) (0.1 g, 0.68 mmol), 
CuI (5 mol%), NiCl2.6H2O (5 mol%) and TMEDA (20 μL) in THF (3 mL) afforded, after 
purification by column chromatography (silica gel, 92:8  CH2Cl2/MeOH), 0.1 g (51%) of the 
titled compound as a colourless oil. 1H-NMR (400.13 MHz, (CD3)2SO): δ  8.47 (s, 1H, H2’), 
8.42 (d, J = 4.3 Hz, 1H, H6’), 7.65 (d, J = 7.7 Hz, 1H, H4’), 7.26 (dd, J = 7.5, 4.9 Hz, 1H, H5’), 
4.59 (t, J = 6.4 Hz, 1H, H8), 2.94 (d, J = 6.3Hz, 2H, 2H9), 2.54 (t, J = 6.9 Hz, 2H, 2H2), 2.41 
(t, J = 6.9 Hz, 2H, 2H3), 1.45 (s, 9H, C(CH3)3) ppm. 13C-NMR (100.62 MHz, DMSO): 
δ 169.3 (s), 149.8 (d), 146.8 (d), 136.0 (d), 132.1 (s), 122.1 (d), 79.6 (s, C(CH3)3), 79.5 (s), 
77.9 (s), 68.6 (s), 64.2 (s), 61.0 (d), 40.1 (t), 33.1 (t), 27.2 (q, C(CH3)3), 14.2 (t) ppm. HRMS 
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(ESI+): Calcd for C18H22NO3 ([M + 1]+), 300.15942; found, 300.16033. IR (NaCl): ν  3600-
3000 (br), 2978 (w, C-H), 2929 (w, C-H), 2254 (w, C≡C), 1727 (s, C=O), 1426 (w), 1367 (m), 
1250 (w), 1151 (s), 1047 (m) cm-1.  UV (MeOH): λmax 261 nm. 
 
tert-Butyl (8E)-8-Acetoxy-9-(thiophen-3’-yl)-nona-8-en-4,6-diynoate (18). General 
procedure for the Dess-Martin oxidation. To a cooled (0 ºC) stirred solution of tert-butyl 8-
aturated aqueous solution of NaHCO3 was added and the 
mixture was extracted with CH2Cl2 (3x). The combined organic layers were dried over 
Na2SO4 and the solvent was evaporated. The residue was used in the next step without further 
purification.  
General procedure for the synthesis of enolacetates. To a cooled (0 ºC) stirred solution of 
2Cl2 (4 mL) were added Et3N (0.12 mL, 0.085 g, 
0.84 mmol), DMAP (0.01 g, 0.084 mmol) and acetic anhydride (96 μL, 0.1 g, 1.01 mmol) and 
the reaction mixture was stirred for 2h at room temperature. A saturated aqueous solution of 
NH4Cl was added and the mixture was extracted with CH2Cl2 (3x). The combined organic 
hydroxy-9-(thiophen-3’-yl)-nona-4,6-diynoate (SI-20) (0.05 g, 0.16 mmol) in CH2Cl2 (15 mL) 
was added Dess-Martin periodinane reagent (0.11 g, 0.25 mmol) and the reaction was stirred 
for 1 h at this temperature. A s
the residue obtained above (0.05 g) in CH
layers were dried over Na2SO4 and the solvent was evaporated. The residue was purified by 
column chromatography (silica gel, 80:20 hexane/EtOAc) to afford 0.03 g (47% over two 
steps) of the Z isomer of the titled compound as a yellow solid. 1H-NMR (400.13 MHz, 
C6D6): δ 6.80 (d, J = 4.6 Hz 1H, H5), 6.61-6.52 (m, 2H, H2 + H4), 6.45 (s, 1H, H9), 2.19 (t, J 
= 7.1 Hz, 2H, 2H3), 2.03 (t, J = 7.1 Hz, 2H, 2H2), 1.76 (s, 3H, COCH3), 1.32 (s, 9H, C(CH3)3) 
ppm. 13C-NMR (100.62 MHz, C6D6): δ 170.1 (s), 166.9 (s), 136.4 (s), 129.9 (s), 128.8 (d), 
128.7 (d), 126.9 (d), 122.1 (d), 86.5 (s), 80.4 (s, C(CH3)3), 78.4 (s), 71.1 (s), 66.1 (s), 33.8 (t), 
28.0 (q, C(CH3)3), 20.6 (q, OCOCH3), 15.8 (t) ppm. HRMS (ESI+): Calcd for C19H20O4SNa 
([M + Na]+), 367.09745; found, 367.09800. IR (NaCl): ν  2924 (m, C-H), 2854 (w, C-H), 
1771 (m, C=O), 1728 (m, C=O), 1422 (w), 1367 (m), 1183 (s), 1152 (s), 1080 (w) cm-1.  UV 
(MeOH): λmax 325 nm. Purity trace: RPHPLC-ESI (Sunfire® C18 5 μm, 46x250 mm, 
acetonitrile/H2O gradient from 70:30 to 100:0, 25 min, 1 mL/min, tR= 11.5 min; 96% purity). 
The 3JH-C det ined with the EXSIDE experiment allowed to assign the geometry of the erm
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double bond to Z (3JH-C = 3 Hz, splittig signal at 73.32 ppm measured in a 17.6T Varian 
INOVA NMR Spectrometer operating at 750 MHz, C6D6). 
 
tert-Butyl (8E)-8-Acetoxy-9-phenyl-8-en-4,6-diynoate (19). Following the general rocedure 
described above for the Dess-Martin oxidation, the reaction of tert-butyl 8-hydroxy-9-
phenylnona-4, 6-diynoate (SI-21) ( 0.053 g, 0.18 mmol) and Dess-Martin periodinane reagent 
(0.11 g,  0.26 mmol) in CH
p
due obtained above (0.054 g), Et3N (0.12 mL, 0.88 mmol), DMAP (0.011 g, 0.088 
mmol) and acetic anhydride (0.1 mL, 1.06 mmol) in CH2Cl2 (5 mL) afforded, after 
purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 0.035 g (59% over 
two steps) of the title compound as a yellow solid. 1H-NMR (400.13 MHz, C6D6): δ 7.25 (d, J 
= 7.5 Hz, 2H, 2H ), 7.03 (t, J = 7.5 Hz, 2H, 2H ), 6.99 – 6.94 (m, 1H, H ), 6.33 (s, 1H, H ), 
2Cl2 (16 mL) at 0 ºC afforded   54 mg of a  residue which was used 
in the next step without further purification.  
Following the general procedure described above for the synthesis of enolacetates, the reaction 
of the resi
2’ 3’ 4’ 9
2.19 (t, J = 7.2 Hz, 2H, 2H3), 2.03 (t, J = 7.2 Hz, 2H2), 1.57 (s, 3H, COCH3), 1.32 (s, 9H, 
C(CH3)3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 170.1 (s), 166.8 (s), 133.9 (s), 129.9 (s), 
129.6 (d), 128.8 (d), 128.7 (d), 128.0 (d), 85.9 (s), 80.4 (s, C(CH3)3), 76.9 (s), 71.5 (s), 66.0 (s), 
33.8 (t), 28.0 (q, C(CH3)3), 20.1 (q, OCOCH3), 15.8 (t) ppm. HRMS (ESI+): Calcd for 
C H O Na ([M + Na]21 22 4 +), 361.14228; found, 361.14103. IR (NaCl): ν  2925 (s, C-H), 2858 
(m, C-H), 1769 (m, C=O), 1729 (m, C=O), 1457 (w), 1368 (m), 1186 (m), 1152 (s), 1082 (w) 
cm-1.  UV (MeOH): λmax 245, 306, 319 nm. Purity trace: RPHPLC-ESI (Sunfire® C18 5 μm,
46x250 mm, acetonitrile/H
 
2O gradient from, 70:30 to 100:0, 25 min, 1 mL/min, tR= 11.5 min; 
> 99% purity). The J
R
17.6T Varian INOVA NMR Spectrometer operating at 750 MHz, C D ). 
3
H-C determined with the EXSIDE experiment allowed to assign the 
geometry of the double bond to Z ( J3 H-C = 3.06 Hz, splittig signal at 73.78 ppm measured in a 
6 6
 
tert-Butyl (8E)-8-Acetoxy-9-(naphtalen-2’-yl)-8-en-4,6-diynoate (20). Following the general 
procedure described above for the Dess-Martin oxidation, the reaction of tert-butyl 8-hydroxy-
9-(naphtalen ’-yl)nona-4, 6-diynoate (SI-22) (0.19 g, 0.57 mmol) and Dess-Martin -2
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periodinane reagent (0.36 g,  0.85 mmol) in CH2Cl2 (51 mL) at 0 ºC afforded  0.24 g of a  
residue which was used in the next step without further purification.  
Following the general procedure described above for the synthesis of enolacetates, the reaction 
of the residue obtained above (0.24 g), Et3N (0.40 mL, 2.84 mmol), DMAP (0.035 g, 0.28 
mmol) and acetic anhydride (0.32 mL, 3.41 mmol) in CH2Cl2 (15 mL) afforded, after 
purification by column hromatography (silica gel, 80:20 hexane/EtOAc), 0.07 g (32% over  c
two steps) of the title compound as a white solid. M.p.: 125-127 ºC (hexane/CH2Cl2). 1H-
NMR (400.13 MHz, C6D6): δ 7.58 (s, 1H, H1’), 7.55-7.45 (m, 4H, ArH), 7.25-7.18 (m, 2H, 
ArH), 6.49 (s, 1H, H9), 2.21 (t, J = 7.1 Hz, 2H, 2H3), 2.04 (t, J = 7.1 Hz, 2H, 2H2), 1.63 (s, 3H, 
COCH3), 1.34 (s, 9H, C(CH3)3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 170.1 (s), 166.9 (s, 
OCOCH3), 133.7 (s), 133.6 (s), 131.4 (s), 130.1 (s), 129.8 (d), 128.8 (d), 128.4 (d), 128.2 (d), 
128.0 (d), 127.0 (d), 126.6 (d), 126.5 (d), 86.0 (s), 80.4 (s, C(CH3)3), 77.2 (s), 71.6 (s), 66.0 (s), 
33.8 (t), 28.0 (q, C(CH3)3), 20.1 (q, OCOCH3), 15.8 (t) ppm. HRMS (ESI+): Calcd for 
C25H25O4 ([M + 1]+), 389.17469; found, 389.17474. IR (NaCl): ν  2924 (s, C-H), 2855 (m, C-
H), 1752 (m, C=O), 1723 (m, C=O), 1460 (w), 1202 (w), 1154 (w) cm-1.  UV (MeOH): λmax 
246, 282, 320 nm. Purity trace: RPHPLC-ESI (Sunfire® C18 5 μm, 46x250 mm, 
acetonitrile/H2O gradient from 70:30 to 100:0, 25 min, 1 mL/min, tR= 11.5 min; 96% purity). 
The J
R
3
H-C determined with the EXSIDE experiment allowed to assign the geometry of the 
double bond to Z ( J3 H-C = 2.62 Hz, splittig signal at 73.32 ppm measured in a 17.6T Varian 
INOVA NMR Spectrometer operating at 750 MHz, C6D6). 
Degradation of the pyridine analogue was observed at the Dess-Martin oxidation step. In the 
case of the benzothiophene analogue, decomposition of the final product ocurred during the 
final enol acetate formation step. 
Scheme SI5.3 Synthesis of ketone 23. 
 
Methyl 4-Pentynoate (SI-24). To a stirred solution of 4-pentynoic acid (0.4 g, 4.08 mmol) 
in MeOH (8 mL) and benzene (28 mL) TMSCHN2 (2.6 mL, 2 M in hexanes, 5.30 mmol) 
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was added dropwise at 25 ºC and the resulting mixture was stirred for 2h. After completion 
of the reaction the solvent was evaporated to afford 0.44 g (96%) of a colourless oil that 
was identified as methyl 4-pentynoate and was used in the next step without further 
purification. 1H-NMR (400.13 MHz, C6D6): δ 3.26 (s, 3H, OCH3), 2.25 – 2.17 (m, 2H, 
2H2), 2.17 – 2.10 (m, 2H, 2H3), 1.73 (t, J = 2.6 Hz, 1H, H5) ppm. 13C-NMR (100.62 MHz, 
C6D6): δ 171.5 (s, C1), 82.7 (s, C4), 69.4 (d, C5), 51.2 (q, CO2CH3), 33.1 (t, C2), 14.5 (t, 
C3) ppm. HRMS (ESI+): Calcd for C6H8O2Na ([M + Na]+), 135.04165; found, 
135.04133. IR (NaCl): ν  2956 (w, C-H), 1739 (s, C=O), 1439 (w), 1366 (w), 1252 (w), 
1218 (w), 1170 (w), 771 (s)  cm-1.  
 
Methyl 5-Iodo-4-pentynoate (SI-25). Following the general procedure described above for 
the iodination of terminal alkynes, the reaction of methyl 4-pentynoate (SI-24) (0.34 g, 3.01 
mmol), NIS (0.81 g, 3.61 mmol) and AgNO3 (0.51 g, 3.01 mmol) in acetone (4.4 mL) 
afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 0.42 
g (60%) of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 3.63 (s, 
3H, OCH3), 2.60 (t, J = 7.5 Hz, 2H, 2H2), 2.47 (t, J = 7.2 Hz, 2H, 2H3) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 172.0 (s, C1), 92.3 (s, C4), 51.9 (q, CO2CH3), 33.0 (t, C2), 16.6 (t, 
C ), -4.8 (s, C ) ppm. MS (EI3 5 +): m/z (%) 239 (M+ + 1, 0.3), 238 (M+, 2), 237 (M+ - 1, 2), 211 
(6), 210 (100), 207 (23), 179 (29), 165 (26), 128 (8), 127 (24), 111 (8), 86 (10), 84 (13). 
HRMS (EI+): Calcd for C6H7IO2 ([M]+), 237.9491; found, 237.9480. IR (NaCl): ν  2952 (w, 
C-H), 1736 (s, C=O), 1437 (m), 1364 (m), 1201 (m), 1170 (m), 1024 (w) cm-1. UV (MeOH): 
λmax 237 nm.  
 
Methyl 8-Hydroxy-tricosa-4,6-diynoate (SI-26). Method A. Following the general 
procedure described above for the synthesis of unsymmetric 1,3-diynes, the reaction of 
octadec-1-yn-3-ol (12) (0.10 g, 0.52  mmol), methyl 4-pentynoate (SI-24) (0.29 g, 2.60 mmol), 
CuI (5 mol%) and NiCl2.6H2O (5 mol%) in THF (4 mL) and TMEDA (16.0 μL) afforded, 
after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 0.16 g (42%) 
of the titled compound as a pink solid.  
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Method B. Following the general procedure described above for the Cadiot-Chodkiewicz 
cross-coupling, the reaction of octadec-1-yn-3-ol (12) (0.24 g, 0.90  mmol) and methyl 5-iodo-
4-pentynoate (SI-25) (0.21 g, 0.90 mmol) in degassed piperidine (1 mL) afforded, after 
purification by column chromatography (silica gel, 80:20 hexane/EtOAc; then reverse phase, 
100% acetonitrile), 0.21 g (64%) of the titled compound as a pink solid. 1H-NMR (400.13 
MHz, CDCl ): δ 4.34 (t, J = 6.5 Hz, 1H, H ), 3.67 (s, 3H, OCH ), 2.64 – 2.49 (m, 4H, 2H  + 
2H ), 1.73 – 1.58 (m, 2H, 2H ), 1.45 – 1.32 (m, 2H, 2H ), 1.33 – 1.14 (m, 24H, 12 x -CH -), 
0.84 (t, J = 6.8 Hz, 3H, CH ) ppm. 
3 8 3 2
3 9 10 2
3
13C-NMR (100.62 MHz, CDCl ): δ 172.1 (s, C ), 78.9 (s), 
77.5 (s), 69.4 (s), 65.3 (s), 62.7 (d, C ), 52.0 (q, CO C
3 1
8 2 H ), 37.6 (t), 32.7 (t), 32.0 (t), 29.83  (t, 
4x), 29.7 (t, 2x), 29.6 (t), 29.5 (t), 29.4 (t), 29.3 (t), 25.1 (t), 22.7 (t), 15.2 (t), 14.2 (q)  ppm. 
HRMS (EI+): Calcd for C24H40O3Na ([M + Na]+), 399.28697; found, 399.28771. IR 
(NaCl): ν  3500−3100 (br, Ο−Η), 2957 (w, C-H), 2915 (s, C-H), 2847 (m, C-H), 1731 (m, 
C=O) cm-1. UV (MeOH): λmax 226, 241, 254 nm.  
 
Methyl 8-Oxo-tricosa-4,6-diynoate (23). To a stirred solution of oxalyl chloride (62 μL, 0.09 
g, 0.71 mmol) in CH2Cl2 (2 mL) at – 60 ºC, DMSO (94 μL,  0.10 g, 1.22 mmol) was added 
dropwise and the reaction was stirred for 5 min at this temperature. Then, a solution of methyl 
8-hydroxy-tricosa-4,6-diynoate (SI-26)  (0.19 g, 0.51 mmol) in CH2Cl2 (7 mL) was added. 
After stirring for 30 min, Et3N (0.47 mL, 0.34 g, 3.35 mmol) was added and the reaction was 
stirred for 10 min at -60 ºC. The mixture was allowed to warm to room temperature, poured 
into water and extracted with CH2Cl2 (3x). The combined organic layers were dried over 
Na2SO4 and the solvent was evaporated. The residue was purified by column chromatography 
(silica gel, 60:40 hexane/EtOAc) to afford 0.16 g (86%) of the titled compound as a yellow 
solid. 1H-NMR (400.13 MHz, CDCl3): δ 3.72 (s, 3H, OCH3), 2.70 (t, J = 7.1 Hz, 2H, 2H2 or 
2H3), 2.60 (t, J = 7.4 Hz, 2H, 2H2 or 2H3), 2.55 (t, J = 7.4 Hz, 2H, 2H9), 1.70 – 1.59 (m, 2H, 
H10), 1.35 – 1.18 (m, 24H, 12 x -CH2-), 0.88 (t, J = 6.7 Hz, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 187.4 (s, C8), 171.6 (s, C1), 87.8 (s), 75.5 (s), 72.8 (s), 64.6 (s), 52.2 
(q, CO2C
2
H3), 45.6 (t), 32.3 (t), 32.0 (t), 29.8 (t, 5x), 29.7 (t), 29.5 (t, 2x), 29.4 (t), 29.0 (t), 24.1 
(t), 22.8 (t), 15.6 (t), 14.2 (q) ppm. HRMS (ESI+): Calcd for C24H38O3Na ([M + Na]+), 
397.27132; found, 397.27236. IR (NaCl): ν 2924 (s, C-H), 2853 (m, C-H), 2237 (w, C≡C), 
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2145 (w, C≡C), 1745 (m, C=O), 1674 (m, C=O) cm-1. UV (MeOH): λmax  226, 254, 267, 283 
nm.  
 
Scheme S4. Synthesis of ketone 24. 
 
1-(Tert-butyldiphenylsilyloxy)-4-pentyne (SI-27). To a cooled (0 ºC) stirred solution of pent-
t was cooled down to 0 ºC, a saturated aqueous 
solution of NaHCO3 was added and the mixture was extracted with Et2O (3x). The combined 
organic layers were washed with brine, dried and the solvent was evaporated. The residue was 
purified by column chromatography (silica gel, 75:25 hexane/EtOAc) to afford 0.33 g (86%) 
of the titled product as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.69 – 7.63 (m, 4H, 
ArH), 7.46 – 7.34 (m, 6H, ArH), 3.74 (t, J = 6.0 Hz, 2H, 2H1), 2.34 (td, J = 7.2, 2.6 Hz, 2H, 
2H3), 1.91 (t, J = 2.7 Hz, 1H, H5), 1.81 – 1.72 (m, 2H, 2H2), 1.04 (s, 9H) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 135.7 (d, 4x), 133.9 (s, 2x), 129.7 (d, 2x), 127.8 (d, 4x), 84.3 (s), 68.5 
(d), 62.4 (t), 31.6 (t), 27.0 (q), 19.4 (s), 15.1 (t) ppm. HRMS (ESI+): Calcd for C21H26OSiNa 
([M + Na]+), 345.16451; found, 345.16450. IR (NaCl): ν 3304 (w, C≡C−Η), 3069 (w), 2953 
(w, C-H), 2934 (w, C-H), 2860 (w), 1468 (w), 1428 (w), 1107 (s), 981 (w) cm-1.   
4-yn-1-ol (0.1 g, 1.19 mmol) in CH2Cl2 (4.3 mL) was added DMAP (8 mg, 0.06 mmol), Et3N 
(0.25 mL, 0.18 g, 1.82 mmol) and tert-butylchlorodiphenylsilane (0.38 mL, 0.40 g, 1.47 
mmol). After 24h at room temperature, i
 
1-Tert-butyldiphenylsilyloxy-5-iodopent-4-yne (SI-28). To a stirred solution of 1-tert-
column chromatography (90:10 hexane/CH2Cl2) to afford 0.11 g (60%) of the titled 
compound as a yellow oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.71 (dd, J = 7.5, 1.6 Hz, 4H), 
7.50 – 7.40 (m, 6H), 3.77 (t, J = 5.9 Hz, 2H, 2H1), 2.57 (t, J = 7.1 Hz, 2H, 2H3), 1.84 – 1.75 
butyldiphenylsilyloxy-4-pentyne (SI-27) (0.13 g, 0.40 mmol) in acetone (1 mL), NIS (0.11 g, 
0.48 mmol) and AgNO3 (0.07 g, 0.40 mmol) were added and the reaction was stirred 
overnight at room temperature. The solvent was evaporated and the residue was purified by 
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(m, 2H, 2H2), 1.09 (s, 9H) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 135.7 (d, 4x), 133.8 (s, 
2x), 129.7 (d, 2x), 127.8 (d, 4x), 94.4 (s), 62.2 (t), 31.4 (t), 27.0 (q), 19.4 (s), 17.5 (t), -7.0 (s, 
C5) ppm. HRMS (ESI+): Calcd for C21H26IOSi, 449.07921; found, 449.07845. IR (NaCl): 
ν 3062 (w, C-H), 2936 (m, C-H), 2861 (m), 1467 (w), 1430 (w), 1105 (s), 997 (w), 953 (w) 
cm-1.   
 
1-(Tert-butyldiphenylsilyloxy)-tricosa-4,6-diyn-8-ol (SI-29). Following the general 
procedure described above for the Cadiot-Chodkiewicz cross-coupling, the reaction of 
l, 95:5  hexane/EtOAc), 0.70 g (71%) of the titled compound 
as a colourless oil. 1H-NMR (400.13 MHz, C6D6): δ 7.76 – 7.70 (m, 4H, ArH), 7.29 – 7.22 
(m, 6H, ArH), 4.16 – 4.08 (m, 1H, H8), 3.56 (t, J = 5.9 Hz, 2H, 2H1), 2.20 (t, J = 7.0 Hz, 2H, 
2H3), 1.61 – 1.54 (m, 2H, 2H2 or 2H9), 1.54 – 1.46 (m, 2H, 2H2 or 2H9), 1.43 – 1.16 (m, 26H, 
13x-CH2-), 1.13 (s, 9H, SiC(CH3)), 0.92 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 
MHz, C6D6): δ 136.0 (d, 4x), 134.1 (s, 2x), 130.0 (d, 2x), 128.1 (d, 4x), 81.2 (s), 77.9 (s), 70.4 
(s), 66.0 (s), 62.9 (d, C8), 62.3 (t), 38.0 (t), 32.4 (t), 31.4 (t), 30.2 (t, 5x), 30.1 (t, 2x), 30.0 (t), 
29.9 (t), 29.7 (t), 27.1 (q, 3x, C(C
octadec-1-yn-3-ol (12) (0.45 g, 1.68 mmol) and 1-tert-butyldiphenylsilyloxy-5-iodopent-4-yn 
(SI-28) (0.75 g, 1.68 mmol) in degassed piperidine (1.3 mL) afforded, after purification by 
column chromatography (silica ge
H3)3), 25.5 (t), 23.2 (t), 19.5 (s, C(CH3)3), 16.0 (t), 14.4 (q) 
ppm. HRMS (ESI+): Calcd for C39H59O2Si ([M + 1]+), 587.42788; found, 587.42672. IR 
(NaCl): ν  3400−3100 (br, O-H), 2925 (s, C-H), 2854 (m, C-H), 1466 (w), 1110 (m) cm-1.  
 
1-(Tert-butyldiphenylsilyloxy)-tricosa-4,6-diyn-8-one (24). Following the general procedure 
described above for the Swern oxidation, the reaction of 1-(tert-butyldiphenylsilyloxy)-tricosa-
4,6-diyn-8-ol (SI-29) (0.70 g, 1.20  mmol), oxalyl chloride (145 μL, 0.21 g, 1.68 mmol), 
DMSO (0.22 mL,  0.22 g, 2.87 mmol), Et3N (1.10 mL, 0.80 g, 7.90 mmol) in CH2Cl2 (22 mL) 
afforded, after purification by column chromatography (silica gel, 85:15 hexane/EtOAc), 0.43 
g (62%) of the titled compound as a yellow oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.68 (dd, J 
= 7.7, 1.2 Hz, 4H, ArH), 7.49 – 7.36 (m, 6H, ArH), 3.75 (t, J = 5.8 Hz, 2H, 2H1), 2.63 – 2.49 
(m, 4H, 2H3 + 2H9), 1.88 – 1.75 (m, 2H, 2H2), 1.75 – 1.62 (m, 2H, 2H10), 1.36 – 1.21 (m, 
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24H, 12 x -CH2-), 1.08 (s, 9H, SiC(CH3)), 0.90 (t, J = 6.7 Hz, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 187.5 (s), 135.6 (d, ), 133.6 (s, 2x), 129.8 (d, 2x), 127.8 (d, 4x), 
9  
(t), 29.7 (t), 29.6 (t),
4x
0.3 (s), 76.2 (s), 72.4 (s), 64.1 (s), 62.0 (t), 45.7 (t) , 32.0 (t), 30.7 (t), 29.8 (t, 4x), 29.8 (t), 29.8
 29.5 (t), 29.4 (t), 29.1 (t), 26.9 (q, 3x, C(CH3)3), 24.1 (t), 22.8 (t), 19.3 (s, 
C(CH3  1]+), 
585.412
2854 (s, C m-1. UV 
(MeOH): λmax  256, 269, 285 nm. 
 
)3), 16.4 (t), 14.3 (q) ppm. HRMS (ESI+): Calcd for C39H57O2Si ([M +
23; found, 585.41177. IR (NaCl): ν 3071 (w, C-H), 3049 (w, C-H), 2925 (s, C-H), 
-H), 2233 (s, C≡C), 2143 (w, C≡C), 1672 (s, C=O), 1110 (s), 702 (s) c
 
Figure SI5.1 Western Blot analysis of U937 cells treated with the compounds or controls at 5 or 50 µM for 
24 hours. p21 (A) and Bcl-2 (B) expression in total cell lysates from U937 cells stimulated with the indicated 
compounds. ERK1 is used to normalize loading. 
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Figure SI5.2 Western Blot analysis of U937 cells treated with the compounds at 5 or 50 µM for 24 hours. 
Acetylation of tubulin in total cell lysates from U937 cells stimulated with the indicated compounds (A); 
acetylation of histone H3 in histonic extracts from U937 cells stimulated with the indicated compounds (B). 
ERK1 is used to normalize loading. 
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Figure SI5.3 Toxicities of diynone 8 and 5-aza-2’-deoxycytidine (5-aza) for primary and immortalized 
MEFs. Phase-contrast views of normal ("MEFs CD1") and immortalized ("MEFs immo") mouse fibroblasts 
treated with 10 µM of 5-aza 1, compound 8 or DMSO as vehicle control for 72h. Photos were taken 1hour 
after changing the cell culture media.  
  
 
6. A SURVEY OF SYNTHETIC APPROACHES 
TO NATURAL (PEYSSONENYNES) AND 
UNNATURAL ACETOXYENEDIYNES 
 
 
 
Four convergent synthetic approaches to acetoxyenediynes have been explored to gain 
access to the peyssonenynes A and B, which are natural products isolated from the red alga 
Peyssonelia caulifera. After optimization of the routes with a palmitic-acid-based model 
system, the synthesis of the peyssonenynes has been completed using as key steps: (a) a 
Ni/Cu co-catalyzed cross-coupling of terminal alkynes, (b) a Sonogashira cross-coupling, 
(c) the addition of a diynyl anion to a Weinreb amide, and (d) the previously reported 
Cadiot–Chodkiewicz cross-coupling. Since bulky amide bases provided stereoselectively 
the E and Z acetoxyenynes from the precursor ynones, the cross-coupling routes using 
these stereochemically homogenous intermediates to obtain the acetoxyenediynes are more 
efficient than the alternatives in which the enolacetate formation of the acetoxyenediyne 
motif takes place late-stage in the synthesis. 
 

Synthetic Approaches to Acetoxyenediynes 
6.1 Introduction 
Peyssonenynes A and B 1a (Scheme 6.1) are oxylipin metabolites that were 
isolated in 2004 from the Fijian red marine alga Peyssonelia caulifera.1 The structures 
were proposed to correspond to the Z and E isomers, respectively, for peyssonenynes A 
and B (Z-1a and E-1a), at the enol acetate bond. The acetoxyenediyne motif, which 
presumably is generated biosynthetically by dehydrogenation of a ω3 polyunsaturated fatty 
acid, was unprecedented at the time of the discovery of 1a. The diyne moiety,2 is also quite 
uncommon among the structurally diverse oxylipins, as is the monoacyl glycerol 
functionality in red algae metabolism.3 All of these structural features make 
peyssonenynes particulary appealing from the chemical and biogenetic perspectives.4  
Of additional interest was the finding that peyssonenynes 1a exhibit DNA methyl 
transferase 1 (DNMT1) inhibitory activity.  DNMT1 is a member of the DNA methyl 
5
omic/parental 
imprin
e
transferase protein family,  which in mammals is responsible for the methylation of the 
cytosine residues at their C5 positions, primarily in the CpG dinucleotides and only 
occasionally at non-CG sites. The methylation of DNA, the most widely studied epigenetic 
modification, is involved in the control of gene expression, regulation of gen
ting, stabilization of X chromosome inactivation and maintenance of the genome 
integrity. This process is also implicated in the development of the immune system and in 
cellular reprogramming, as well as in brain function and behavior.6 Aberrant patterns of 
DNA methylation are associated with several neurological disorders and autoimmune 
diseases and are also involved in cancer initiation and progression. 7 Cancer cells often 
show genome-wide hypomethylation and site-specific hypermethylation 
. 
DNMTs inhibitors might reactivate the silenced tumor suppressors or several DNA repair 
                                                
of DNA promot r 
regions (in particular, of tumor suppressor genes), which are normally unmethylated
 
1 McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H. J. Nat. Prod. 2004, 67, 1010. 
i, R. R. Acetylene Chemistry: Chemistry, Biology and Material 
3 a. Jiang, Z. D.; Gerwick, W. H. Lipids 1991, 26, 960. b. Jiang, Z. D.; Gerwick, W. H. Phytochemistry 1990, 
29, 1433
4 Minto,
l Bi .
2 Diederich, F.; Stang, P. J.; Tykwinsk
Science; Wiley-VCH: Weinheim, 2005. 
. c. Paul, V. J.; Fenical, W. Tetrahedron Lett. 1980, 21, 3327. 
 R. E.; Blacklock, B. J. Prog. Lip. Res. 2008, 47, 233. 
5 a. Cheng, X.; Blumenthal, R. M. Structure 2008, 16, 341. b. Hellebrekers, D. M. E. I.; Griffioen, A. W.; van 
Engeland, M. Biochim. Biophys. Acta (BBA) – Rev. Cancer 2007, 1775, 76. 
6 Jurkowska, R. Z.; Jurkowski, T. P.; Jeltsch, A. ChemBioChem 2011, 12, 206. 
7 a. De Carvalho, D. D.; You, J. S.; Jones, P. A. Trends Cel ol  2010, 20, 609. b. Portela, A.; Esteller, M. 
Nat. Biotech. 2010, 28, 1057. 
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genes and therefore are novel and promising anticancer drugs8 that in combination with 
other therapies could lead to growth inhibition of tumor cells or alteration of their 
sensitivity to other anticancer therapies.9  
The interest of our group in the development of new epigenetic modulators inspired 
by the structures of natural products10 prompted us to synthesize the four possible 
stereoisomers (geometric isomers and enantiomers at the glycerol moiety) of the proposed 
structure following the approach indicated in Scheme 6.1 (see A in Scheme 6.2).11 The 
four stereoisomers proved to be roughly equipotent when tested in radioactive DNMT1 
enzymatic assays and showed similar biological activities in the cell cycle, cell 
differen
e developed unambiguous 
methods for the determination of the geometries of synthetic acetoxyenynes and 
acetoxyenediynes. Both the value of 3JH-C calculated using EXSIDE (Excitation-sculptured 
Indirect Detection Experiment)12 and the value of the chemical shift of the C6 carbon of 
the alkyne attached to the enolacetate unit are useful fingerprints of the acetoxyenediyne 
geometrical isomers.13 The application of the spectroscopic analysis to the natural 
peyssonenynes isolated by Gerwick et al.1 from Peyssonelia caulifera led us to propose 
that the natural compounds are not geometric isomers at the enol acetate unit, but 
regioisomers of the Z enolacetate at the glycerol moiety (i.e., the sn-1,3 Z-1a and the sn-2 
Z-2a positional isomers). The finding that both isomers interconvert rapidly in solution11b 
(and possibly on the time scale of the biological tests) lend further support to the observed 
tiation and apoptosis of K562 human leukemia cells. Neither the enol acetate 
geometry nor the configuration of the glycerol stereocenter appears to play important roles 
in the activity of these compounds.11 Moreover, after noticing spectroscopic 
inconsistencies between the synthetic and natural products, w
lack of enantiomeric discrimination by the DNMT1 enzyme.  
                                                 
8 a. Kelly, T. K.; De Carvalho, D. D.; Jones, P. A. Nat. Biotech. 2010, 28, 1069. b. Rodriguez-Paredes, M.; 
.; Jung, M. Epigenetic Targets in Drug Discovery; Wiley-
rmacol. Toxicol. 2009, 49, 243. 
9 Goll, M. G.; Kirpekar, F.; Maggert, K. A.; Yoder, J. A.; Hsieh, C.-L.; Zhang, X.; Golic, K. G.; Jacobsen, S. 
; de Lera, 
A. R. J. e
L.; de L
M
11 a. García, P.; Franco, P.; Álvarez, R.; de Lera, Á. R. J. Sep. Sci. 2011, 34, 999. b. Garcia-Dominguez, P.; 
Lepore, I.; Erb, C.; Gronemeyer, H.; Altucci, L.; Alvarez, R.; de Lera, A. R. Org.Biomol. Chem. 2011, 9, 
6979. 
astor, M.; de Lera, Á. R.; Álvarez, R. Mag. Res. Chem. 2010, 48, 543. 
Esteller, M. Nat. Med. 2011, 17, 330. c. Sippl, W
VCH: Weinheim, 2009. d. Szyf, M. Ann. Rev. Pha
E.; Bestor, T. H. Science 2006, 311, 395. 
10 a. Perez-Balado, C.; Nebbioso, A.; Rodriguez-Grana, P.; Minichiello, A.; Miceli, M.; Altucci, L.
Med. Chem. 2007, 50, 2497. b. Souto, J. A.; Bened tti, R.; Otto, K.; Miceli, M.; Álvarez, R.; Altucci, 
era, A. R. ChemMedChem 2010, 5, 1530. c. Souto, J. A.; Conte, M.; Álvarez, R.; Nebbioso, A.; 
Carafa, V.; Altucci, L.; de Lera, A. R. Chem edChem 2008, 3, 1435. d. Souto, J. A.; Vaz, E.; Lepore, I.; 
Pöppler, A.-C.; Franci, G.; Álvarez, R.; Altucci, L.; de Lera, A. R. J. Med. Chem. 2010, 53, 4654. 
12 Krishnamurthy, V. V. J. Magn. Res. A 1996, 121, 33. 
13 García, P.; Martín-P
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Scheme
rat
6.2 Results and discussion 
njugated to 
xplored, and these involved Csp–Csp (with variants labeled as A and B) 
 6.1. Original structures proposed for the peyssonenyne A (Z-1a, the sn-1 or sn-3 glycerol Z-
acetoxyenediyne fatty acid) and the peyssonenyne B (E-1a, the sn-1 or sn-3 glycerol E-acetoxyenediyne fatty 
acid), and the corrected structure of the latter (Z-2a, the sn-2 glycerol Z-acetoxyenediyne fatty acid). The 
first-gene ion approach to the proposed structure of these natural products is also shown.11 
Given the unprecedented acetoxyenendiyne functionality, which has only been 
found thus far in these natural products, and their biological relevance of these compounds 
as inhibitors of the epigenetic enzyme DNMT1, we have carried out in-depth synthetic 
studies into complementary strategies to gain access to sufficient amounts of the target 
compounds for biological evaluation as well as to pave the way for the synthesis of 
analogs. In this full account of the synthetic work (for the first synthetic approach, see 11) 
we report on the preparation of natural and unnatural acetoxyenediynes, represented by the 
peyssonenynes and their analogs derived from palmitic acid, respectively. The latter 
compound was used as a model system to optimize the synthetic approaches. The 
advantages and limitations of the routes studied will be discussed.  
It was clear at the outset that the most challenging task to synthesize the target 
s
the diyne functionality. In principle, two general convergent strategies to obtain this 
arrangement were e
tructures was the stereoselective construction of the E and Z-enol acetates co
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or Csp2–Csp (labeled as C and D) bond formation processes. In the first-generation 
approach (A in Scheme 6.2, see also Scheme 6.1) the Csp–Csp bond was constructed using 
a Cadiot-Chodkiewicz cross-coupling reaction14between iodoalkyne 4 and propargylic 
alcohol 3a. We have also explored the stereoselective formation of the acetoxyenynes 5 
prior to the Cadiot–Chodkiewicz Pd-Cu co-catalyzed cross-coupling reaction (B). It was 
envisaged that the alternative Csp2–Csp bond formation could be achieved by the 
Sonogashira cross-coupling between diyne 7 and pre-formed α-chloroenol acetates (8) (C) 
or by the addition of the diynyl anion derived from 7 to a Weinreb amide (6 (D). The ) 
synthetic survey benefits from the common use of intermediates in some of the routes.  
Moreover, in order to streamline these alternative pathways and compare their 
efficacy, the skipped diene chain of the peyssonenynes (system a)11was replaced with a 
saturated model system (system b), which was conveniently derived from palmitic acid. 
Protected glycerol was used in any of the enantiomeric forms. 
 
Scheme 2. Retrosynthetic analysis of the acetoxyenediynes and proposed precursors for the synthesis 
followin
s 
g variants A, B, C and D based on the two key disconnections shown.  
6.2.1 Csp-Csp bond formation strategie
A. Cadiot–Chodkiewicz cross-coupling of a iodoalkyne and a propargylic alcohol 
Variant A in Scheme 6.2, in which the Csp–Csp bond formation step uses a Cadiot–
Chodkiewicz cross-coupling reaction14between iodoalkyne 4 and propargylic alcohol 3a 
                                                 
14 a. Chodkiewicz, W. Ann. Chim. 1957, 2, 819. b. Chodkiewicz, W.; Cadiot, P. C. R. Hebd. Seances Acad. 
Sci. 1955, 241, 1055. 
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has already been successfully executed (see Scheme 6.1).11 The enol acetates were 
generated at a late stage in the sequence, albeit with poor (2:1) E/Z diastereoselectivity.  
B. Cadiot-Chodkiewicz cross-coupling of iodoalkynes and acetoxyenynes 
The implementation of variant B required the stereoselective synthesis of the 
acetoxyenynes 11b from propargylic ketone 10b. Treatment of 10b, which was prepared in 
two steps from palmitic acid 9b (Scheme 6.3),11with Ac2O, Et3N and DMAP15under a 
variety of conditions provided in quantitative yields enol acetate 11b but disappointingly as 
50:50 mixtures of isomers. Treatment of the unsaturated ketone 10b with Ac2O in EtOAc 
containing a catalytic amount of perchloric acid16 led to improved (27:73) Z/E selectivity 
but the yield was low (43%). Higher concentrations of HClO4 (0.01M) helped shorten the 
reaction time and led to higher E selectivity (26:74 after 4 , 53%; 11:89 after 24 h, 84%) 
but some degradation of the starting material and products was noted.  
The use of lithium amides for the generation of the enolacetates of 10b provided 
better results, as shown in Table 6.1.
h
onditions (–78 ºC) enol 
acetates 11b were generally obtained in good yields and with high selectivities. Trapping 
with Ac2O of the enolates generated using common lithium diisopropylamide (LDA) alone 
or in the presence of the cation solvating agent 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-
pyrimidinone (DMPU) afforded a mixture of the E/Z enolacetates 11b with moderate and 
opposite diastereoselectivities in good yields (entries 1 and 2). Also an opposite 
stereochemical outcome could be obtained with the bulkier lithium 
bis(dimethylphenylsilyl)amide (11b 72:28 Z/E ratio) and lithium bis(trimethylsilyl)amide 
(11b 7:93 Z/E ratio) in almost quantitative yields (entries 3 and 4). Lithium 2,2,6,6-
tetramethylpiperidide (LTMP) gave also excellent E stereoselectivity (entry 5), which 
could be improved in the presence of LiBr, but at the cost of decrease in yield (entry 6). 
The addition of DMPU as co-solvent had a detrimental role in this case (entry 7). The 
results are consistent with those previously reported for the formation of enol acetates 
                                                
17 Under kinetic control c
 
15 Compernolle, F.; Toppet, S.; Brossette, T.; Mao, H.; Koukni, M.; Kozlecki, T.; Medaer, B.; Guillaume, M.; 
Lang, Y.; Leurs, S.; Hoornaert, G. J. Eur. J. Org. Chem. 2006, 2006, 1586. 
16 Tochtrop, G. P.; DeKoster, G. T.; Cistola, D. P.; Covey, D. F. J. Org. Chem. 2002, 67, 6764. 
 Am. 
t, T.; Mukhopadhyay, T.; Simson, 
. 
7516. 
17 a. Bartlett, P. A. Tetrahedron 1980, 36, 2. b. Evans, D. A.; Dart, M. J.; Duffy, J. L.; Yang, M. G. J.
Chem. Soc. 1996, 118, 4322. c. Juaristi, E.; Beck, A. K.; Hansen, J.; Mat
M.; Seebach, D. Synthesis 1993, 1993, 1271 . d. Xie, L.; Isenberger, K. M.; Held, G.; Dahl, L. M. J. Org
Chem. 1997, 62, 
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starting from ketones with non-bulky substituents,18 and can be rationalized using the 
transition state model proposed by Ireland.19 The geometry of the chromatographically 
separated double-bond isomers was assigned by analysis of the NOE experiments. 
 
Scheme 6.3. Reagents and reaction conditions: (a) EDC, DMAP, HN(OMe)Me . HCl, CH2Cl2, 25 ºC 
(>99%). (b) n-BuLi, THF, –40 to 25 ºC (92%). (c) Et3N, DMAP, Ac2O, CH2Cl2, 25 ºC, 44 h (57%, 50:50 
Z/E). (d) HClO4, Ac2O, EtOAc, 25 ºC, 4 h (43%, 17:83 Z/E). (e) LiNR2, –78 to 0 ºC, then Ac2O, see Table 
6.1. (f) n-Bu4NF, THF, 25 ºC, 0.5 h (63% Z-5b; 69% E-5b). DMAP = 4-(N,N-dimethylamino)pyridine; EDC 
= 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; LDA = lithium diisopropylamide; DMPU 
= 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; TBAF = tetra-n-butylammonium fluoride. 
Table 6.1. Enol acetate formation by deprotonation of propargylic ketone 10b with lithium amide bases and 
trapping with Ac2O. 
No. LiNR2 Z/E 11b (%) 
1 LDA 20:80 84 
2 LDA/DMPU 73:27 86 
3 (Me2PhSi)2NLi 72:28 99 
4 LHMDS 7:93 98 
5 LTMP 9:91 99 
6 LTMP/LiBr <1:>99 37 
7 LTMP/DMPU 46:54 86 
 
After removing the silyl-protecting group with TBAF, the resulting acetoxyenynes 
5 were treated with iodoalkyne (R)-411b under the modified reaction conditions for the 
Cadiot–Chodkiewicz cross-coupling14 developed by Alami and Ferri20 (CuI/CuCl, 
piperidine). In contrast to the successful coupling of the same iodoalkyne (R)-4 and 
propargylic alco oh l 3a (Scheme 6.1),11b only enaminone 13b was obtained starting from 5b 
                                                 
18 a. Davis, F. A.; Yang, B. J. Am. Chem. Soc. 2005, 127, 8398. b. Hall, P. L.; Gilchrist, J. H.; Collum, D. B. 
J. Am. Chem. Soc. 1991, 113, 9571. c. Galiano-Roth, A. S.; Kim, Y. J.; Gilchrist, J. H.; Harrison, A. T.; 
Fuller, D. J.; Collum, D. B. J. Am. Chem. Soc. 1991, 113, 5053. 
19 Ireland, R. E.; Mueller, R. H.; Willard, A. K. J. Am. Chem. Soc. 1976, 98, 2868. 
20 Alami, M.; Ferri, F. Tetrahedron Lett. 1996, 37, 2763. 
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and (R)-4 (Scheme 6.4). This derivative is likely formed by 1,4-addition of the secondary 
amine to the propargylic ketone resulting from the piperidine-mediated transacylation of 
the enol acetate and tautomerization.21  
As an alternative to the Cadiot–Chodkiewicz reaction for the synthesis of 
unsymmetrical 1,3-diynes, we turned our attention to the recently reported Ni/Cu co-
catalyzed oxidative cross-coupling reaction of different alkynes.22 This methodology 
employs tetramethylethylenediamine (TMEDA) as a ligand and oxygen or air as oxidant 
and requires the use of an excess of one of the two terminal alkynes to maximize cross vs. 
homocoupling. Given the mild reaction conditions and the absence of an interfeering 
nucleophile in the reaction media, we adapted this method for the construction of the 
acetoxyenediyne motif. The reaction of Z or E-enol acetate 5b with excess (five 
equivalents) of the glycerol ester-containing alkyne (R)-1411b promoted by NiCl2 .6H2O and 
CuI in THF/TMEDA under air, led to the desired compounds (Z,R)-12b and (E,R)-12b in 
29 and 40% yield, respectively. Lastly, ketal deprotection using catalytic amounts of 
cerium (IV) ammonium nitrate (CAN)23 provided the analogs 1b. 
                                                 
21 Treatment of acetoxyenyne E-5b with piperidine for 30 minutes led to enaminone 13b in 89% yield. 
Vanherck, J.-C.; Markó, I. E. Tetrahedron 
22 Yin, W.; He, C.; Chen, M.; Zhang, H.; Lei, A. Org. Lett. 2009, 11, 709. 
23 Ates, A.; Gautier, A.; Leroy, B.; Plancher, J.-M.; Quesnel, Y.; 
2003, 59, 8989. 
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mixture of Z/E isomers). TMEDA= tetramethylethylenediamine. 
which in turn was prepared by semihydrogenation of the 1,4-diyne 15a (itself prepared 
to the skipped 1,4-
                                                
 
Scheme 6.4. Reagents and reaction conditions: (a) CuCl, piperidine, 0 ºC. (b) NiCl2 . 6H2O, CuI, TMEDA, 
THF, air, 25
The extension of this approach to the peyssonenyne natural products (series a) to 
include acetoxyenediynes required the preparation of propargylic ketone 10a. This 
compound was obtained by the addition of triisopropylsilylacetylene to Weinreb amide 6a, 
from the corresponding alkyne and propargylic bromide precursors11b) 
diene24 using the P2-Ni catalyst,25 as described in our first-generation synthesis of the 
peyssonenynes.11  
 
24 a. Caruso, T.; Spinella, A. Tetrahedron 2003, 59, 7787. b. Ege, S. N.; Wolovsky, R.; Gensler, W. J. J. Am. 
abi, J.; Martin, B.; Muller, E.; 
0, 6627. 
 
Chem. Soc. 1961, 83  3080. c. Georg Pohnert, W. B. Eur. J. Org. Chem. 2000, 2000, 1821. d. Jeffery, T.; 
Gueugnot, S.; Linstrumelle, G. Tetrahedron Lett. 1992, 33, 5757. e. Lapitskaya, M. A.; Vasiljeva, L. L.; 
Pivnitsky, K. K. Synthesis 1993, 1, 65. f. Montel, F.; Beaudegnies, R.; Kess
Wendeborn, S.; Jung, P. M. J. Org. Lett. 2006, 8, 1905. g. Sandri, J.; Viala, J.  J. Org. Chem. 1995, 6
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The lithium amides that offered the best E/Z selectivities in the case of the model 
system were selected for the generation of the enolates in the more unsaturated substrate 
10a. Although the E/Z selectivities showed the same trends as in the model system 10b, 
yields of 11a were lower [with (Me2PhSi)2NLi, 88% yield in a 79:21 Z/E ratio; with 
LHMDS, 78% yield in a <1:>99 Z/E ratio]. Moreover, separation of the isomers by flash 
chroma
f the ‘naked’ fluoride, such 
as nucleophilic substitutions, eliminations27 including the decomposition of the 
tetrabutylammonium counter-ion,28 and cyclizations.29 Therefore, we surmised that in 
aprotic reaction conditions fluoride plays the role of nucleophile towards the enol acetate, 
but also functions as a base on the acidic positions of substrate 11a. Since TMS-substituted 
alkynes can be deprotected under milder basic conditions than the more robust TIPS-
alkynes, propargylic ketone 16a was prepared by following the same sequence (Scheme 
6.5). In this case small amounts of the terminal alkynone 18a, which arises from the 
removal of the silyl group under the basic conditions used in this step, were also obtained 
together with 16a. With the same limitations indicated above, we decided to deprotect the 
TMS group at this stage and separate both terminal acetoxyenynes. However, treatment of 
16a with potassium carbonate in methanol did not afford the terminal alkyne, but led 
                                                                                                                                                   
tography was cumbersome, and the determination of the E Z ratio by integration of 
the corresponding signals in the 1H-NMR spectrum was complicated by the presence of 
additional vinylic and allylic proton resonances. Given these shortcomings we decided to 
deprotect the silyl group in the E Z mixtures and separate the terminal alkynes 5a. To our 
surprise, the deprotection of 11a in the presence of TBAF led to decomposition, probably 
due to the incompatibility of the skipped diene moiety with the basic fluoride anion. It is 
well known that the fluoride anion, given its large negative charge density, acts as a strong 
hydrogen-bond acceptor and in polar aprotic solvent as a very potent nucleophile and 
base.26 Many well-documented reactions support the basicity o
 
h. Sevin, A.; Chodkiewicz, W.; Cadiot, P. Bull. Soc. Chim. Fr. 1974, 5-6, 913. i. Sevin, MM. A.; 
Chodkiewicz, W.; Cadiot, P. Tetrahedron Lett. 1965, 6, 1953. 
25 a. Brown, C. A.; Ahuja, V. K. J. Chem. Soc., Chem. Comm. 1973, 553. b. Brown, C. A.; Ahuja, V. K. J. 
Org. Chem. 1973, 38, 2226. c. Oger, C.; Bultel-Poncé, V.; Guy, A.; Balas, L.; Rossi, J.-C.; Durand, T.; 
Galano, J.-M. Chem. Eur. J. 2010, 16, 13976. 
26 Kirsch, P. Modern Fluoroorganic Chemistry 1st ed.; WILEY-VCH: Weinheim, 2004. 
27 a. Cox, D. P.; Terpinski, J.; Lawrynowicz, W. J. Org. Chem. 1984, 49, 3216. b. Liotta, C. L.; Harris, H. P. 
J. Am. Chem. Soc. 1974, 96, 2250. 
28 a. Bartsch, R. A. J. Org. Chem. 1970, 35, 1023. b. Sharma, R. K.; Fry, J. L. J. Org. Chem. 1983, 48, 2112. 
c. Sun, H.; DiMagno, S. G. J. Am. Chem. Soc. 2005, 127, 2050. 
29 Hiroya, K.; Jouka, R.; Kameda, M.; Yasuhara, A.; Sakamoto, T. Tetrahedron 2001, 57, 9697. 
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instead to dimethyl ketal 19a.30 This product most likely originates from cleavage of the 
enol acetate followed by double conjugate addition of methanol to the unsaturated ketone. 
This reactivity parallels the behavior observed for the model system (5b) in the presence of 
Enol acetates 17a with Z and E geometries were generated using the previously 
80% yield; and 
LHMD
piperidine (see above, Scheme 6.4). 
optimized protocols (LDA/DMPU, which gave a 70:30 Z/E ratio in 
S, which afforded a <1:>99 Z/E ratio in 81% yield, followed by an Ac2O trap).  
 
Scheme 6.5. Reagents and reaction conditions: (a) Ni(OAc)2 . 4H2O, NaBH4, ethylenediamine, EtOH, 1 atm 
H2 (82% combined yield). (b) n-BuLi, THF, –40 to 25 ºC (10a,  94%; 16a, 84%). (c) LiNR 
with recovered starting material. After HPLC separation (Sunfire  5 μm, 4.6 × 250 mm, 
99:1 hexane/t-butyl methyl ether, 1 mL/min or Waters Spherisorb® 5 μm silica gel, 10 × 
2, THF, Ac2O, –
78 to 0 ºC (see text). (d) TBAF, THF, 25 ºC. (e) K2CO3, MeOH, 0 ºC (66%). (f) K2CO3, t-BuOH/H2O, 25 
ºC (61–62%). 
To circumvent the incompatibility of the acetoxyenyne moiety with nucleophiles, 
potassium carbonate in a t-BuOH/H2O mixture was used instead for TMS release,31 and 
this modification afforded the desired products 5a in moderate yields (61–62%), together 
TM
250 mm, 99:1 hexane/t-butyl methyl ether, 1.5 mL/min) each isomer was coupled to excess 
(R)-14 using the Ni/Cu co-catalyzed cross-coupling procedure to afford 12a (Scheme 6.6). 
Homocoupled products derived from the acetoxyenynes were also isolated. Lastly, 
                                                 
30 a. Greene, T. W.; Wuts, P. G. M. Green’s Protecting groups in organic synthesis 4th Edition ed.; John 
b. Perry, M. A.; Morin, M. D.; Slafer, B. W.; 
10, 132, 9591. 
 A. Organometallics 2008, 27, 5430. 
Wiley & Sons, Inc.: Hoboken, New Yersey, 2007. 
Wolckenhauer, S. A.; Rychnovsky, S. D. J. Am. Chem. Soc. 20
31 Fletcher, J. T.; Bumgarner, B. J.; Engels, N. D.; Skoglund, D.
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efficien
o steps. However, approach B is 
limited
ols 3a11and 3b (Scheme 6.6). In the case of the 
model system the yield of 20b was higher with an excess of the propargylic alcohol 3b, but 
this version is impractical in the case of the peyssonenynes since the skipped diene moiety 
is more valuable. Therefore, the use of excess (S)-14 (the S enantiomer was used for this 
study) allowed the skeleton of these compounds to be built, but the yields were lower for 
both the model system and the peyssonenynes, which confirms the limitations of the Ni/Cu 
co-catalyzed cross-coupling of alkynes22 in a complex setting.  
t CAN-mediated cleavage of the isopropylidene ketal of 12a provided 
peyssonenynes (1a) as described previously,11and therefore this constitutes a formal total 
synthesis of the natural products. Relative to the first-generation route A, strategy B is 
more convergent, more stereoselective, and saves tw
 by the moderate yield of the key condensation step. 
To complement variant A and further document the application of the reaction to 
give functionalized systems, the Ni/Cu co-catalyzed cross-coupling reaction of alkyne 14 
was also performed with propargylic alcoh
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Scheme 6.6. Rea action conditions: (a) NiC , CuI, TMEDA, THF, air, 25 ºC [(E,R)-12a, 
29%; (Z, 12a, 28 , see Sc 20a  (3 m ) CH3CN/H , 70 ºC (86% of 
a 1:2 mixture of Z/ . TMEDA = tetramethyle ine. 
6.2.2 Csp2-Csp bond formation strategies 
C. Sonogashira cross-coupling of an alkyne and an 
gents and re l2 .6H2O
R)- %; (S)-20b heme; (S)- , 20%]. (b) CAN ol% 2O
E isomers) thylenediam
α-chloroenol acetate 
Variant C in this strategy is based on a Sonogashira coupling reaction between the 
α-chloroenol ester 8 and diyne 7 (see Scheme 6.7). The main limitation found in this 
approach is the synthesis of α-chloroenol esters with the desired geometry, since only a 
method for the preparation of the Z isomers has been reported.32 
A model system was considered to optimize this bond construction step, and 
commercially available decanal 21 was chosen as the starting material. The synthesis of the 
(Z)-α-chloroenol ester (Z)-24 is shown in Scheme 6.7. The preparation of this type of 
substrate usually requires two or three steps and involves the formation of 
trihalomethylcarbinol and the derived trihalomethylcarbinol esters as intermediates.33 
Among the methods described for the synthesis of trihalomethylcarbinols the base-
promoted addition of the chloroform anion to aldehydes or ketones is the most commonly 
reported. The use of common bases such as tBuOK or NaH in DMF,34 or cyclic amidine 
bases such as DBU or DBN,35 failed to provide the decanal-derived 
trichloromethylcarbinol 22 or led to trichloromethylcarbinol ester 23, albeit in low yields. 
es the room 
temper
A more efficient method was that reported by Corey,36 which involv
ature decarboxylation of a 1:1 mixture of trichloroacetic acid and sodium 
trichloroacetate in dimethylformamide to generate the highly nucleophilic trichloromethyl 
anion. Reaction with decanal gave trichloromethylcarbinol 22 in excellent yield, and this 
was efficiently acetylated to 23 by treatment with Ac2O in pyridine.  
                                                 
32 Bejot, R.; Tisserand, S.; Reddy, L. M.; Barma, D. K.; Baati, R.; Falck, J. R.; Mioskowski, C. Angew. 
Chem. Int. Ed. 005, 44, 2008.  2
for the synthesis of alkynes and vinyl dichlorides. b. Wang, Z.; 
Campagna
1889. c. 
33 Trihalomethylcarbinols are useful intermediates in organic synthesis as they can be easily transformed into 
α-amino, α-hydroxy and α-thioacids. a. Corey, E. J.; Link, J. O. J. Am. Chem. Soc. 1992, 114, 1906. More 
recently these compounds have been used 
, S.; Yang, K.; Xu, G.; Pierce, M. E.; Fortunak, J. M.; Confalone, P. N. J. Org. Chem. 2000, 65, 
Wang, Z.; Campagna, S.; Xu, G.; Pierce, M. E.; Fortunak, J. M.; Confalone, P. N. Tetrahedron Lett. 
2000, 41, 4007.  
34 Russell, J.; Roques, N. Tetrahedron 1998, 54, 13771. 
35 Aggarwal, V. K.; Mereu, A. J. Org. Chem. 2000, 65, 7211. 
36 Corey, E. J.; Link, J. O. J. Am. Chem. Soc. 1992, 114, 1906. 
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Compound 23 was subjected to the conditions for the chromous chloride-induced 
synthesis of (Z)-α−haloenol esters [and (Z)-β-haloenol ethers] from 
trichloromethylcarbinol esters developed by Falck, Mioskowski and coworkers32and this 
produced (Z)-24 stereoselectively in good yield (88%).  
Given the scarcity of data on the reactivity of (Z)-α-chloroenolesters,32 and the lack 
of precedents for their use in cross-coupling reactions, we adopted the conditions described 
for the Sonogashira cross-coupling of the structurally related 4,6-dichloro-2-pyrones or 6-
chloro-2-pyrones with terminal alkynes.37  
OAc
Cl
TIPS
AcO
TIPS
Table 6.2
H
O
6 CCl3
OH
6 CCl3
O
6
O
21 22 23
(Z)-24(E)-25
a b
c
d
 
Scheme 6.7. Reagents and reaction conditions: (a) Cl3CCO2H/Cl3CCO2Na (1:1), DMF, 25 ºC, 14 h (94%). 
(b) Ac2O, pyridine, 25 ºC, 24 h (94%). (c) i. DBN, CHCl3, 25 ºC; ii. Ac2O (31%). (d) CrCl2, THF, reflux, 72 
h (88%). (e) See Table 6.2.  
Table 6.2. Conditions for the Sonogashira cross-coupling of α-chloroenolacetate (Z)-24 and TIPS-ethyne (2 
equiv.). 
No Pd catalyst (mol%) CuI (mol %) Solvent T (ºC) Yield (E)-25 (%) 
1 
PdCl2(PPh3)2 
(2 mol%) 
4 mol% 
THF/Et3N 
(4 :1) 
25 20 
2 
PdCl2(PPh3)2 
(2 mol%) 
8 mol% 
THF/Et3N 
(4 :1) 
25 22 
3 
PdCl2(PPh3)2 
(2 mol%) 
8 mol% 
THF/Et3N 
(4 :1) 
70 14 
4 
PdCl2(PPh3)2 
(2 mol%) 
8 mol% 
DMF/Et3N 
(4 :1) 
25 4 
5 
PdCl2(PPh3)2 
(2 mol%) 
8 mol% 
toluene/Et3N 
(4 :1) 
25 13 
                                                 
37 a. Biagetti, M.; Bellina, F.; Carpita, A.; Rossi, R. Tetrahedron Lett. 2003, 44, 607. b. Fairlamb, I. J. S.; 
4, 1213. O'Brien, C. T.; Lin, Z.; Lam, K. C. Org. Biomol.Chem. 2006, 
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6 
PdCl2(PPh3)2 
(5 mol%) 
15 mol% 
toluene 
(3 equiv. Et3N) 
25 5 
7 
Pd(PPh3)4 
(2 mol%) 
8 mol% 
THF/Et3N 
(4 :1) 
25 28 
 
The results from the treatment of α−chloroenol ester (Z)-24 with triisopropylsilyl 
acetylene as a model alkyne are shown in Table 6.2. Initial screening conditions employed 
dichloropalladium bis(triphenylphosphine) as catalyst, a 4:1 THF/Et3N mixture as solvent, 
and co-catalytic amounts of CuI in a 1:2 ratio relative to Pd. The reaction mixture was 
stirred at room temperature overnight and the coupled product (E)-25 was obtained in 20% 
yield. An increase in the Pd/Cu ratio from 1:2 to 1:4 only resulted in a slight increase in 
yield (entries 1 and 2). Changes in both the temperature (70 ºC) and the solvent (DMF or 
toluene) were detrimental (entries 3–5), whereas an increase in the amount of palladium 
and copper to 5 and 15% (a 1:3 Pd/Cu ratio), respectively, in toluene with only 3 
equivalents of base led to low conversions to E-25 with TIPS-acetylene (entry 6). The use 
of tetrakis(triphenylphosphine)palladium as the catalyst led to a slight improvement in 
r
mers present in the natural products 
(1a, 2a), led to us abandon this route to the peyssonenynes. 
yield (entry 7) but this was insufficient for synthetic applications. The low yields obtained 
in the c oss-coupling reaction and the lack of a procedure for the synthesis of the (E)-α-
chloroenolesters, which are the precursors of the iso
D. Formation of diynones by the addition of diynyl anion to Weinreb amides 
Route D was explored with a focus on the condensation of Weinreb amide 6 with 
the diynyl anion derived from 7. A two-step sequence was initially proposed for the 
preparation of 7, namely a cross-coupling of alkynes using either Cadiot–Chodkiewicz 
conditions or the Ni/Cu co-catalyzed reaction followed by deprotection of the terminal 
alkyne (Scheme 6.8). Cross-coupling of iodoalkyne (R)-4 with excess 
triisopropylsilylacetylene using the conditions reported by Alami and Ferri (CuI, 
piperidine) 20 led to (R)-26 in good yields. The alternative Ni/Cu co-catalyzed coupling of 
alkyne (R)-14 and excess triisopropylsilylacetylene also provided (R)-26, but in this case 
disappointing yields were obtained. 
Deprotection of the silyl group of (R)-26 with TBAF afforded two new compounds 
in moderate yields. These compounds were separated by HPLC (Waters Spherisorb® 5 μm 
silica gel, 10 × 250 mm, 90:10 hexane/EtOAc, 3 mL/min) and identified as the 
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diastereomeric hepta-2,4-dien-6-ynoates (R)-27 (Scheme 6.7). These new structures 
probably result from the reaction of the fluoride anion on the α- and β-(propargylic) 
positions of the formal glycerol-derived hepta-4,6-diynoate through the mediation of yne-
allenes and the corresponding ketene enolate intermediates followed by protonation. 
Interestingly, the cyclohexylideneglycerol-derived octa-5,7-diynoate (a related homolog 
not shown) afforded the terminal diyne in 67% yield under the same reaction conditions. 
This result indicates that the concomitant activation of both acidic positions is required to 
induce the isomerization of the butyne to the butadiene unit as in compound (R)-26.  
An alternative deprotection of (R)-26 with the HF.Py, in which the fluoride is 
involved in the formation of pyridinium poly(hydrogenfluoride) complexes,38 failed to 
provide the terminal alkyne and the starting material was fully recovered. The Cadiot–
Chodkiewicz cross-coupling between the iodoalkyne (S)-4 and trimethylsilylacetylene 
(with a more labile silyl protecting group) furnished diyne (R)-28 in good yield (Scheme 
6.8). As in route B, the trimethylsilyl group was removed with potassium carbonate in t-
BuOH/H2O (in this case the use of methanol also induced the trans-esterification with the 
glycerol ester to give the hepta-4,6-diynoate 2939). The addition of the diynyl anion of (R)-
7, generated in situ, to Weinreb amide 6b was first attempted using the lithium amide bases 
that had proven successful in the preparation of the propargylic ketones 10b, 10a and 16a 
(see Schemes 6.3 and 6.5). However, these experiments failed to afford the desired 
product, even on using two equivalents of base at –40 ºC. In all cases the Weinreb amide 
6b was fully recovered. The failure of this approach was probably due to the competing 
deprotonation of the α-enolizable position and, despite the fact that two equivalents of base 
were used, only the starting materials were recovered.  
                                                 
38 Olah, G. A.; Welch, J. T.; Vankar, Y. D.; Nojima, M.; Kerekes, I.; Olah, J. A. J. Org. Chem. 1979, 44, 
hem. 1988, 53, 2655. 
3872. 
39 Kende, A. S.; Smith, C. A. J. Org. C
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Scheme 6.8. Reagents and reaction conditions: (a) NiCl2 .6H2O, CuI, TMEDA, THF, air, 25 ºC (32%). (b) 
CuCl, piperidine, 0 ºC [(R)-26, 66%; (R)-28, 81%]. (c) TBAF, THF, 25 ºC (39%). (d) HF.Py, THF, 0 to 25 
ºC. (e) K2CO3, MeOH, 0 ºC (20%). (f) K2CO3, t-BuOH/H2O, 25 ºC (63%). (g) n-BuLi or t-BuLi or 
LHMDS, THF, –40 to 25 ºC. LHMDS = lithium bis(trimethylsilyl)amide. 
In an effort to avoid the incompatibility of functional groups with the reaction 
conditions, we opted to postpone the formation of the glycerol ester and use instead the 
corresp
 MAP and Ac2O took place with poor E/Z 
stereoselectivities, as observed in variant B. However, we decided to optimize the 
remaining steps of the synthesis with the mixture of the two isomers. Deprotection of the 
silyl ether with TBAF afforded alcohol 38b, which was converted into the corresponding 
                                                
onding alcohol as the precursor. Commercially available 5-pentyn-1-ol 31 was 
protected as tert-butyldiphenylsilyl ether 3240 which was iodinated to 33 and then 
subjected to the Cadiot–Chodkiewicz coupling with trimethylsilylacetylene to give the 
corresponding diyne 34 in excellent yield (Scheme 6.9). Orthogonal deprotection of the 
trimethylsilyl group with potassium carbonate in methanol provided the desired terminal 
diyne 35. The addition to 6b of the diynyl anion generated by in situ treatment of 35 with 
n-BuLi at –40 ºC afforded diynone 36b. The formation of the enol acetates using the 
standard conditions with Et N, D3
 
1, 18266. 40 Takimoto, M.; Usami, S.; Hou, Z. J. Am. Chem. Soc. 2009, 13
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carboxylic acid 40b after a consecutive Swern and Lindgren41 two-step oxidation protocol. 
HPLC separations were successful after each of the steps of this sequence (tert-
butyldiphenylsilyl ether 37b, alcohol 38b and carboxylic acid 40b intermediates) to afford 
the corresponding E and Z isomers, which were fully characterized. Final esterification of 
40b with (R)-isopropylidene glycerol (R)-41 in the presence of DCC and DMAP as 
coupling agents led to the desired compounds (S)-12b in moderate yield. As in variant B, 
the final ketal CAN-catalyzed deprotection to (S)-1b was accomplished in a 
straightforward manner.  
 
Scheme 6.9. Reagents and reaction conditions: (a) TBDPSCl, DMAP, Et3N, CH2Cl2, 0 to 25 ºC (86%). (b) 
NIS, AgNO3, acetone, 25 ºC, 12 h (60%). (c) CuCl, piperidine, 0 ºC (93%). (d) K2CO3, MeOH, 0 ºC (96%). 
(e) n-BuLi, THF, –40 to 25 ºC (74%). (f) Et3N, DMAP, Ac2O, CH2Cl2, 25 ºC, 44 h (93%, 41:59 Z/E). (g) 
TBAF, THF, 25 ºC (50%). (h) DMSO, (COCl)2, Et3N, CH2Cl2, –60 to 25 ºC. (i) NaClO2, 2-methyl-2-
butene, NaH2PO4, t-BuOH/H2O (69%, over two steps). (j) (R)-41, DCC, DMAP, CH2Cl2, 25 ºC, 8h (58%). 
(k) CAN (3 mol%), CH3CN/H2O, 70 ºC (74% of a 30:70 mixture of Z/E isomers). NIS = N-Iodosuccinimide; 
TBDPSCl = tert-butyldiphenylsilyl chloride; LHMDS = lithium bis(trimethylsilyl)amide; DMAP = 4-N,N-
dimethylaminopyridine; TBAF = tetra-n-butylammonium fluoride; DMSO = dimethylsulfoxide; DCC = 
dicyclohexylcarbodiimide.  
                                                 
41 a. Bal, B. S.; Childers Jr, W. E.; Pinnick, H. W. Tetrahedron 1981, 37, 2091. b. Lindgren, B. O.; Nilsson, 
T. Acta Chem. Scand. 1973, 27, 888. 
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Variant D was subsequently extended to the synthesis of the natural products. 
Addition of the diynyl anion of compound 35 to Weinreb amide 6a afforded the 
corresponding diynone 36a in an improved yield compared to the model system (Scheme 
6.10). 
t with our substrates E selectivity was 
the preferred outcome in the case of LHMDS. In both types of substrates the 1,2-allylic 
hain of the peyssonenynes and a TIPS/TMS-alkyne (10a, 
16a; see B) or a diyne (36a, see D) are weak. In the Ireland model system, the 1,3-diaxial 
                                                
The poor E/Z selectivity obtained in the formation of the enol acetate with Et3N, 
DMAP and Ac2O in the model diynone forced us to modify this methodology and generate 
the enolates with lithium amide bases followed by trapping with acetic anhydride. As in 
variant B using ynones 10a and 16a, (Me2Ph)2NLi and LHMDS were chosen to obtain the 
Z or E acetoxyenediynes as major isomers, respectively (Scheme 6.10). Surprisingly both 
the yields and the E/Z selectivities obtained in this case were lower than those achieved in 
route B. In the literature LHMDS and (Me2Ph)2NLi have been reported to induce the 
formation of Z enolates as major products,15,16,42 bu
interactions between the alkyl c
interactions between the substituents of the disilazide base and the alkyl chain should also 
be weak as the trialkylsilyl groups withdraw charge from the nitrogen, an effect that 
reduces the electrostatic interaction with the lithium cation and thus leads to a more 
favored/open transition state. The phenyl group is the only substituent that differentiates 
these two bases. The electron-withdrawing character of this substituent further enhances 
the tendency for a more open transition state and thus for the generation of the product 
with the Z geometry.  
Although the two isomeric alcohols 38a – obtained by deprotection of the silyl 
ethers 37a with TBAF – were separated by HPLC and characterized, the synthetic 
sequence was continued with the mixture of isomers obtained with each lithium amide 
base. As in the model system, consecutive Swern and Lindgren oxidations afforded the 
carboxylic acids 40a, which were separated by HPLC. The final DCC-induced coupling of 
a mixture of isomers of acid 40a with the glycerol isopropylidene ketal (R)-41 provided 
peyssonenyne precursors (S)-12a in moderate yields, thus completing a third formal 
approach to these natural products.11  
 
5. 42 Nahm, S. W., Steven M. Tetrahedron Lett. 1981, 22, 381
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Scheme 6.10. Reagents and reaction conditions: (a) n-BuLi, THF, –40 to 25 ºC (92%). (b) LiNR2, -78 to 0 
cross-coupling of terminal alkynes. Despite the fact than the terminal 
ºC, then Ac2O (67:33 Z/E, 50% using (Me2PhSi)2NLi; 13:87 Z/E, 82% using LHMDS). (c) TBAF, THF, 25 
ºC (46-59%). (d) DMSO, (COCl)2, Et3N, CH2Cl2, –60 to 25 ºC. (e) NaClO2, 2-methyl-2-butene, NaH2PO4, 
t-BuOH/H2O (74–78% combined). (f) DCC, DMAP, CH2Cl2, 25 ºC (46% of a 13:87 mixture of Z/E 
isomers). (g) CAN (3 mol%) CH3CN/H2O, 70 ºC (86% of a 33:67 mixture of Z/E isomers). 
In summary, complementary stereoselective and convergent synthetic approaches 
to the natural products peyssonenynes have been developed following optimization of the 
different routes with a model system derived from palmitic acid. The number of steps in 
the three new synthetic schemes has been reduced relative to the previously reported first-
generation approach to these natural products. This initial approach was based on a 
Cadiot–Chodkiewicz cross-coupling and late stage construction of the enol acetate, a step 
that was limited by the low stereoselectivity. We have found that the formation of the 
acetoxyenynes is highly stereoselective with particular lithium amide bases. The sketelon 
of the peyssonenynes was completed using the isolated isomers of this component in the 
Ni/Cu co-catalyzed 
functionalization of one alkyne is avoided compared to the Cadiot–Chodkiewicz cross-
coupling, the yields obtained in the construction of these complex molecules are moderate, 
which makes further optimization of the process desirable. Moreover, although the (Z)-α-
chlorovinylacetate was obtained with complete stereoselectivity, the subsequent 
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Sonogashira cross-coupling gave only low yields. Finally, the addition of the diynyl anions 
to Weinreb amides to generate the diynones directly is highly efficient, but the sequence is 
limited by the low stereoselectivity in the generation of the Z-acetoxyenediyne. 
The methodological survey reported here is expected to guide ensuing synthetic 
efforts to prepare new analogs endowed with the acetoxyenediyne functionality that show 
greater stability and contain more drug-like structural features than the natural products. 
 system. Et3N, piperidine and pyridine were dried by 
sure. UV/Vis spectra were recorded with a Cary 100 Bio 
spectrophotometer in MeOH. IR spectra were obtained on a JASCO IR 4200 
spectrophotometer from a thin film deposited onto NaCl glass. Mass spectra were obtained on 
a Hewlett-Packard HP59970 instrument operating at 70 eV by electron ionization and on an 
The acetoxyenediynes are considered as pro-drugs that release the highly reactive Michael 
acceptor diynone, which can undergo conjugate additions with reactive thiols (much like 
those observed in this study with the formation of secondary products 13b and 19a). The 
peyssonenynes are, in this respect, one of the ‘chemical weapons’ natural products that are 
disguised in the form of a less-reactive precursor.43  
6.3 Experimental Section 
General procedures. Solvents (acetone, CHCl3, EtOAc and EtOH) were dried according to 
published methods and distilled before use. THF, CH2Cl2, DMF and MeOH were dried using 
a PuresolvTM solvent purification
distillation with CaH2. All other reagents were commercial compounds of the highest purity 
available. All reactions were carried out under argon atmosphere, and those not involving 
aqueous reagents were carried out in oven-dried glassware. All solvents and anhydrous 
solutions were transferred through syringes and cannulae previously dried in the oven for at 
least 12 h and kept in a dessicator with KOH. For reactions at low temperature, icewater or 
CO2/acetone systems were used. Analytical thin layer chromatography (TLC) was performed 
on aluminium plates with Merck Kieselgel 60F 254 and visualised by UV irradiation (254 nm) 
or by staining with an ethanolic solution of phosphomolybdic acid or an ethanolic solution of 
anisaldehyde. Flash column chromatography was carried out using Merck Kieselgel 60 (230-
400 mesh) under pres
APEX III FT-ICR MS (Bruker Daltonics, Billerica, MA) equipped with a 7T actively shielded 
magnet. Ions were generated using an Apollo API electrospray ionization (ESI) source, with a 
                                                 
43 Kwan, J. C.; Luesch, H. Chem. Eur. J. 2010, 16, 13020. 
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voltage between 1800 and 2200 V (to optimize ionization efficiency) applied to the needle, and 
a counter voltage of 450 V applied to the capillary. Samples were prepared by adding a spray 
solution of 70:29.9:0.1 (v/v/v) CH3OH/water/formic acid to a solution of the sample at a v/v 
ratio of 1 to 5% to give the best signal-to-noise ratio. High-resolution mass spectra were taken 
on a VG Autospec instrument. 1H-NMR spectra were recorded in CDCl3, C6D6 or acetone at 
ambient temperature on a Bruker AMX-400 spectrometer at 400 MHz with residual protic 
solvent as the internal reference [CDCl3, δH = 7.26 ppm; (CD3)2CO, δH = 2.05 ppm; C6D6, δH 
= 7.16 ppm]; chemical shifts (δ) are given in parts per million (ppm), and coupling constants 
(J) are given in Hertz (Hz). The proton spectra are reported as follows: δ (multiplicity, 
coupling constant J, number of protons, assignment). 13C-NMR spectra were recorded in 
CDCl3 and C6D6 at ambient temperature on the same spectrometer at 100 MHz, with the 
central peak of CDCl3 (δC = 77.16 ppm), C6D6 (δC = 128.06 ppm) or (CD3)2CO (δC = 29.84 
ppm) as the internal reference. The DEPT135 pulse sequence was used to aid in the 
assignment of signals in the 13C NMR spectra. 
 
Route B 
(E)- and (Z)-1-Triisopropylsilyloctadec-3-en-1-yn-3-yl Acetate (11b). General procedure 
for enol formation and subsequent trapping with acetic anhydride. Method A. n-
Butyllithium (0.11 mL, 1.56 M in THF, 0.18 mmol) was added dropwise to a cooled (0 ºC) 
stirred solution of diisopropylamine (34 μL, 24 mg, 0.24 mmol) in THF (0.5 mmol/mL), and 
the solution was allowed to stir for 30 min. After cooling down to -78 ºC, a solution of 1-
(triisopropylsilyl)-octadec-1-yn-3-one 10b (0.05 g, 0.12 mmol) and DMPU (72 μL, 76 mg, 
0.59 mmol) in THF (0.06 mmol/mL) was added and the resulting solution was stirred for 2h. 
Subsequently, acetic anhydride (56 μL, 0.06 g, 0.59 mmol) was added dropwise and the 
reaction was stirred for a further 1 h at -78 ºC. A saturated aqueous solution of NaHCO3 was 
added and the mixture was extracted with Et2O (3x). The combined organic layers were 
washed with brine (2x), dried (Na2SO4) and the solvent was evaporated. The residue was 
1.35 (m, 2H, 2H7), 1.35-1.16 (m, 22H, 10 x -CH2-), 1.14-0.95 (m, 21H, i-Pr3-Si), 0.88 (t, J = 
purified by column chromatography (silica gel, 98:2 hexane/EtOAc) to afford 48 mg (86%) of 
a colourless oil that was identified as the titled product as a 27:73 mixture of E/Z isomers of 
acetoxyenyne 11b.  
(E)-1-Triisopropylsilyloctadec-3-en-1-yn-3-yl Acetate (E)-11b. 1H-NMR (400.13 MHz, 
CDCl3): δ 5.67 (t, J = 8.0 Hz, 1H, H4), 2.36-2.21 (m, 2H, 2H5), 2.13 (s, 3H, CO2CH3), 1.55-
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6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 168.8 (s, CO2CH3), 130.6 (s, C3), 
129.5 (d, C4), 98.7 (s, C1 or C2), 96.8 (s, C1 or C2), 32.1 (t), 29.8 (t, 6x), 29.6 (t), 29.5 (t), 29.3 
(t), 29.0 (t), 28.3 (t), 22.8 (t), 20.9 (q, CO2CH3), 18.7 (q, 6x, i-Pr3-Si), 14.2 (q, C18), 11.3 (d, 
3x, i-Pr3-Si) ppm. MS (FAB+): m/z (%) 463 ([M + 1]+, 24), 462 ([M]+, 6), 461 ([M - 1]+, 8), 
421 (12), 419 (22), 377 (12), 174 (14), 173 (100). HRMS (FAB+): Calcd for C29H55O2Si ([M 
+ 1]+), 463.3971; found 463.3963. IR (NaCl): ν  2926 (s, C-H), 2857 (m, C-H), 1769 (m, 
C=O), 1463 (m), 1205 (m)  cm-1. UV (MeOH): λmax 235 nm.  
(Z)-1-Triisopropylsilyloctadec-3-en-1-yn-3-yl Acetate (Z)-11b. 1H-NMR (400.13 MHz, 
CDCl3): δ 5.70 (t, J = 7.6 Hz, 1H, H4), 2.17 (s, 3H, CO2CH3), 2.08-1.96 (m, 2H, 2H5), 1.42-
1.15 (m, 24H, 12 x -CH2-), 1.14-0.96 (m, 21H, i-Pr3-Si), 0.88 (t, J = 6.8 Hz, 3H, CH3) ppm. 
13C-NMR (100.62 MHz, CDCl3): δ 168.1 (s, CO2CH3), 129.9 (s, C3), 129.1 (d, C4), 101.0 (s, 
C1 or C2), 91.1 (s, C1 or C2), 32.1 (t), 29.8 (t, 6x), 29.7 (t), 29.5 (t), 29.4 (t), 28.6 (t), 26.3 (t), 
22.8 (t), 20.7 (q, CO2CH3), 18.7 (q, 6x, i-Pr3-Si), 14.2 (q, C18), 11.3 (d, 3x, i-Pr3-Si) ppm. MS 
(FAB+): m/z (%) 463 ([M + 1]+, 27), 462 (M+, 7), 461 ([M - 1]+, 10), 421 (14), 419 (23), 377 
(12), 174 (16), 173 (100). HRMS (FAB+): Calcd for C29H55O2Si ([M + 1]+), 463.3971; found 
463.3971. IR (NaCl): ν 2926 (s, C-H), 2859 (m, C-H), 1770 (m, C=O), 1463 (m), 1193 (m) 
cm-1. UV (MeOH): λmax 234 nm.  
Method B. Using a modification of the general procedure described above for the synthesis of 
enol acetates, the reaction of 1-(triisopropylsilyl)-octadec-1-yn-3-one 10b (0.07 g, 0.17 mmol), 
diisopropylamine (47 μL, 34 mg, 0.33 mmol), n-butyllithium (0.19 mL, 1.32 M in THF, 0.25 
mmol) and acetic anhydride (79 μL, 85 mg, 0.83 mmol) in THF at -78 ºC afforded, after 
purification by column chromatography (silica gel, 98:2 hexane/EtOAc), 65 mg (84%) of a 
colourless oil that was identified as the titled product as a 80:20 mixture of E/Z isomers of the 
acetoxyenyne 11b. Separation by HPLC (Spherisorb 5 μm, 10x250 mm, 95.5:0.5 
hexane/EtOAc, 2 mL/min, tR = 9.8 min; tR RR (Z-11b) = 7.9 min; tR (E-11b) = 10.9 min) allowed 
the isolation of both isomers together with small amounts of a by-product, characterized as 
propargylic acetate SI-1. 
R
 
1-Triisopropylsilyloctadec-1-yn-3-yl Acetate (SI-1). 1H-NMR (400.13 MHz, CDCl3): 
δ 5.38 (t, J = 6.7 Hz, 1H, H3’), 2.06 (s, 3H, CO2CH3), 1.81 – 1.66 (m, 2H, 2H4’), 1.50 – 1.39 
(m, 2H, 2H ), 1.36-1.18 (s, 22H, 12x-CH -), 1.12 – 0.99 (m, 21H, i-Pr -Si), 0.88 (t, J = 6.8 5’ 2 3
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Hz, 3H, CH3) ppm.  1H-NMR (400 MHz, C6D6) δ 5.64 (t, J = 6.7 Hz, 1H, H3’), 1.85 – 1.71 
(m, 2H, 2H4’), 1.64 (s, 3H, CO2CH3), 1.57 – 1.45 (m, 2H, 2H5’), 1.39 – 1.20 (m, 24H, 12x-
CH2-), 1.20 – 1.00 (m, 21H, i-Pr3-Si), 0.92 (t, J = 6.1 Hz, 3H, CH3) ppm. 13C-NMR (100.62 
MHz, C6D6): δ 169.1 (s, C1), 106.3 (s, C2’), 86.4 (s, C1’), 64.7 (d, C3’), 35.4 (t), 32.3 (t), 30.2 
(t, 5x), 30.1 (t), 30.0 (t, 2x), 29.9 (t), 29.5 (t), 25.5 (t), 23.2 (t), 20.5 (q, CO2CH3), 18.8 (q, 6x, i-
Pr3-Si), 14.4 (d, C18’), 11.5 (q, 3x, i-Pr3-Si) ppm. MS (EI+): m/z (%) 422 ([M+ - i-Pr + H]+, 1), 
421 ([M - i-Pr] +, 4), 361 (9), 174 (80), 173 (100), 145 (16), 139 (11), 131 (50), 127 (12), 125 
(10), 111 (24), 109 (12), 103 (26), 99 (9), 97 (12), 95 (12), 87 (10), 85 (11), 75 (16). HRMS 
(EI+): (Calcd for C29H56O2Si ([M]+), 464.4050; found, 464.4048). IR (NaCl): ν 2926 (m, C-
H), 2857 (w, C-H), 1741 (m, C=O), 1699 (m), 1650 (m), 1520 (s), 1461 (m) cm-1.  
Method C. Using a modification of the general procedure described above for the synthesis of 
enol acetates, the reaction of 1-(triisopropylsilyl)-octadec-1-yn-3-one 11b (0.05 g, 0.12 mmol), 
2,2,6,6-tetramethylpiperidine (41 μL, 34 mg, 0.24 mmol), n-butyllithium (0.14 mL, 1.26 M in 
THF, 0.18 mmol) and acetic anhydride (56 μL, 0.06 g, 0.59 mmol) in THF (2.5 mL) at -78 ºC 
afforded, after purification by column chromatography (silica gel, 98:2 hexane/EtOAc), 51.9 
mg (100%) of a colourless oil that was identified as the titled product as a 91:9 mixture of E/Z 
isomers of the acetoxyenyne 11b. 
Method D. n-Butyllithium (0.14 mL, 1.26 M in THF, 0.18 mmol) was added dropwise to a 
cooled (0 ºC) stirred solution of 2,2,6,6-tetramethylpiperidine (41 μL, 34 mg, 0.24 mmol) and 
lithium bromide (16 mg, 0.18 mmol) in THF (0.5 mmol/mL), and the solution was allowed to 
stir for 30 min. After cooling down to -78 ºC, a solution of 1-(triisopropylsilyl)-octadec-1-yn-
3-one 10b (0.05 g, 0.12 mmol) in THF (0.06 mmol/mL) was added and the resulting solution 
was stirred for 2h. Subsequently, acetic anhydride (56 μL, 0.06 g, 0.59 mmol) was added 
dropwise and the reaction mixture was stirred for a further 1 h at -78 ºC. A saturated aqueous 
solution of NaHCO3 was added and the mixture was extracted with Et2O (3x). The combined 
organic layers were washed with brine (2x), dried (Na2SO4) and the solvent was evaporated. 
The residue was purified by colum atography (silica gel, 98:2 hexane/EtOAc) to afford n chrom
20.4 mg (37%) of a colourless oil that was identified as the titled product 11b as E isomer.  
Method E. Using a modification of th above for the synthesis of 
o (0.05 g, 0.12 mmol), 
e general procedure described 
enol acetates, the reaction of 1-(triisopr pylsilyl)-octadec-1-yn-3-one 10b 
2,2,6,6-tetramethylpiperidine (41 μL, 34 mg, 0.24 mmol), n-butyllithium (0.14 mL, 1.26 M in 
THF, 0.18 mmol), DMPU (72 μL, 76 mg, 0.59 mmol) and acetic anhydride (56 μL, 0.06 g, 
0.59 mmol) in THF (2.5 mL) at -78 ºC afforded, after purification by  column chromatography 
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(silica gel, 98:2 hexane/EtOAc), 48 mg (86%) of a colourless oil that was identified as the 
titled product as a 54:46 mixture of E/Z isomers E/Z. 
Method F. Using a modification of the general procedure described above for the synthesis of enol 
acetates, the reaction of 1-(triisopropylsilyl)-octadec-1-yn-3-one (0.05 g, 0.12 mmol), 1,1,3,3-
tetramethyl-1,3-diphenyldisilazane (69 μL, 68 mg, 0.24 mmol), n-butyllithium (0.14 mL, 1.26 
M in THF, 0.18 mmol) and acetic anhydride (56 μL, 0.06 g, 0.59 mmol) in THF (2.5 mL) at -
78 ºC afforded, after purification by  column chromatography (silica gel, 98:2 hexane/EtOAc), 
55 mg (100%) of a colourless oil that was identified as the titled product as a 28:72 E/Z 
mixture of isomers of the acetoxyenyne 11b. 
Method G. Using a modification of the general procedure described above for the synthesis of enol 
acetates,  the reaction of 1-(triisopropylsilyl)-octadec-1-yn-3-one 10b (0.05 g, 0.12 mmol), 
hexamethyldisilazane (50 μL, 38.4 mg, 0.24 mmol), n-butyllithium (0.14 mL, 1.26 M in THF, 
0.18 mmol) and acetic anhydride (56 μL, 0.06 g, 0.59 mmol) in THF (2.5 mL) at -78 ºC 
afforded after purification by column chromatography (silica gel, 98:2 hexane/EtOAc) 54.1 mg 
(98%) of a colourless oil that was identified as the titled product as a 93:7 mixture of E/Z 
isomers of the acetoxyenyne 11b. 
Method H. To a stirred solution of 1-(triisopropylsilyl)-octadec-1-yn-3-one 10b (44 mg, 0.10 
mmol) in CH2Cl2 (2.6 mL) at 0 ºC were added Et3N (73 μL, 53 mg, 0.52 mmol), DMAP (6.4 
mg, 0.05 mmol) and acetic anhydride (60 μL, 64 mg, 0.63 mmol) and the reaction mixture was 
stirred for 72h at room temperature. A saturated aqueous solution of NH4Cl was added and the 
mixture was extracted with CH2Cl2 (3x). The combined organic layers were dried (Na2SO4) 
and the solvent was evaporated. The residue was purified by column chromatography (silica 
gel, 98:2 hexane/EtOAc) to afford 48.4 mg (quantitative) of a colourless oil that was identified 
as the titled product as a 50:50 mixture of E/Z isomers of the acetoxyenyne 11b.  
Method I. To 1-(triisopropylsilyl)-octadec-1-yn-3-one 10b (0.85 g, 2.01 mmol) was added a 
0.01M solution of HClO4 in AcOEt containing 10% acetic anhydride (61 mL). After stirring 
acetate (Z)-11b (0.05 g, 0.11 mmol) in THF (3 mL) was added n-Bu4NF (0.12 mL, 1M in 
for 24h, the mixture was washed with a saturated aqueous solution of NaHCO3, dried 
(Na2SO4) and the solvent was removed under vacuum. The residue was purified by column 
chromatography (silica gel, 98:2 hexane/EtOAc) to afford 0.79 g (84%) of a colourless oil that 
was identified as the titled product as a 89:11 mixture of E/Z isomers of the acetoxyenyne 11b. 
(Z)-Octadec-3-en-1-yn-3-yl Acetate (Z)-5b. General procedure for the deprotection of 
triisopropylsilylalkynes. To a stirred solution of  (Z)-1-triisopropylsilyloctadec-3-en-1-yn-3-yl 
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THF, 0.12 mmol) and the reaction was stirred for 45 minutes at 25 ºC. A saturated aqueous 
solution of NaHCO3 was added and the mixture was extracted with Et2O (3x). The combined 
organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated. 
The residue was purified by column chromatography (silica gel, 95:5 hexane/EtOAc) to afford 
0.02 g (63%) of the titled compound as a white solid. 1H-NMR (400.13 MHz, CDCl3): δ 5.75 
(t, J = 7.6 Hz, 1H, H4), 2.96 (s, 1H, H1), 2.19 (s, 3H, CO2CH3), 2.10-1.97 (m, 2H, 2H5), 1.40-
1.18 (m, 24H, 12 x -CH2), 0.88 (t, J = 6.8 Hz, 1H, CH3) ppm. 13C-NMR (100.62 MHz, 
CDCl3): δ 168.4 (s, CO2CH3), 130.6 (d), 129.1 (s), 78.3 (s), 77.0 (d), 32.1 (t), 29.8 (t, 5x), 29.7 
(t), 29.5 (t, 2x), 29.3 (t), 28.5 (t), 26.2 (t), 22.8 (t), 20.7 (q, CO2CH3), 14.3 (q, C18) ppm. MS 
(FAB+): m/z (%)307 ([M + 1]+, 100), 306 ([M]+, 4), 305 ([M -1]+, 7). HRMS (FAB+): Calcd 
for C20H35O2, 307.2637 ([M + 1]+); found 307.2641. IR (NaCl): ν 2924 (s, C-H), 2854 (m, C-
H), 1768 (s, C=O), 1462 (w), 1370 (w), 1200 (s) cm-1. UV (MeOH): λma
, 2H, 2H5), 1.62 (s, 3H, CO2CH3), 1.39-1.16 (m, 24H, 12 x -CH2-),  0.92 (t, J = 6.8 
x 220 nm. 
(E)-Octadec-3-en-1-yn-3-yl Acetate (E)-5b. Following the general procedure for the 
deprotection of triisopropylsilylalkynes described above, the reaction of  (E)-1-
triisopropylsilyloctadec-3-en-1-yn-3-yl acetate (E)-11b (0.1 g, 0.22 mmol) with n-Bu4NF 
(0.24 mL, 1M in THF, 0.24 mmol) in THF (6 mL) afforded, after purification by column 
chromatography (silica gel, 95:5 hexane/EtOAc), 46 mg (69%) of the titled product as a white 
solid. 1H-NMR (400.13 MHz, C6D6): δ 5.62 (t, J = 8.0 Hz, 1H, H4), 2.75 (s, 1H, H1), 2.29-
2.15 (m
Hz, CH3) ppm. 1H-NMR (400.13 MHz, CDCl3): δ 5.75 (t, J = 8.0 Hz, 1H, H4), 3.23 (s, 1H, 
H1), 2.34-2.22 (m, 2H, 2H5), 2.15 (s, 3H, CO2CH3), 1.47 – 1.38 (m, 2H, -CH2-),  1.36 – 1.17 
(m, 22H, 11 x -CH2-), 0.88 (t, J = 6.8 Hz, 3H).  13C-NMR (100.62 MHz, C6D6): δ 168.0 (s, 
CO2CH3), 130.5 (d),  130.4 (s), 82.3 (d), 76.8 (s), 32.4 (t), 30.2 (t, 2x), 30.1 (t), 30.0 (t), 29.9 
(t), 29.8 (t), 29.4 (t), 29.2 (t), 28.2 (t), 23.2 (t), 20.2 (q, CO2CH3), 14.4 (q, C18) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 169.0 (s, CO2CH3), 130.9 (d), 129.4 (s), 82.2 (d), 76.2 (s), 32.1 (t), 
29.8 (t, 5x), 29.7 (t), 29.5 (t, 2x), 29.2 (t), 28.9 (t), 27.9 (t), 22.8 (t), 20.9 (q, CO2CH3), 14.3 (q, 
C18) ppm. HRMS (ESI+): Calcd for C20H34O2Na ([M + Na]+), 329.24510; found, 329.24480. 
IR (NaCl): ν  3307 (w, -C≡C-H), 2925 (s, C-H), 2854 (m, C-H), 1766 (m, C=O), 1564 (m), 
1458 (m), 1370 (m), 1208 (m), 1107 (m) cm-1. UV (MeOH): λmax 220, 309 nm. 
(E)-1-(Piperidin-1-yl)octadec-1-en-3-one (E)-13b. A solution of (E)-octadec-3-en-1-yn-3-yl 
acetate (E)-5b (45.4 mg, 0.15 mmol) in piperidine was stirred at 25 ºC for 30 min. A saturated 
aqueous solution of NH4Cl was added and the mixture was extracted with CH2Cl2 (3x). The 
combined organic layers were washed with brine, dried (Na2SO4) and the solvent was 
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evaporated. The residue was purified by column chromatography (silica gel, 70:30 
hexane/EtOAc) to afford 45.8 mg (89%) of (E)-1-(piperidin-1-yl)octadec-1-en-3-one 13b as a 
yellow solid. M.p.: 49-51 ºC (hexane/Et2O). 1H-NMR (400.13 MHz, CDCl3): δ 7.47 (d, J = 
12.8 Hz, 1H, H1), 5.12 (d, J = 12.8 Hz, 1H, H2), 3.31-3.13 (m, 4H, 2H2’ + 2H6’), 2.29 (t, J = 
7.7 Hz, 2H, 2H4), 1.65-1.54 (m, 8H, 2H5 + 2H3’ + 2H4’ + 2H5’), 1.32-1.18 (m, 26H, 13 x -
CH2-), 0.86 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 198.9 (s, C3), 
151.3 (d, C1), 94.6 (d, C2), 41.9 (t, 2x), 32.0 (t), 29.8 (t, 11x), 29.7 (t), 29.5 (t), 26.2 (t), 24.2 (t), 
. 
cribed above, the reaction of (Z)-octadec-3-en-1-yn-3-yl acetate (Z)-5b (37 mg, 0.12 
mol) and 
22.8 (t), 14.2 (q, C18) ppm. MS (EI): m/z (%) 349 ([M]+, 2), 153 (56), 138 (100). HRMS (EI): 
Calcd for C23H43ON ([M]+), 349.3345; found 349.3350. IR (NaCl): ν 2952 (s, C-H), 2849 (m, 
C-H), 1651 (m, CO), 1551 (s),  1458 (m), 1378 (m) cm-1 UV (MeOH): λ  311 nm. 
(8E,2’R)-2,3-O-Isopropylidene-2,3-Dihydroxyprop-1-yl 8-Acetoxytricosa-8-en-4,6-
diynoate (E,R)-12b. General procedure for the oxidative Ni/Cu co-catalyzed cross-coupling of 
terminal alkynes. A suspension of CuI (5 mol%) and NiCl
max
2 
. 6H O (5 mol%) in THF (1 mL) 
and TMEDA (4.53 μL) was stirred for 2 minutes at room temperature. (E)-Octadec-3-en-1-yn-
3-yl acetate (E)-5b (46 mg, 0.15 mmol) and (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-
yl pent-4-ynoate (R)-14 (0.16 g, 0.75 mmol) were subsequently added and the reaction mixture 
was stirred at room temperature for 24 hours under air. After completion of the reaction the 
solvent was evaporated and the residue was purified by column chromatography (silica gel, 
85:15 hexane/EtOAc) to afford 31 mg (40%) of the titled compound as a colourless oil. 
(8Z,2’R)-2,3-O-Isopropylidene-2,3-Dihydroxyprop-1-yl 8-Acetoxytricosa-8-en-4,6-
diynoate (Z,R)-12b. Following the general procedure for the synthesis of unsymmetric 1,3-
diynes des
2
mmol), (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl pent-4-ynoate (R)-14 (0.13 g, 0.60 
mmol), CuI (5 mol%) and NiCl2 . 6H2O (5 mol%) in THF (1 mL) and TMEDA (4.0 μL) at 
room temperature under air afforded, after purification by column chromatography (silica gel, 
85:15 hexane/EtOAc), 18.2 mg (29%) of the titled compound as a colourless oil. 
(5Z,8Z)-N-Methoxy-N-methylundeca-5,8-dienamide (6a). To a stirred suspension of 
Cs2CO3 (5.66 g, 17.36 mmol), NaI (2.60 g, 17.36 mmol) and CuCl (1.72 g, 17.36 mmol) in 
DMF (29 ml), were added N-methoxy-N-methylhex-5-ynamide (2.24 g, 14.46 m
propargylic bromide (1.5 mL, 2.13 g, 14.46 mmol) and the reaction mixture was vigorously 
stirred at 25 ºC for 3 h. After the addition of a saturated aqueous solution of NH4Cl the mixture 
was extracted with EtOAc (3x). The combined organic layers were washed with water (4x), 
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dried (Na2SO4) and the solvent was evaporated to afford a residue that was used in the next 
step without further purification. 
A solution of sodium borohydride (0.09 g, 2.31 mmol) in ethanol (32 mL) was added to a 
suspension of nickel acetate tetrahydrate (0.58 g, 2.31 mmol) in ethanol (32 mL) under a H2 
3) ppm. 13C-NMR (100.62 MHz, 
atmosphere and the reaction was vigorously stirred for 30 min. Then ethylenediamine (0.31 
mL, 0.28 g, 4.63 mmol) and a solution of the residue obtained above in ethanol (32 mL) were 
added. After stirring for 4 hours, the mixture was filtered through a small pad of silicagel and 
the solvent was evaporated. The residue was purified by column chromatography (silica gel, 
80:20 hexane/EtOAc) to afford 2.69 g (82% over two steps) of the titled compound as a yellow 
oil. 1H-NMR (400.13 MHz, CDCl3): δ 5.40 – 5.21 (m, 4H), 3.64 (s, 3H, OCH3), 3.14 (s, 3H, 
NCH3), 2.74 (t, J = 6.0 Hz, 2H, 2H7), 2.40 (t, J = 7.5 Hz, 2H, 2H2), 2.15 – 1.94 (m, 4H, 2H4 + 
2H10), 1.73 – 1.63 (m, 2H, 2H3), 0.93 (t, J = 7.5 Hz, 3H, CH
CDCl3): δ 174.6 (s, C1), 131.9 (d), 129.2 (d), 129.0 (d), 127.2 (d), 61.2 (q, OCH3), 32.2 (q, 
NCH3), 31.3 (t), 26.8 (t), 25.6 (t), 24.5 (t), 20.6 (t), 14.3 (q, C11) ppm. MS (EI+): m/z (%) 226 
([M + H]+, 1), 225 ([M]+, 3), 165 (40), 164 (51), 147 (29), 121 (24), 119 (16), 107 (14), 105 
(22), 103 (90), 97 (27), 95 (51), 93 (37), 91 (37), 81 (100), 79 (80). HRMS (EI+): Calcd for 
C13H23NO2, 225.1729; found, 225.1728. IR (NaCl): ν 3008 (m, -C=C-H), 2963 (m, C-H), 
2936 (m, C-H), 1669 (s, C=O), 1461 (m), 1414 (m), 1385 (m), 1178 (w), 1107 (w), 997 (m) 
cm-1.   
(7Z,10Z)-1-(Triisopropylsilyl)trideca-7,10-dien-1-yn-3-one (10a). General procedure for 
as extracted with Et2O (3x). 
the addition of alkynyllithium compounds to Weinreb amides. General procedure for the 
synthesis of propargylic ketones. n-BuLi (2.42 mL, 1.45 M in THF, 3.51 mmol) was added 
dropwise to a cooled (-40 ºC) stirred solution of triisopropylsilylacetylene (0.90 mL, 0.74 g, 
4.05 mmol) in THF (0.2 mmol/mL), and the resulting solution was stirred for 1 h. 
Subsequently, it was taken to -10 ºC, a solution of (5Z,8Z)-N-methoxy-N-methylundeca-5,8-
dienamide 6a (0.61 g, 2.70 mmol) in THF (0.84 mmol/mL) was added dropwise and the 
reaction mixture was further stirred for 1 h at -10 ºC and for 1 h at room temperature. A 
saturated aqueous solution of NH4Cl was added and the mixture w
The combined organic layers were washed with brine, dried (Na2SO4) and the solvent was 
evaporated. The residue was purified by column chromatography (silica gel, 97:3 
hexane/EtOAc) to afford 0.88 g (94%) of  (7Z,10Z)-1-(triisopropylsilyl)trideca-7,10-dien-1-yn-
3-one 10a as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 5.43 – 5.21 (m, 4H, H7 + H8 
+ H10 + H11), 2.74 (t, J = 6.8 Hz, 2H, 2H9), 2.56 (t, J = 7.4 Hz, 2H, 2H4), 2.14-1.97 (m, 4H, 
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2H6 + 2H12), 1.80-1.69 (m, 2H, 2H5), 1.17 – 1.02 (m, 21H, i-Pr3Si), 0.95 (t, J = 7.5 Hz, 3H, 
CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 187.6 (s, C3), 132.1 (d), 129.5 (d), 128.6 (d), 
127.1 (d), 104.3 (s), 95.4 (s), 45.1 (t), 26.4 (t), 25.6 (t), 24.1 (t), 20.6 (t), 18.6 (q, 6x, i-Pr3-Si), 
14.3 (q), 11.1 (d, 3x, i-Pr3-Si) ppm. HRMS (ESI+): Calcd for C22H38OSiNa ([M + Na]+), 
369.25841; found, 369.25799. IR (NaCl): ν 3008 (w, -C=C-H), 2948 (s, C-H), 2868 (s, C-H), 
2145 (w, -C≡C-), 1678 (s, C=O), 1461 (m), 1213 (w), 1110 (w), 1066 (w), 1000 (w) cm-1.  UV 
(MeOH): λmax 235 nm. 
(7Z,10Z)-1-(Trimethylsilyl)trideca-7,10-dien-1-yn-3-one (16a). Following the general 
procedure described above for the synthesis of propargylic ketones, the reaction of 
(5Z,8Z)-N-methoxy-N-methylundeca-5,8-dienamide 6a (0.84 g, 3.74 mmol), 
), 5.26 – 5.11 (m, 1H), 2.71 (t, J = 6.8 Hz, 2H, 2H9), 2.37 (s, 1H, H1), 2.19 (t, J 
isopropylsilyl)trideca-3,7,10-trien-1-yn-3-yl Acetate 
triimethylsilylacetylene (0.74 mL, 0.51 g, 5.23 mmol) and n-butyllithium (2.9 mL, 1.52 M 
in THF, 4.48 mmol) in THF at -40 ºC afforded after purification by  column 
chromatography (silica gel, 97:3 hexane/EtOAc) 0.83 g (84%) of the titled compound as a 
colourless oil. 1H-NMR (400.13 MHz, C6D6): δ 5.45 – 5.29 (m, 3H), 5.29 – 5.15 (m, 1H), 
2.72 (t, J = 6.6 Hz, 2H, 2H9), 2.31 (t, J = 7.3 Hz, 2H, 2H4), 2.07 – 1.95 (m, 2H, 2H6), 
1.94-1.85 (m, 2H, 2H12), 1.66 – 1.53 (m, 2H, 2H5), 0.91 (t, J = 7.6 Hz, 3H, 3H13), 0.05 (s, 
9H, Me3Si) ppm. 13C-NMR (100.62 MHz, C6D6): δ 186.3 (s, C3), 132.1 (d), 129.5 (d), 
129.0 (d), 127.6 (d), 103.2 (s), 95.9 (s), 44.8 (t), 26.5 (t), 25.9 (t), 23.9 (t), 20.9 (t), 14.5 (q), 
-0.9 (q, 3x, Me3Si) ppm. HRMS (ESI+): Calcd for C16H26OSiNa ([M + Na]+), 285.16451; 
found, 285.16478. IR (NaCl): ν 3010 (m, -C=C-H), 2963 (m, C-H), 2933 (m, C-H), 2874 
(w, C-H), 2149 (w, -C≡C-), 1679 (s, C=O), 1252 (m), 1109 (m), cm-1. UV (MeOH): λmax 
226 nm. 
(7Z,10Z)-trideca-7,10-dien-1-yn-3-one (18a). 1H-NMR (400.13 MHz, C6D6): δ 5.48 – 
5.29 (m, 3H
= 7.3 Hz, 2H, 2H4), 2.04 – 1.95 (m, 2H, 2H6), 1.90 – 1.80 (m, 2H, 2H12), 1.56-1.46 (m, 
2H, 2H5), 0.91 (t, J = 7.5 Hz, CH3). 13C-NMR (100.62 MHz, C6D6): δ 186.1 (s), 132.1 
(d), 129.6 (d), 128.9 (d), 127.5 (d), 81.9 (s), 77.7 (d), 44.8 (t), 26.4 (t), 25.9 (t), 23.7 (t), 
20.9 (t), 14.5 (q) ppm. IR (NaCl): ν 3268 (m, -C≡C-H), 3010 (m, -C=C-H), 2963 (m, C-
H), 2933 (m, C-H), 2873 (w, C-H), 2093 (s, -C≡C-), 1684 (s, C=O), 1105 (m) cm-1.  
(3E,7Z,10Z)- and (3Z,7Z,10Z)-1-(Tri
(11a). Following the general procedure for the synthesis of enol acetates (Method G) described 
above, the reaction of (7Z,10Z)-1-(triisopropylsilyl)trideca-7,10-dien-1-yn-3-one 10a (0.05 g, 
0.16 mmol), hexamethyldisilazane (65 μL, 51 mg, 0.31 mmol), n-butyllithium (0.15 mL, 1.6  
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M in THF, 0.23 mmol) and acetic anhydride (74 μL, 0.08 g, 0.78 mmol) in THF (3.2 mL) at -
78 ºC afforded, after purification by column chromatography (silica gel, 98:2 hexane/EtOAc), 
47 mg (78%) of a yellow oil that was identified as the titled product as a >99:1 mixture of E/Z 
isomers.  
(3E,7Z,10Z)- and (3Z,7Z,10Z)-1-(Triisopropylsilyl)trideca-3,7,10-trien-1-yn-3-yl Acetate 
) described 
L
, 0.54 
L
hexane/EtOAc), 0.26 g (100%) of a yellow oil that was identified as the titled product as a 
 
THF, 0.52 mmol), DMPU (0.26 mL, 0.28 g, 2.17 mmol) and acetic anhydride (0.20 mL, 0.22 
/Z isomers. 
(11a). Following the general procedure for the synthesis of enol acetates (Method F) described 
above, the reaction of (7Z,10Z)-1-(triisopropylsilyl)trideca-7,10-dien-1-yn-3-one 10a (0.05 g, 
0.16 mmol), 1,1,3,3-dimethyl-1,3-diphenyldisilazane (90 μL, 89 mg, 0.31 mmol), n-
butyllithium (0.15 mL, 1.6 M in THF, 0.23 mmol) and acetic anhydride (74 μL, 0.08 g, 0.78 
mmol) in THF (3.2 mL) at -78 ºC afforded, after purification by column chromatography 
(silica gel, 98:2 hexane/EtOAc), 52.3 mg (88%) of a yellow oil that was identified as the titled 
product as a 21:79 mixture of E/Z isomers. 
(3E,7Z,10Z)- and (3Z,7Z,10Z)-1-(Trimethylsilyl)trideca-3,7,10-trien-1-yn-3-yl Acetate 
(17a). Following the general procedure for the synthesis of enol acetates (Method A
above, the reaction of (7Z,10Z)-1-(trimethylsilyl)trideca-7,10-dien-1-yn-3-one 16a (0.28 g, 
1.07 mmol), hexamethyldisilazane (0.33 mL, 0.26 g, 1.60 mmol), n-butyllithium (0.84 m , 
1.52 M in THF, 1.28 mmol) and acetic anhydride (0.51 mL g, 5.34 mmol) in THF (21 
m ) at -78 ºC afforded, after purification by column chromatography (silica gel, 97:3 
>99:1 mixture of E/Z isomers. 
(3E,7Z,10Z)- and (3Z,7Z,10Z)-1-(Trimethylsilyl)trideca-3,7,10-trien-1-yn-3-yl Acetate
(17a). Following the general procedure for the synthesis of enol acetates (Method G) described 
above, the reaction of (7Z,10Z)-1-(trimethylsilyl)trideca-7,10-dien-1-yn-3-one 16a (0.11 g, 
0.43 mmol), diisopropylamine (92 μL, 66 mg, 0.65 mmol), n-butyllithium (0.35 mL, 1.50 M in 
g, 2.17 mmol) in THF (8.5 mL) at -78 ºC afforded, after purification by column 
chromatography (silica gel, 97:3 hexane/EtOAc), 105 mg (80%) of a yellow oil that was 
identified as the titled product as a 30:70 mixture of E
(7Z,10Z)-1,1-dimethoxytrideca-7,10-dien-3-one (19a). Potassium carbonate (0.10 g, 0.76 
mmol) was added o a cooled (0 ºC) stirred solution of (3E,7Z,10Z)- and (3Z,7Z,10Z)-3-
acetoxy-1-(trimethylsilyl)trideca-3,7,10-trien-1-yn-3-yl acetate 16a (0.19 g, 0.63 mmol) in 
MeOH (2.5 mL). After stirring for 15 min the reaction mixture was passed through a pad of 
Celite and the solvent was removed under vacuum. The residue was purified by column 
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chromatography (silica gel, 85:15 hexane/EtOAc) to provide 0.11 g (66%) of a colourless oil 
that was identified as the titled product. 1H-NMR (400.13 MHz, C6D6): δ 5.47 – 5.24 (m, 4H, 
H7 + H8 + H10 + H11), 4.81 (t, J = 5.6 Hz, 1H, H1), 3.11 (s, 6H, 2 x OCH3), 2.76 (t, J = 6.1 Hz, 
2H, 2H9), 2.48 (d, J = 5.6 Hz, 2H, 2H2), 2.14 – 1.89 (m, 6H, 2H4 + 2H6 + 2H12), 1.62 – 1.49 
(m, 2H, 2H5), 0.91 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 206.1 (s), 
132.0 (d), 129.5 (d), 129.2 (d), 127.7 (d), 102.1 (d), 53.5 (q, 2x), 46.7 (t), 43.1 (t), 26.7 (t), 25.9 
(t), 23.5 (t), 20.9 (t), 14.5 (q) ppm. HRMS (ESI+): Calcd for C15H26O3Na ([M + Na]+), 
277.17742; found, 277.17745. IR (NaCl): ν 2961 (s, C-H), 2934 (s, C-H), 2877 (w, C-H), 
2093 (w, -C≡C-), 1713 (s, C=O), 1452 (w), 1407 (w), 1368 (m), 1193 (m), 1120 (s), 1056 (s), 
970 (m) cm-1.  UV (MeOH): λmax  232 nm. 
(3E,7Z,10Z)- and (3Z,7Z,10Z)-trideca-3,7,10-trien-1-yn-3-yl Acetate (5a). General 
procedure for deprotection of trimethylsilylalkynes. Method A. To a stirred solution of a 
30:70 mixture of (3E,7Z,10Z)- and (3Z,7Z,10Z)-3-acetoxy-1-(trimethylsilyl)trideca-3,7,10-
trien-1-yn-3-yl acetate 17a (78 mg, 0.26 mmol) in a t-BuOH/H2O mixture (1.3 mL, 1:1 v/v) at 
25 ºC, was added potassium carbonate (0.07 g, 0.51 mmol). After stirring for 24 h the tert-
butanol was evaporated under vacuum. The reaction mixture was diluted with water and the 
mixture was extracted with Et2O (3x). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was removed. The residue was purified by column 
chromatography (silica gel, 97:3 hexane/EtOAc) to afford 36.5 mg (61%) of a colourless oil 
that was identified as the titled product as a 30:70 mixture of E/Z isomers. These were 
separated by HPLC (SunfireTM 5 μm, 4.6 x 250 mm, 99:1 hexane/t-butyl methyl ether, 1 
mL/min, tR(E) = 20.4 min and tR RR n; alternatively: Waters Spherisorb® 5 μm 
silica gel, 10 x 250 mm, 99:1 hexane/t-butyl methyl ether, 1.5 mL/min, tR(E) = 37 min and 
tR(Z) = 32.5 min). 
Following the general procedure for the deprotection of trimethylsilylalkynes described above, 
the reaction of a >99:1 mixture of (3E,7Z,10Z)- and (3Z,7Z,10Z)-3-acetoxy-1-
)
H1), 2.77 (t, J = 7.1 Hz, 2H, 2H9), 2.19 (s, 3H, OC(O)C
(Z) = 172.5 mi
(trimethylsilyl)trideca-3,7,10-trien-1-yn-3-yl acetate 17a (0.05 g, 0.16 mmol) and potassium 
carbonate (0.03 g, 0.20 mmol  in a t-BuOH/H2O mixture (1.0 mL, 1:1 v/v) at 25 ºC afforded, 
after purification by column chromatography (silica gel, 97:3 hexane/EtOAc), 24 mg (62%) of 
the E isomer of 12a as a colourless oil. 
(3Z,7Z,10Z)-Trideca-3,7,10-trien-1-yn-3-yl Acetate (Z)-5a. 1H-NMR (400.13 MHz, 
CDCl3): δ 5.76 (t, J = 7.4 Hz, 1H, H4), 5.46 – 5.24 (m, 4H, H7 + H8 + H10 + H11), 2.97 (s, 1H, 
H3), 2.17 – 2.01 (m, 6H, 2H5 + 2H6 + 
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2H12), 0.97 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 168.3 (s), 132.2 
(d), 129.7 (d), 129.6 (d), 129.3 (s), 128.2 (d), 127.1 (d), 78.2 (s), 77.2 (d), 26.2 (t), 26.1 (t), 25.7 
t), 20.7 (q), 14.4 (q) ppm. HRMS (ESI+): Calcd for C15H20O2Na ([M + Na]+), (t), 20.7 (
255.13555; found, 255.13564. IR (NaCl): ν 3289 (w, -C≡C-H), 3010 (w, -C=C-H), 2962 (w, 
C-H), 2930 (w, C-H), 2866 (w, C-H), 1769 (s, C=O), 1200 (s) cm-1.  UV (MeOH): λmax 219 
nm. 
(3E,7Z,10Z)-Trideca-3,7,10-trien-1-yn-3-yl Acetate (E)-5a. 1H-NMR (400.13 MHz, 
CDCl3): δ 5.76 (t, J = 7.8 Hz, 1H, H4), 5.46 – 5.23 (m, 4H, H7 + H8 + H10 + H11), 3.25 (s, 1H, 
H1), 2.77 (t, J = 6.4 Hz, 2H, 2H9), 2.39 – 2.31 (m, 2H, 2H5), 2.25 – 2.17 (m, 2H, 2H6), 2.15 (s, 
3H, OC(O)CH3), 2.11 – 2.01 (m, 2H, 2H12), 0.97 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 168.9 (s), 132.2 (d), 129.9 (d), 129.8 (s), 129.6 (d), 128.3 (d), 127.1 
(d), 82.4 (s), 76.0 (d), 28.0 (t), 26.6 (t), 25.7 (t), 20.9 (q), 20.7 (t), 14.4 (q) ppm. HRMS (ESI+): 
Calcd for C H O Na ([M + Na]15 20 2 w
7
11 9 1 5 6 
12
+), 255.13555; found, 255.13553. IR (NaCl): ν 3289 ( , -
C≡C-H), 3013 (w, -C=C-H), 2963 (w, C-H), 2934 (w, C-H), 2871 (w, C-H), 2012 (w, -C≡C-), 
1763 (s, C=O), 1370 (m), 1205 (s), 1113 (s) cm-1.  UV (MeOH): λmax 223 nm. 
1H-NMR (400 MHz, C6D6) δ 5.62 (t, J = 7.9 Hz, 1H, H4), 5.51 – 5.26 (m, 4H, H  + H8 + H10 
+ H ), 2.81 – 2.65 (m, 3H, 2H  + H ), 2.32 – 2.19 (m, 2H, 2H ), 2.09 – 1.93 (m, 4H, 2H + 
2H ), 1.61 (s, 3H, OC(O)CH3 13
1 .7 (d), 128.6 (d), 128.4 (d), 127.5 (d), 82.5 (s), 76.7 
2 2
,10 )-trideca-3,7,10-tri
1-yl pent-4-ynoate (R)-14 (93 mg, 0.44 mmol), CuI (5 mol%) and NiCl2  6H2O (5 mol%) in 
), 0.91 (t, J = 7.5 Hz, 3H, 3H ) ppm. C-NMR (100.62 MHz, 
C
 13
6 6
(d), 28.2 (t), 26.8 (t), 25.9 (t), 20.9 (t), 20.1 (q), 14.5 (q) ppm. 
(8E,12Z,15Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl  8-Acetoxyoctadeca-
8,12,15-trien-4,6-diynoate (E,R)-12a. Following the general procedure for the synthesis of 
unsymmetrical 1,3-diynes described above, the reaction of (3E,7Z,10Z)-trideca-3,7,10-trien-1-
yn-3-yl acetate (E)-5a (36 mg,  0.16 mmol), (2’R)-2,3-O-isopropylidene-2,3-dihydroxy-1-
prop-1-yl pent-4-ynoate (R)-14 (0.16 g, 0.78 mmol), CuI (5 mol%) and NiCl . 6H O (5 mol%) 
D ): δ 167.9 (s), 132.1 (d), 130.8 (s), 29
in THF (1 mL) and TMEDA (5 μL, 3.6 mg, 0.03 mmol) at room temperature and under air 
afforded, after purification by column chromatography (silica gel, 85:15 hexane/EtOAc), 20 
mg (29%) of the titled compound as a colourless oil. 
 (8Z,12Z,15Z)-(2’R)- 2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl  8-Acetoxyoctadeca-
8,12,15-trien-4,6-diynoate (Z,R)-12a. Following the general procedure for the synthesis of 
unsymmetrical 1,3-diynes described above, the reaction of (3Z,7Z Z en-1-
yn-3-yl acetate (Z)-5a (20.3 mg, 0.09 mmol), (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-
.
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THF (1 mL) and TMEDA (2.6 μL) at room temperature and under air afforded, after 
purification by column chromatography (silica gel, 85:15 hexane/EtOAc), 11 mg (28%) of the 
titled compound as a colourless oil. 
 
(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-Hydroxy-tricosa-4,6-diynoate 
(S)-20b. Following the general procedure for the synthesis of unsymmetrical 1,3-diynes 
described above, the reaction of (2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl pent-
4-ynoate (S)-14 (0.71 g, 3.33 mmol), octadec-1-yn-3-ol 3b (0.13, 0.66 mmol), CuI (5 
mol%) and NiCl2.6H2O (5 mol%) in THF (4.7 mL) and TMEDA (21.0 μL) at room 
temperature and under air afforded, after purification by column chromatography (silica 
gel, 80:20 hexane/EtOAc), 73 mg (27%) of the titled compound as a white solid. 
 
(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-Hydroxy-tricosa-4,6-diynoate (S)-
20b. Following the general procedure for the synthesis of unsymmetrical 1,3-diynes described 
above, the reaction of (2’S)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl pent-4-ynoate (S)-
14 (32 mg, 0.15 mmol), octadec-1-yn-3-ol 3b (0.2 g, 0.75 mmol), CuI (5 mol%) and NiCl2 . 
6H2O (5 mol%) in THF (1 mL) and TMEDA (5 μL) at room temperature and under air 
afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 26 
mg (36%) of the titled compound as a white solid. 
(12Z,15Z)-(2’S)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-Hydroxyoctadeca-12,15-
dien-4,6-diynoate (S)-20a. Following the general procedure for the synthesis of 
unsymmetrical 1,3-diynes described above, the reaction of (2’S)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl pent-4-ynoate (S)-14 (0.23 g, 1.06 mmol), (7Z,10Z)-trideca-7,10-dien-1-
yn-3-ol 3a (41 mg, 0.21 mmol), CuI (5 mol%) and NiCl2 . 6H2O (5 mol%) in THF (1.5 mL) 
and TMEDA (7 μL) at room temperature and under air afforded, after purification by column 
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chromatography (silica gel, 80:20 hexane/EtOAc), 17 mg (20%) of the titled compound as a 
colourless oil. 
Route C 
1,1,1-Trichloroundecan-2-ol (22). To a stirred solution of decanal 21 (0.12 mL, 0.10 g, 
0.64 mmol) in DMF (1 mL) was added trichloroacetic acid (0.16 g, 0.96 mmol) and 
sodium trichloroacetate (0.18 g, 0.96 mmol) keeping the temperature at 23 ºC with a water 
bath. The mixture was stirred for 1h, diluted with ether-hexane (9:1 v/v) and washed with a 
saturated aqueous solution of NaHCO3 (3x) and NaCl (1x). The combined organic layers 
were dried (Na2SO4) and the solvent was evaporated. The residue was purified by column 
chromatography (silica gel, 97:3 hexane/EtOAc)  give 0.152 g (8to 6%) of 1,1,1-
ndecan-2-ol as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 4.00 (app trichlorou
ddd, J = 9.4, 5.6, 1.9 Hz, 1H, H2), 2.66 (m, 1H, H3A), 2.10 – 1.99 (m, 1H, H3B), 1.71 – 
1.57 (m, 2H, 2H4), 1.51 – 1.19 (m, 12H, 6 x -CH2-), 0.88 (t, J = 6.9 Hz, 3H, CH3) ppm. 
13C-NMR (100.62 MHz, CDCl3): δ 104.5 (s), 83.0 (d), 32.0 (t), 31.6 (t), 29.6 (t, 2x), 29.4 
(t, 2x), 26.2 (t), 22.8 (t), 14.2 (q) ppm. MS (EI+): m/z (%) 157 ([M - CCl3]+, 36), 149 (13), 
124 (26), 122 (43), 114 (13), 112 (22), 111 (13), 97 (82), 95 (11), 84 (11), 83 (100), 82 
(13), 81 (18), 71 (19), 70 (16), 69 (75), 67 (18). HRMS (EI+): Calcd for C10H21O ([M - 
CCl3]+), 157.1595; found, 157.1595. IR (NaCl): ν 3600−3200 (br, Ο−Η), 2926 (s, C-H), 
2856 (m, C-H), 1462 (m), 812 (m) cm-1.  
1,1,1-Trichloroundecan-2-yl Acetate (23). Method A.  To a solution of 1,1,1-
trichloroundecan-2-ol 22 (0.50 g, 1.80 mmol) in piperidine (6 mL) was added acetic anhydride 
(0.85 mL, 0.92 g, 9.01 mmol) and the mixture was stirred at 25 ºC for 14 h. When the reaction 
was completed it was diluted with Et2O and washed with a saturated aqueous solution of 
CuSO4 (2x). The combined organic layers were dried (Na2SO4) and the solvent was 
evaporated to obtain 0.53 g (94%) of a colourless oil that was identified as 1,1,1-
trichloroundecan-2-yl acetate 23, and was used in the next step without further purification. 
Method B. To a solution of decanal 22 (0.36 mL, 0.30 g, 1.92 mmol) in CHCl3 (0.31 mL, 0.46 
g, 3.84 mmol) was added dropwise DBN (0.24 mL, 0.24 g, 1.92 mmol) and the reaction 
mixture was stirred for 3h. Acetic anhydride (0.20 mL, 0.22 g, 2.11 mmol) was slowly added 
at 0 ºC and the reaction was stirred for a further 2 h. The reaction mixture was diluted with 
AcOEt and washed with a 0.5 N aqueous solution of HCl (3x) and a saturated aqueous solution 
of Na2CO3 (3x). The combined organic layers were dried (Na2SO4) and the solvent was 
evaporated. The residue was purified by column chromatography (silica gel, 97:3 
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hexane/EtOAc) to afford 0.19 g (31%) of 1,1,1-trichloroundecan-2-yl acetate 23 as a 
colourless oil.  1H-NMR (400.13 MHz, CDCl3): δ 5.49 (app d, J = 10.2 Hz, 1H, H2’), 2.22 – 
 25 ºC was added a solution of 1,1,1-
lting 
 (t, 2x), 29.4 (t), 28.8 (t), 27.7 (t), 23.1 (t), 19.8 (q), 14.4 (q) ppm. HRMS 
 IR 
C
a2SO4) 
2.02 (m, 4H, CO2CH3 + H3A’), 1.91 – 1.72 (m, 1H, H3B’), 1.41 – 1.11 (m, 14H, 7 x -CH2-), 
0.88 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 169.7 (s), 100.3 (s), 
80.9 (d), 31.9 (t), 30.5 (t), 29.5 (t), 29.4 (t), 29.3 (t), 29.2 (t), 25.6 (t), 22.7 (t), 20.7 (q), 
14.2 (q) ppm. MS (FAB+): m/z (%) 317 ([M + 1]+, 47), 316 ([M]+, 5), 315 (22), 302 (18), 300 
(15), 296 (24), 295 (100), 294 (19), 293 (25), 283 (45), 281 (71), 185 (28), 184 (70), 155 (71), 
154 (29). HRMS (FAB+): Calcd for C13H24Cl3O2 ([M + 1]+), 317.0842; found 317.0840. IR 
(NaCl): ν 2927 (s, C-H), 2857 (m, C-H), 1762 (s, C=O), 1462 (w), 1371 (m), 1215 (s) cm-1.  
(Z)-1-Chloroundec-1-en-1-yl Acetate (Z)-24. To a stirred suspension of chromium (II) 
chloride (81.3 mg, 0.66 mmol) in THF (1 mL) at
trichloroundecan-2-yl acetate 23 (0.07 g, 0.22 mmol) in THF (1 mL) and the resu
mixture was heated at reflux for 72 h. The reaction was cooled down to room temperature, 
quenched with a 5% aqueous solution of HCl and diluted with Et2O. The layers were 
separated and the aqueous layer was extracted with Et2O (2x). The combined organic 
layers were washed with brine (3x), dried (Na2SO4) and the solvent was evaporated.  The 
residue was purified by column chromatography (silica gel, 97:3 hexane/EtOAc) to afford 
47.6 mg (88%) of a colourless oil that was identified as (Z)-1-chloroundec-1-en-1-yl 
acetate (Z)-24. 1H-NMR (400.13 MHz, C6D6): δ 5.20 (t, J = 7.4 Hz, 1H, H2’), 2.10-1.97 
(m, 2H, 2H3’), 1.54 (s, 3H, CO2CH3), 1.35-1.11 (m, 14H, 7 x -CH2-), 0.91 (t, J = 7.0 Hz, 
3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 167.1 (s), 134.9 (s), 118.6 (d), 32.3 (t), 
30.0 (t), 29.8
(ESI+): Calcd for C13H23ClO2Na ([M + Na]+), 269.12788; found, 269.12773.
(NaCl): ν 2926 (s, C-H), 2856 (m, C-H), 1788 (s, C=O), 1462 (w), 1370 (w), 1215 (w), 
1193 (w), 1100 (w) cm-1.  
(E)-1-Triisopropylsilyltridec-3-en-1-yn-3-yl Acetate (E)-25. General procedure for the 
Sonogashira cross-coupling. A solution of (Z)-1-chloroundec-1-en-1-yl acetate (Z)-24 (0.05 
g, 0.20 mmol) and triisopropylsilylacetylene (0.09 mL, 74 mg, 0.40 mmol) in THF (2.2) and 
uI (3.1 mg, 0.02 mmol) were subsequently added to a stirred solution of PdCl2(PPh3)2 (4.7 
mg, 4.0 μmol) in THF (1 mL) and the mixture was degassed at -78 ºC three times. Then Et3N 
(0.75 mL) was added and the mixture was stirred at room temperature for 24h. After 
completion of the reaction it was poured into a saturated aqueous solution of NH4Cl and the 
mixture was extracted with CH2Cl2 (3x). The combined organic layers were dried (N
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and the solvent was evaporated. The residue was purified by column chromatography (silica 
gel, 100% acetonitrile) to afford 22 mg of pure (E)-1-triisopropylsilyltridec-3-en-1-yn-3-yl 
acetate (E)-25 as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 5.68 (t, J = 8.0 Hz, 1H, 
H4), 2.34 – 2.21 (m, 2H, 2H5), 2.13 (s, 3H, CO2CH3), 1.49 – 1.36 (m, 2H, 2H6), 1.36 – 1.20 
(m, 12H, 6x -CH2-), 1.15 – 1.00 (m, 21H, i-Pr3-Si), 0.88 (t, J = 6.9 Hz, 3H, CH3) ppm. 13C-
NMR (100.62 MHz, CDCl3): δ 168.8 (s), 130.5 (s), 129.6 (d), 98.6 (s), 96.8 (s), 32.0 (t), 29.7 
(t), 29.6 (t), 29.4 (t), 29.3 (t), 29.0 (t), 28.3 (t), 22.8 (t), 20.9 (q), 18.7 (q, 6x), 14.3 (q), 11.3 (d, 
3x) ppm. HRMS (ESI+): Calcd for C24H45O2Si ([M + H]+), 393.31833; found 393.31809. IR 
(NaCl): ν 2926 (s, C-H), 2865 (m, C-H), 2151 (w, -C≡C-), 1768 (m, C=O), 1464 (w), 1367 
(w), 1209 (m), 1107 (m), 883 (w) cm-1. UV (MeOH): λmax 225, 244, 289 nm. 
Route D 
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 7-(Triisopropylsilyl)hepta-4,6-
diynoate (26). Method A. Following the general procedure for the synthesis of unsymmetrical 
1,3-diynes described above, the reaction of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-
yl pent-4-ynoate (R)-14 (0.5 g, 2.36 mmol), triisopropylsilylacetylene (2.62 mL, 2.15 g, 11.79 
mmol), CuI (5 mol%) and NiCl2 . 6H2O (5 mol%) in THF (10 mL) and TMEDA (71 μL) at 
room temperature and under air afforded, after purification by column chromatography (silica 
gel, 80:10:10 hexane/CH2Cl2/EtOAc), 0.28 g (32%) of the titled compound as a colourless oil.  
Method B. General procedure for the Cadiot-Chodkiewicz cross-coupling reaction. To a 
stirred solution of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 5-iodopent-4-ynoate 
(R)-4 (0.1 g, 0.3 mmol) and triisopropylsilylacetylene (0.16 mL, 0.14 g, 0.74 mmol) in 
degassed piperidine (0.5 mL), at 0 ºC, was added copper chloride (3 mg,  0.03 mmol). After 
stirring for 2 hours, a saturated aqueous solution of NH4Cl was added and the mixture was 
extracted with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and the 
solvent was removed under vacuum. The residue was purified by column chromatography 
(silica gel, 85:15 hexane/EtOAc) to provide 76 mg (66%) of a colourless oil that was identified 
as the titled product. 1H-NMR (400.13 MHz, CDCl3): δ 4.34 – 4.24 (m, 1H, H2’), 4.16 (dd, J = 
11.5, 4.7 Hz, 1H, H1’A), 4.09 (dd, J = 11.5, 5.9 Hz, 1H, H1’B), 4.05 (dd, J = 8.5, 6.5 Hz, 1H, 
H3’A), 3.72 (dd, J = 8.5, 6.0 Hz, 1H, H3’B), 2.60-2.55 (m, 4H, 2H2 + 2H3), 1.39 (s, 3H), 1.33 (s, 
3H), 1.06-1.01 (m, 21H, i-Pr3Si) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 171.2 (s, C1), 
109.9 (s, C1’’), 89.7 (s), 81.1 (s), 76.1 (s), 73.5 (d, C2’), 66.7 (s), 66.3 (t), 65.1 (t), 32.7 (t), 26.7 
(q), 25.4 (q), 18.6 (q, 6x, SiCH(CH3)2), 15.2 (t), 11.3 (d, 3x, SiCH(CH3)2) ppm. HRMS 
(ESI+): Calcd for C22H36O4SiNa ([M + Na]+), 415.22751; found 415.22705. IR (NaCl): ν  
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2946 (s, C-H), 2870 (s, C-H), 2225 (w, -C≡C-), 2103 (w, -C≡C-), 1744 (s, C=O), 1461 (m), 
1374 (m), 1219 (s), 1168 (s), 1062 (m)  cm-1.  
(2E,4Z)- and (2E,4E)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-ylhepta-2,4-dien-
6-ynoate (27). Following the general procedure for the deprotection of triisopropylsilylalkynes 
described above, the reaction of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 7-
(triisopropylsilyl)hepta-4,6-diynoate (R)-26 (0.1 g, 0.25 mmol) with n-Bu4NF (0.28 mL, 1M in 
THF, 0.28 mmol) in THF (6.4 mL) afforded, after purification by column chromatography 
(silica gel, 80:20 hexane/EtOAc), 23.4 mg (39%) of the titled compound as a 2:1 mixture of 
4Z/4E isomers. The isomers were separated by HPLC (Spherisorb 5 μm, 10x250 mm, 90:10 
hexane/EtOAc, 3 mL/min) to afford 2.8 mg (5%) of the (2E,4E) isomer (tR=  19.2 min) and 
5.6 mg (9%) of the (2Z,4E) isomer (t
R
RR
), 139.4 (d), 
C-NMR (100.62 MHz, (CD3)2CO): δ 166.4 (s, C1), 143.9 (d), 141.3 (d), 124.3 (d), 
= 21.6 min) of 27.  
(2E,4Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-ylhepta-2,4-dien-6-ynoate 
(2E,4Z, 2’R)-27. 1H-NMR (400.13 MHz, (CD3)2CO): δ 7.76 (dd, J = 15.4, 11.5 Hz, 1H, H3), 
6.79 (t, J = 11.1 Hz, 1H, H4), 6.20 (d, J = 15.5 Hz, 1H, H2), 5.94 (dd, J = 10.6, 2.2 Hz, 1H, 
H5), 4.42 – 4.29 (m, 1H, H2’), 4.26 – 4.15 (m, 2H, 2H1’), 4.13 (d, J = 2.2 Hz, 1H, H7), 4.09 
(dd, J = 8.4, 6.6 Hz, 1H, H3’A), 3.78 (dd, J = 8.4, 6.1 Hz, 1H, H3’B), 1.36 (s, 3H, CH3), 1.30 (s, 
3H, CH3) ppm. 13C-NMR (100.62 MHz, (CD3)2CO): δ 166.6 (s, C1), 140.8 (d
125.2 (d), 117.1 (d), 110.0 (s, C1’’), 88.9 (d), 80.4 (s), 74.5 (d, C2’), 66.8 (t), 65.4 (t), 27.1 (q), 
25.7 (q) ppm. HRMS (ESI+): Calcd for C13H16O4Na ([M + Na]+), 259.09408; found, 
259.09395. IR (NaCl): ν 3263 (w, -C≡C-H), 2986 (w, C-H), 2937 (w, C-H), 1717 (s, C=O), 
1628 (w), 1376 (w), 1305 (w), 1264 (s), 1221 (m), 1167 (s), 1105 (m), 1055 (m), 998 (m) cm-1.  
UV (MeOH): λmax 283 nm. 
(2E,4E)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-ylhepta-2,4-dien-6-ynoate 
(2E,4E,2’R)-27. 1H-NMR (400.13 MHz, (CD3)2CO): δ 7.35 (ddd, J = 15.3, 11.3, 0.7 Hz, 1H, 
H3), 6.87 (dd, J = 15.6, 11.3 Hz, 1H, H4), 6.20 (ddt, J = 15.6, 2.4, 0.7 Hz, 1H, H5), 6.13 (d, J = 
15.3 Hz, 1H, H2), 4.34 (ddd, J = 12.2, 6.0, 4.7 Hz, 1H, H2’), 4.21 (dd, J = 11.5, 4.7 Hz, 1H, 
H1’A), 4.16 (dd, J = 11.5, 5.8 Hz, 1H, H1’B), 4.09 (dd, J = 8.5, 6.5 Hz, 1H, H3’A), 3.88 (d, J = 
2.4 Hz, 1H, H7), 3.77 (dd, J = 8.5, 6.0 Hz, 1H, H3’B), 1.35 (s, 3H, CH3), 1.30 (s, 3H, CH3) 
ppm. 13
119.4 (d), 110.0 (s, C1’’), 85.4 (d), 82.8 (s), 74.5 (d, C2’), 66.9 (t), 65.5 (t), 27.0 (q), 25.7 (q) 
ppm. HRMS (ESI+): Calcd for C13H16O4Na ([M + Na]+), 259.09408; found, 259.09399. IR 
(NaCl): ν 3267 (w, -C≡C-H), 2985 (w, C-H), 2927 (w, C-H), 1715 (s, C=O), 1627 (m), 1377 
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(m), 1322 (m), 1231 (s), 1177 (m), 1136 (s), 1053 (m), 995 (m) cm-1.  UV (MeOH): λmax 279 
nm. 
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 7-(Trimethylsilyl)hepta-4,6-diynoate 
(R)-28. Following the general procedure for the Cadiot-Chodkiewicz cross-coupling reaction 
described above, the reaction of (2’R)-2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 5-
iodopent-4-ynoate (R)-4 (0.96 g, 2.84 mmol), trimethylsilylacetylene (1.0 mL, 0.70 g, 7.1 
mmol) and copper chloride (28 mg,  0.28 mmol) in degassed piperidine (2.3 mL) at 0 ºC 
afforded, after purification by column chromatography (silica gel, 85:15 hexane/EtOAc), 0.71 
g (81%) of the titled compound as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 4.29 – 
4.19 (m, 1H, H1’A), 4.11 (dd, J = 11.4, 4.7 Hz, 1H, H1’B), 4.08 – 3.98 (m, 2H, H2’ + H3’A), 3.67 
(dd, J = 8.5, 6.0 Hz, 1H, H3’B), 2.55 – 2.49 (m, 4H, 2H2 + 2H3), 1.35 (s, 3H, CH3), 1.28 (s, 
3H, CH3), 0.10 (s, 9H, Me3Si) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 171.0 (s, C1), 109.7 
(s, C1’’), 88.1 (s), 83.9 (s), 77.3 (s), 73.4 (d, C2’), 66.2 (t), 65.0 (t), 32.6 (t), 26.6 (q, CH3), 25.3 
(q, CH3), 15.1 (t), -0.4 (q, 3x) ppm. HRMS (ESI+): Calcd for C16H25O4Si ([M + H]+), 
309.15166; found 309.15087. IR (NaCl): ν 2985 (w, C-H), 2959 (w, C-H), 2896 (w, C-H), 
2228 (w, -C≡C-), 2109 (w, -C≡C-), 1742 (s, C=O), 1371 (m), 1252 (s), 1211 (m), 1182 (m), 
1160 (m), 1056 (w), 846 (s) cm-1. UV (MeOH): λmax 225, 238, 251, 266 nm. 
Methyl Hepta-4,6-diynoate (29). Following the procedure for the deprotection of 
trimethylsilylalkynes described above, the reaction of  (2’R)-2,3-O-isopropylidene-2,3-
dihydroxyprop-1-yl 7-(trimethylsilyl)hepta-4,6-diynoate (R)-28 (0.14 g, 0.45mmol), potassium 
carbonate (0.08 g, 0.54 mmol) in MeOH (1.8 mL) at 0 ºC afforded, after purification by 
column chromatography (silica gel, 90:10 hexane/EtOAc), 12 mg (20%) of the titled 
compound as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ  3.71 (s, 3H, OCH3), 2.65 – 
2.49 (m, 4H, 2H2 + 2H3), 1.98 (s, 1H, H7) ppm. 
(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-ylhepta-4,6-diynoate (R)-7. Following 
the procedure for deprotection of trimethylsilylalkynes described above, the reaction of (2’R)-
2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl 7-(trimethylsilyl)hepta-4,6-diynoate (R)-28 
(0.16 g, 0.52 mmol), potassium carbonate (0.09 g, 0.62 mmol) in t-BuOH/H2O (2 mL, 1:1 v/v) 
at 25 ºC, afforded, after purification by column chromatography (silica gel, 80:20 
hexane/EtOAc), 77 mg (63%) of the titled compound as a colourless oil. 1H-NMR (400.13 
MHz, C6D6): δ  4.03 – 3.78 (m, 3H, 2H1’ + H2’), 3.64 (dd, J = 8.4, 6.3 Hz, 1H, H3’A), 3.40 (dd, 
J = 8.4, 5.9 Hz, 1H, H3’B), 2.11 – 2.05 (m, 2H, 2H2), 2.02 – 1.95 (m, 2H, 2H3), 1.53 (t, J = 1.0 
Hz, 1H, H7), 1.34 (s, 3H, CH3), 1.23 (s, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 
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170.6 (s, C1), 109.7 (s, C1’’), 76.5 (s), 73.8 (d, C2’), 68.6 (s), 66.3 (t), 66.1 (s), 65.9 (d), 65.1 (t), 
32.4 (t), 26.9 (q), 25.6 (q), 14.9 (t) ppm. HRMS (ESI+): Calcd for C13H17O4 ([M + H]+), 
237.11214; found 237.11121. IR (NaCl): ν  3265 (m, C≡C-H), 2988 (m, C-H), 2938 (w, C-H), 
2889 (w, C-H), 2228 (w, -C≡C-), 1740 (s, C=O), 1372 (m), 1212 (m), 1165 (s), 1055 (m), 839 
(m) cm-1.  UV (MeOH): λmax  214, 224, 237, 250 nm. 
1-(Tert-butyldiphenylsilyloxy)-4-pentyne (32). To a cooled (0 ºC) stirred solution of pent-4-
yn-1-ol 31 (0.1 g, 1.19 mmol) in CH2Cl2 (4.3 mL) was added DMAP (8 mg, 0.06 mmol), Et3N 
z, CDCl3): δ 135.7 (d, 4x), 133.9 (s, 2x), 129.7 (d, 2x), 127.8 (d, 4x), 84.3 (s), 68.5 
.7 (d, 4x), 133.8 (s, 
(0.25 mL, 0.18 g, 1.82 mmol) and tert-butylchlorodiphenylsilane (0.38 mL, 0.40 g, 1.47 
mmol). After 24h stirring at room temperature, it was cooled down to 0 ºC, a saturated aqueous 
solution of NaHCO3 was added and the mixture was extracted with Et2O (3x). The combined 
organic layers were washed with brine, dried and the solvent was evaporated. The residue was 
purified by column chromatography (silica gel, 75:25 hexane/EtOAc) to afford 0.33 g (86%) 
of the titled product as a colourless oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.69 – 7.63 (m, 4H, 
ArH), 7.46 – 7.34 (m, 6H, ArH), 3.74 (t, J = 6.0 Hz, 2H, 2H1), 2.34 (td, J = 7.2, 2.6 Hz, 2H, 
2H3), 1.91 (t, J = 2.7 Hz, 1H, H5), 1.81 – 1.72 (m, 2H, 2H2), 1.04 (s, 9H) ppm. 13C-NMR 
(100.62 MH
(d), 62.4 (t), 31.6 (t), 27.0 (q), 19.4 (s), 15.1 (t) ppm. HRMS (ESI+): Calcd for C21H26OSiNa 
([M + Na]+), 345.16451; found, 345.16450. IR (NaCl): ν 3304 (w, C≡C−Η), 3069 (w), 2953 
(w, C-H), 2934 (w, C-H), 2860 (w), 1468 (w), 1428 (w), 1107 (s), 981 (w) cm-1.   
1-Tert-butyldiphenylsilyloxy-5-iodopent-4-yne (33). To a stirred solution of 1-tert-
butyldiphenylsilyloxy-4-pentyne 32 (0.13 g, 0.40 mmol) in acetone (1 mL), were added NIS 
(0.11 g, 0.48 mmol) and AgNO3 (0.07 g, 0.40 mmol) and the reaction mixture was stirred 
overnight at room temperature. The solvent was evaporated and the residue was purified by  
column chromatography (90:10 hexane/CH2Cl2) to afford 0.11 g (60%) of the titled 
compound as a yellow oil. 1H-NMR (400.13 MHz, CDCl3): δ 7.71 (dd, J = 7.5, 1.6 Hz, 4H), 
7.50 – 7.40 (m, 6H), 3.77 (t, J = 5.9 Hz, 2H, 2H1), 2.57 (t, J = 7.1 Hz, 2H, 2H3), 1.84 – 1.75 
(m, 2H, 2H2), 1.09 (s, 9H) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 135
2x), 129.7 (d, 2x), 127.8 (d, 4x), 94.4 (s), 62.2 (t), 31.4 (t), 27.0 (q), 19.4 (s), 17.5 (t), -7.0 (s, 
C5) ppm. HRMS (ESI+): Calcd for C21H26IOSi ([M + H]+), 449.07921; found, 449.07845. IR 
(NaCl): ν 3062 (w, C-H), 2936 (m, C-H), 2861 (m), 1467 (w), 1430 (w), 1105 (s), 997 (w), 
953 (w) cm-1.   
1-tert-Butyldiphenylsilyloxy-7-(trimethylsilyl)hepta-4,6-diyne (34). Following the general 
procedure for the Cadiot-Chodkiewicz cross-coupling reaction described above, the reaction of 
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1-tert-butyldiphenyloxy-5-iodopent-4-yne 33 (3.83 g, 8.56 mmol), trimethylsilylacetylene (3 
mL, 2.10 g, 21.38 mmol) and copper chloride (85 mg,  0.86 mmol) in degassed piperidine (6.7 
mL) at 0 ºC, afforded, after purification by column chromatography (silica gel, 98:2 
hexane/EtOAc), 3.62 g (100%) of the titled compound as a colourless oil. 1H-NMR (400.13 
MHz, C6D6): δ 7.75 – 7.63 (m, 4H), 7.31 – 7.18 (m, 6H), 3.52 (t, J = 5.9 Hz, 2H, 2H1), 2.13 (t, 
J = 7.0 Hz, 2H, 2H3), 1.49 – 1.39 (m, 2H, 2H2), 1.10 (s, 9H, Sit-Bu), 0.09 (s, 9H, SiMe3) ppm. 
13C-NMR (100.62 MHz, C6D6): δ 136.0 (d, 4x), 134.0 (s, 2x), 130.0 (d, 2x), 128.1 (d, 4x), 
90.0 (s), 83.1 (s), 80.0 (s), 67.0 (s), 62.2 (t), 31.2 (t), 27.1 (q, C(CH3)3), 19.4 (s, C(CH3)3), 15.9 
(t), -0.2 (q, 3x, Si(CH3)3) ppm. HRMS (ESI+): Calcd for C26H35OSi2 ([M + H]+), 419.22210; 
found 419.22211. IR (NaCl): ν  3066 (w, Ar-H), 2954 (m, C-H), 2861 (w, C-H), 2223 (w, -
C≡C-), 2107 (w, -C≡C-), 1427 (w), 1251 (w), 1110 (m), 844 (s), 772 (s) cm-1. UV (MeOH): 
λmax 219 nm. 
1-tert-Butyldiphenyloxy-hepta-4,6-diyne (35). General procedure for deprotection of 
trimethylsilylalkynes. Method B. Potassium carbonate (1.43 g, 10.38 mmol) was added o a 
cooled (0 ºC) stirred solution of 1-tert-butyldiphenyloxy-7-(trimethylsilyl)hepta-4,6-diyne 34 
(3.62 g, 8.65 mmol) in MeOH (33 mL). After stirring for 15 min the reaction mixture was 
passed through a pad of Celite and the solvent was removed under vacuum. The residue was 
purified by column chromatography (silica gel, 98:2 hexane/EtOAc) to provide 2.86 g (95%) 
of a colourless oil that was identified as the titled product. 1H-NMR (400.13 MHz, C6D6): 
δ 7.75 – 7.62 (m, 4H), 7.29 – 7.20 (m, 6H), 3.51 (t, J = 5.9 Hz, 2H, 2H1), 2.09 (t, J = 7.0 Hz, 
2H, 2H3), 1.48 (s, 1H, H7), 1.47 – 1.39 (m, 2H, 2H2), 1.10 (s, 9H, Sit-Bu) ppm. 13C-NMR 
(100.62 MHz, C6D6): δ 135.9 (d, 4x), 134.0 (s, 2x), 130.0 (d, 2x), 128.1 (d, 4x), 78.2 (s), 69.1 
(s), 65.9 (s), 65.2 (d), 62.2 (t), 31.0 (t), 27.1 (q, C(CH3)3), 19.4 (s, C(CH3)3), 15.6 (t) ppm. 
HRMS (ESI+): Calcd for C23H27OSi ([M + H]+), 347.18257; found 347.18251. IR (NaCl): ν  
3304 (m, C≡C-H), 3071 (w, Ar-H), 3048 (w, Ar-H), 2956 (m, C-H), 2931 (m, C-H), 2858 (m, 
C-H), 2225 (w, -C≡C-), 1471 (w), 1427 (m), 1110 (s), 702 (s) cm-1.  
1-(tert-Butyldiphenylsilyloxy)-tricosa-4,6-diyn-8-one (36b). Following the general 
procedure for the synthesis of propargylic ketones described above, the reaction of N-methoxy-
N-methylhexadecanamide 6b (0.19 g, 0.63 mmol), 1-tert-butyldiphenylsilyloxy-hepta-4,6-
diyne 35 (0.30 g, 0.88 mmol) and n-butyllithium (0.49 mL, 1.54 M in THF, 0.76 mmol) in 
THF (5.2 mL) at -40 ºC afforded, after purification by column chromatography (silica gel, 
90:8:2 hexane/CH2Cl2/EtOAc), 0.38 g (74%) of a yellow oil that was identified as the titled 
compound. 1H-NMR (400.13 MHz, CDCl3): δ 7.68 (dd, J = 7.7, 1.2 Hz, 4H, ArH), 7.49 – 7.36 
239 
Synthetic Approaches to Acetoxyenediynes 
(m, 6H, ArH), 3.75 (t, J = 5.8 Hz, 2H, 2H1), 2.63 – 2.49 (m, 4H, 2H3 + 2H9), 1.88 – 1.75 (m, 
2H, 2H2), 1.75 – 1.62 (m, 2H, 2H10), 1.36 – 1.21 (m, 24H, 12 x -CH2-), 1.08 (s, 9H, 
SiC(CH3)), 0.90 (t, J = 6.7 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 187.5 (s), 
135.6 (d, 4x), 133.6 (s, 2x), 129.8 (d, 2x), 127.8 (d, 4x), 90.3 (s), 76.2 (s), 72.4 (s), 64.1 (s), 
62.0 (t), 45.7 (t) , 32.0 (t), 30.7 (t), 29.8 (t, 4x), 29.8 (t), 29.8 (t), 29.7 (t), 29.6 (t), 29.5 (t), 29.4 
(t), 29.1 (t), 26.9 (q, 3x, C(CH3)3), 24.1 (t), 22.8 (t), 19.3 (s, C(CH3)3), 16.4 (t), 14.3 (q) ppm. 
HRMS (ESI+): Calcd for C39H57O2Si ([M + 1]+), 585.41223; found, 585.41177. IR (NaCl): ν 
3071 (w, C-H), 3049 (w, C-H), 2925 (s, C-H), 2854 (s, C-H), 2233 (s, -C≡C-), 2143 (w, -C≡C-
), 1672 (s, C=O), 1110 (s), 702 (s) cm-1. UV (MeOH): λmax  256, 269, 285 nm. 
(8E)- and (8Z)-1-(tert-Butyldiphenylsilyloxy)-tricosa-7-en-4,6-diyn-8-yl Acetate (37b). 
Following the general procedure for the synthesis of enol acetates described above, the reaction 
of 1-(tert-butyldiphenylsilyloxy)-tricosa-4,6-diyn-8-one 36b (0.38 g, 0.65 mmol), Et3N (0.45 
mL, 0.33 g,  3.24 mmol), DMAP (0.04 g, 0.32 mmol) and acetic anhydride (0.37 mL, 0.40 g, 
3.89 mmol) in CH2Cl2 (8 mL) at 0 ºC afforded, after purification by  column chromatography 
(silica gel, 95:5 hexane/EtOAc), 0.38 g (93%) of a colourless oil that was identified as the 
titled compound as a 59:41 Z:E mixture of isomers. These were separated by HPLC 
(Spherisorb 5 μm, 10x250 mm, 98:2 hexane/EtOAc, 3 mL/min, tR(Z)= 12.7 min and tR RR
9), 
(E)= 
15.6 min).  
(8Z)-1-(tert-Butyldiphenylsilyloxy)-tricosa-7-en-4,6-diyn-8-yl Acetate (Z)-37b. 1H-NMR 
(400.13 MHz, C6D6) δ 7.77 – 7.65 (m, 4H), 7.31 – 7.20 (m, 6H), 5.65 (t, J = 7.7 Hz, 1H, H
3.51 (t, J = 5.9 Hz, 2H, 2H1), 2.14 (t, J = 7.0 Hz, 2H, 2H3), 2.02-1.88 (m, 2H, 2H10), 1.62 (s, 
3H, OC(O)CH3), 1.48 – 1.39 (m, 2H, 2H2), 1.36 – 1.20 (m, 18H, 9 x -CH2-), 1.20 – 1.14 (m, 
6H, 3 x -CH2-), 1.12 (s, 9H, Sit-Bu), 0.92 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 
MHz, C6D6) δ 167.3 (s), 136.0 (d, 4x), 134.0 (s, 2x), 131.5 (d), 130.3 (d), 130.0 (d, 2x), 128.2 
(d, 4x), 85.9 (s), 75.0 (s), 70.30 (s), 65.9 (s), 62.2 (t), 32.4 (t), 31.1 (t), 30.2 (t, 4x), 30.1 (t), 30.0 
(t), 29.9 (t), 29. 8 (t), 29.5 (t), 28.7 (t), 27.1 (q, 3x, C(CH3)3), 26.7 (t), 23.2 (t), 19.9 (q), 19.4 (s, 
C(CH3)3), 16.2 (t), 14.4 (q) ppm. HRMS (ESI+): Calcd for C41H59O3Si ([M + H]+), 
627.42280; found, 627.42333. IR (NaCl): ): ν 2925 (s, C-H), 2854 (m, C-H), 1769 (m, C=O), 
1427  (w), 1197 (m), 1110 (s) cm-1.  UV (MeOH): λmax  215, 239, 252, 266, 282 nm. 
(8E)-1-(tert-Butyldiphenylsilyloxy)-tricosa-7-en-4,6-diyn-8-yl Acetate (E)-37b. 1H-NMR 
(400.13 MHz, C6D6) δ 7.78 – 7.66 (m, 4H), 7.32 – 7.21 (m, 6H), 5.69 (t, J = 8.0 Hz, 1H, H9), 
3.49 (t, J = 5.9 Hz, 2H, 2H1), 2.29 – 2.19 (m, 2H, 2H10), 2.14 (t, J = 7.0 Hz, 2H, 2H3), 1.61 (s, 
3H, OC(O)CH3), 1.46 – 1.38 (m, 2H, 2H2), 1.37 – 1.17 (m, 24H, 12 x -CH2-), 1.12 (s, 9H, Sit-
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Bu), 0.92 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6) δ 168.0 (s, 
OC(O)CH3), 136.0 (d, 4x), 134.0 (s, 2x), 132.0 (d), 130.7 (s), 130.0 (d, 2x), 128.2 (d, 4x), 87.1 
(s), 79.8 (s), 68.1 (s), 65.7 (s), 62.2 (t), 32.4 (t), 31.1 (t), 30.2 (t), 30.2 (t, 4x), 30.0 (t), 29.9 (t, 
2x), 29.4 (t), 29.3 (t), 28.4 (t), 27.1 (q, 3x, C(CH3)3), 23.2 (t), 20.1 (q, OC(O)CH3), 19.4 (s, 
C(CH3)3), 16.2 (t), 14.4 (q) ppm. HRMS (ESI+): Calcd for C41H59O3Si ([M + H]+), 
627.42280; found, 627.42383. IR (NaCl): ν 2925 (s, C-H), 2854 (m, C-H), 1771 (m, CO), 
1428 (w), 1204 (s), 1108 (s) cm-1.  UV (MeOH): λmax 216, 240, 252, 266, 282 nm. 
(8E)- and (8Z)-1-Hydroxytricosa-7-en-4,6-diyn-8-yl Acetate (38b). Following the general 
procedure for the deprotection of triisopropylsilylalkynes described above, the reaction of a 
59:41 mixture of (8Z)- and (8E)-1-(tert-butyldiphenylsilyloxy)-tricosa-7-en-4,6-diyn-8-yl 
acetate 37b (0.21 g, 0.33 mmol) with n-Bu4NF (0.36 mL, 1M in THF, 0.36 mmol) in THF (9 
mL) afforded, after purification by  column chromatography (silica gel, 70:30 hexane/EtOAc), 
64 mg (50%) of the titled compound. The isomers were separated by HPLC (Spherisorb 5 μm, 
10x250 mm, 80:20 hexane/EtOAc, 3 mL/min, tR(E) =  21.2 min and tR RR(Z) = 23.8 min).  
(8E)-1-Hydroxytricosa-7-en-4,6-diyn-8-yl Acetate (E)-38b. 1H-NMR (400.13 MHz, 
CDCl3): δ 5.78 (t, J = 8.0 Hz, 1H, H9), 3.75 (t, J = 6.1 Hz, 2H, 2H1), 2.48 (t, J = 7.0 Hz, 2H, 
2H3), 2.31–2.21 (m, 2H, 2H10), 2.13 (s, 3H, OC(O)CH3), 1.85–1.74 (m, 2H, 2H2), 1.49–1.35 
(m, 2H, 2H11), 1.36–1.18 (m, 22H, 11 x -CH2-), 0.87 (t, J = 6.8 Hz, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, CDCl3): δ 169.0 (s), 132.3 (d), 129.7 (s), 86.2 (s), 78.9 (s), 67.1 (s), 65.2 (s), 
61.4 (t), 32.1 (t), 30.8 (t), 29.8 (t), 29.8 (t), 29.8 (t, 2x), 29.7 (t, 2x), 29.6 (t), 29.5 (t), 29.2 (t), 
29.0 (t), 28.1 (t), 22.8 (t), 20.9 (q), 16.2 (t), 14.3 (q) ppm. HRMS (ESI+): Calcd for C25H41O3 
([M + H]+), 389.30502; found, 389.30628. IR (NaCl): ): ν 3600-3200 (br, OH), 2924 (s, C-H), 
2853 (m, C-H), 2233 (w, -C≡C-), 1764 (m, C=O), 1365 (w), 1204 (m), 1093 (m) cm-1.  UV 
(MeOH): λmax  215, 240, 252, 266, 282 nm. 
(8Z)-1-Hydroxytricosa-7-en-4,6-diyn-8-yl Acetate (Z)-38b. 1H-NMR (400.13 MHz, 
CDCl3): δ 5.77 (t, J = 7.7 Hz, 1H, H9), 3.74 (t, J = 6.1 Hz, 2H, 2H1), 2.46 (t, J = 7.0 Hz, 2H, 
2H3), 2.17 (s, 3H, OC(O)CH3), 2.11 – 1.98 (m, 2H, 2H10), 1.88 – 1.70 (m, 2H, 2H2), 1.45 – 
1.15 (m, 24H, 12 x -CH2-), 0.88 (t, J = 6.8 Hz, 3H, CH3). 13C-NMR (100.62 MHz, CDCl3): δ 
168.2 (s), 131.8 (d), 129.2 (s), 85.1 (s), 74.1 (s), 69.3 (s), 65.2 (s), 61.4 (t), 32.1 (t), 30.9 (t), 
29.8 (t, 5x), 29.6 (t), 29.5 (t, 2x), 29.3 (t), 28.5 (t), 26.5 (t), 22.8 (t), 20.7 (q), 16.2 (t), 14.3 (q) 
ppm. HRMS (ESI+): Calcd for C25H41O3 ([M + H]+), 389.30502; found, 389.30616. IR 
(NaCl): ν 3600-3200 (br, OH), 2924 (s, C-H), 2853 (m, C-H), 2235 (w, -C≡C-), 1769 (m, 
C=O), 1371 (w), 1197 (s), 1069 (m) cm-1.  UV (MeOH): λmax  215, 239, 251, 265, 281 nm. 
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(8E)- and (8Z)-8-Acetoxytricosa-8-en-4,6-diynoic Acid (40b). General procedure for the 
Swern oxidation. To a cooled (– 60 ºC) stirred solution of oxalyl chloride (45 μL, 65 mg, 0.51 
mmol) in CH2Cl2 (4 mL) was added dropwise DMSO (68 μL, 69 mg, 0.88 mmol) and the 
reaction was stirred for 5 min at this temperature. Then, a solution of a 59:41 mixture of (8Z)- 
and (8E)-8-acetoxytetracosa-8-en-4,6-diyn-1-ol 38b (0.14 g, 0.36 mmol) in CH2Cl2 (4 mL) 
2PO4 (0.17 g, 1.40 mmol) in H2O (2.2 mL) 
 
was added. After stirring for 30 min, Et3N (0.34 mL, 0.24 g, 2.41 mmol) was added and the 
resulting solution was stirred for 10 min at -60 ºC. The mixture was allowed to warm to room 
temperature, poured into water and extracted with CH2Cl2 (3x). The combined organic layers 
were dried (Na2SO4) and the solvent was evaporated. The residue was used in the next step 
without further purification. 
General procedure for the Lindgren oxidation. To a solution of the residue obtained before 
(0.36 mmol) and 2-methyl-2-butene (0.17 mL, 0.11 g, 1.61 mmol) in t-BuOH (5.5 mL), a 
solution of NaClO2  (0.16 g, 1.83 mmol) and NaH
was added dropwise. The reaction mixture was stirred for 2 h at 25 ºC, basified to pH 8 with a 
2M aqueous solution of NaOH and the t-BuOH was removed under vacuum. The resulting 
mixture was diluted with H2O and brine and then extracted with hexane (3x). The aqueous 
layer was acidified to pH 3 with a 0.5 N aqueous solution of HCl and extracted with Et2O (3x). 
The combined organic layers were dried (Na2SO4) and the solvent was evaporated. The 
residue was purified by column chromatography (silica gel, 95:5 CH2Cl2/MeOH) to afford 
102 mg (69% over two steps) of a white solid that was identified as the titled product. The 
isomers were separated by RP-HPLC (Phenomenex Luna 5 μm, 10x100 mm, 70:30 
acetonitrile/H2O with 0.1% formic acid, 3 mL/min, tR(E) =  23.0 min and tR RR(Z) = 28.0 min).  
(8E)-8-Acetoxytricosa-8-en-4,6-diynoic Acid (E)-40b. 1H-NMR (500 MHz, CDCl3): δ 5.79 
(t, J = 8.0 Hz, 1H, H9), 2.71 – 2.59 (m, 4H, 2H2 + 2H3), 2.30 – 2.22 (m, 2H, 2H10), 2.13 (s, 
3H, OC(O)CH3), 1.46 – 1.37 (m, 2H, 2H11), 1.36 – 1.19 (m, 22H, 11 x -CH2-), 0.88 (t, J = 6.9 
Hz, 3H, CH3) ppm. 13C-NMR (126 MHz, CDCl3): δ 175.9 (s), 169.2 (s), 132.7 (d), 130.0 (s), 
84.5 (s), 79.0 (s), 68.0 (s), 65.8 (s), 32.8 (t), 32.4 (t), 32.2 (t), 30.2 (t, 6x), 29.4 (t, 2x), 29.2 (t), 
29.0 (t), 23.1 (t), 19.7 (q), 15.7 (t), 14.5 (q)  ppm. HRMS (ESI+): Calcd for C25H39O4 ([M + 
H]+), 403.28429; found, 403.28444. IR (NaCl): ν 3300-3000 (br, O-H), 2924 (s, C-H), 2853 
(m, C-H), 1763 (m, C=O), 1714 (m, C=O), 1204 (s), 1093 (w) cm-1.  UV (MeOH): λmax  216, 
239, 252, 266, 282 nm. 
(8Z)-8-Acetoxytricosa-8-en-4,6-diynoic Acid (Z)-40b. 1H-NMR (500 MHz, CDCl3): δ 5.79 
(t, J = 7.7 Hz, 1H, H9), 2.70 – 2.57 (m, 4H, 2H2 + 2H3), 2.18 (s, 3H, OC(O)CH3), 2.09-1.97 
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(m, 2H, 2H10), 1.39 – 1.18 (m, 22H, 12 x -CH2-), 0.87 (t, J = 7.1 Hz, 3H, CH3) ppm. 13C-
NMR (126 MHz, CDCl3): δ 176.5 (s), 168.4 (s), 131.9 (d), 129.2 (s), 84.2 (s), 74.1 (s), 69.5 
(s), 65.2 (s), 45.7 (t), 32.0 (t), 29.8 (t, 5x), 29.7 (t), 29.5 (t, 2x), 29.4 (t), 28.6 (t), 26.5 (t), 22.8 
(t), 20.6 (q), 15.0 (t), 14.3 (q) ppm. HRMS (ESI+): Calcd for C25H38O4Na ([M + Na]+), 
425.26623; found, 425.26679. IR (NaCl): ν 3300-3000 (br, O-H), 2924 (s, C-H), 2852 (m, C-
less 
 chromatography 
d), 
cm-1.  UV (MeOH): λmax 255, 270, 285 nm. 
H), 1769 (m, C=O), 1713 (m, C=O), 1196 (s) cm-1.  UV (MeOH): λmax  215, 239, 252, 266, 
281 nm. 
(8E,2’R)- and (8Z,2’R)-2,3-O-Isopropylidene-2,3-Dihydroxyprop-1-yl 8-Acetoxytricosa-8-
en-4,6-diynoate (E,R)-12b. General procedure for ester formation. To a stirred solution of 
a 59:41 E/Z mixture of isomers of 8-acetoxytricosa-8-en-4,6-diynoic acid 40b (45 mg, 0.11 
mmol), DCC (23 mg, 0.11 mmol) and DMAP (14 mg, 0.11 mmol) in CH2Cl2 (0.3 mL) was 
added a solution of  (R)-2,3-O-isopropylidene-2,3-dihydroxy-1-propanol (R)-41 (14 μL, 45 
mg, 0.34 mmol) in CH2Cl2 (0.3 mL). After stirring the resulting mixture at room temperature 
overnight, the solvent was evaporated and the residue was purified by column chromatography 
(silica gel, 75:25 hexane/EtOAc) to afford 25 mg (58%) of the titled compound as a colour
oil. 
 (12Z,15Z)-1-(tert-Butyldiphenylsilyloxy)-octadeca-4,6-diyn-8-one (36a). Following the 
general procedure for the synthesis of propargylic ketones described above, the reaction of 
(5Z,8Z)-N-methoxy-N-methylundeca-5,8-dienamide 6a (1.0 g, 4.44 mmol), 1-tert-
butyldiphenyloxy-hepta-4,6-diyne 35 (2.16 g, 6.22 mmol) and n-butyllithium (3.6 mL, 1.50 M 
in THF, 5.33 mmol) in THF at -40 ºC afforded, after purification by column
(silica gel, 98:2 hexane/EtOAc), 2.08 g (92%) of a colourless oil that was identified as the 
titled compound. 1H-NMR (400.13 MHz, C6D6): δ 7.76 – 7.60 (m, 4H, ArH), 7.32 – 7.19 (m, 
6H, ArH), 5.47 – 5.29 (m, 3H), 5.26 – 5.13 (m, 1H), 3.48 (t, J = 5.8 Hz, 2H, 2H1), 2.72 (t, J = 
6.8 Hz, 2H, 2H14), 2.22 (t, J = 7.3 Hz, 2H, 2H3), 2.10 (t, J = 7.0 Hz, 2H, 2H9), 2.05 – 1.95 (m, 
2H, 2H11), 1.92 – 1.83 (m, 2H, 2H17), 1.59 – 1.49 (m, 2H, 2H10), 1.45 – 1.36 (m, 2H, 2H2), 
1.10 (s, 9H, Sit-Bu), 0.92 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): 
δ 185.8 (s), 135.9 (d, 4x), 133.8 (s, 2x), 132.1 (d), 130.1 (d, 2x), 129.6 (d), 128.9 (d), 128.2 (
127.6 (d, 4x), 90.0 (s), 75.4 (s), 73.2 (s), 64.7 (s), 62.1 (t), 44.9 (t), 30.8 (t), 27.1 (q, 3x), 26.5 
(t), 25.9 (t), 23.9 (t), 20.9 (t), 19.4 (s), 16.2 (t), 14.6 (q) ppm. HRMS (ESI+): Calcd for 
C34H43O2Si ([M + H]+), 511.30268; found, 511.30291. IR (NaCl): ν 2959 (m, C-H), 2930 (m, 
C-H), 2857 (m, C-H), 2231 (s, -C≡C-), 2142 (w, -C≡C-), 1671 (s, C=O), 1427 (m), 1109 (s) 
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(8E,12Z,15Z)- and (8Z,12Z,15Z)-1-(tert-Butyldiphenylsilyloxy)octadeca-8-en-4,6-diyn-8-yl 
Acetate (37a). Following the general procedure for the synthesis of enol acetates (Method F) 
-yl 
) e 6
t
P-HPLC (Phenomenex Luna 5 μm, 10x100 mm, 
described above, the reaction of (12Z,15Z)-1-(tert-butyldiphenylsilyloxy)-octadeca-4,6-diyn-8-
one 36a (0.42 g, 0.82 mmol), 1,1,3,3-tetramethyl-1,3-diphenyldisilazane (0.36 mL, 0.35 g, 
1.24 mmol), n-butyllithium (0.66 mL, 1.50 M in THF, 0.99 mmol) and acetic anhydride (0.39 
mL, 0.42 g, 4.12 mmol) in THF (16.5 mL) at -78 ºC afforded, after purification by column 
chromatography (silica gel, 97:3 hexane/EtOAc), 0.23 g (50%) of a colourless oil that was 
identified as the titled product as a 33:67 mixture of E/Z isomers. 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-1-(tert-Butyldiphenylsilyloxy)octadeca-8-en-4,6-diyn-8
Acetate (37a). Following the general procedure for the synthesis of enol acetates (Method G) 
described above, the reaction of (12Z,15Z)-1-(tert-butyldiphenylsilyloxy -octad ca-4, -diyn-8-
one 36a (0.83 g, 1.63 mmol), hexamethyldisilazane (0.51 μL, 0.39 g,  2.44 mmol), n-
butyllithium (1.28 mL, 1.50 M in THF, 1.92 mmol) and acetic anhydride (0.77 μL, 0.83 g, 
8.13 mmol) in THF (32 mL) at -78 ºC afforded, after purification by column chromatography 
(silica gel, 97:3 hexane/EtOAc), 0.74 g (82%) of a colourless oil that was identified as the 
titled product as a 87:13 mixture of E/Z isomers. 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-1-hydroxyoctadeca-8-en-4,6-diyn-8-yl acetate (38a). 
Following the general procedure for the deprotection of triisopropylsilylalkynes described 
above, the reaction of a 33:67 mixture of (8E,12Z,15Z)- and (8Z,12Z,15Z)-1-(tert-
butyldiphenylsilyloxy)oc adeca-8-en-4,6-diyn-8-yl acetate 37a (0.12 g, 0.22 mmol) with n-
Bu4NF (0.24 mL, 1M in THF, 0.24 mmol) in THF (6 mL) afforded, after purification by 
column chromatography (silica gel, 60:40 hexane/EtOAc), 0.04 g (59%) of the titled 
compound. The isomers were separated by R
50:50 acetonitrile/H2O with 0.1% formic acid, 3 mL/min, tR(E) =  27 min and tR RR
e 8
butyldiphenylsilyloxy)octadeca-8-en-4,6-diyn-8-y cetate 37a (0.39 g, 0.71 mmol) with n-
4,6-d
1 14 3
(Z) = 31 min). 
Following the general procedure for the deprotection of triisopropylsilylalkynes described 
above, the reaction of a 87:13 mixtur  of ( E,12Z,15Z)- and (8Z,12Z,15Z)-1-(tert-
l a
Bu4NF (0.78 mL, 1M in THF, 0.78 mmol) in THF (20 mL) afforded, after purification by 
column chromatography (silica gel, 60:40 hexane/EtOAc), 0.10 g (46%) of the titled 
compound. 
(8E,12Z,15Z)-1-Hydroxyoctadeca-8-en- iyn-8-yl Acetate (E)-38a. 1H-NMR (400.13 
MHz, CDCl3): δ 5.79 (t, J = 7.9 Hz, 1H, H9), 5.48 – 5.23 (m, 4H, H12 + H13 + H15 + H16), 
3.75 (t, J = 6.1 Hz, 2H, 2H ), 2.77 (t, J = 6.4 Hz, 2H, 2H ), 2.48 (t, J = 7.0 Hz, 2H, 2H ), 
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2.42-2.27 (m, 2H, 2H10 or 2H11), 2.24-2.17 (m, 2H, 2H10 or 2H11), 2.14 (s, 3H, OC(O)CH3), 
2.11 – 2.01 (m, 2H, 2H17), 1.88 – 1.73 (m, 2H, 2H2), 0.97 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-
NMR (100.62 MHz, CDCl3): δ 168.9 (s), 132.2 (d), 131.3 (d), 130.0 (s, C8), 129.6 (d), 128.2 
(d), 127.1 (d), 86.4 (s), 79.2 (s), 66.9 (s), 65.1 (s), 61.4 (t), 30.8 (t), 28.1 (t), 26.7 (t), 25.7 (t), 
20.9 (q), 20.7 (t), 16.2 (t), 14.4 (q) ppm. HRMS (ESI+): Calcd for C20H27O3 ([M + H]+), 
315.19547; found, 315.19551. IR (NaCl): ν 3600−3100 (br, O-H), 3009 (w, C-H), 2930 (m, C-
H), 2234 (m, -C≡C-), 1761 (s, C=O), 1366 (m), 1203 (s), 1090 (m) cm-1. UV (MeOH): λmax 
252, 267, 282 nm. 
(8Z,12Z Z)-1-Hydroxyoctadeca-8-en-4,6-diyn-8-yl Acetate (Z)-38a. 1H-NMR (400.13 
MHz, CDCl3): δ 5.77 (t, J = 7.5 Hz, 1H, H9), 5.48 – 5.16 (m, 4H, H12 + H13 + H15 + H16), 
3.73 (t, J = 6.1 Hz, 2H, 2H1), 2.75 (t, J = 7.1 Hz, 2H, 2H14), 2.45 (t, J = 7.0 Hz, 2H, 2H3), 2.17 
(s, 3H, OC(O)C
,15
H3), 2.15 – 2.10 (m, 4H, 2H10 + 2H11), 2.10 – 2.01 (m, 2H, 2H17), 1.83 – 1.74 
(m, 2H, 2H2), 0.96 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, CDCl3): δ 168.2 
(s), 132.2 (d), 130.7 (d), 129.7 (d), 130.0 (s, C8), 129.5 (d), 128.2 (d), 127.0 (d), 85.2 (s), 74.3 
(s), 69.1 (s), 65.1 (s), 61.4 (t), 30.8 (t), 26.5 (t), 26.1 (t), 25.6 (t), 20.7 (q), 20.6 (t), 16.2 (t), 14.4 
(q) ppm. HRMS (ESI+): Calcd for C20H27O3 ([M + H]+), 315.19547; found, 315.19547. IR 
(NaCl): ν 3600−3100 (br, O-H), 3009 (w, C-H), 2959 (m, C-H), 2235 (w, -C≡C-), 1767 (s, 
C=O), 1372 (w), 1196 (s), 1064 (m) cm-1.  UV (MeOH): λmax 215, 239, 252, 266, 282 nm. 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-8-Acetoxyoctadeca-8-en-4,6-diynoic Acid (40a). 
Following the general procedure for the Swern oxidation described above, the reaction of a 
33:67 mixture of isomers of (8E,12Z,15Z)- and (8Z,12Z,15Z)-1-hydroxyoctadeca-8-en-4,6-
diyn-8-yl acetate 38a (0.04 g, 0.13 mmol), oxalyl chloride (16 μL, 23 mg, 0.18 mmol), DMSO 
(24 μL,  24 mg, 0.30 mmol) and Et3N (0.12 mL, 0.08 g, 0.84 mmol) in CH2Cl2 (3 mL) 
afforded a residue that was used in the next step without further purification. 
Following the general procedure for the Lindgren oxidation described above, the reaction of 
the residue obtained above (0.13 mmol), 2-methyl-2-butene (59 μL, 0.04 g, 0.56 mmol), 
NaClO2  (0.06 g, 0.64 mmol) and NaH2PO4 (0.06 g, 0.49 mmol) in a mixture of t-BuOH (2 
mL) and H2O (1 mL) afforded, after purification by column chromatography (silica gel, 97:3 
CH2Cl2/MeOH), 31 mg (74% over two steps) of a white solid that was identified as the titled 
product. The isomers were separated by RP-HPLC (Phenomenex Luna 5 μm, 10x100 mm, 50: 
50 acetonitrile/H2O with 0.1% formic acid, 3 mL/min, tR(E) =  22 min and tR(Z) = 26 min). 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-8-Acetoxyoctadeca-8-en-4,6-diynoic Acid (40a). 
Following the general procedure for the Swern oxidation described above, the reaction of a 
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87:13 mixture of isomers of (8E,12Z,15Z)- and (8Z,12Z,15Z)-1-hydroxyoctadeca-8-en-4,6-
diyn-8-yl acetate 38a (0.05 g, 0.16 mmol), oxalyl chloride (20 μL, 29 mg, 0.23 mmol), DMSO 
(31 μL,  31 mg, 0.39 mmol) and Et3N (0.15 mL, 0.11 g, 1.07 mmol) in CH2Cl2 (3.7 mL) 
afforded a residue that was used in the next step without further purification. 
Following the general procedure for the Lindgren oxidation described above, the reaction of 
the residue obtained above (0.13 mmol), 2-methyl-2-butene (76 μL, 0.05 g, 0.72 mmol), 
NaClO2  (74 mg, 0.81 mmol) and NaH2PO4 (0.08 g, 0.62 mmol) in a mixture of t-BuOH (2.4 
mL) and H2O (1 mL) afforded, after purification by column chromatography (silica gel, 97:3 
CH2Cl2/MeOH), 41 mg (78% over two steps) of a white solid that was identified as the titled 
product. The isomers were separated by RP-HPLC (Phenomenex Luna 5 μm, 10x100 mm, 50: 
50 acetonitrile/H2O with 0.1% formic acid, 3 mL/min, tR(E) =  22 min and tR(Z) = 26 min). 
 (8E,12Z,15Z)-8-Acetoxyoctadeca-8-en-4,6-diynoic Acid (E)-40a. 1H-NMR (400.13 
MHz, CDCl3): δ 5.80 (t, J = 7.9 Hz, 1H, H9), 5.48 – 5.24 (m, 4H, H12 + H13 + H15 + H16), 
2.77 (t, J = 6.7 Hz, 2H, 2H14), 2.70 – 2.57 (m, 4H, 2H2 + 2H3), 2.39 – 2.28 (m, 2H, 2H10), 
2.24 – 2.16 (m, 2H, 2H11), 2.14 (s, 3H, OC(O)CH3), 2.11 – 2.00 (m, 2H, 2H17), 0.97 (t, J = 
7.5 Hz, 3H, CH3) ppm. 1H-NMR (400.13 MHz, C6D6): δ 5.78 (t, J = 7.9 Hz, 1H, H9), 
5.60 – 5.47 (m, 3H), 5.47 – 5.36 (m, 1H), 2.84 (t, J = 6.7 Hz, 2H, 2H14), 2.34 (dd, J = 14.9, 
7.4 Hz, 2H, 2H2), 2.26 – 1.92 (m, 8H, 2H3 + 2H10 + 2H11 + 2H17), 1.67 (s, 3H, 
OC(O)CH3), 1.03 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): 
δ 183.6 (s), 168.0 (s), 132.1 (d), 131.4 (d), 130.8 (s), 129.7 (d), 128.7 (d), 127.6 (d), 85.3 
(s), 79.6 (s), 68.6 (s), 65.9 (s), 30.2 (t), 28.3 (t), 26.8 (t), 25.9 (t), 20.9 (t), 20.1 (q), 15.5 (t), 
14.5 (q) ppm. HRMS (ESI+): Calcd for C20H25O4 ([M + H]+), 329.17474; found, 
329.17469. IR (NaCl): ν 3500-3000 (br, O-H), 3011 (m, C-H), 2924 (s, C-H), 2851 (s, C-
H), 2236 (w, -C≡C-), 1756 (s, C=O), 1715 (m, C=O), 1422 (m), 1365 (m), 1203 (s), 1088 
(s), 1027 (m) cm-1.  UV (MeOH): λmax 215, 240, 252, 267, 282 nm. 
 (8Z,12Z,15Z)-8-Acetoxyoctadeca-8-en-4,6-diynoic Acid (Z)-40a. 1H-NMR (400.13 MHz, 
C6D6): δ 5.61 (t, J = 7.4 Hz, 1H, H9), 5.46 – 5.31 (m, 3H), 5.27 – 5.18 (m, 1H), 2.71 (t, J = 6.9 
Hz, 2H, 2H14), 2.10 – 1.87 (m, 10H, 2H2 + 2H3 + 2H10 + 2H11 + 2H17), 1.57 (s, 3H, 
OC(O)CH3), 0.92 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C-NMR (100.62 MHz, C6D6): δ 176.5 (s), 
167.3 (s), 132.2 (d), 131.0 (d), 130.3 (s), 129.7 (d), 128.4 (d), 127.4 (d), 84.1 (s), 74.7 (s), 70.7 
(s), 66.0 (s), 32.3 (t), 26.7 (t), 26.3 (t), 25.9 (t), 20.9 (t), 19.8 (q), 15.2 (t), 14.5 (q) ppm. HRMS 
(ESI+): Calcd for C20H24O4Na ([M + Na]+), 351.15668; found, 351.15648. IR (NaCl): 
ν 3500-3000 (br, O-H), 3010 (m, C-H), 2963 (m, C-H), 2932 (m, C-H), 2237 (w, -C≡C-), 1766 
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(s, C=O), 1714 (s, C=O), 1431 (m), 1370 (m), 1198 (s), 1017 (m) cm-1.  UV (MeOH): λmax 
215, 239, 252, 266, 282 nm. 
(8E,12Z,15Z)- and (8Z,12Z,15Z)-(2’R)-2,3-O-Isopropylidene-2,3-dihydroxyprop-1-yl 8-
 
acetoxyo lidene-
2,3-dihy ol) and 
DM n 
chr as 
identified as the titled product. 
 
 
Acetoxyoctadeca-8,12,15-trien-4,6-diynoate (12a). Following the general procedure for ester
formation described above, the reaction of a 87:13 8E/8Z mixture of isomers of (12Z,15Z)-8-
ctadeca-8-en-4,6-diynoic acid 40a (29 mg, 0.09 mmol), (R)-2,3-O-isopropy
droxy-1-propanol (R)-41 (33 μL, 35 mg, 0.26 mmol), DCC (19 mg, 0.09 mm
AP (11 mg, 0.09 mmol) in CH2Cl2 (0.5 mL) afforded, after purification  by  colum
omatography (silica gel, 75:25 hexane/EtOAc), 18 mg (46%) of a colourless oil that w

  
 
7. SYNTHETIC APPROACHES TO SGI-
1027, A DNMT INHIBITOR, AND 
EFFECTS ON THE U937 LEUKEMIA 
CELL LINE 
 
 
 
The known DNMT inhibitor SGI-1027 4 has been synthesized using alternative sequential 
or convergent strategies that use Pd-catalyzed CAr-N bond formation reactions. In the 
former approach, by-product 13, which corresponds to the two-fold formation of CAr-N 
bonds of 4-chloroquinoline was also isolated. The biological effects of both DNMT1 
inhibitors 4 and 13 in the U937 human leukemia cell line are also described. 

Synthetic Approaches to SGI-1027 
7.1 Introduction 
Within the epigenetic modification in humans methylation of DNA at the C5 
position of cytosine in CpG nucleotide islands (and other regions of the genome, including 
the so-called DNA shores1) is known to play a key role in development,2 X-chromosome 
inactivation in females and genomic imprinting.3 In addition, cancer cells present a global 
loss of DNA methylation (hypomethylation),4 and increased de novo methylation 
(hypermethylation) of a subset of promoters of tumor suppressor genes.4,5 The transfer of 
the methyl group of S-adenosyl-L-methionine (S-AdoMet, SAM) to DNA is promoted by 
DNMT enzymes (a family that includes DNMT1, DNMT3A, DNMT3B, DNMT3L and 
DNMT2 in mammals, although the last two are inactive). DNMT3A and DNMT3B are de 
novo methyltransferases that establish embryonic methylation patterns, which are then 
copied to daughter cells during the S phase by the maintenance DNMT1.4,5b,6  
Inhibitors of DNA methyltransferases (DNMTis) and also of other epigenetic 
or suppressor genes and thereby decrease tumor cell growth.  
Two azanucleosides (5-aza-cytidine 1 and 5-aza-2’-deoxycytidine 2) are approved for the 
treatme
ine 3 (Figure 7.1), solves some of these limitations, presents 
greater
enzymes that modify chromatin, such as histone deacetylases (HDACis) can reactivate 
epigenetically silenced tum 7
nt of myelodysplastic syndrome. At low doses they sequester DNMTs leading to 
global demethylation as cell divide and DNA is repaired. Among the limitations of these 
drugs are the requirement for metabolic transformation into the corresponding 
triphosphates, their sensitivity to undergo deamination by cytidine or deoxycytidine 
deaminase, their instability in neutral aqueous solutions and their citotoxicity at higher 
doses. An analogue, zebular
 selectivity for tumour cells and can be administered orally.8 S110, is a 
dinucleotide of 5-aza-2´-deoxycytidine and deoxyguanosine, and has shown in mice a 
better stability and lower toxicity profiles than 2, retarding tumor growth in tumor 
                                                 
1 Irizarry, R. A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montano, C.; Onyango, P.; Cui, H.; Gabo, K.; Rongione, 
M.; Webster, M.; Ji, H.; Potash, J. B.; Sabunciyan, S.; Feinberg, A. P. Nat. Genet. 2009, 41, 178. 
 P. A. Nat. Biotech. 2010, 28, 1069. 
, 66, 2794. 
2 Ooi, S. K. T.; Bestor, T. H. Cell 2008, 133, 1145. 
3 Reik, W.; Lewis, A. Nat. Rev. Genet. 2005, 6, 403. 
4 Kelly, T. K.; De Carvalho, D. D.; Jones,
5 a. Esteller, M. Oncogene 2002, 21, 5427. b. Portela, A.; Esteller, M. Nat. Biotech. 2010, 28, 1057. 
6 Brown, R.; Strathdee, G. Trends Mol. Med. 2002, 8, S43. 
7 a. Sharma, S.; Kelly, T. K.; Jones, P. A. Carcinogenesis 2010, 31, 27 . b. Taby, R.; Issa, J.-P. J. CA Cancer 
J. Clin. 2010, 60, 376. 
8 Stresemann, C.; Brueckner, B.; Musch, T.; Stopper, H.; Lyko, F. Cancer Res. 2006
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xenografts.9 Both 5-aza-2'-deoxycytidine and zebularine 3 have also antiangiostatic 
activity in addition to their inhibitory effects on tumor cells.10 
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Figure 7.1. Selected DNMT inhibitors (DNMTis). 
Among the non-nucleoside DNMT inhibitors reported,11 the quinoline-based 
compound SGI-1027 4 is noteworthy, since it inhibits in vitro with micromolar IC50 values 
DNMT1, DNMT3A and DNMT3B12 by competing with SAM in the methylation reaction. 
Treatment of cancer cell lines with SGI-1027 induced DNMT1 degradation (but not 
DNMT3A or DNMT3B) via the proteasome,12 a mechanism also shared by 5-aza-2’-
deoxycytidine 2.13 Upon treatment with SGI-1027 4 RKO cells showed reexpression of the 
silenced tumor supressor genes p16, MLH1 and TIMP3, whereas rat hepatoma cell line did 
not exhibit significant toxicity.12 
The details on the five-step synthesis of SGI-1027 4 were not provided in the 
original submission,12 but can be found in the patent literature.14 In brief, the sequence 
entails the reaction of 4-nitroaniline 7 with 2-amino-4-chloro-6-methylpyrimidine 6 and 
reduction of the nitro group of 8 to afford the corresponding aniline 9, which was coupled 
with 4-nitrobenzoyl chloride 10. A new reduction of the nitro group of amide 11 to the 
aniline 12 and substitution of 4-chloroquinoline 13 with the latter provided 4. Although the 
                                                 
9 Chuang, J. C.;
Jones, P. A. Mo
10
 Warner, S. L.; Vollmer, D.; Vankayalapati, H.; Redkar, S.; Bearss, D. J.; Qiu, X.; Yoo, C. B.; 
l. Cancer Ther. 2010, 9, 1443. 
 Hellebrekers, D. M. E. I.; Jair, K.-W.; Viré, E.; Eguchi, S.; Hoebers, N. T. H.; Fraga, M. F.; Esteller, M.; 
Fuks, F.; Baylin, S. B.; van Engeland, M.; Griffioen, A. W. Mol. Cancer Ther. 2006, 5, 467. 
11 Sippl, W.; Jung, M. In Epigenetics Targets in Drug Discovery; Wiley-VCH: Weinheim, 2009; p. 163. 
12 Datta, J.; Ghoshal, K.; Denny, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, 
K.; Jodrell, D.; Ramsahoye, B. Nucleic Acids Res. 2010, 38, 4313. 
ooke, D.; Denny, W.; Bearss, D. J.; Vankayalapati, H.  2008, 
S. T. Cancer Res. 2009, 69, 4277. 
13 Patel, K.; Dickson, J.; Din, S.; Macleod, 
14 Phiasivongsa, P.; Redkar, S.; Gamage, S.; Br
WO 2008046085  (A2). 
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overall yield reported was 17%,12 the yields for the individual steps shown in Scheme 7.1 
have been taken from the patent description.14  
 
Scheme 7.1. Original synthesis of SGI-1027.14 Reagents and reaction conditions: a. 2-ethoxyethanol, cat. 
conc. HCl, reflux, 30 min (8, 51%; 4, 4%). b. Fe, AcOH, EtOH/H2O  (9, 100%; 12, 90%). c. 10, dioxane, 50 
ºC, 5 day
proved conditions of 
precatalyst activation with water.17 In fact, the cross coupling reaction between the 
commercially available 4-nitroaniline 7 and 2-amino-4-chloro-6-methylpyrimidine 6 led to 
the desired product 8 in good yields using Pd(OAc)2 as catalyst and a 
                                                
s (11, 41%).  
Taking into consideration the limitations of the synthesis due to the low yields in 
the substitution of (hetero)arylhalides by anilines (in particular the last step), and given the 
continuous development of palladium-catalyzed cross-coupling reactions15 spurred by the 
discovery of novel ligands and pre-catalysts,16 we felt there was room for improving the 
yields of the N-CAr bond formation steps and thus the overall yield of the above sequence 
using these methodologies.  
Selecting the same disconnections of the original disclosure (Scheme 7.1), we first 
examined these key N-CAr bond formation steps using Buchwald' im
 
15 a. Billingsley, K.; Buchwald, S. L. J. Am. Chem. Soc. 2007, 129, 3358. b. Biscoe, M. R.; Barder, T. E.;
Buchwald, S. L. Angew. Chem. In. Ed .2007, 46, 7232. c. Hartwig, J. F. Acc. Chem. Res. 2008, 41, 1534. d
Hartwig, J. F. Nature 2008, 455, 314. 
, J. F. J. Am. Chem. Soc. 2009, 131, 11049. 
17 Fors, B. P.; Krattiger, P.; Strieter, E.; Buchwald, S. L. Org. Lett. 2008, 10, 3505. 
 
. 
16 a. Anderson, K. W.; Tundel, R. E.; Ikawa, T.; Altman, R. A.; Buchwald, S. L. Angew. Chem. In. Ed.  2006, 
45, 6523 . b. Barder, T. E.; Buchwald, S. L. J. Am. Chem. Soc. 2007, 129, 12003. c. Biscoe, M. R.; Fors, B. 
P.; Buchwald, S. L. J. Am. Chem. Soc. 2008, 130, 6686. d. Surry, D. S.; Buchwald, S. L. Angew. Chem Ed. 
Int. 2008, 47, 6338. e. Vo, G. D.; Hartwig
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biaryldialkylphosphine (XPhos) as ligand (Scheme 7.2). Reduction of the nitro group using 
the recently reported zinc nanopowder catalyst in combination with ammonium chloride18 
e of decaborane in methanol in the 
presenc
ctive using either the formation 
of the acid chloride with thionyl chloride or the activation of the 4-nitrocarboxylic acid 
with EDCI and HOBt, owing to the poor solubility of the aniline 9 even under refluxing 
conditions. The use of the commercially available 4-nitrobenzoyl chloride 10 with excess 
aniline 9 and three equivalents of cesium carbonate in DMF20 afforded the desired product 
in moderate to good yields. Surprisingly, the reduction of the nitro group of 11 with Ni-
Raney led in this case to recovery of the starting material with only a small amount formed 
of the desired product, but the use of decaborane with catalytic amounts of Pd/C produced 
the aniline 12 in 94% yield. Application of Buchwald' conditions17 to the coupling of 12 
and commercially available 4-chloroquinoline 13 led surprisingly in 70% yield to product 
14, which corresponds to bond formation of both amine functions with the arylhalide. This 
n mixture, and was also favored by the 
ht in the case of 14; cf. 2 hours 
in the case of 8; not shown). Other solvents that are commonly used with Buchwald’ 
protoco
failed to give the corresponding amine, but the us
e of 10% Pd/C and acetic acid19 afforded the aniline 12 in good yield (93%). 
Owing to the use of acetic acid a monoacetylated derivative was obtained as by-product of 
the reduction. Recourse to the more classical conditions with Ni-Raney catalyst under a 
hydrogen atmosphere19 allowed to obtain the product 9 in a quantitative yield without need 
of further purification. The amide formation step was ineffe
result was ascribed to the poor solubility of the aniline 12 in t-BuOH, and the higher 
concentration of the aryl chloride 13 in the reactio
extended reaction times in this step of the synthesis (overnig
l, such as 1,4-dioxane, did not solve the solubility problem either. Changing to a 
tBuOH:DMF (1:1, v/v) solvent mixture and monitoring the reaction progress by LC-MS, 
the formation of SGI-1027 4 (yield of 73% estimated by 1H-NMR) could be optimized 
relative to that of bis-coupled compound 14, but with partial consumption of substrates. 
The difficult separation of the mixture using flash chromatography (even with reverse 
phase and using acetonitrile/H2O solvent mixtures as eluents) prompted us to modify the 
sequence. 
                                                 
18 Shaginian, A.; Whitby, L. R.; Hong, S.; Hwang, I.; Farooqi, B.; Searcey, M.; Chen, J.; Vogt, P. K.; Boger, 
otin, S. G. Synthesis 2001, 1659. 
D. L. J. Am. Chem. Soc. 2009, 131, 5564. 
19 Rogers, D. Z. J. Org. Chem. 1986, 51, 3904. 
20 Serebryakov, E. A.; Kislitsin, P. G.; Semenov, V. V.; Zl
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Scheme 7.2. First-generation synthesis of SGI-1027 4. Reagents and reaction conditions: a. Pd(OAc)2 (1 
mol%), XPhos (3 mol%), K2CO3, t-BuOH/H2O (96:4, v/v), 110 ºC, 76-85%. b. H2 (1 atm), Ni-Raney, 
EtOH, 100%. c. Cs2CO3, DMF, 25 ºC, 37-64%. d. B10H14, Pd/C, cat. AcOH, MeOH, reflux, 94%. e. 
Pd(OAc)2 (1 mol%), XPhos (3 mol%), K2CO3, t-BuOH/DMF (50:50, v/v), H2O (4 mol%), 110 ºC, 73% (by 
1H-NMR). 
Alternatively we explored a more convergent route using as last step the formation 
of the central amide bond by condensation of fragments 9 and 17, which have similar 
complexity. The latter was derived from 16, which was also obtained by the Pd-catalyzed 
CAr-N cross-coupling reaction17 between ethyl 4-aminobenzoate 15 and 4-chloroquinoline 
13 (85% yield) followed by saponification using excess lithium hydroxide (quantitative 
yield).  SGI-1027 4 was obtained in 59% yield by condensation of 9 and 17 using EDCI 
and HOBt as coupling agents in DMF. The second synthetic route has clear advantages 
relative to the first approach: fragments 9 and 17 are more soluble, the overall yield of the 
five steps is higher, and the formation of by-products is minimized.  
 
Scheme 7.3. Second-generation synthesis of SGI-1027 4.  Reagents and reaction conditions: a. Pd(OAc)2 (1 
mol%), XPhos (3 mol%), K2CO3, t-BuOH/H2O (96:4, v/v), 110 ºC, 85%. b. LiOH, THF/H2O, 100%. c. 
EDCI, HOBt, DMF, Et3N, 25 ºC, 59%.  
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7.2 Biological Evaluation 
7.2.1 SGI-1027 activity on human DNMT1 enzyme 
Confirming the previously described activity,12 SGI-1027 4 decreased human 
DNMT1 activity in vitro as shown after immunoprecipitation of K562 human cells 
followed by radioactive enzymatic assay. Similar inhibition was also measured for 14 at 
the same concentration (50 µM) (Fig. 7.2). Both compounds displayed a stronger 
inhibitory profile than RG10821 at the same concentration. 
 
Figure 7.2 Inhibition of DNMT1 enzymatic activity by SGI-1027 4 and its analogue 14 at 50 µM. DMSO 
and RG108 were used as control and reference, respectively. 
7.2.2 Effects of SGI-1027 4 on cell cycle  
Citofluorimetric analyses carried out in U937 cells after 30 h of treatment with 
SGI-1027 or compound 14 at the concentration of 5 µM and 50 µM have been performed 
to evaluate their effects on cell cycle progression and apoptosis. As reference, RG108 and 
AZA were also included since these compounds are known inhibitors of DNMT1 and 
DNA methylation.8,21 As internal control MS-27522 at 5 µM was used, given its well 
characterized activity on U937 cells.31 Both SGI-1027 4 and analogue 14 increased, in a 
dose dependent manner, the amount of cells in pre-G1 after 30 h of treatment (Fig. 7.3A). 
No major alterations of the cell cycle phases were observed when SGI-1027 4 or 14 were 
used at 5 µM and 50 µM (Fig. 7.3B). 
                                                 
i
21Brueckner, B.; Garcia Boy, R.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; 
W essler, M.; Lyko, F. Cancer Res. 2005, 65, 6305. 
22 Rosato, R. R.; Grant, S. Cancer Biol.Ther. 2003, 2, 30. 
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Figure 7.3 Analysis of apoptosis (A) and cell cycle (B) after treatment of U937 cells with the indicated 
compounds for 30 hours. DMSO was used as control, and MS-275, 5-aza and RG108 were used as and 
reference. 
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7.3 Experimental Section 
General Procedures. Solvents (t-BuOH and EtOH) were dried according to published 
methods and distilled before use. THF, DMF and MeOH were dried using a PuresolvTM 
solvent purification system. Et3N was dried by distillation with CaH2. All other reagents were 
commercial compounds of the highest purity available. All reactions were carried out under 
argon atmosphere, and those not involving aqueous reagents were carried out in oven-dried 
glassware. All solvents and anhydrous solutions were transferred through syringes and 
cannulae previously dried in the oven for at least 12 h and kept in a dessicator with KOH. 
Analytical thin layer chromatography (TLC) was performed on aluminium plates with Merck 
Kieselgel 60F254 and visualised by UV irradiation (254 nm) or by staining with an ethanolic 
chromatography was carried out using Merck Kieselgel 60 (230-400 mesh) under pressure. 
UV/Vis spec
solution of phosphomolibdic acid or an ethanolic solution of anisaldehyde. Flash column 
tra were recorded with a Cary 100 Bio spectrophotometer in MeOH. IR spectra were 
6 H
v
 as follows: δ (multiplicity, coupling constant J, 
 at ambient 
obtained on a JASCO IR 4200 spectrophotometer from a thin film deposited onto NaCl glass. 
Mass spectra were obtained on a Hewlett-Packard HP59970 instrument operating at 70 eV by 
electron ionisation and APEX III FT-ICR MS (Bruker Daltonics, Billerica, MA), equipped 
with a 7T actively shielded magnet. Ions were generated using an Apollo API electrospray 
ionization (ESI) source, with a voltage between 1800 and 2200 V (to optimize ionisation 
efficiency) applied to the needle, and a counter voltage of 450 V applied to the capillary. 
Samples were prepared by adding a spray solution of 70:29.9:0.1 (v/v/v) CH3OH/water/formic 
acid to a solution of the sample at a v/v ratio of 1 to 5% to give the best signal-to-noise ratio. 
High-resolution mass spectra were taken on a VG Autospec instrument. 1H NMR spectra were 
recorded in DMSO-d6 at ambient temperature on a Bruker AMX-400 spectrometer at 400 
MHz with residual protic solvent as the internal reference [DMSO-d , δ  = 2.50 ppm]; 
chemical shifts (δ) are given in parts per million (ppm), and coupling constants (J) are gi en in 
Hertz (Hz). The proton spectra are reported
number of protons, assignment). 13C NMR spectra were recorded in DMSO-d6
temperature on the same spectrometer at 100 MHz, with the central peak of DMSO-d6 (δC = 
39.52 ppm) as the internal reference. The DEPT135 pulse sequence was used to aid in the 
assignment of signals in the 13C NMR spectra. 
N4-(4-Nitrophenyl)-2,4-diamino-6-methylpyrimidine (8). A sealed tube was charged 
with Pd(OAc)2 (14.1 mg, 0.021 mmol) and XPhos (0.03 g, 0.06 mmol) and degassed t-
258 
Synthetic Approaches to SGI-1027 
BuOH/water (4.3 mL, 2mL:1mL v/v) was added. The resulting solution was heated for 1 
min at 80 ºC. Potassium carbonate (0.40 g, 2.92 mmol), 4-nitroaniline 7 (0.35 g, 2.51 
mmol) and 2-amino-4-chloro-6-methylpyrimidine 6 (0.3 g, 2.09 mmol) were added and the 
reaction mixture was stirred for 1.5 hours at 110 ºC. When the reaction was completed it 
was cooled to room temperature, diluted with AcOEt, washed with water and the solvent 
concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 95:5 
CH2Cl2/MeOH) to afford 0.44 g (85%) of the titled compound as a yellow solid. 1H-NMR 
(400.13 MHz, DMSO-d6): δ 9.80 (s, 1H, NH), 8.13 (d, J = 9.3 Hz, 2H), 8.01 (d, J = 9.3 
Hz, 2H), 6.44 (s, 2H, NH2), 5.99 (s, 1H, H5), 2.14 (s, 3H, CH3) ppm. 13C-NMR (100.62 
MHz, DMSO-d6): δ 166.3 (s, C4), 162.7 (s, C6), 160.5 (s, C2), 147.6 (s), 139.9 (s), 124.8 
(d, 2x), 117.9 (d, 2x), 96.0 (d, C5), 23.5 (q, CH3) ppm. HRMS (ESI+): Calcd for 
C11H12N5O2, 246.09855; found, 246.09749. IR (neat, ATR): ν 3426 (w), 3350 (w), 3300 
304 
2 atmosphere the reaction was vigorously stirred for 24 h. 
(w) , 3098 (w), 2920 (w), 1639 (w), 1569 (s), 1524 (w), 1488 (s), 1414 (w), 1381 (w), 1
(s), 1235 (s), 1173 (s), 1108 (s), 1005 (s) cm-1. UV (DMSO): λmax 275, 388 nm. 
N4-(4-aminophenyl)-2,4-diamino-6-methylpyrimidine (9). To a stirred solution of N4-(4-
nitrophenyl)-2,4-diamino-6-methylpyrimidine 8 (0.70 g, 2.86 mmol) in MeOH (58 mL) was 
added decaborane (0.10 g, 0.86 mmol), 10% Pd/C (0.16 g, 1.46 mmol) and two drops of acetic 
acid. After stirring the mixture at reflux for 2 h, the solvent was evaporated and the residue was 
purified by flash chromatography (silica gel, 85:15 CH2Cl2/MeOH) to afford 0.570 g (93%) of 
the titled compound as a brown solid. 
N4-(4’-Aminophenyl)-2,4-diamino-6-methylpyrimidine (9). To a stirred solution of N4-(4-
nitrophenyl)-2,4-diamino-6-methylpyrimidine 8 (0.2 g, 0.82 mmol) in EtOH (4 mL) was added 
Ni Raney (33 mg) and under a H
Then the reaction mixture was filtered through a small pad of celite, washed with CH2Cl2 and 
the solvent evaporated under vacuo. The residue was purified by flash chromatography (silica 
gel, 80:20 CH2Cl2/MeOH) to afford 0.18 g (quantitative) of the titled compound as a brown 
solid. 1H-NMR (400.13 MHz, DMSO-d6): δ 8.79 (s, 1H, NH), 7.17 (d, J = 7.9 Hz, 2H), 6.53 
(d, J = 8.6 Hz, 2H), 6.31 (s, 2H, NH2), 5.75 (s, 1H, H5), 2.05 (s, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, DMSO-d6): δ 172.6 (s, C4), 162.0 (s, C6), 161.4 (s, C2), 144.7 (s), 128.5 (s), 
123.1 (d, 2x), 114.0 (d, 2x), 93.8 (d, C5), 22.2 (q, CH3) ppm. HRMS (ESI ): Calcd for 
C
+
11H14N5, 216.12437; found, 216.12379. IR (neat, ATR): 
ν 3856 (w), 3738 (w), 3619 (w), 3320 (w), 3194(w), 2918 (w), 1579 (s), 1513 (s), 1411 (m), 
1265 (w) cm-1. UV (DMSO): λmax 310 nm.  
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N-[4-(2’-Amino-6’-methylpyrimidine-4’-ylamino)-phenyl]-4-nitrobenzamide (11). To a 
stirred solution of N4-(4’-aminophenyl)-2,4-diamino-6-methylpyrimidine 9 (0.18 g, 0.84 
mmol) and 4-nitrobenzyl chloride 10 (0.12 g, 0.64 mmol) in DMF (6.5 mL), Cs2CO3 (0.63 g, 
1.94 mmol) was added. After stirring the mixture at room temperature for 2 h, the solvent was 
evaporated and the residue was purified by flash chromatography (silica gel, 80:20 
CH2Cl2/MeOH) to afford 0.15 g (64%) of the titled compound as an orange solid. 1H-NMR 
(400.13 MHz, DMSO-d6): δ 10.50 (s, 1H, CONH), 9.11 (s, 1H, NH), 8.37 (d, J = 8.7 Hz, 2H, 
2H3), 8.20 (d, J = 8.7 Hz, 2H, 2H2), 7.74 – 7.66 (m, 4H, 2H2’ + 2H3’), 6.26 (s, 2H, NH2), 5.90 
(s, 1H, H5’’), 2.10 (s, 3H, CH3) ppm. 13C-NMR (100.62 MHz, DMSO-d6): δ 164.1 (s, 
CONH), 163.4 (s), 162.4 (s), 161.4 (s), 149.0 (s), 140.8 (s), 137.0 (s), 132.6 (s), 129.1 (d, 2x), 
123.5 (d, 2x), 121.0 (d, 2x), 119.7 (d, 2x), 94.8 (d, C5’), 23.1 (q, CH3) ppm. HRMS (ESI+): 
Calcd for C18H17N6O3, 365.13566; found, 365.13398. IR (neat, ATR): ν cm-1. UV (DMSO): 
λmax 274, 312 nm.  
N-[4’-(2’’-Amino-6’’-methylpyrimidine-4’’-ylamino)-phenyl]-4-aminobenzamide (12). 
Following the general procedure described above for the reduction of nitrocompounds with 
decaborane, the reaction of N-[4-(2’-amine-6’-methylpyrimidine-4’-ylamino)-phenyl]-4-
nitrobenzamide 11 (0.08 g, 0.23 mmol), decaborane (9 mg, 0.07 mmol), 10% Pd/C (13 mg, 
0.12 mmol) and two drops of acetic acid in MeOH (5 mL) at reflux afforded after 
purification by flash chromatography (silica gel, 85:14:1 CH2Cl2/MeOH/Et3N) 0.072 g 
(94%) of the titled product as a white solid. 1H-NMR (400.13 MHz, DMSO-d6): δ 10.23 
(s, 1H, CONH), 9.49 (s, 1H), 7.87 – 7.67 (m, 4H, 2H2 + 2H2’), 7.58 (d, J = 8.8 Hz, 2H3’), 
6.66 (d, J = 8.5 Hz, 2H, 2H3), 6.19 (s, 1H, H5’’), 2.29 (s, 3H, CH3) ppm. 13C-NMR 
(100.62 MHz, DMSO-d6): δ 174.5 (s, C2’’) , 165.2 (s, CONH), 155.8 (s, C6’’), 152.2 (s, 
 18.3 (d), 
l) 12, 4-chloroquinoline 13 (22.0 mg, 0.13 mmol) and 
3 g, 0.18 mmol) in DMF (1 mL). The resulting mixture was stirred for 
C2’’), 129.4 (d, 2x), 120.9 (s), 120.4 (d), 112.5 (d, 2x), 62.5 (s), 52.0 (q), 45.3 (q),
8.4 (d), 7.2 (d).ppm. HRMS (ESI+): Calcd for C18H19N6O, 335.16149; found, 335.16229. 
IR (neat, ATR): ν cm-1. UV (DMSO): λmax 325 nm.  
N-[4’-(2’’-Amino-6’’-methylpyrimidin-4’’-ylamino)-phenyl]-4-(quinolin-4’’’-
ylamino)benzamide, SGI-1027 (4). A sealed tube was charged with Pd(OAc)2 (1 mg, 1.32 
μmol) and XPhos (2 mg, 3.97 μmol) and degassed t-BuOH/water (1 mL, 2mL:1mL v/v) was 
added. The resulting solution was heated for 1 min at 80 ºC and cannulated into another sealed 
tube charged with N-[4’-(2’’-amine-6’’-methylpyrimidin-4’’-ylamino)-phenyl]-4-
aminobenzamide (0.07g, 0.20 mmo
potassium carbonate (0.0
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24 hours at 110 ºC. When the reaction was completed the solvent was concentrated in vacuo 
and the residue was purified by flash chromatography (silica gel, 85:13:2 
eOH/Et3N) to afford 0.045 g (73%) of the titled compound as a yellow solid. 1H-
), 161.4 (s), 157.1 (s), 154.9 (s), 149.5 (s), 147.8 (d), 145.0 (s), 142.9 (s), 135.4 (s), 
 130.2 (s), 129.3 (d, 2x), 125.9 (d, 2x), 123.0 (d, 2x), 121.7 (d), 121.6 (d, 
. Following the general procedure described above 
n of anilines with aryl chlorides, the reaction of N-[4’-(2’’-
6
(neat, ATR): 
g, 36.7 μmol) and potassium carbonate (0.24 g, 1.71 
(2.5 mL, 2mL:1mL v/v) at 110 ºC led after purification by flash 
CH2Cl2/M
NMR (400.13 MHz, DMSO-d6): δ 10.22 (s, 1H, CONH), 9.98 (s, 1H, NH), 8.59 (d, J = 5.6 
Hz, 1H), 8.48 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.7 Hz, 2H), 8.00-7.94 (m, 2H), 7.86 – 7.75 (m, 
3H), 7.74 – 7.61 (m, 4H), 7.57 – 7.50 (m, 3H), 7.44 – 7.37 (m, 1H), 7.15 (d, J = 5.6 Hz, 1H), 
6.04 (s, 1H, H5’’), 2.22 (s, 3H, CH3) ppm. 13C-NMR (100.62 MHz, DMSO-d6): δ 164.7 (s, 
CONH
134.2 (s), 131.3 (d),
2x), 120.8 (d, 2x), 119.4 (s), 102.5 (d), 96.4 (d), 19.4 (q, CH3)  ppm. HRMS (ESI+): Calcd for 
C27H24N7O, 462.20368; found, 462.20330. IR (neat, ATR): ν 2976 (w), 2891 (w), 1584 (m), 
1510 (m), 1444 (m), 1380 (m), 1318 (m), 1228 (w), 1180 (w), 1095 (w) cm-1. UV (DMSO): 
λmax 258, 355 nm.  
N-[4’-((2’’-Amino-6’’-methylpyrimidin-4’’-yl)-(quinolin-4’’-yl)amino)-phenyl]-4-
(quinolin-4’’’-ylamino)-benzamide 14
for the cross-coupling reactio
amino-6’’-methylpyrimidin-4’’-ylamino)-phenyl]-4-aminobenzamide 12 (0.07g, 0.22 
mmol), 4-chloroquinoline 13 (0.03 g, 0.18 mmol), Pd(OAc)2 (1.2 mg, 1.8 μmol), XPhos 
(2.6 mg, 5.4 μmol) and potassium carbonate (0.04 g, 0.25 mmol) in t-BuOH/water (0.4 
mL, 2mL:1mL v/v) at 110 ºC led after purification by flash chromatography (silica gel, 
85:14:1 CH2Cl2/MeOH/Et3N) to 0.037 g (70%) of the titled product as a yellow solid. 1H-
NMR (400.13 MHz, DMSO-d6): δ  ppm. 13C-NMR (100.62 MHz, DMSO-d ): δ  ppm. 
HRMS (ESI+): Calcd for C H N O, 589.24588; found, 589.24543. IR 36 29 8
ν cm-1. UV (DMSO): λmax  nm. 
Ethyl 4-(Quinolin-4’-ylamino)benzoate (16). Following the general procedure described 
above for the cross-coupling reaction of anilines with aryl chlorides, the reaction of ethyl 4-
aminobenzoate 15 (0.24 g, 1.47 mmol), 4-chloroquinoline 13 (0.20 g, 1.22 mmol), Pd(OAc)2 
(8.2 mg, 12.2 μmol), XPhos (17.5 m
mmol) in t-BuOH/water 
chromatography (silica gel, 85:14:1 CH2Cl2/MeOH/Et3N) to 0.34 g (94%) of the titled product 
as a yellow solid. M.p.: 202-204 ºC (EtOH reflux). Elem. Anal. Calcd for: C18H16N2O2: C, 
73.95%; H, 5.52%; N, 9.58%; found: C, 73.66%; H, 5.60%; N, 9.41%  1H-NMR (400.13 
MHz, DMSO-d6): δ 9.32 (s, 1H, NH), 8.60 (d, J = 5.1 Hz, 1H), 8.35 (d, J = 8.2 Hz, 1H), 8.01-
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7.87 (m, 3H), 7.72 (t, J = 7.3 Hz, 1H), 7.56 (t, J = 7.4 Hz, 1H), 7.44 (d, J = 8.6 Hz, 2H, 2H3), 
7.26 (d, J = 5.1 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 1.31 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3) ppm. 13C-NMR (100.62 MHz, DMSO-d6): δ 165.4 (s, CO2Et), 150.7 (d), 149.1 
(s), 146.1 (s), 145.7 (s), 130.7 (d), 129.5 (d), 129.3 (d), 125.1 (d), 123.0 (s), 122.4 (d), 120.8 
(s), 118.9 (d), 104.8 (d), 60.3 (t, CO2CH2CH3), 14.2 (q, CO2CH2CH3) ppm. HRMS (ESI+): 
Calcd for C18H17N2O2, 293.12845; found, 293.12896. IR (neat, ATR): 
ν 3156 ), 2973 (w), 2896 (w), 1707 (m, CO), 1572 (m), 1521 (m), 1423 (w), 1384 (m), 1321 
(m), 1257 (s), 1168 (m), 1099 (m), 1019 (m) cm-1. UV (DMSO): λmax 283, 354 nm.  
4-(Quinolin-4’-ylamino)benzoic Acid (17). To a stirred solution of ethyl 4-(quinolin-4’-
ylamino)benzoate 16 (0.10 g, 0.34 mmol) in THF/MeOH (2.8 mL, 1:1 v/v), lithium hydroxide 
monohydrate (0.14 g, 3.42 mmol) and water (3.42 mL) were added and the mixture was stirred 
at room temperature for 24 h. The resulting basic suspension was acidified by the addition of 
aqueous 1 M HCl solution and the precipitate was filtrated and rinsed with cold water. The 
process was repeated with the supernatants until no precipitate was observed with the 
acidification. The solid obtained was dried under reduced pressure at 50 ºC overnight to afford 
0.09 g (quantitative) of the titled compound as a yellow solid. M.p.: > 300 ºC (EtOH reflux). 
1H-NMR (400.13 MHz, DMSO-d6): δ 8.93 (d, J = 8.5 Hz, 1H), 8.58 (d, J = 6.9 Hz, 1H), 8.15 
(d, J = 8.4 Hz, 1H), 8.08 (d, J = 8.4 Hz, 2H, 2H2), 8.03 (t, J = 7.7 Hz, 1H), 7.80 (t, J = 7.6 Hz, 
1H), 7.65 (d, J = 8.4 Hz, 2H, 2H3), 7.04 (d, J = 6.9 Hz, 1H) ppm. 13C-NMR (100.62 MHz, 
DMSO-d6): δ 166.7 (s, C
(w
O2H), 154.3 (s), 143.0 (d), 141.6 (s), 138.5 (s), 134.0 (d), 131.0 (d), 
128.8 (s), 127.2 (d), 124.6 (d), 124.1 (d), 120.4 (d), 117.7 (s), 100.7 (d) ppm. HRMS (ESI+): 
Calcd for C16H13N2O2, 265.09715; found, 265.09646. IR (neat, ATR): ν 3500−2500 (br), 
1710 (m, CO), 1591 (s), 1530 (m), 1440 (m), 1378 (m), 1226 (s), 1173 (m), 1110 (s), 1010 
(w) cm-1. UV (DMSO): λmax 258, 353 nm.  
N-[4’-(2’’-Amino-6’’-methylpyrimidin-4’’-ylamino)-phenyl]-4-(quinolin-4’’’-
ylamino)benzamide, SGI-1027 (4). To a solution of 4-(quinolin-4’-ylamino)benzoic acid 
17 (45 mg, 0.17 mmol) and N4-(4’-aminophenyl)-2,4-diamino-6-methylpyrimidine 9 (37 
mg, 0.17 mmol) in DMF (1.7 mL) was added N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.06 g, 0.34 mmol) and 1-hydroxybenzotriazole hydrate 
(0.03 g, 0.17 mmol) and the reaction was stirred 24 h at 65 ºC. When the reaction was 
completed the solvent was concentrated in vacuo and the residue was purified by flash 
chromatography (silica gel, 85:13:2 CH2Cl2/MeOH/Et3N) to afford 0.05 g (59%) of the 
titled compound as a yellow solid. 
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Reference compounds 
MS-275 (Bayer-Schering AG) and ALX-270-415 (Alexis-Biochemicals) were dissolved in
DMSO (Sigma-Aldrich) and used at 5 μM, 50 μM or 100 μM as specified in the text.  
Cell lines 
U937 (Human leukemic monocyte lymphoma cell line- ATCC) and K562 (Human 
erythromyeloblastoid leukemia cell line-ATCC) were grown in RPMI 1640 medium
(Euroclone) supplemented with heat-inactivated FBS (Euroclone), 1% glutamine (Lonza), 1%
penicillin/streptomycin (Euroclone) and 0.1% gentamycin (Lonza), at 37 °C in air and 5%
CO2.  
Cell cycle analysis  
2.5 x 105 U937 cells were collected by centrifugation after 30 h stimulation with reference
compounds or with SGI-1027. The cells were resuspended in 500 µL of a hypotonic buffer
(0.1% NP-40, 0.1% sodium citrate, 50 µg/mL PI, RNAse A) and incubated in the dark for 30
minutes. The analysis was performed by FACS-Calibur (Becton Dickinson) using the Cel
Quest Pro software (Becton Dickinson) and ModFit LT version 3 software (Verity). The
experiment was performed in duplicate. 
Dnmt1 Immunoprecipitation 
K562 cells were lysed in TAP buffer pH 7-7.5 (50 m
NP40 v/v,  10% Glycerol  v/v, 1.5 mM MgCl2, 1 mM NaMO4, 0.5 mM NaF, 1 mM DTT, 0.2 
mM PMSF and protease inhibitor cocktail) for 10 minutes in ice and centrifuged at 13000 rpm 
for 30 minutes. 650 µg of extracts were diluted in TAP buffer up to 1 mL and pre-cleared by 
incubating with 20 µL A/G plus Agarose (Santa Cruz) for 1 h on a rocking table at 4°C. 
Supernatant was transferred into a new tube and 3.25 μg of antibody against DNMT1 (Abcam) 
was added and IP was allowed to proceed overnight at 4 °C on a rocking table. 
As negative control the same amount of protein extracts were immunoprecipitated with 
purified IgG rabbit (Santa Cruz). After day 50 µL A/G plus Agarose were added and 
incubation was continued for 2 hours. The beads were recovered by brief centrifugation and 
washed with cold TAP buffer several times. At this point the resin was resuspended in 10 µL 
of Dnmt buffer (5 mM EDTA, 0.2 mM DTT, 26 mM NaCl, 20 mM Tris HCl pH 7.4) in order 
to proceed with the radioactive assay. 
Dnmt1 radioactive assay 
Dnmt1 radioactive assay was performed in presence of the compounds at 50 µM concentration 
plus a reaction mixture composed of 10 µL of Dnmt1-bound resin, 5 µCi of AdoMet 
(radioactive methyl donor), 0.1 µg of poly dI-dC (methyl acceptor), and Dnmt buffer. The 
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M Tris pH 7.0, 180 mM NaCl, 0.15% 
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reaction was carried out for 2 hours at 37 °C with gently stirring and the experiment was 
performed in duplicate. Subsequently each sample was spread on Whatman DE-81 paper (in 
quadruplicate) and the papers were washed three times with 5% HNa2PO4 and once with 
distilled water. In the end the papers were transferred in the scintillation vials containing 5 mL 
of scintillation fluid in order to read the DPM values.  
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1. Se han desarrollado cuatro estrategias sintéticas para la preparación de los 
peyssoneninos A y B, productos naturales aislados del alga roja Peyssonelia 
caulífera,  y sus análogos. Estas rutas difieren en el tipo de enlace (Csp-Csp o Csp-
Csp P2 P) formado en la etapa clave de la síntesis: 
• En la Ruta A se utilizó como etapa clave una reacción de acoplamiento 
de Cadiot-Chodkiewicz entre un alcohol propargílico y un yodoalquino, 
lo que permitió obtener el esqueleto básico de los peyssoneninos en un 
buen rendimiento. La formación de los enol acetatos se postergó a la 
penúltima etapa de la síntesis, pero su formación empleando EtR3RN, 
DMAP y AcR2RO transcurrió con una selectividad E/Z moderada.  
• En la Ruta B la formación estereoselectiva de los enol acetatos se llevó a 
cabo utilizando diferentes amiduros de litio que dieron lugar a buenas 
selectividades E/Z. Dada la incompatibilidad de las aminas secundarias 
requeridas para la reacción de Cadiot-Chodkiewicz con esta 
funcionalidad, se utilizó un acomplamiento oxidativo co-catalizado por 
Ni y Cu para acoplar ambos acetoxieninos con los correspondientes 
alquinos terminales que contienen el fragmento del éster de glicerol. 
• En la Ruta C se utilizó una reacción de condensación entre una amida de 
Weinreb y el anión de un diino generado in situ con un organolítico para 
formar el esqueleto básico de los peyssoneninos. 
• En la Ruta D se ha llevado a cabo una reacción de Sonogashira entre un 
Z-cloroenol éster y TIPS-acetileno para formar el acetoxienino de 
geometría E. 
2. Se han sintetizado una serie de análogos de los peyssoneninos que difieren en la 
naturaleza de la cadena alquílica (alquilo, arilo o heteroarilo) y en el carboxilato.  
Todos estos compuestos, junto con los peyssoneninos, han sido evaluados 
biológicamente. 
3. Se ha determinado el exceso enantiomérico  de los peyssoneninos y de una serie de 
monoacilgliceroles (MAGs) derivados de ácidos grasos mediante el empleo de la 
columnas quirales ChiralpakP®P IC o ChiralpakIAP®P. Se ha comprobado que este tipo 
de compuestos presentan bajas purezas enantioméricas debido a la migración del 
grupo acilo entre las posiciones sn-1 y sn-3. 
Conclusiones 
268 
4. Se ha asignado la geometría del acetoxienodiino de los peyssoneninos y 
palmiteninos usando el valor de la constante de acoplamiento heteronuclear P3 PJRCH, 
RqueR Rha resultado ser la más sensible a la configuración E/Z del doble enlace, 
calculada mediante experimentos 2D EXSIDE. Los acetoxienodiinos y 
acetoxieninos de geometría Z dan lugar a valores de P3 PJRCH Rconsiderablemente más 
pequeños (≤ 5.24 Hz) que los correspondientes isómeros E (≥10.49 Hz). Además, 
se comprobó que el desplazamiento químico de P13PC-RMN en los carbonos Csp 
cercanos al doble enlace de los acetoxienodiinos también es sensible a la geometría 
E/Z del enol éster, encontrándose diferencias de hasta 5 ppm en el desplazamiento 
químico del C6 de los isómeros geométricos. Cálculos DFT han corroborado este 
procedimiento para la asignación estructural de los acetoxienodiinos. 
5. Tras la síntesis de las estructuras propuestas para los productos naturales, y el 
análisis espectroscópico anterior, se ha podido establecer que el peyssonenino B 
corresponde al isómero posicional sn-2 del peyssonenino A y ambos se presentan 
en la Naturaleza como isómeros geométricos Z del enol acetato. 
6. La diinona derivada del ácido palmítico que mantiene el fragmento de éster de 
glicerol de los peyssoneninos es un nuevo inhibidor de DNMT1 y activante de 
DNMT3A/B, que puede tener interés en el tratamiento de procesos asociados a la 
hiperproliferación de fibroblastos. 
7. Se han desarrollado dos estrategias sintéticas diferentes (convergente y por etapas) 
para la obtención de SGI-1027, conocido inhibidor de DNMT, y se ha evaluado 
biológicamente en células humanas de leucemia humana U937. 
 
